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Abstract 
Cardiovascular diseases are a leading cause of death throughout the developed world. With the demand 
for donor hearts far exceeding the supply, a bridge-to-transplant or permanent solution is required. This 
is currently achieved with ventricular assist devices (VADs), which can be used to assist the left ventricle 
(LVAD), right ventricle (RVAD), or both ventricles simultaneously (BiVAD). Earlier generation VADs were 
large, volume-displacement devices designed for temporary support until a donor heart was found. The 
latest generation of VADs use rotary blood pump technology which improves device lifetime and the 
quality of life for end stage heart failure patients. 
 
VADs are connected to the heart and greater vessels of the patient through specially designed tubes 
called cannulae. The inflow cannulae, which supply blood to the VAD, are usually attached to the left 
atrium or ventricle for LVAD support, and the right atrium or ventricle for RVAD support. Few studies 
have characterized the haemodynamic difference between the two cannulation sites, particularly with 
respect to rotary RVAD support. Inflow cannulae are usually made of metal or a semi-rigid polymer to 
prevent collapse with negative pressures. However suction, and subsequent collapse, of the cannulated 
heart chamber can be a frequent occurrence, particularly with the relatively preload insensitive rotary 
blood pumps. Suction events may be associated with endocardial damage, pump flow stoppages and 
ventricular arrhythmias. While several VAD control strategies are under development, these usually rely 
on potentially inaccurate sensors or somewhat unreliable inferred data to estimate preload. Fixation of 
the inflow cannula is usually achieved through suturing the cannula, often via a felt sewing ring, to the 
cannulated chamber. This technique extends the time on cardiopulmonary bypass which is associated 
with several postoperative complications. 
 
The overall objective of this thesis was to improve the placement and design of rotary LVAD and RVAD 
inflow cannulae to achieve enhanced haemodynamic performance, reduced incidence of suction events, 
reduced levels of postoperative bleeding and a faster implantation procedure. Specific objectives were: 
 in-vitro evaluation of LVAD and RVAD inflow cannula placement, 
 design and in-vitro evaluation of a passive mechanism to reduce the potential for heart chamber 
suction, 
 design and in-vitro evaluation of a novel suture-less cannula fixation device. 
 
iv 
 
In order to complete in-vitro evaluation of VAD inflow cannulae, a mock circulation loop (MCL) was 
developed to accurately replicate the haemodynamics in the human systemic and pulmonary 
circulations. Validation of the MCL’s haemodynamic performance, including the form and magnitude of 
pressure, flow and volume traces was completed through comparisons of patient data and the 
literature. The MCL was capable of reproducing almost any healthy or pathological condition, and 
provided a useful tool to evaluate VAD cannulation and other cardiovascular devices. 
 
The MCL was used to evaluate inflow cannula placement for rotary VAD support. Left and right atrial 
and ventricular cannulation sites were evaluated under conditions of mild and severe heart failure. With 
a view to long term LVAD support in the severe left heart failure condition, left ventricular inflow 
cannulation was preferred due to improved LVAD efficiency and reduced potential for thrombus 
formation. In the mild left heart failure condition, left atrial cannulation was preferred to provide an 
improved platform for myocardial recovery. Similar trends were observed with RVAD support, however 
to a lesser degree due to a smaller difference in right atrial and ventricular pressures. 
 
A compliant inflow cannula to prevent suction events was then developed and evaluated in the MCL. As 
rotary LVAD or RVAD preload was reduced, suction events occurred in all instances with a rigid inflow 
cannula. Addition of the compliant segment eliminated suction events in all instances. This was due to 
passive restriction of the compliant segment as preload dropped, thus increasing the VAD circuit 
resistance and decreasing the VAD flow rate. Therefore, the compliant inflow cannula acted as a passive 
flow control / anti-suction system in LVAD and RVAD support. 
 
A novel suture-less inflow cannula fixation device was then developed to reduce implantation time and 
postoperative bleeding. The fixation device was evaluated for LVAD and RVAD support in cadaveric 
animal and human hearts attached to a MCL. LVAD inflow cannulation was achieved in under two 
minutes with the suture-less fixation device. No leakage through the suture-less fixation device – 
myocardial interface was noted. Continued development and in-vivo evaluation of this device may result 
in an improved inflow cannulation technique with the potential for off-bypass insertion. 
 
Continued development of this research, in particular the compliant inflow cannula and suture-less 
inflow cannulation device, will result in improved postoperative outcomes, life span and quality of life 
for end-stage heart failure patients.  
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Chapter 1 
Introduction 
 
Cardiovascular diseases are a leading cause of death throughout the developed world [1, 2]. With the 
demand for donor hearts far exceeding the supply [3], a bridge-to-transplant or permanent solution is 
required. Current mechanical solutions to treat end stage heart failure include ventricular assist devices 
(VADs) and total artificial hearts (TAHs). VADs are connected to the heart and greater vessels of the 
patient through specially designed tubes called cannulae. The inflow cannulae, which supply blood to 
the VAD, are attached to the left atrium or ventricle for left ventricular assist device (LVAD) support, and 
the right atrium or ventricle for right ventricular assist device (RVAD) support. The outflow cannulae, 
which supply blood to the circulatory system from the BiVAD, are usually connected to the aorta and 
pulmonary artery for LVAD and RVAD respectively. The inflow cannulae are usually made of metal or a 
wire reinforced, semi-rigid polymer to prevent collapse with negative pressures [4]. Outflow cannulae 
are usually two stage designs, the first a semi-rigid polymer attached to the pump and the second a 
Dacron sleeve which can be cut to length and sutured to the outflow vessel [4]. Inflow and outflow 
cannula fixation is achieved by suturing the cannula to the chamber/vessel, and often requires 
reinforcement with felt pledgets to prevent severe bleeding [5, 6]. 
 
Previous research on mechanical circulatory assistance has been dominated by pump design, while the 
peripheral system, including the cannulae, has received less attention. This is surprising, as several 
limitations with VAD support can be, at least partially, attributed to VAD cannulation. For instance, 
common complications during VAD implantation and throughout the duration of VAD support, such as 
extended time on cardiopulmonary bypass, intra- and post-operative bleeding, and suction events, can 
be in some way attributed to cannula design or placement [7, 8]. Meanwhile, incidences of thrombus 
formation which may lead to postoperative stroke has been reported in both pulsatile and continuous 
flow VADs [9] and previous work has identified significant correlation between cannula design / 
positioning and postoperative stroke rate [10].  
 
The site of VAD inflow cannula attachment to the heart is dependent on the device, preference of the 
surgeon, and anatomical constraints [11]. While the resultant haemodynamics of atrial or ventricular 
inflow cannulation are different, no validated recommendations exist which define the optimal 
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cannulation site for varying degrees of heart failure. LVAD inflow cannulation site has been investigated 
in healthy animals [12, 13] and numerical simulations [14], yet a repeatable study of various degrees of 
heart failure has not been carried out. As expected, the few previous studies of LVAD inflow cannulation 
site have demonstrated changes of the resultant haemodynamics with atrial and ventricular cannulation 
[13, 15]. However, the degree to which the haemodynamics change, and therefore the conclusions that 
can be associated with these studies, are difficult to identify in healthy animals as the starting 
haemodynamics are not representative of a heart failure scenario. Furthermore, the effect of RVAD 
inflow cannula site has not been evaluated. This thesis outlines the haemodynamic evaluation of LVAD 
and RVAD inflow cannula site in both the atria and ventricles under various degrees of heart failure.  The 
results from this study, completed in a hydraulic rig capable of repeatable results, can be used to direct 
the surgeon in their choice of which vessel is more suitable for LVAD and RVAD inflow cannulation on a 
patient by patient basis.  
 
The hydraulic test rig used for inflow cannulation site evaluation was required to be a detailed and 
validated representation of the heart and circulatory system. Mechanical representations of the heart 
and circulatory system, usually called mock circulation loops (MCLs), have been developed and 
described previously [16, 17]. A MCL, described in this thesis, was designed and constructed based on a 
previous design by Timms et al. [18]. For the purpose of this thesis, the MCL required a simulated 
ventricular Frank-Starling mechanism (also referred to as Starling response), which essentially changes 
ventricular contractility in response to changing ventricular preload. The Starling response was 
implemented with a controller which based ventricular driving pressure on ventricular end diastolic 
volume, a measure of preload. The MCL with Starling response was validated under a wide range of 
healthy and pathological conditions against human data, and provided a valuable test platform for the 
studies described in this thesis and has the potential for use in other research. 
 
The Starling responsive MCL presented in this thesis was also suitable for evaluation of suction events 
caused by VADs. Unlike some pulsatile VADs, continuous flow VADs are not passively filled and low inlet 
pressures due to imbalances in the systemic and pulmonary circulations may result in negative atrial or 
ventricular pressure causing chamber suction [19, 20]. Suction of the cannulated chamber may draw the 
septum or free wall onto the cannula, resulting in intermittent LVAD flow stoppages, endocardial 
damage and ventricular arrhythmias [14, 19, 21, 22]. If left untreated, this septal shift may impair right 
ventricular function and potentially result in right ventricular failure requiring RVAD support [23]. Active 
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control systems which reduce VAD speed when a suction event is detected have been reported 
previously [24-26]. These systems rely on sensors or sensor-less feedback control. With unreliable 
sensors, such as pressure sensors which are prone to drift [27], and potentially inaccurate sensor-less 
systems, suction events may still pose a problem during VAD support [28]. A passive flow control 
system, in the form of a compliant inflow cannula, was evaluated in the Starling responsive MCL and is 
presented in this thesis. The compliant inflow cannula was designed to restrict in cross-sectional area 
prior to suction of the cannulated chamber, thus increasing the circuit resistance and reducing VAD flow. 
Therefore, the addition of a compliant inflow cannula acted as a passive control system to reduce 
suction events during VAD support. 
 
The most common complication during VAD support is bleeding, which is the major contributing factor 
of operative mortality during VAD implantation and explantation [29-32]. Often occurring at the 
cannulation sites, significant hemorrhage is partially due to the anticoagulation regime following VAD 
implantation, which is required to prevent thrombus formation in the VAD, cannulae and circulation [6].  
Continuous flow devices have been shown to result in higher degrees of bleeding during VAD support 
and heart transplant due to a bleeding disorder known as acquired von Willebrand syndrome [33, 34]. 
Meanwhile, extended time on cardiopulmonary bypass (CPB) during VAD implantation has been shown 
to increase the risk of severe postoperative bleeding [35]. Therefore, improved cannulation techniques 
to reduce postoperative, surgical related bleeding are essential to improve the chances of survival for 
these end-stage heart failure patients. A novel inflow cannula fixation technique is described in this 
thesis which aims to reduce the time on CPB, postoperative bleeding and thrombus formation. The 
novel suture-less method of attachment allows faster implantation compared to standard inflow 
cannulae while using the myocardium to self-seal and reduce postoperative bleeding. A flared, collared 
section which expands within the cannulated chamber during implantation serves to improve the flow 
dynamics within the chamber and thus reduce the incidence of thrombus formation during VAD 
support. This thesis describes the development, construction and evaluation of the novel inflow cannula 
fixation technique. 
 
In summary, the research, development and associated results described in this thesis aimed to improve 
the inflow cannula design for LVAD, RVAD and BiVAD systems. A Starling responsive MCL is described, 
which provided a suitable test rig for evaluation of cannula design. Inflow cannulation site was evaluated 
and characterized for a variety of heart failure conditions to provide insight and recommendations to 
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the VAD surgeon. A novel compliant inflow cannula is described and evaluated to present initial 
development of an implantable design and to characterize the device operation if used for 
extracorporeal support. A novel inflow cannula fixation technique is presented which aimed to improve 
several limitations observed during VAD support, while recommendations are provided to assist 
progression to the clinical environment. Finally, conclusions and future work are presented to 
summarize each chapter and provide recommendations for further development of each study. 
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1.1 Significance 
The significance of this research relates to the development of inflow cannulation techniques for 
ventricular assist devices. The findings presented in this thesis outline where the surgeon should attach 
the device to the heart, how a novel compliant inflow cannula can be used to reduce suction events, and 
the application of a novel cannula fixation technique to potentially reduce CPB time, postoperative 
bleeding and thrombus formation. These developments will improve the outcomes and quality of life for 
end stage heart failure patients worldwide. 
 
Determination of the most appropriate LVAD and RVAD inflow cannulation site is vital to improve 
resultant patient outcomes. Cannula placement in the atrium or ventricle can influence the potential for 
thrombus formation, cardiac output and VAD efficiency. Meanwhile, full recovery of myocardial function 
after VAD implantation is a rare, but valuable occurrence and could be influenced by the site of inflow 
cannulation. Characterization of the inflow cannulation site under various degrees of heart failure would 
assist surgeons in choosing the best option on a patient by patient basis. The results of this study, 
presented in chapter 4 of this thesis, provided a clinical recommendation of inflow cannulation site for 
continuous flow LVADs and RVADs which would result in improved patient outcomes. 
 
The cannulated heart chamber is also susceptible to suction events, particularly in rotary VADs. These 
events can cause harmful flow stoppages, endocardial damage and ventricular arrhythmias. A passive 
control system to prevent suction events would drastically improve VAD function and patient quality of 
life. Development of a compliant inflow cannula, presented in chapter 5 of this thesis, showed promise 
as a passive, preload-based LVAD or RVAD flow control system. Further development of this device 
should result in a simple, but effective solution to flow balancing issues with rotary blood pumps. 
 
Improvements to current cannula fixation techniques are vital to the long term success of VADs. VAD 
recipients frequently require re-operations due to bleeding or incorrect cannula position, resulting in 
poor patient outcomes due to this risky surgery at a great cost to healthcare services worldwide. The 
associated complications with severe postoperative bleeding are extensive while transfusions are 
required to cope with the extensive blood loss, thus increasing the demand on a limited blood donor 
pool and increasing the risk of infection and right heart failure. With an improved cannula fixation 
design, blood transfusions and re-operations due to bleeding would likely be reduced.  Cardiopulmonary 
bypass times could also be reduced or potentially eliminated, resulting in improved postoperative 
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outcomes and reduced costs for VAD patients. Presented in chapter 6 of this thesis, the novel suture-
less inflow cannulation device allowed for a much faster cannulation procedure without the need for 
cardio-pulmonary bypass and potential for reduced postoperative bleeding. 
 
The development of a MCL will enable significant cardiovascular device development and evaluation 
prior to expensive in-vivo and clinical trials. The addition of a Starling response to the MCL will further 
refine the MCL and provide a more accurate representation of the native heart’s response to changes in 
preload. This is of particular importance when evaluating cardiovascular devices when low ventricular 
volumes are present, such as the onset of suction events. The MCL developed in this thesis, presented in 
chapter 3, provided a detailed, validated representation of the systemic and pulmonary circulations with 
left and right ventricular Starling responses. This mock circulation provided an ideal platform for BiVAD 
cannula design evaluation and will be a vital tool for future cannula and VAD development. 
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1.2 Aims 
The primary aim of this research is to improve the design, implantation technique and functional 
operation of inflow cannulae for ventricular assist devices. The specific objectives of this research are to: 
- Conduct an in-depth review of literature on the following topics: 
o Heart failure and ventricular assist devices. 
o Cannula design. 
o Cannula placement. 
o Cannula fixation. 
o In-vitro and in-vivo evaluation of cardiovascular devices. 
- Develop an accurate MCL for inflow cannula evaluation of cardiovascular devices, including: 
o Systemic and pulmonary circulations. 
o Arterial and venous compliance. 
o Variable vascular resistance. 
o Variable heart function including contractility, heart rate and systolic time. 
o Starling responsive ventricles. 
o Connections for cardiovascular device evaluation. 
- Investigate the optimal inflow cannulation site for various degrees of left and right heart failure, 
specifically aiming to: 
o Reduce ventricular stroke work to promote myocardial recovery. 
o Increase ventricular ejection fraction to reduce the risk of thrombus formation. 
o Increase flow to provide better perfusion to the end organs. 
o Increase VAD efficiency to promote longer battery life. 
- Develop and characterize a compliant inflow cannula for use with LVAD and RVAD support to: 
o Increase the preload sensitivity of rotary VADs. 
o Reduce incidences of atrial / ventricular suction. 
o Eliminate intermittent flow stoppages from the VAD. 
- Develop a novel cannula fixation technique to: 
o Reduce cardiopulmonary bypass time during VAD implantation. 
o Reduce postoperative bleeding. 
o Improve the washout within the chamber to reduce the risk of thrombus formation. 
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1.3 Thesis Outline 
This thesis is presented in seven chapters which outline the development of new inflow cannulation 
design and implantation techniques with the assistance of a MCL for in-vitro evaluation.  
 
A detailed background and literature review is presented in Chapter 2. Topics of heart failure, 
ventricular assist devices, cannula design, cannula placement, cannula fixation and in-vitro evaluation of 
cardiovascular devices are discussed to provide the reader with an up-to-date and detailed 
understanding of previous work in the field. The clear gap in the literature relating to inflow cannula 
design for ventricular assist devices is outlined by articles presenting new fixation techniques to reduce 
postoperative bleeding. Furthermore, multiple articles outlining control strategies to reduce suction 
events identify the issue of potential ventricular suction whilst using rotary VADs. Critical analysis of 
these articles reveals limitations with sensor and sensor-less based control strategies and the required 
additional time on CPB to improve cannula fixation. The review of previously developed MCLs for in-
vitro evaluation of cardiovascular devices uncovers a lack of detailed systems with incorporated auto-
regulatory responses. 
 
Chapter 3 details the design, construction and validation of a MCL for cardiovascular device evaluation. 
This system was required for several studies reported in this thesis. Details of the entire system are 
described, including the pneumatically operated atria and ventricles, systemic and pulmonary 
circulations, variable vascular resistance valves, arterial and venous compliance chambers, anatomical 
defects, data acquisition and control. Implementation and validation of a variable Starling response in 
the MCL’s ventricles is then described. 
 
The MCL was used to evaluate inflow cannula implantation site with LVAD and RVAD support, described 
in Chapter 4. The resulting haemodynamics during both atrial and ventricular inflow cannulation were 
evaluated for both left and right ventricular assistance and, when combined, biventricular assistance. 
Testing was completed under mild and severe left and right heart failure conditions to determine if the 
results can be applied to all patients. Results are presented and discussed as a recommendation to 
surgeons for optimal inflow cannula placement to treat patients with either mild or severe heart failure, 
with a view to destination therapy or bridge to recovery. 
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Evaluation of a compliant inflow cannula to reduce suction events is discussed in Chapter 5. The 
performance of the compliant inflow cannula was evaluated in both atrial and ventricular cannulation 
under mild and severe heart failure conditions. Comparative results are shown for the compliant inflow 
cannula and a standard, semi-rigid cannula for tests of ramped VAD speed and a sudden increase in 
vascular resistance which would normally induce a suction event. The performance of the compliant 
inflow cannula was then characterized at various heights to demonstrate its dependence on preload. 
Results for both LVAD and RVAD inflow are displayed and discussed, with recommendations provided 
for the use of the compliant inflow cannula to reduce suction events. 
 
Chapter 6 presents a novel inflow cannula fixation technique to reduce the incidence of postoperative 
bleeding and thrombus formation with an expanding, implanted collar. Design iterations which led to 
the final device are discussed, along with the engineering techniques used to approach each 
development stage. The final device is presented and the manufacturing techniques for a prototype are 
discussed. Development and validation of a test rig, in the form of a cadaveric heart attached to a 
simplified MCL, is outlined. Evaluation of the novel inflow cannula fixation technique in the cadaveric 
heart model is presented. 
 
Finally, Chapter 7 draws conclusions from the previous chapters and provides recommendations for 
future work for each of the studies.  
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1.4 Thesis Outcomes and Contributions 
This thesis describes a significant and novel contribution in the development of inflow cannula design 
and fixation for BiVADs. Specifically, these significant and novel contributions are: 
1. Development and validation of a systemic and pulmonary MCL for cardiovascular device 
evaluation which: 
a) Outputs accurately shaped, pneumatically operated, ventricular pressure waveforms. 
b) Includes a non-linear, variable left and right ventricular Starling response. 
2. Evaluation of VAD inflow cannula implantation site for LVADs and RVADs in an in-vitro, 
repeatable, Starling responsive, variable heart failure model. 
3. Development and evaluation of a compliant inflow cannula which acts as a passive flow control 
system, to reduce suction events in both atrial and ventricular cannulation for LVADs and 
RVADs. 
4. Development and validation of an in-vitro test rig for evaluation of cannula fixation which 
includes: 
a) Systemic and pulmonary circulations with variable resistance and compliance. 
b) A cadaveric human heart. 
5. Development and evaluation of a new inflow cannula fixation technique which: 
a) Includes an inserted, expanding, flared collar which compresses the myocardium to self-
seal. 
b) Employs a suture-less fixation technique. 
c) Has the potential to reduce postoperative bleeding, thrombus formation and time on CPB. 
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Chapter 2 
Background and Literature Review 
 
Development of a new inflow cannula system requires a detailed knowledge of the cardiovascular 
system, heart failure, VAD development, cannula design, cannula placement, cannula fixation, and in-
vitro testing methods used to evaluate cardiovascular devices. This chapter presents a review of 
literature on these topics and discusses the gaps in research in this field. 
 
2.1 The Heart 
The heart (Figure 1) has two sides, each consisting of an atrium and ventricle. The left side of the heart, 
including the left atrium and left ventricle, pumps oxygenated blood to the systemic circulation. The 
right side of the heart, which includes the right atrium and right ventricle, pumps deoxygenated blood to 
the pulmonary circulation.  The two sides of the heart are separated by a flexible septum. Therefore, the 
contraction and relaxation of each side of the heart is dependent on the other through septal 
interaction. The atrium and ventricle, on each side, is separated by an atrioventricular (AV) valve which 
prevents backflow from the ventricle to the atrium. The mitral valve is located between the atrium and 
ventricle on the left side, while the tricuspid valve is located in the same location for the right side of the 
heart. Valves are also located between the ventricles and corresponding arteries to prevent backflow, 
with the aortic valve on the left side of the heart and the pulmonary valve on the right.  
 
The walls of the heart consist of three layers. The endocardium, made of epithelial tissue, is the inner 
most layer and is in direct contact with blood within the cardiac chambers. The surface of the 
endocardium is smooth to allow for improved blood flow dynamics, and has an endocrine function to 
release hormones such as endocardin which prolongs myocardial contraction. The myocardium, the 
middle, muscular layer, is the thickest portion of the heart wall and is made from cardiac muscle cells 
(myocytes). The epicardium, also known as the visceral pericardium, is the outer most layer and is 
separated from the pericardium (a protective casing around the heart) by a thin wall of pericardial fluid. 
The wall of the heart receives blood supply from the coronary arteries which are connected to the root 
of the aorta. 
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Figure 1 – The heart [36] 
 
2.1.1 The Frank Starling Law of the Heart 
The Frank Starling law of the heart (referred to as the Starling response from this point forward) states 
that the heart has an intrinsic capability of increasing its force of contraction, and therefore stroke 
volume, in response to an increase in venous return [37]. Simplified, this law states that what goes into 
each ventricle must come out.  As venous return, and hence preload, to the ventricle increases, the 
ventricle will fill at an increased rate. This results in a larger ventricular end diastolic volume (EDV) (the 
heart's maximum volume) and stretches the cardiac muscles. The response to this increased EDV is a 
more forceful ventricular contraction, which outputs a larger stroke volume. Figure 2 demonstrates the 
relationship between preload and stroke volume is not the same for all hearts. The sensitivity of the 
heart to change contractility, and hence stroke volume, with a change in preload is decreased in heart 
failure [17, 38]. 
 
2.2 The Cardiac Cycle 
Cardiac function occurs in cycles, where each cycle can be divided into two stages; diastole and systole.  
Diastole is the stage where the ventricle relaxes and fills with blood, while systole is the process of 
forcing the blood out of the ventricle through ventricular contraction.  These portions can then be 
broken down into smaller phases, as shown in Figure 3. 
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Phase 1 (atrial contraction) is the final stage of ventricular filling (diastole). The atrium contracts to 
increase the pressure gradient across the AV valve which promotes blood flow into the ventricle.  This 
contraction provides a small increase in venous pressure while accounting for about 10-20% of 
ventricular filling in normal heart function.  In the same phase, atrial contraction ceases and the atrial 
pressure falls, causing the AV valve to close.  By this stage, the ventricle has reached maximum volume 
(EDV). 
 
Isovolumetric contraction occurs in phase 2.  This phase is the start of ventricular contraction (systole) 
and causes a rapid increase in ventricular pressure while the ventricular volume remains constant.  The 
ventricle becomes more spherical and pushes the AV valve back into the atrium slightly after it has 
closed.  This, accompanied with continuous venous return, increases the atrial pressure. 
 
The third phase is rapid ejection.  This occurs when the pressures inside the ventricle exceeds that of the 
corresponding artery, causing the semilunar valve to open and blood to flow from the ventricle.  
Ventricular pressure stays slightly higher than the arterial pressure during this stage while a rapid 
decrease in ventricular volume can be noticed.  The base of the atrial chamber is pulled downward 
during this phase, resulting in increased atrial volume and reduced atrial pressure. 
 
 
Figure 2 – Starling curve of the heart demonstrates increased stroke volume with increased preload [39]. 
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Phase 4, reduced ejection, occurs when the rate of ventricular ejection falls.  The ventricular pressure 
falls just below that of the aortic / pulmonary pressure, but flow continues for a short time due to the 
inertia of the blood.  The atrial pressure rises slowly during this phase due to venous return. 
 
Isovolumetric relaxation (phase 5) occurs when the ventricular pressure falls well below that of the 
arterial pressure, and the semilunar valve suddenly closes.  This valve closure causes a small amount of 
backflow from the artery to the ventricle and is represented by a small increase in arterial pressure 
(dicrotic notch).  During this phase the ventricular volume remains constant as all of the valves are 
closed.  This volume is known as end systolic volume (ESV).  Atrial pressure continues to rise in phase 5 
due to continuous venous return. 
 
The sixth phase is known as rapid filling.  This phase is caused by the ventricular pressure dropping 
below that of the atrial pressure.  This causes a rapid inflow of blood into the ventricles, while the 
ventricular pressure continues to drop due to relaxation of the ventricle walls.  The atrial pressure drops 
rapidly as the volume of the atrium is decreased.  Arterial pressure decreases gradually, a property of 
both the arterial compliance and vascular resistance, as blood flows through the circulation.  
 
Phase 7 (reduced filling) occurs as the ventricle continues to fill with blood.  The compliance of the 
ventricular walls decreases as the ventricular volume increases, causing the rate of filling to slow.  Atrial 
pressure continues to rise as it is filled while the arterial pressure falls due to blood flowing to the 
circulation [37]. 
 
2.3 The Circulatory System 
The circulatory system (Figure 4) consists of the systemic system, which provides oxygenated blood to 
the body, and the pulmonary system, which delivers deoxygenated blood to the lungs.  Deoxygenated 
blood returns to the heart from the body into the right atrium.  It continues to flow through the 
tricuspid valve into the right ventricle, where it is then pumped through the pulmonary valve into the 
pulmonary artery.  The pulmonary artery bifurcates to supply blood to both the left and right lungs via 
the arterioles and finally the capillaries in the lungs. The blood is then oxygenated and flows through the 
pulmonary veins into the left atrium.  From there the blood travels through the mitral valve into the left 
ventricle, where it is pumped under high pressure through the aortic valve and into the aorta.  The 
circulatory system then branches into many arteries that carry the oxygenated blood to the body.  Blood 
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then flows back to the heart through the systemic venous system.  Blood from the upper body flows into 
the right atrium via the superior vena cava, while blood from the lower body travels into the right 
atrium via the inferior vena cava.  From this point, the cycle of blood through the body starts over to 
continually supply oxygenated blood to the entire body. 
 
 
Figure 3 – The seven phases of the cardiac cycle. Press – pressure, LV Vol – left ventricular volume, ECG – 
electrocardiograph, sec – seconds, AP - aortic pressure LVP – left ventricular pressure, LAP – left atrial 
pressure, LVEDV – left ventricular end diastolic volume, LVESV – left ventricular end systolic volume, a – a 
wave of the ECG, c – c wave of the ECG, v – v wave of the ECG [37]. 
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Figure 4 – A simplified schematic of the circulatory system including oxygenated (red) and deoxygenated 
(blue) blood [40]. 
 
2.4 Heart Failure 
Heart failure is essentially a partial or full failure of the pumping function of the heart. This pump failure 
can be represented through systolic dysfunction, where the heart fails to provide an adequate stroke 
volume during systole, and/or diastolic dysfunction, where the heart fails to fill properly. Heart failure 
can be acute or chronic. Acute heart failure involves symptoms which develop rapidly, and may not 
require long term circulatory support. Chronic heart failure develops slowly over time, and may require 
long term therapy. 
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2.4.1 The Prevalence of Heart Failure 
The prevalence of heart failure throughout the US and Europe is approximately 2.8%, with similarly high 
values recorded throughout the world [2, 41]. In the US alone, over one million hospital admissions 
were attributed to heart failure in 2008 [3]. Meanwhile, it is estimated that approximately 660,000 new 
cases of heart failure are diagnosed each year in the US for people aged over 45 [3]. The costs 
associated with heart failure, both direct and indirect, are massive, with $34.4 billion spent in 2010 in 
the US alone [41]. This value is projected to increase significantly, with estimated spending on heart 
failure treatment in the US estimated to be approximately $95 billion by 2030 [41]. 
 
2.4.2 Causes of Heart Failure 
There are many potential causes for heart failure. Coronary artery disease is a common cause of systolic 
dysfunction as it can prevent adequate blood flow to the heart muscle. This inadequate blood flow can 
destroy an area of the heart muscle, rendering that area unable to contribute to the heart’s pumping 
function. Myocarditis, caused by bacterial, viral or some other infection, is an inflammation of the heart 
muscle and can impair the heart’s pumping function. Overworking the heart over a prolonged period of 
time may also induce systolic and/or diastolic heart failure. This can occur through heart valve disorders, 
such as stenotic (resistance to forward flow) or regurgitant (allowing retrograde flow) valves. Atrial 
(ASD) or ventricular (VSD) septal defects may also contribute to heart failure through overworking the 
heart. For the same reason, systemic or pulmonary hypertension may also contribute to the 
development of heart failure over time. Other causes of heart failure may include old age, diabetes, 
atrial fibrillation, disorders which affect the heart’s electrical conductive system, and many more. A 
common form of congestive heart failure is cardiomyopathy, which can be classed as dilated, 
hypertrophic, or restrictive. Dilated cardiomyopathy is the most common form of heart failure and 
consists of a dilated ventricle with diminished pumping capacity. This larger ventricular volume, 
combined with reduced flow, presents an additional risk of thrombus formation which may release and 
travel to the brain, causing a stroke. Hypertrophic cardiomyopathy (HCM) involves thickening of the 
ventricular wall through addition of muscle mass and may block the flow of blood through the heart. 
Restrictive cardiomyopathy, the rarest of the three, is a stiffening of the cardiac muscles which results in 
diastolic dysfunction. 
 
Several native compensatory mechanisms exist for heart failure. The body releases hormones such as 
epinephrine and norepinephrine which causes the heart rate and contractility to increase. Another 
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compensatory mechanism is to increase the amount of salt and water retained by the kidneys, rather 
than excreting it into urine. This increases the volume of blood and helps maintain blood pressure 
through the Starling response of the heart. The increased workload of the heart serves to increase the 
muscle mass of the ventricles (eg. HCM), thus providing additional short term support. These 
compensatory mechanisms assist in maintaining adequate cardiac output over the short term. However, 
long term reliance on these mechanisms is detrimental. Hormone release increases the work being 
completed by the heart and, over time, these increased demands lead to further deterioration of the 
heart’s already impaired pumping function. Additional blood volume and stretching of the ventricular 
walls may lead to dilation of the heart and subsequent deterioration of the pumping mechanism. 
Meanwhile, the thickened heart muscle may eventually stiffen, thus worsening diastolic dysfunction. 
 
2.4.3 Symptoms of Heart Failure 
Symptoms of heart failure may begin suddenly in acute heart failure, however usually no symptoms are 
present at the start of chronic heart failure. With chronic heart failure, symptoms usually develop 
gradually and may include shortness of breath, fatigue, confusion and disorientation in the earlier 
stages. Progression of heart failure may result in fluid accumulation and swelling, nausea, loss of 
appetite, loss of muscle mass, severe fatigue and shortness of breath, and reduced blood flow 
potentially resulting in thrombus formation and stroke. Ultimately, progression of heart failure results in 
firstly a loss of quality of life, and finally a loss of life. 
 
2.4.4 Treatment of Heart Failure 
Treatment of heart failure may include changes of lifestyle and medical therapy. Lifestyle changes may 
include additional exercise, improved diet and cessation of smoking and drinking alcohol. Treatment 
options aimed specifically at the cause of heart failure may involve replacement of a regurgitant or 
stenotic heart valve, repair of an ASD or VSD or coronary artery bypass grafting. Drug therapy to treat 
heart failure can be achieved with several different types of drugs, such as diuretics, angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers and more. Diuretics help the kidneys eliminate salt 
and water and therefore reduce fluid volume, and hence blood pressure, in the body. ACE inhibitors 
reduce hormone levels of angiotensin II and aldosterone which causes the arteries and veins to dilate. 
This helps the kidneys excrete excess water and reduces the workload on the heart. Beta-blockers are 
used to block the action of the hormone norepiniphrine, thus producing a long-term improvement in 
heart function and survival. As beta-blockers reduce the force of ventricular contraction, they are usually 
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introduced after patient stabilisation has been achieved with other drugs. While additional drug 
therapies exist, the ultimate treatment for heart failure is cardiac transplantation. However, there is a 
severe discrepancy between the supply and demand of donor hearts, with only about 2,000 transplants 
occurring each year in the US [3]. Compared to the 100,000 patients in the US with advanced stage heart 
failure who could benefit from a donor heart, the transplanted population is almost insignificantly small 
[3]. Therefore, a mechanical solution is required to support patients who are ineligible for a donor heart, 
or for those on the waiting list.  
 
2.5 Ventricular Assist Devices 
Cardiovascular device intervention to treat patients with heart failure can be attempted with intra-aortic 
balloon pumps (IABPs), ventricular assist devices (VADs) or total artificial hearts (TAHs). IABPs are 
essentially balloon pumps temporarily implanted within the descending aorta in patients with stage 3 
heart failure to increase perfusion, particularly to the coronary arteries. However, IABPs are not capable 
of supporting the most severe heart failure patients which exist in stage 4. Options for mechanical 
intervention for these patients include only VADs and TAHs. VADs can be used to provide mechanical 
circulatory assistance to the left (LVAD), right (RVAD) or both sides of the heart (BiVAD) (Figure 5). VADs 
are capable of providing simultaneous mechanical 
circulatory support to the left and/or right ventricles by 
pumping blood to the systemic and/or pulmonary systems. 
Unlike a total artificial heart (TAH), which requires the 
removal of the native heart, a VAD provides assistance in 
parallel to the native heart. Implantation of a TAH provides 
greater anatomical space for device placement through 
removal of the native ventricles. However, leaving the 
native ventricles in place for VAD support allows the 
ventricles to act as a natural inflow reservoir, and the 
remaining ventricular contractility assists in balancing left 
and right pump flows. However, some ventricular function 
is necessary to avoid thrombus formation within the 
hypostatic ventricles during VAD support. Although their 
function is limited, the remaining ventricles may produce 
enough cardiac output for patient survival in the event of 
 
Figure 5 – The left and right heart attached 
to a LVAD and RVAD respectively. PA – 
pulmonary artery, RA – right atrium, Ao - 
aorta [42]. 
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device malfunction. Retaining the ventricles in VAD support also maintains the potential for myocardial 
recovery and subsequent patient discharge without the requirement for a donor heart [43].  
 
Ventricular assist devices are currently used as a bridge to transplant (BTT), bridge to recovery (BTR) or 
destination therapy (DT).  Clinical experience has shown that an implanted VAD can assist in the 
recovery of the patient, such as improving renal function and reducing pulmonary hypertension [44]. 
With the continued development of these devices, it is hoped that a longer lasting, permanent solution 
can be obtained.  A detailed investigation into VAD  success rates with the HeartMate vented electric 
device (Thoratec, Pleasanton, California, U.S.A), known as the REMATCH study, was conducted over 3 
years with more than 120 patients assigned to either VAD support or standard medical therapy across 
several medical centers [45].  The results of this study showed a 48% reduction in risk of death, and 
improved quality of life for the VAD group compared to the medical therapy group.  Serious adverse 
events were, however, noted to be twice as likely in the VAD group with bleeding and infection at the 
drive line site the most common. 
 
2.5.1 Recovery of Ventricular Function 
There is varied incidence of myocardial recovery reported in the literature. Early reports were usually 
case studies from various institutes, however a large trial in Germany reported recovery with LVAD 
explantation in 32 of 131 patients with chronic idiopathic dilated cardiomyopathy [46, 47]. Of these 32 
patients, 31.3% had recurring heart failure in the three years after weaning. Two of those patients with 
recurring heart failure died, while the remaining population were transplanted. Birks et al. (2006) [48] 
reported even more positive results, with 11 of 15 patients having sufficient myocardial recovery to 
remove the LVAD. The high rate of myocardial recovery was attributed to the combined use of LVAD and 
an aggressive pharmacological treatment including administration of lisinopril, carvedilol, 
spironolactone and losarten to enhance reverse remodeling. Meanwhile, myocardial atrophy was 
prevented through administration of the β2-adrenergic–receptor agonist clenbuterol after left 
ventricular volume was maintained for two weeks. Freedom from recurrent heart failure was high in this 
study, with 100% and 89% at one and four years respectively. While these results are positive, the study 
was quite selective. Only patients with non-ischemic cardiomyopathy with no histologic evidence of 
active myocarditis were included. However these positive results were not reported by Maybaum et al. 
(2007) [49], who reported a multi-institutional trial with 67 patients on LVAD support. In this study, only 
six patients (9%) recovered sufficient myocardial function for LVAD explantation. This study reported a 
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more general LVAD recipient population, with acute and chronic heart failure including ischemic and 
non-ischemic etiologies. The discrepancy between the incidences of myocardial recovery can be partially 
attributed to patient selection; however protocols for device explantation must also be included. No 
uniformly accepted criteria exist for VAD explantation, and as such, the procedure relies on the 
clinicians’ recommendation at each individual centre.  
 
2.5.2 Generations of VAD Support 
VADs can be categorized as first, second and third generation pumps (Figure 6), which are classified 
depending on their operational characteristics [3, 50]. First generation devices are volume displacement 
pumps which use pneumatics or electromagnetically actuated pusher plates to deform a membrane to 
deliver pulsatile flow.  These devices have poor durability due to membrane rupture, bearing and 
mechanical valve wear. They require large control consoles with limited portability, and have associated 
risks of postoperative infection, significant haemolysis, thrombus formation and severe postoperative 
bleeding [51]. Second generation devices use rotary centrifugal, diagonal, or axial impellers that produce 
continuous outflow, while having few moving, contacting parts.  This reduces device wear, while smaller 
drive consoles promote increased patient mobility. Though they demonstrate marked improvements 
over first generation devices, these rotary pumps are associated with increased thrombogenicity and 
acquired platelet dysfunction due to the lack of pulsatile flow and high shear forces near the bearings 
and seals [7, 52, 53]. Third generation, rotary pumps completely eliminate mechanical wear of the pump 
components through the use of contactless impeller drive and suspension systems. Electromagnetic 
and/or hydrodynamic forces are used to levitate the impeller within the housing, while active 
electromagnetic forces are used to rotate the impeller. Although clinical experience with third 
(a)
 
(b)
 
(c)
 
Figure 6 – Examples of a) first (PVAD, Thoratec Corporation, Pleasanton, CA, USA), b) second (Jarvik 2000, 
Jarvik Heart Inc., New York, USA) and c) third (HVAD, HeartWare Inc, Massachusetts, USA) generation 
VADs. 
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generation devices is limited compared to the vast number of first generation device implantations, it is 
anticipated that they will provide a support system that consumes low power with reduced 
complications [50]. 
 
2.5.3 Requirement for biventricular support 
As the muscular left ventricle (LV) constitutes the bulk of the myocardial tissue, the majority of 
ventricular dysfunction is initially seen in this region.  Thus, the majority of patients with end stage heart 
failure treated with mechanical circulatory support receive left ventricular assistance with a LVAD to 
increase end organ perfusion.  However, the incidence of right heart dysfunction after LVAD insertion 
may vary between 10-50% [54-58], and is considered one of the most serious complications within the 
LVAD postoperative period [23, 59]. Management of acute right ventricular (RV) failure post LVAD is 
difficult, and although pharmaceutical treatment strategies including pulmonary vasodilators, inotropic 
agents, and phosphodiesterase agents may temporarily improve RV function, these strategies are 
generally short term, expensive, and require prolonged intensive care management. Some patients do 
regain adequate RV function to avoid mechanical RV support, but equally, there are many who fail to 
adequately respond to these modalities [60]. In fact, the requirement for RVAD placement has been 
reported in 5-50% of LVAD supported patients [54, 61-65].  This discrepancy in the reported need for 
biventricular support is remarkable. Potapov et al. (2008) [54] reported the requirement for 
biventricular support in 47.9% of patients in a study of 1025 various VAD implants. Yet the studies by 
Lee et al. (2010) and Kormos et al. (2010), both completed solely with the HeartMate II LVAD (Thoratec 
Corporation, Pleasanton, CA, USA),  report significantly reduced incidence of RV failure requiring RVAD 
support (5% of 40 patients and 6% of 484 patients respectively).  Comparisons between these studies 
may indicate a higher degree of RV failure after LVAD implantation with pulsatile devices compared to 
continuous flow pumps, as found in a multi-institutional study by Slaughter et al. (2009) involving 200 
patients [66]. Perhaps the type of VAD and its controller, along with the patient’s condition and clinical 
management, is a defining factor in right ventricular failure post LVAD implantation. Yet until a multi-
institutional study is completed with various VAD designs and drive mechanisms, the unexplained 
discrepancy of RVAD requirement remains.  
 
While the statistics of RV failure are commonly presented, it remains uncertain whether the right heart 
has failed before LVAD insertion due to congestion in the pulmonary system, or post LVAD insertion due 
to disrupted systolic interaction of the ventricles, or a combination of the two [59, 67, 68].  Regardless, 
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the timing of this diagnosis and subsequent intervention is critical, as mortality in patients with delayed 
re-admittance to surgery for RVAD implantation is up to 90% [60, 69].  Assisting the function of both 
ventricles at an earlier stage improves survival by reducing the need for re-operation, improving organ 
perfusion and allowing patients to leave hospital more rapidly through potentially reversing multi-organ 
failure [61]. It is for this reason that BiVAD support must be initiated as early as possible, while close 
attention must be given following surgery for any associated complications such as significant bleeding, 
thrombus formation or systemic-pulmonary flow imbalance.  
 
The risks associated with BiVAD therapy are great, with this particularly moribound population facing a 
much higher risk of mortality compared with those implanted with only a LVAD. Cleveland et al. (2011) 
[70] evaluated the survival and complication rates of 1440 LVAD patients and 206 BiVAD patients using 
the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. Pediatric 
patients were excluded from the study. Generally, the BiVAD patients were in a worse condition prior to 
device support, with 55% of BiVAD patients in INTERMACS class 1 compared to only 26% of LVAD 
patients. 64% of patients in the LVAD group had continuous flow pumps, compared to only 15% in the 
BiVAD group, indicating earlier generation devices were used for the BiVAD group, most likely to achieve 
flow balancing between the systemic and pulmonary circulations. The six month survival while a VAD 
was in place (eg. excluding patients weaned from VAD or transplanted) was 86% and 56% for LVAD and 
BiVAD respectively, as shown in Figure 7. Meanwhile, complications while on VAD support (Figure 8) 
revealed twice the amount of infections, four times the amount of bleeding complications, greater 
neurologic complications and more device malfunctions in the BiVAD group compared to the LVAD 
group. 
 
2.5.4 Flow Balancing 
Native human circulation is auto-regulated through a number of closed loop biological control systems. 
Arterial pressure and ventricular contractility are regulated by baroreceptor stimulation and the Starling 
response respectively, both of which influence cardiac output [71, 72]. Auto-regulation of 
systemic/pulmonary volumes during uni-ventricular support, (e.g. LVAD support), may rely heavily on 
having one functional ventricle’s native control mechanisms.  Pulsatile devices operating in full-to-empty 
mode have an ability to balance outflow, and do not require further flow control for circuit volume 
balancing [50].  For instance, the Thoratec PVAD device (Thoratec Corporation, Pleasanton, CA, USA),  
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Figure 7 – Kaplan-Meier analysis of survival after LVAD implantation (dark blue line) or BiVAD 
implantation (light blue line) [70]. 
 
 
 
Figure 8 – Adverse event rates for LVAD (dark blue bars) and BiVAD (light blue bars) groups [70]. 
 
 
29 
 
capable of uni- or biventricular support, achieves flow balancing through a variable pulse rate which is 
dependent on preload [3]. As preload increases, the flow through the inlet valve of the PVAD increases, 
thus taking a shorter time to fill the 65 mL blood sac. Once the sac is full, a Hall-effect sensor is triggered 
which relays the signal through the controller to initiate PVAD systole. Therefore, increased preload 
results in increased PVAD pulse rate and thus increased flow, similar to the Starling response. Other first 
generation VADs rely on similar strategies to achieve a Starling-like response and hence flow balancing 
[3]. 
 
However, the few documented clinical studies of rotary biventricular support warn of haemodynamic 
instability [25, 73-77]. All report the importance of continued controller development to prevent 
pulmonary edema and incidence of suction events in the cannulated heart chamber.  Endo et al. (2000) 
[73] described an early attempt at BiVAD flow control in six piglets with two mixed flow pumps.  Global 
ischemia was replicated through clamping the base of the ascending aorta for 30 minutes and BiVAD 
support was initiated. Nitric oxide inhalation and defibrillation were performed to recover ventricular 
function in an attempt to assess the controller’s response to ventricular recovery. Target flow rates were 
set as 50-75 mL/kg/min, while ventricular collapse was detected through a current amplitude index. 
While it was reported that the BiVAD could be controlled in the same manner despite cardiac function, 
the controller required measurement of VAD flow, thus relying on sensors for implementation. Nosé et 
al. (2004) [26] incorporated inlet pressure sensors in two Gyro VADs to regulate flow depending on 
preload, similar to the Starling mechanism. However, blood pump control systems like these can be 
limited by the low reliability of long term blood pressure and flow sensors [78].  
 
Nonaka et al. (2002) [74] evaluated the effect of changing the right/left flow ratio to avoid pulmonary 
congestion with BiVAD support in six calves. The calves were healthy, and thus not representative of a 
heart failure scenario which would require BiVAD support, however this study aimed to observe the flow 
balancing response with a contractile heart. One of the six calves had a right/left flow ratio of 1.57 and 
experienced pulmonary dysfunction. The remaining five calves all had right/left flow ratios below 1 and 
did not experience pulmonary dysfunction. While a maximum pulmonary arterial flow rate to prevent 
pulmonary dysfunction was identified (160 mL/kg/min), the small sample size in this study limited the 
impact of the results. Saeed et al. (2008) [25] also used a small sample size, only two calves, to 
investigate the effect of changing either LVAD or RVAD speed while keeping the other constant. This 
study demonstrated that right atrial pressure was less sensitive to LVAD speed increase compared to left 
30 
 
atrial pressure with an increase in RVAD speed. This was potentially due to the larger venous compliance 
in the systemic circulation compared to the pulmonary circulation, thus partially compensating for the 
additional fluid volume pumped by the LVAD. The importance of maintaining LVAD flow higher than 
RVAD flow was also identified in this study. 
 
Gaddum et al. (2010) [79] characterized a passive biventricular control system which used an axially 
floating hub to alter impeller clearance gaps of the LVAD and RVAD due to changes in VAD afterload 
(Figure 9). The non-rotating, floating hub included both LVAD and RVAD shrouds and was connected 
with an axially orientated central shaft. A linear bearing allowed axial movement of the hub assembly. 
Axially distal from each shroud was an inverted impeller, 50 mm in diameter for RVAD and 25 mm in 
diameter for LVAD. The larger RVAD impeller size was chosen to increase surface area and thus axially 
centralize the hub position by opposing the pressure-related force from the LVAD. Transition of the hub 
in the axial direction occurred due to the pressure differential between the two sides. However, due to 
the much larger surface area around the outer edges of the impeller, the hub movement was 
hypersensitive to afterload and perhaps too insensitive to preload. Therefore, this mechanism served to 
increase afterload sensitivity of the pump, similar to a baroreceptor response, while preload sensitivity 
was limited.  
 
Figure 9 – Sectioned view of the prototype BiVAD used by Gaddum et al. (2010) [79]. 
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2.5.5 Current Options for Biventricular Support 
Until recently, options for biventricular support solely involved the pulsatile, first generation devices. 
However, rotary second and third generation devices have now been clinically implemented as a BiVAD, 
while several devices are under development which aim to improve on the current selection of devices. 
BiVADs classified according to their generation, surgical placement and clinical implementation are 
shown in Figure 10, while their drive mechanism, flow profile and clinical purpose are compared in Table 
1. A detailed description of BiVADs which are clinically available or under development is presented in 
Appendix 1. 
 
Figure 10 - Flow chart of the three generations of intracorporeal and paracorporeal/extracorporeal BiVADs 
including those applied clinically (not shaded) and under development (shaded). 
 
2.5.6 Summary of Heart Failure and Ventricular Support 
Despite major advances in the management of acute and chronic end stage heart failure, the prevalence 
of heart failure is increasing due to the lack of donor organs [80]. The requirement for biventricular 
mechanical assistance is not only highlighted by the number of patients who present with end stage 
biventricular failure, but also the looming risk of right heart failure following LVAD implantation.  
Developed through either form, biventricular failure is a serious issue affecting a substantial 
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demographic of heart disease patients. Unfortunately though, there are limited options compared to 
left heart failure treatment.  Several devices are available which provide biventricular support; however 
each is limited by size, durability or clinical experience. The technical characteristics for these devices 
are summarized in Table 2. The continued improvement of the presented devices is necessary to achieve 
the goal of a long term device capable of supporting critically ill patients as a destination therapy. 
Successful development of a reliable, durable BiVAD will ultimately lead to an improved patient survival 
rate and quality of life for those suffering from end stage biventricular heart failure. 
 
The various implantation techniques may also contribute to the long term success or failure of these 
devices to infiltrate the clinical market. First generation devices are not implantable and therefore not 
suitable for long term biventricular support, excluding the Thoratec IVAD and Korean AnyHeart which 
require considerable abdominal dissection for placement. The CentriMag system is also incapable of 
intracorporeal placement and thus can only be used for short-term applications. Pericardial placement 
of the HeartWare or Jarvik devices is an undoubted advantage, however the cost of the combined 
pumps for BiVAD support must be considered. The Gyro, CorAide/DexAide and BiVACOR devices are 
Device Drive 
Mechanism 
 
Flow profile Clinical Purpose 
Clinically applied 
     Abiomed BVS5000 
     Abiomed AB5000 
     Thoratec PVAD 
     Thoratec IVAD 
     Berlin Heart EXCOR 
     Medos HIA-VAD 
     Levitronix CentriMag 
     Jarvik 2000 
     Heartware HVAD 
 
PD, FP 
PD, FP 
PD, FV 
PD, FV 
PD, FV 
PD, FV 
ED, CE 
ED, AX 
ED, CE 
 
Pulsatile 
Pulsatile 
Pulsatile 
Pulsatile 
Pulsatile 
Pulsatile 
Continuous 
Continuous 
Continuous 
 
Short term support 
Short term support 
Medium term support 
Medium term support 
Medium term support 
Short term support 
Short term support 
Long term support 
Long term support 
Under development 
     CorAide/DexAide 
     Korean AnyHeart 
     Gyro 
     BiVACOR BV Assist 
 
ED, CE 
ED, MA 
ED, CE 
ED, CE 
 
Continuous 
Pulsatile 
Continuous 
Continuous 
 
Medium term support 
Medium term support 
Long term support 
Long term support 
Table 1– BiVAD drive mechanism, flow profile and clinical purpose for applied and under development 
devices.  PD – pneumatically driven, ED – electrically driven, FP – filled passively, FV – vacuum assisted 
filling, AX – axial flow pump, CE – centrifugal flow pump, MA – mechanically actuated pump.  Short term 
support indicates bridging to recovery, transplant or longer term support.  Medium term support indicates 
bridging to recovery or transplant.  Long term support indicates bridging to recovery, transplant or 
destination therapy. 
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currently suitable for sub-diaphragmatic placement, however with continued development of these 
systems it is possible that pericardially placed versions will become available. Meanwhile, the easily 
attachable sewing ring of the HeartWare device [81] may be favored by surgeons, and additional 
techniques to easily attach the cannulae while reducing the high rates of postoperative bleeding should 
be investigated [31]. 
 
2.6 Cannula Design 
The LVAD and RVAD inflow and outflow cannula design and cannulation site can pose major limitations 
in long term VAD support [82]. This section presents a literature review of the design aspects of inflow 
and outflow cannulae, focusing primarily on their geometry and materials selection. 
 
2.6.1 Inflow Cannula Design 
Clinically Available Cannulae 
Several cannula designs are available clinically, often for one VAD (Figure 11); however they vary 
significantly in size, shape and material selection.  Several cannulae are available for insertion of the 
Abiomed BVS 5000 device. All have an attached Dacron velour sleeve which is placed at the exit site  
Device Size  
(mL/mm) 
Weight 
(g) 
Flow 
Range  
(L min-1) 
Speed Range 
(RPM/BPM) 
Power 
Consumption 
(W) 
Clinically Applied      
  Abiomed BVS5000 660 mL 1700* ≤5.0 3-140 BPM 280 
  Abiomed AB5000 155x80x60 mm  300 2.0-6.0 0-150 BPM 250 
  Thoratec PVAD 125x80x60 mm 417 1.3-7.2 0-110 BPM - 
  Thoratec IVAD 125x80x50 mm 339 1.3-7.2 0-110 BPM - 
  Berlin Heart EXCOR - - 1.5-12.0 30-150 BPM 12/8+ 
  Medos HIA-VAD - - 5-6.3 40-180 BPM - 
  Levitronix CentriMag Ø100x82 mm 1700 ≤9.9 1500-5500 RPM 120 
  Jarvik 2000 Ø25x50 mm 90 ≤7.0 6000-12000 RPM 4-8 
  HeartWare HVAD 50 mL 145 ≤10.0 1800-4000 RPM 4.5 
Under Development      
  CorAide/DexAide 84/69 mL+ 293/ 
280+ 
2.0-8.0 1800-3600 RPM 6/2.6+ 
  Korean AnyHeart 110x88x66 mm 780 0.0-9.0 0-178 BPM 9-29 
  Gyro Ø65x53 mm 305 0.0-5.0 1300-2650 RPM 15 
  BiVACOR BV Assist Ø60x70 mm - 0.0-8.0 ≤3750 RPM 15 
Table 2 – Reported technical characteristics of clinically applied and under development BiVADs. * indicates 
the weight of the device including cannulae, - indicates the information is not available in the literature, 
+
 
indicates values for LVAD/RVAD. 
 
34 
 
from the skin to improve haemostasis and 
encourage tissue in-growth. The two atrial 
cannulae include a 36F with a malleable tip and 
a 42F with a lighthouse tip. Meanwhile, the 
outflow cannulae are 42F with a 14 mm 
elastomer-coated Dacron graft [84].  
 
The Medos HIA-VAD cannulae come in various 
shapes and sizes. The inflow cannulae are 
designed to be placed in the left or right atria 
or the left ventricle. The apical cannula for the 
Medos HIA-VAD includes a suture ring for easy fixation, infection barriers, an insertion aid and is kink 
resistant to prevent inflow obstruction [85]. The atrial cannulae for the HIA-VAD include a cage which 
prevents the suction of the endocardium into the cannula. There is also a two-stage transmitral cannula, 
designed to be placed through the left atrial appendage. Most of the Medos inflow cannulae have a 
malleable tip which allows adjustable tip angle during insertion (Figure 12). The body of the cannulae 
are reinforced with wire to prevent collapse, while the ends of the atrial cannulae have a lighthouse 
design. The body of each cannula is covered with polyester velour to encourage tissue integration, for 
stabilization and to act as a barrier to infection. Outflow cannulae are similar in design; however the 
distal portion is made of a polyurethane coated Dacron graft for flexibility and anastomosis to the 
arteries [4]. A selection of Medos HIA-VAD inflow and 
outflow cannulae are shown in Figure 13.  
 
The Thoratec PVAD atrial cannulae are 11mm inner 
diameter (ID) polyvinyl chloride coated with thrombus 
resistant polyurethane and a caged tip that can be 
angled at 90 ± 10˚. The apical cannula comes with 
either a smooth polyurethane tip with two side holes or 
covered in polyester velour. The polyester heals to the 
endocardium and reduces thrombus formation [86]. 
Arterial cannulae are 14 or 18 mm (ID) two stage 
designs with a wire reinforced, solid polyurethane tube  
 
Figure 11 – Available arterial (A), atrial (B) and 
ventricular (C) cannulae for the Berlin Heart EXCOR 
VAD [83]. 
 
Figure 12 – Malleable tip of the Medos atrial 
inflow cannula with three different insertion 
angles displayed. 
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which connects to the VAD and an intrathoracic portion which is a woven polyester graft for 
anastomosis to the artery. This polyester portion must be pre-clotted before insertion.  
 
The Terumo DuraHeart has three different inflow cannula lengths to suit a variety of patient sizes and 
comprises a flexible apical cuff which connects to the ventricle and a rigid inflow conduit which connects 
to the pump. The apical cuff is made of a flexible material called Gelweave which is capable of being 
clamped, a property which can assist with preventing blood loss during implantation without CPB [87]. 
The rigid inflow conduit is made of titanium and is inserted through the apical cuff either before 
(without CPB) or after (with CPB) apical coring. Inflow and outflow ports are orientated towards the top 
of the pump to assist with de-airing. The MicroMed DeBakey VAD also has a titanium inflow conduit 
which is curved to suit the axial flow pump and includes a sewing ring [88]. 
 
Cannula Coatings 
Coatings on inflow cannulae have been used to encourage tissue growth. The Thoratec HMII inflow 
cannula has a textured titanium microsphere surface to prevent thrombus development [89]. Yamada et 
 
Figure 13 – Medos HIA-VAD cannulae with infection barriers (top left), insertion aids (bottom left), apical 
cannulae (middle left), arterial cannulae (middle right) and atrial cannulae (far right) [85]. 
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al. (2009) [90] coated the portion of inflow cannula which protrudes into the ventricle with a titanium 
mesh to create an autologous neointima to prevent wedge thrombus formation. The mesh included fine 
titanium wire and protruded up to 20mm from the apex. Four bovine experiments with an LVAD 
revealed no thrombus formation in the pump or the inflow cannula, while the mesh was enveloped with 
neointima tissue which had grown from the ventricular myocardium. Coatings such as this on the blood 
contacting portions of the VAD system may reduce thrombus formation; however a larger clinical trial is 
required before clinical acceptance.  
 
Mussivand et al. (2004) [91] reported the use of expanded polytetrafluoroethylene (ePTFE) as a 
replacement for the polyester material typically used on inflow cannulae. ePTFE was used as it is less 
thrombogenic and has reduced platelet activation in a venous system, which is representative of the 
LVAD inflow conduit. 398 patients were evaluated retrospectively, with 155 receiving the Cooley 
polyester inflow conduit (low-porosity polyester material), 155 with the Vascutek inflow conduit (knitted 
polyester material), and 88 with the ePTFE conduit. A 55% decrease in the risk of embolic 
cerebrovascular accident (CVA) was noted in the ePTFE conduit compared with the polyester group. 
Only 9 events in 88 implants (10%) were recorded with the ePTFE conduit compared to 73 events in 310 
implants (24%) with the polyester conduits. As the durations of support were different between the two 
groups, the results were characterized as events per patient month, with the ePTFE group reporting 
improved results compared to the polyester group (0.025 vs 0.034 events/patient-month respectively). 
 
Figure 14 – Comparison of linearised rates (events/patient-month) for embolic CVA between the three inflow 
conduits at specific time intervals after implantation presented by Mussivand et al. [91] (2004). 
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More specifically, the embolic CVA events for various time intervals after implantation are shown in 
Figure 14. Limitations with this study include different anticoagulation regimes at the various institutes 
involved in this retrospective study and differences in inflow conduit length (Cooley conduit was usually 
90mm, Vascutek and ePTFE conduits were usually 60mm). 
 
Fluid Dynamics and Tissue Growth 
The fluid dynamics within the ventricle are greatly influenced by the geometrical design and alignment 
of the inflow cannula tip, while incorrect inflow cannula design or placement may result in cannula 
obstruction and subsequent suction events and pump flow stoppages [92, 93]. Inlet cannula obstruction 
is quite common and may be caused by kinking of the inflow cannula or occlusion by the surrounding 
tissue, such as the ventricular free wall or septum [94, 95]. Goerbig-Campbell et al. (2010) [96] observed 
serious adverse events in 17 consecutive patients who received an axial flow LVAD. Eight patients 
experienced dynamic inflow occlusion events, defined as near or complete cessation of flow in systole or 
diastole, with 19 separate serious adverse events (including bleeding requiring blood transfusion or 
invasive intervention, intractable ventricular arrhythmia, stroke (CVA), thromboembolic event other 
than CVA, pump thrombosis, surgical pump revision, admissions in which the principle diagnosis was 
heart failure) occurring in seven of those patients. Only nine serious adverse events were recorded in 
the 9 patients who did not experience dynamic inflow occlusion events. While this study demonstrated 
a large proportion of patients with cannula related VAD malfunctions and associated serious adverse 
events, the small sample size limited the impact of the results. 
 
Ootaki et al. (2008) [82] presented the development of the DexAide RVAD inflow cannula to reduce 
obstruction by tissue growth into the cannula. Seven RVAD inflow cannula designs (Figure 15) were 
evaluated in 19 healthy calves. The designs included: 
1. An angled titanium conduit with a caged tip (two calves), 
2. A flexible polyurethane coated polyvinyl chloride (PVC) cannula with wire reinforcement (one 
calf),  
3. An open ended titanium cannula (one calf),  
4. A titanium cannula with a flange between the endocardium and the orifice (six calves), 
5. Cannula number 4 with a gelatin coated flange (five calves), 
6. Cannula number 5 with a modified, angled flange (one calf), 
7. An open ended titanium cannula with side holes and sintered titanium beads (three calves). 
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All were inserted into the infundibular portion of the right ventricle through a left thoracotomy except 
for the 7th cannula design, which was positioned through the diaphragmatic surface of the right ventricle 
through a right thoracotomy. The first cannula showed severe obstruction by endocardial tissue growth, 
while moderate to severe growth was noticed in the second and third cannulae. Mild and 
moderate/severe tissue growth was observed in two and three cases respectively with the fourth 
cannula, while the fifth cannula generally had reduced tissue growth excluding one case. The sixth 
cannula showed severe tissue growth, while the seventh cannula only had mild or no tissue growth. This 
study revealed that the seventh cannula had good biocompatibility and reduced tissue overgrowth, thus 
preventing flow obstruction. Meanwhile, the gelatin coating generally reduced tissue growth. However, 
the different implantation site with the seventh cannula, and the low sample sizes in all cases, makes 
clinically significant comparison of the cannula designs difficult. 
 
Park et al. (2007) [97] used 3D numerical analysis tools to investigate the effect of the number and 
placement of side holes on venous cannulae. The venous cannulae (Figure 16) all had a 7 mm inner 
diameter, 200 mm length and 0, 4, 12 or 20 side holes arranged in a staggered array (SA), in-line array  
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
Figure 15 – Six of the seven inflow cannula evaluated by Ootaki et al. (2008) including (a) the first cannula 
with an angled titanium conduit with a caged tip, (b) the second cannula with a flexible polyurethane coated 
PVC tube with wire reinforcement, (c) the third cannula with an open ended titanium tip, (d) the fourth, 
titanium cannula with a flange between the endocardium and the orifice, (e) the sixth cannula which was a 
modification of the fifth cannula with an angled flange and (f) the seventh, open ended, titanium cannula with 
two side holes and sintered titanium beads. 
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 (IA) or alternative in-line array (AIA). The flow rate initially decreased as the number of side holes 
increased due to disturbances in the flow disrupting the straight streamline seen in the case with no side 
holes. A change from 2.13 L/min with no side holes to a minimum value of 1.75 L/min with 12 side holes 
in the AIA configuration was noted. However, flow rate then began to increase with 20 side holes, but 
not to the same level as the case with no side holes. The maximum difference in flow rate for all models 
was 18%. Meanwhile, additional side holes were found to generally reduce the mechanical load placed 
on blood cells; however these results may also be limited by the lack of any pulsatile flow in the 
simulation. 
 
Sumikura et al. (2011) [98] detailed a novel inflow 
cannula design which was referred to as the Lantern 
cannula (Figure 17). The cannula was made of elastic 
silicone reinforced with metal wires and comprised of 
six slits on the side which allowed expansion or 
contraction of six circumferentially placed struts. 
Therefore, an introducer could be placed through the 
cannula to increase the axial length, and thus reduce 
the diameter, during cannula insertion. Once the 
 
Figure 16 – Cannulae with side holes evaluated by Park et al. (2007) [97]. 
 
 
Figure 17 - The Lantern cannula in its axially 
expanded state for implantation [98]. 
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cannula has been introduced within the vessel, the introducer 
could be removed, hence shortening the axial length and 
opening the slits for VAD inflow. The pressure loss through the 
cannula, measured using a mock circulation loop, was less 
than two comparable, clinically available cannulae. 
Meanwhile, the flow patterns around the cannula tip were 
numerically analyzed using CFD software which revealed the 
low inflow cannula pressure drop was due to a high inflow 
orifice area between the struts. This study also outlined an 
acute animal (51.4 kg goat) experiment which again revealed 
reduced pressure loss compared to clinically available cannulae. However, insertion was achieved via 
standard techniques (a sutured cuff to the left ventricular apex) and, therefore, would not significantly 
reduce operative time. 
 
A 'trumpet mouth' cannula (Figure 18), developed by Antaki et al. [100], was evaluated by Bachman et 
al. (2011) [99]. The trumpet mouth cannula is made of a 80A durometer polyurethane and consists of a 
an internal and external flange which sit either side of the apical myocardium. The cannula was inserted 
through the ventricular apex of a cadaveric ovine heart attached to a mock circulation loop. Although no 
beating heart was simulated, flow visualization techniques were employed to assess the potential of the 
cannula to reduce regions of poor ventricular washout. While a standard, beveled cannula resulted in 
accumulation of particles about the apex, the trumpet design resulted in improved ventricular washout 
and reduced severity of ventricular suction. However, the pull-out strength of this cannula without any 
sutures must be further assessed. 
 
Inflow Obstruction and Bend Relief 
Inflow cannulae with no bend relief are susceptible to obstruction and therefore suction events, 
particularly as the heart remodels. Carr et al. (2010) [94] identified the need for bend relief in the inflow 
cannula of an LVAD. Four devices were presented (HeartMate XVE, HeartMate II, Jarvik 2000 and 
VentrAssist pumps) and the inflow cannula of each was evaluated with the use of computed 
tomography (CT) scans. The HeartMate XVE and HeartMate II both incorporated bend relief, while the 
VentrAssist pump did not. The advantage of the bend relief is that the inflow cannula can stay in the axis 
of the left ventricle, thus reducing the risk of contacting the septum or free walls and causing potential 
 
Figure 18 - The trumpet mouth cannula 
[99] 
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suction events and myocardial damage. The VentrAssist inflow cannula 
(Figure 19) is straight and connects to the pump at a 90 degree angle, 
resulting in the trumpet shaped inflow cannula butting against the 
ventricular wall. Carr et al. identified this feature as a potential source of 
ventricular tachycardia and obstruction if the left ventricle collapses 
around the inflow cannula.  
 
While cannula obstruction is usually caused by incorrect cannula 
placement or ventricular remodeling, it may also be caused by movement 
of the VAD itself.  Nonaka et al. (2001) [101] evaluated the use of two 
Baylor Gyro PI 700 pumps for biventricular support and noted suction 
events in the first two studies which were attributed to dislocation of the 
LVAD due to compression by the RVAD. A flexible inflow cannula (Figure 
20) was then developed to overcome this problem. This flexible inflow 
cannula was made from an 11 mm UBE woven polyester graft (thickness 
0.2 mm) reinforced with stainless steel wire and coated externally with 
silicone rubber adhesive. The wire and silicone were added to maintain 
the shape of the graft under negative pressure and create a minimally permeable conduit respectively. 
The inlet tip was made from a titanium alloy. Only one suction event was noted in the remaining four 
animals following addition of the flexible inflow cannula, however the small sample size limited the 
significance of these results.  
 
Other groups have also used compliant inflow cannulae to prevent cannula obstruction. The Thoratec 
HMII inflow cannula has flexible section to 
accommodate for ventricular recovery. The 
inflow flexible section consists of a woven 
polyester graft that is reinforced and covered 
with a flexible silicone sleeve which allows for 
movements between the left ventricle and LVAD. 
The flexible section was also designed to assist in 
maintaining the cannula position inside the 
ventricle, thus preventing suction of the 
 
Figure 19 – VentrAssist 
inflow cannula 
 
Figure 20 – The Baylor Gyro PI 700 pump with 
flexible inflow cannula 
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ventricular wall or septum [102]. Lick et al. (2001) [103] employed a compliant inflow cannula for a 
paracorporeal artificial lung. However, the aim of the compliant segment was not to eliminate suction 
events, but to compensate for the reduced pulmonary compliance when bypassing the native lungs. 
 
The Smart cannula (Smartcanula LLC, Lausanne, Switzerland) (Figure 21) is a novel device which uses a 
collapsible section for venous access, predominantly for CPB and extracorporeal membrane oxygenation 
(ECMO) applications. The Smart cannula consists of interlaced wired with memory shape properties. An 
introducer is placed through the cannula which is used to flatten the cannula while under stress. 
Essentially, the introducer pushes one end of the Smart cannula, causing it to increase in length and 
decrease in diameter due to the interlaced wire mesh. Once inserted within the vessel, with the help of 
a guide wire, the introducer can be removed, causing the cannula to expand due to the removal of 
stress. The cannula can expand up to the original size, however is usually restricted by the size of the 
vessel [104].  Mueller et al. (2002) [105] presented flow rate comparisons between the Smart cannula 
and standard 21 F, 25 F and 27 F percutaneous cannulae. A sternotomy was performed and extended to 
reveal the entire right jugular vein in 6 calves. The standard percutaneous cannulae were inserted 
through the jugular vein and the tip was fed to the junction of the superior vena cava and right atrium. A 
standard CPB circuit was initiated with negative draining pressure of 44 mmHg. Experiments were 
repeated in each animal with the Smart cannula, with the vein restricted by tape to simulate a 21 F, 25 F 
and 27 F (depending on the standard percutaneous cannula used) smaller entrance vessel. In all cases, 
the flow with the Smart cannula was higher than the standard percutaneous cannula, with an increase 
of 34%, 42% and 53% for the 27 F, 25 F and 21 F restrictions respectively. The Smart cannula has also 
been used in patients with similar success [106, 107], while the self-expanding nature of the Smart 
 
Figure 21 – The Smart cannula with the mandrel inserted to collapse the wire mesh (top) and the mandrel 
removed to allow maximum orifice size (bottom) [104]. 
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cannula  doubles as a temporary stent, thus preventing venous collapse during extracorporeal support 
[108]. Limitations with the Smart cannula include the potential for tissue growth around the wire mesh 
which can be problematic upon removal, and the short length of coated mesh which may slip from the 
vessel, resulting in severe hemorrhage or air entrainment within the support circuit [109]. 
 
An adjustable mechanism to prevent inflow cannula occlusion (Figure 22) was presented by Shiose et al. 
(2010) [110] and evaluated in four cadaveric calves and one live calf. The adjustable cannula consisted of 
wire-reinforced, flexible silicone rubber tubing positioned between the adjustable inflow portion and 
the LVAD to prevent significant movement of the LVAD. Two threaded nylon rods were fixed near the 
cannula sewing ring and passed through two flexible sheaths which were attached below the flexible 
portion of the inflow cannula and passed percutaneously across the skin. One sheath and rod was fixed 
just distal to the major outside radius of the cannula and the other was placed 90 degrees laterally. 
Therefore, pushing or pulling each rod with external actuation allowed movement of the cannula tip at 
angles of up to ±15 degrees through 360 degrees of motion. Fitting studies in four calves and a feasibility 
study in one calf were performed. This study demonstrated the adjustable inflow cannula could cause 
and then easily rectify suction events in the left ventricle through remote adjustment of the inflow 
cannula angle. The authors recommended the device could be applied with any LVAD and suggested 
their intent for further investigation in long-term studies. Such a design seems suitable for short term 
support; however the percutaneous control cables may cause infection issues and become tangled. 
Figure 22 – Adjustable inflow cannula (left) presented by Shiose et al. (2010) [110], with the degrees of 
potential adjustment shown (right). 
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Cannula obstruction may occur at the cannula tip or through the side holes which exist on some inflow 
cannulae. Grigioni et al. (2002) [111] evaluated the use of side holes in venous cannulae inserted within 
rigid vessels in a parametric 3D model. Inserted within a 20 mm ID rigid walled vessel, the two cannulae 
(ID 14 mm) included a tapered tip with an end hole (ID 4 mm) and two or four side holes. The cannula 
with four side holes produced a higher degree of flow symmetry, lower maximum fluid velocity (35.7 vs 
28.5 cm/s), lower shear rate at various locations (40% lower at peak shear rate) and a lower pressure 
drop (18.52 vs 12.96 Pa) across the cannula. While these results could be expected, the clinical 
relevance of this study was limited by the lack of a pulse, use of rigid vessels, perfect axial alignment of 
the cannula and vessel and modeling blood as a Newtonian fluid.  
 
Inflow Cannula Durability 
The durability of the inflow cannula is also of vital importance to prevent erosion or kinking. Mehta et al. 
(1996) [112] reported the erosion of a Dacron inflow cannula for a HeartMate I LVAD. Severe bleeding 
was noted around the LVAD driveline site and an expanding collection of fluid was identified within the 
preperitoneal implantation pocket of the patient after 32 days of support. After opening the 
preperitoneal pocket, a collection of approximately 2 litres of dark, clotted blood was found and 
removed to identify the underlying bleeding site. A defect in the inlet cannula was found, however 
before CPB could be initiated and the pump stopped, the patient’s heart, aorta and LVAD filled with air, 
resulting in patient death. This catastrophic failure of the LVAD inflow cannula reveals the importance of 
a durable design which will not perforate under normal use.  
 
2.6.2 Outflow Cannula Design 
If incorrectly designed or placed, the outflow cannula may become kinked or distorted while on VAD 
support and tension or torque applied to the cannula-arterial interface may tear the artery with severe 
consequences. Meanwhile, the direction of flow from the outflow cannula may influence the flow 
dynamics within the aorta and subsequently alter perfusion through the aortic arch vessels. Benaroia et 
al. (1998) [113] evaluated whether the design of CPB outflow cannulae influences neurologic 
dysfunction due to cerebral microemboli. 32 patients undergoing first-time aorto-coronary bypass 
surgery, all of which were free of neurologic dysfunction and peripheral vascular disease, were 
supported with 7.2 mm internal diameter (ID) curved (n=19), 6.6 mm ID straight (n=6) or 5.9 mm 
straight (n=7) aortic cannulae. Even though different blood velocities were noted for each cannula,  
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 transcranial Doppler did not identify 
differences in detected emboli 
between the three cannula designs. 
The authors acknowledged that the 
technique used to identify microemboli 
was insufficient as transcranial Doppler 
was unable to distinguish between 
types of microemboli, such as solid or 
gaseous emboli.  
 
Joubert-Hubner et al. (1999) [114] used 
a glass aorta and mock circulation loop 
(Figure 23) to evaluate aortic arch 
vessel perfusion with several outflow 
cannula designs (Figure 24). The arch 
vessels, each 100 mm long, had 
diameters of 12 mm (innominate artery), 8 mm (left carotid artery) and 10 mm (left subclavian artery). 
Pump flow was set at a continuous flow of 3, 4.5 or 6 L/min and the cannula jet stream was directed to 
flow optimally into the aortic arch without being directed at one of the arch vessels, and then directed 
alternatively at each different arch vessel. One of the key findings of this study was the effect of facing 
single stream outflow cannulae towards the aortic arch vessels. As the jet velocity from the cannula 
increased, the flow through the directed arch vessel increased, however the flow through the other 
vessels decreased. This was more noticeable with smaller outflow cannulae with higher velocities. These 
results demonstrated the change in aortic arch vessel perfusion, and identified the potential risk of 
neurological complications associated with suboptimal flow rates. Yet these results may not be relevant 
to VAD support due to the lack of a pulse, the non-compliant aorta and no cerebral auto-regulation.  
 
2.6.3 Summary of Cannula Design 
This review of cannula design has revealed the variability of inflow and outflow cannula design. Several 
cannula designs are often available for a single pump, while each device appears to have its own inflow 
cannula. The shape and placement of the cannula within the vessel influences the flow dynamics around 
it, and may result in increased risk of blood damage and thrombus formation if not optimized. The  
 
Figure 23 – Mock circulation loop and aortic arch model 
including the innominate artery (1), common carotid artery (2), 
left subclavian artery (3), glass aortic arch (4), aortic cannula 
(5), outflow reservoir (6), cardiotomy reservoir (7), venous 
reservoir (8), roller pump (9), oxygenator (10), arterial filter 
(11), throttle valves (12) and cannulation site (13). Arrows 
indicate the direction of flow. 
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cannula design may also be improved to prevent obstruction by the 
surrounding tissue and potentially reduce suction events. 
Obstruction may be attributed with rigid inflow cannulae which 
don’t have the flexibility to move as the patient changes body 
position or as the heart remodels after initiation of VAD support. In 
this case, some compliance is desirable to compensate for these 
changes in the VAD-patient interface. Meanwhile, the self expanding 
nature of the Smart cannula presents a novel, passive way to 
increase the flow through a circuit by making use of the maximum 
geometry of the cannulated vessel. 
 
2.7 Cannula Placement 
Virchow’s triad described the three key predisposing factors to 
thromboembolic complications; vessel wall abnormalities, abnormal 
flow, and coagulation state. The choice of cannulated vessel, point 
of vessel cannulation, cannula insertion length and cannula insertion 
angle are all potential contributing factors to the flow dynamics 
within the cannulated chamber. If any of the mentioned features are 
not optimal, the subsequent flow dynamics may result in abnormal 
flow and thus thromboembolic and potentially neurologic 
complications.  Neurologic complications remain one of the most 
serious adverse events for mechanical circulatory support [91]. This 
section describes cannula placement and its impact on 
haemodynamics and thromboembolic and neurologic complications. 
 
2.7.1 Atrial or Ventricular Inflow Cannulation 
The VAD inflow cannulation site represents the primary interface, and positioning the cannula in either 
the atrium or ventricle induces major haemodynamic changes. This choice, however, is often dependant 
on the preference of the surgeon, and can be limited by anatomical constraints or the presence of 
thrombus within a vessel [11, 115]. Ventricular cannulation (VC) is often regarded as the preferred site 
for implantable LVADs [116-118]. This is due to improved LVAD inflow conditions resulting from 
remnant heart activity, which in turn increases pump flows and reduces the risk of thromboembolism 
 
Figure 24 – Outflow cannula 
designs evaluated by Joubert-
Hubner et al. (1999) [114] 
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[86]. Atrial cannulation (AC), on the other hand, allows for easier surgical insertion (generally off 
cardiopulmonary bypass) and also promotes the potential for cardiac ventricular recovery by alleviating 
ventricular workload and preserving remaining cardio-myocytes [116, 119].  However, a reduction in 
support efficiency is observed, resulting in lower VAD flow for comparable pump speed [117].  RVAD 
inflow cannulation has previously been favored in the right atrium. However, some are now favoring the 
right ventricular free wall, such as those implanting the DexAide RVAD or HeartWare HVAD as an RVAD 
[56, 82].  
 
Ventricular unloading is vital for patients identified for bridge to recovery treatment, as the aim of this 
strategy is to reduce the workload of the heart until it recovers, and thus is less critical for bridge to 
transplant and destination therapy patients.  The workload of the heart is ultimately determined by the 
myocardial oxygen consumption of the ventricle, which is directly related to the amount of energy 
consumed by the heart during each cardiac cycle [120, 121]. This energy is influenced by the external 
stroke work, and the end systolic volume and pressure inside the ventricle. These parameters change 
significantly with each cannulation site.  
 
The ejection fraction (EF) of the supported ventricle is also important when selecting the cannulation 
site. The reduced ejection fraction often encountered in heart failure patients creates a condition of 
relative stasis within the ventricle that may predispose it to the risk of thromboembolic events [117, 
122-125]. The risk of stroke has been found to increase with a decreasing EF [126, 127]. For example, 
patients with an ejection fraction below 28% have been shown to suffer a marked increase in 
thromboembolic incidence [122]. AC is generally considered to reduce EF, and is therefore discouraged 
due to enhanced concerns of thrombus formation within the unloaded ventricle. VC, however, appears 
to decompress the ventricle and thus produces less blood stagnation and thromboembolic events [117, 
119]. Additionally, cyclic changes to inlet pressure caused by remnant ventricular contractions improves 
the washout of rotary type VAD internal surfaces [116].  The resulting ejection fraction during VAD 
support is not only dependant on cannulation site, but also the level of remaining systolic contractility of 
the failing heart. Therefore, research in this area must focus on evaluating VAD haemodynamic 
performance with VC and AC for varying levels of heart failure. 
 
Numerical simulation of the cardiovascular system is one technique used to evaluate VAD performance 
for each cannulation site [128-130]. These models allow for the alteration of individual system 
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parameters, including the level of heart failure, thus predicting their relative effect on performance. 
Morley et.al (2007) [129] employed a numerical simulation of the cardiovascular system which revealed 
the haemodynamic benefits of partial support with AC were greater than VC in less dilated and less 
dysfunctional hearts. However, VC was predicted to increase reverse remodeling of the ventricle due to 
the reductions in preload volume, preload pressure, and myocardial oxygen consumption.  This study 
was limited by its inability to simulate atrial or ventricular suction which may influence LVAD 
performance under certain conditions. 
 
Korakianitis et al. (2007) [14] evaluated left atrial vs left ventricular inflow cannulation for rotary and 
pulsatile VADs in simulation. Outflow cannulation was simulated in the ascending aorta in all cases. The 
numerical simulation was a lumped parameter model which included resistance, compliance and inertial 
components. Both systemic and pulmonary circulations were simulated and each included an atrium, 
ventricle, arterial sinus, arterial, arteriole, capillary and venous system in series. Left atrial cannulation 
recorded lower left atrial pressures, thus minimizing the potential for pulmonary edema. Left atrial 
cannulation recorded an increase in left ventricular systolic pressure of approximately 10 mmHg to 
80mmHg from the simulated heart failure condition, while left ventricular cannulation recorded a 
decrease to about 40 mmHg which may assist with ventricular recovery. Atrial cannulation recorded 
zero flow through both mitral and aortic valves, while ventricular cannulation recorded high flows 
through the mitral valve yet zero aortic flow. This indicated potential for low flow regions, and thrombus 
formation, about the aortic valve in both cases and mitral valve in atrial cannulation. Meanwhile, 
stenosis may be induced by zero flow crossing the valve. Left ventricular cannulation restored 
ventricular volumes to similar levels as the simulated healthy condition, while atrial cannulation 
increased ventricular volumes beyond those in the simulated heart failure condition. The larger 
ventricular volumes may induce valve incompetence and deleterious morphological changes in both the 
tissue and cell levels with ventricle remodeling. Atrial cannulation did not pressure or volume unload the 
ventricles, although the ventricular work was almost zero due to almost no change in ventricular 
volume. Ventricular cannulation also reduced stroke work. Suction events were easier to induce with 
left atrial cannulation compared to left ventricular cannulation due to the thin and flexible left atrial wall 
compared to the thicker and stiffer ventricular wall. The overall conclusion of this study was that 
ventricular cannulation is the preferred option to reduce valve stenosis, flow stagnation, suction events 
and improve the chances of myocardial recovery, however atrial cannulation may be beneficial for 
ventricular recovery as it spares the myocardial tissue. 
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Numerical models lack the unforeseen practicalities encountered in real world testing, particularly 
regarding modeling VAD characteristics. In-vivo studies therefore enhance the results by including the 
pump and introducing the effect of haemodynamic feedback mechanisms of the living animal [13, 116, 
117, 129, 131].  Vandenberghe et al. (2004) [13] demonstrated reduced stroke volume, stroke work and 
end-diastolic pressure with AC in an in-vivo study.  Higher mechanical efficiency was detected with VC, 
however no significant differences were noted in EF between the two cannulation techniques.  This 
experiment was limited through use of healthy animal hearts with increased Starling responsiveness 
compared to dilated, diseased hearts.  
 
Cannulation site evaluation in VAD supported humans is the gold standard. Schlensak et al. (2011) [132] 
evaluated RVAD inflow cannulation site in 31 patients with two Thoratec PVADs providing biventricular 
support. LVAD cannulation was achieved with the left ventricular apex and ascending aorta for inflow 
and outflow respectively in all cases. The 15 patients with right ventricular inflow cannulation 
demonstrated higher RVAD flow rates compared to those with right atrial cannulation (4.9 ± 0.3 vs 4.2 ± 
0.3 L/min respectively) due to the higher RVAD inflow pressures promoting rapid RVAD filling. This 
increased flow rate resulted in improved perfusion of the end organs and subsequent improved kidney 
and liver function. However, right atrial cannulation was the chosen technique prior to the 
implementation of right ventricular cannulation, thus the clinical experience with VAD support may have 
promoted improved results in the right ventricular cannulation group, even though survival was 
relatively similar between the two groups. While this study revealed improved haemodynamics with 
right ventricular cannulation over right atrial cannulation, the high overall mortality rate on device 
support (48%) revealed the difficulty in maintain these end stage patients with total heart failure. 
Meanwhile, this study was completed with first generation devices which are gradually being replaced 
by the more durable third generation pumps. A similar study which characterizes the effect of right atrial 
and ventricular inflow cannulation for rotary blood pumps would serve to enhance future BiVAD support 
with continuous flow devices.  
 
2.7.2 Inflow Cannula Insertion Location 
Cannulation of each vessel can occur at various points. Left atrial cannulation is usually achieved 
through the dome of the left atrium (between the superior vena cava and aorta), on the right side of the 
heart behind the interatrial groove or through the left atrial appendage. Left atrial cannulation may also 
be achieved through the junction between the left and right superior pulmonary veins. Left ventricular 
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cannulation, which unloads the failing left ventricle more than left atrial cannulation, is usually achieved 
through the apex of the left ventricle [133]. LVAD outflow cannulation is best achieved in the ascending 
aorta, close to the aortic valve. RVAD inflow cannulation should be achieved though the right atrial free 
wall or right atrial appendage, while the anterior aspect of the main pulmonary artery should be 
employed for outflow cannulation [84]. While the right atrium is usually employed for RVAD inflow, 
some institutions are now favoring the right ventricle [34, 134].  Right ventricular cannulation is usually 
placed in the right ventricular free wall, halfway between the right ventricular base and apex. 
Alternative techniques have been developed for special circumstances, such as insertion of the left 
ventricular inflow cannula through the ascending aorta and traversing the aortic valve [11]. 
 
Demirozu et al. (2011) [135] compared the clinical outcomes of 171 patients with the Thoratec 
HeartMate II LVAD implanted in either the apex (131 patients) or free wall (40 patients) of the left 
ventricle.  The free wall incision was made at 1/3 the distance from the apex to the base of the 
diaphragmatic surface of the left ventricle and the cannula was positioned parallel to the septum and 
superior to mitral valve papillary muscles. Statistically significant differences were found in post-
operative infection (5% vs 17%) and ventricular arrhythmias (8% vs 32%) for diaphragmatic and apical 
cannulation respectively. It was concluded that diaphragmatic placement of the inflow cannula is 
technically easy and may reduce contact between the inflow cannula and septum while preventing 
suction events and arrhythmias. 
 
2.7.3 Cannula Tip Length and Orientation 
The cannula tip length and orientation influences the flow dynamics within the chamber and the 
interaction between the cannula and surrounding tissue. Cardiac anatomy and function can significantly 
influence the surgical approach, choice of assist device and cannula placement [115]. Positioning of the 
cannula tip within the left atrium is vital, with a small angle possibly resulting in impingement upon the 
left atrial roof, while a larger angle may extend the cannula across the mitral valve [136]. Intra-operative 
transoesophageal echocardiography (Figure 25) is routinely performed to guide the surgical team during 
VAD insertion to achieve satisfactory anatomic positioning of the cannulae within the cardiac chambers. 
If placed in the LV, imaging is required to ensure that the mitral valvular or sub-valvular apparatus does 
not interfere with adequate cannula flow. It can also be used to ensure the cannula is not placed in the 
LV outflow tract, left atrium or directly against a LV wall which may impede cannula flow [115].  
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The inflow cannula should be directed posteriorly toward the mitral valve, otherwise obstruction may 
result. The placement of the inflow cannula should also accommodate anticipated reductions in left 
ventricular chamber size [31]. Improper positioning of the LVAD inflow cannula may alter the left 
ventricular geometry and potentially place more strain on the right ventricle, promoting right ventricular 
failure [137]. Septal occlusion of the inflow cannula has been reported previously, and may be difficult 
to diagnose, even with the help of transesophageal echocardiography [138]. CT scans may be used to 
identify cannula malposition. Bolen et al. (2011) [139] used CT to identify a patient with steep cannula 
orientation towards the distal anterior wall resulting in suction events and low flow alarms on the VAD. 
As the change in cannula orientation was attributed with myocardial recovery and a change in 
ventricular dimensions, the VAD was removed and the patient was stable.  
 
Movement of the inflow cannula may occur over time due to pericardial changes or suboptimal 
intraoperative preparation. This movement may lead to partial occlusion of the cannula with 
subsequent haemolysis, low pump flow, arrhythmias and chronic inadequate LV unloading, potentially 
resulting in right heart failure. Surgical repositioning may be required [140]. Milano et al. (2011) [141] 
reported four patients, from a sample size of 154 implanted with continuous flow LVADs, who required 
reoperation due to inflow cannula malposition. The inflow cannula abutted the septum (3) or free wall 
(1) and was altered by tying two heavy sutures around the inflow cannula and passing them over a 
bridge which repositioned the cannula tip. The heavy sutures were removed one month after 
repositioning, with new adhesions maintaining the new inflow cannula position. 
 
Meanwhile, inflow cannula malposition may result in thrombus formation within the cannulated 
chamber. A wedge thrombus (Figure 26) may form at the junction between the wound site, caused by 
myocardial coring, and the inflow cannula due to abnormal (low velocity) blood flow at this point and 
 
Figure 25 – Two (left and middle) and three (right) dimensional transoesophageal echocardiographic images 
of a left ventricular inflow cannula [115]. 
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the vessel wall abnormality, two of the three features 
identified in Virchow’s triad. Wedge thrombi have 
been reported in several previous studies and may 
release, potentially travelling to the brain and causing 
a stroke [77, 142, 143].  
 
Schmid et al. (2008) [10] compared a short (24 mm) 
and long (34 mm) inflow cannula (Figure 27) placed in 
the left ventricular apex and attached to a Berlin 
Heart INCOR (Berlin Heart GmbH, Berlin, Germany) 
axial flow VAD in a total of 216 patients. 138 patients 
received the short cannula, with the remaining 78 
patients receiving the longer cannula and both groups 
had similar baseline characteristics. The difference in cannula length changed the protrusion length of 
the cannula tip within the ventricle, thus changing the flow dynamics within the chamber. The longer 
cannula also protruded above the ventricular trabeculae and prevented tissue in-growth. Patients with 
the longer cannula demonstrated improved survival rate compared with those with the short cannula at 
the end of the observation period, with survival rates of 63.4% and 52.9% respectively. The one and two 
year survival rates (Figure 28), based on Kaplan-Meier survival curves, for the short cannula was 50 and 
33% respectively which, when compared with the longer cannula (61 and 53% respectively), reveal 
vastly improved results with the longer version. Meanwhile, only 3 patients with the longer cannula 
(3.8%) had a thromboembolic adverse event, which was much less than the 32 patients with the shorter 
cannula (23.2%). The thromboembolic event 
rate per year was 0.11 and 0.5 in the long 
and short cannula groups respectively. The 
relative risk of stroke was 6.03 times higher 
with the short cannula compared to the 
longer cannula. The incidence of cerebral 
bleeding was also lower with the longer 
cannula group compared to the shorter 
version, with 0.11 compared to 0.21 events 
per patient year respectively. This study 
 
Figure 26 – Arrow pointing towards a wedge 
thrombus found after 437 days of LVAD 
support in a patient with a Terumo DuraHeart 
LVAD [143]. 
 
Figure 27 – Short (left) and long (right) inflow cannulae 
evaluated by Schmid et al. (2005) [10]. 
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demonstrated that the cannula design and placement, in this case protrusion length, had a significant 
impact on patient morbidity and mortality. However, this study only evaluated two different cannula 
lengths, and thus did not define an ideal cannula insertion length for optimal flow dynamics within the 
ventricle. Meanwhile, the majority of short cannulae were implanted before the longer version had 
been developed, meaning that the clinical experience gained in VAD support over that time may have 
improved the patient outcomes with the longer cannula. 
 
Few studies have been published which outline the ideal RVAD inflow cannula insertion length and 
orientation. Hill et al. (2002) [86] stated that right atrial cannulation can be achieved by inserting the 
cannula into the mid right atrial wall and directly toward the inferior vena cava. The right atrial cannula 
tip should be placed approximately 2 cm above and midway between the tricuspid valve and orifice of 
the inferior vena cava. However, if inserted incorrectly, it may result in the leaflets of the tricuspid valve 
being sucked into the cannula from the negative pump pressure and thus reducing RVAD flow. 
 
Figure 28 – Probability of survival with the long and short LVAD inflow cannulae by Schmid et al. (2005) 
[10]. 
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Meanwhile, the compliant right atrial wall may also collapse around the cannula and interrupt RVAD 
flow [144].  
 
VAD outflow location also influences haemodynamics and perfusion to vessels such as those branching 
from the aortic arch.  Ascending (AA) vs descending (DA) aortic cannulation was compared with pulsatile  
(PF) and continuous (CF) flow LVADs in-vivo by Litwak et al. (2004) [145] with bypass support ranging 
from 20% to 100%.  VAD failure was also simulated through turning off the VAD and leaving the 
cannulae unclamped.  As cannulation of the AA root was nearly impossible in this calf model, AA 
cannulation was achieved through the brachiocephalic trunk near the aortic root which could result in 
incorrect flow dynamics through the aorta and brachiocephalic artery. Both AA and DA cannulation was 
achieved on each animal with clamps used to switch the LVAD outflow site.  No difference was recorded 
in aortic or brachiocephalic mean flow between PF or CF support under all levels of bypass, however the 
flow waveforms differed.  The mean aortic flow was higher with AA compared to DA cannulation, while 
the simulated pump failure produced higher backflow with CF pumps and was particularly greater with 
AA cannulation.  The use of healthy animals in this study resulted in a major limitation, particularly in the 
investigation of pump failure. Tuzun et al. (2010) [146] evaluated the effect of VAD outflow cannulation 
site on myocardial perfusion in-vivo with four calves receiving ascending aortic cannulation and four 
calves with descending aortic cannulation.  No changes were noted in myocardial perfusion between the 
two groups; however the small sample size was a limitation in this study. These studies demonstrated 
the varying haemodynamics that can be experienced with alternative cannulation sites for both LVAD 
and RVAD inflow and outflow.  
 
2.7.4 Summary of Cannula Placement 
Cannula placement influences the resultant haemodynamics and flow dynamics within the 
cardiovascular system. Left ventricular cannulation is generally the first choice for LVAD inflow, while the 
ascending aorta is usually chosen for LVAD outflow. Left ventricular inflow cannulation provides 
increased ventricular ejection fraction and improved washout of the pump due to the pressure pulses 
supplied by any remaining contractility. For RVAD inflow, the right atrium was previously favored, 
however some institutes are now preferring the right ventricular free wall, such as those implanting the 
HeartWare HVAD for biventricular support. This review has demonstrated the lack of research in RVAD 
inflow cannulation site for continuous flow devices. Ultimately, the ideal cannula placement can be 
recommended, however the choice depends on patient anatomy, surgical constraints and preference of 
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the surgeon. These factors may also influence the cannula tip orientation and insertion length, which 
was shown by Schmid et al. (2008) to have a significant effect on postoperative outcomes – in this case 
the cannula which protruded into the left ventricle by 10 mm more produced improved results in terms 
of postoperative stroke rate. The movement of the cannula over time as the heart remodels is also an 
important factor in cannula placement.  
 
2.8 Cannula Insertion and Fixation 
The insertion and fixation of LVAD and RVAD inflow cannulae can vary between devices and the surgical 
team. The surgical procedures and cannula design can influence the postoperative outcomes of the 
patient, particularly in respect to postoperative bleeding from the cannulation site. This section presents 
a literature review of the insertion and fixation of VADs and the complications which are associated with 
the procedure. 
 
2.8.1 Significance of Postoperative Hemorrhage 
Pre-operative abnormal coagulation is common in heart failure patients due to hepatic dysfunction and 
the use of anti-coagulant or anti-platelet medications. However, studies have shown the incidence of 
thrombotic events is much lower than bleeding events [31]. Bleeding is the most common complication 
during VAD support and is a major contributing factor of operative mortality during VAD implantation 
and explantation [29-32, 138, 147-149].  Previous studies have shown up to 76% of patients experience 
excessive bleeding in the acute phase following VAD implantation, with as many as 60% requiring 
operative intervention [6, 33, 84, 140, 149-152]. Kirklin et al. (2011) [153] found that in the first month 
of destination therapy of 385 patients from the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) database, 11% of deaths were attributed to postoperative, surgery 
related hemorrhage. Decades of improvements to medical therapy, particularly focusing on 
anticoagulation regimes, has done little to overcome this complication [34, 154].  Often occurring at the 
cannulation sites, significant hemorrhage is partially due to the anticoagulation regime following VAD 
implantation, which is required to prevent clot formation in the VAD and cannulae [6]. Meanwhile, 
bleeding complications are increased with biventricular support [155], with Cleveland et al. (2011) [70] 
reporting a four-fold increase in postoperative hemorrhagic complications in patients supported with a 
BiVAD compared to those on only LVAD support. 
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2.8.2 Causes and Risk Factors of Postoperative Hemorrhage 
There are several causes and risk factors associated with severe postoperative bleeding. Postoperative 
bleeding is a particularly significant problem during the acute phase of mechanical circulatory support 
(first 24-48 hours), occurring at suture lines and cannulation sites and can be difficult to localize [115, 
149]. Haemodynamic instability is common during the early postoperative period, most commonly due 
to low flow rates due to cannula obstruction, tamponade and hypovolemia from hemorrhage [94]. Risk 
factors for significant hemorrhage include coagulopathy due to hepatic congestion, compromised 
nutritional status, preoperative anticoagulation, previous cardiac surgeries,  extended cardiopulmonary 
bypass time and extensive surgical dissection [94]. Surgery-induced bleeding may also be due to 
hemodilution of clotting factors during CPB and device-induced coagulopathies [149]. Anticoagulation is 
usually withheld in this early period to help address bleeding issues.  
 
Continuous flow devices have been shown to result in higher degrees of bleeding during VAD support 
and heart transplant due to acquired von Willebrand (AVWS) syndrome [33, 34]. The high shear stress 
associated with rotary blood pumps may increase postoperative bleeding due to AVWS [156]. Platelets 
usually work to prevent bleeding by attaching to injured vessel walls, such as the sites of inflow and 
outflow cannulation, and activate and aggregate at the site.  AVWS is a bleeding disorder characterized 
by the loss of high molecular weight multimers of von Willebrand factor which are responsible for 
platelet adhesion and aggregation. With the already high instances of postoperative bleeding in pulsatile 
VADs, AVWS magnifies this complication even further with the high shear rotary devices currently on 
the market or under development. However, the 200 patient, multi-centre trial by Slaughter et al. (2009) 
[157] did not report higher instances of postoperative bleeding in patients supported with a continuous 
flow device compared to those supported with pulsatile flow devices. 
 
2.8.3 Additional Complications of Postoperative Hemorrhage 
Complications associated with increased postoperative bleeding include hypoperfusion, multi-organ 
failure and intracranial bleeding, while the necessary blood transfusions increase the risk of infection, 
respiratory failure and right heart failure [154].  Unfortunately, massive blood transfusions are also 
linked with allosensitization and transplant-precluding viral transmission, both of which can complicate 
or prevent successful heart transplantation [29, 31, 144]. Bleeding can cause cardiac tamponade which 
results in haemodynamic instability and can be difficult to diagnose, often requiring transesophageal 
echocardiography. Small, localized fluid collections in the pericardial space may have significant 
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consequences, particularly if they are around critical locations such as the atria, which may limit VAD 
inflow [115]. 
 
Previous studies report varying degrees of postoperative hemorrhage. The Thoratec HeartMate II 
instructions for use listed bleeding (perioperative or late) as the most commonly occurring complication 
while on LVAD support in the clinical study of 126 patients [89]. 29% of patients in this cohort required 
reoperation due to bleeding, while 69% required greater than or equal to 2 units of packed red blood 
cells. Broussard et al. (2011) reported blood loss averaged 4,031 ± 2,310 mL in the first 48 hours after 
VAD implantation when the chest was closed directly after implantation. For those patients who had a 
delayed operation to close the chest, blood loss averaged 3,845 mL before closure and 2,694 mL after 
closure. The difference was attributed to a patient selection bias, as the earlier closed patients had 
favorable coagulation status, lesser degree of cardiac decompensation and absence of anticoagulation 
medications prior to surgery.  
 
Matthews et al. (2010) [149] aimed to assess the capabilities of a model for end-stage liver disease 
(MELD) score to predict total perioperative blood product exposures (TBPE) in 211 VAD implants. Both 
pulsatile and continuous flow devices were included in the study. A median score of 74 units of TBPE 
was recorded in the study, with 182 survivors and 29 deaths. The risk of mortality increased 30% per five 
units of packed red blood cells and 5% per ten units of TBPE. Patients who died operatively had longer 
times on cardiopulmonary bypass (128 ± 7.2 minutes) than survivors (103 ± 2.6 minutes). Meanwhile, 
exposure to blood products was associated with increased odds of developing postoperative right 
ventricular failure, renal failure, and neurological events. In conclusion, this study demonstrated that 
bleeding in the LVAD perioperative period is associated with increased risk of morbidity and mortality 
and developing right ventricular and renal failure. 
 
2.8.4 Cardiopulmonary Bypass 
Minimizing bypass time decreases the risk of bleeding and end-organ dysfunction, both of which are 
complications of prolonged CPB [35]. However, LVAD inflow cannulation is particularly difficult off CPB 
as the heart is often enlarged in congestive heart failure, making access to the left ventricular apex and 
left lateral atrial wall mechanically impossible. Dislocating the heart to gain access in a 
haemodynamically unstable patient can be unsafe. Meanwhile, the reduced blood flow velocities caused 
by heart failure may promote thrombus formation in the left ventricular apex or left atrial appendage 
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and require removal before VAD support is initiated, thus requiring CPB support [115, 158]. In fact, 
insertion of the LVAD inflow cannula requires CPB in almost 100% of patients requiring a VAD [86]. 
Meticulous surgical procedures to ensure haemostasis lengthen the CPB time. Extended time on CPB 
requires additional anticoagulation therapy, resulting in greater degrees of postoperative bleeding and 
has been shown to be a significant predictor of patient survival to transplant [8].  CPB may also result in 
atheroembolic events which have been identified as a source of morbidities such as cognitive 
impairment and stroke [159].  
 
2.8.5 Alternative Treatments for Postoperative Hemorrhage 
Treatment of severe hemorrhage with powerful coagulants such as rFVIIa [160] has shown some 
promising results, however medical therapy such as this may promote thrombus formation which could 
potentially lead to post-operative stroke or pulmonary embolism. Preoperative and postoperative 
treatment with Vitamin K has also been shown to decrease the incidence of severe bleeding, however 
aspirin was the only anticoagulant used in this study which may limit these results to VADs which 
require minimal anticoagulation [161].  Devices such as the HeartMate pulsatile LVAD employ textured 
surfaces as a pseudoneointima to reduce the need for anticoagulation, however still report significant 
bleeding in up to 39% of patients [161]. Several previous studies have aimed to control postoperative 
bleeding through manipulation of drug therapy [160, 162], however little research has focused on 
improving the connection between the VAD and the native heart and arteries to reduce postoperative 
blood loss.  Other methods to reduce bleeding include minimizing CPB time and surgical dissection and 
attaching felt reinforcements in areas of friable tissue [31]. 
 
2.8.6 State of the Heart and Vessels 
The state of the patient’s heart and surrounding vessels can provide additional difficulty in maintaining 
haemostasis. Insertion of VAD cannulae cannot be hurried as the myocardial and arterial tissue is often 
in a condition where suboptimal fixation will almost certainly result in postoperative bleeding.  The 
RVAD inflow site, usually achieved through the right atrium, poses a problematic surgical procedure due 
to the elevated atrial pressures rendering the right atrium a distended and friable vessel [163].  Previous 
studies have recommended care to be taken when inserting the right atrial inflow cannula to prevent 
catastrophic failure of the vessel wall [29].  Increased pulmonary pressures and pulmonary vascular 
resistance may also result in pulmonary hypertension and render the pulmonary artery thin walled and 
weak.   
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During chest closure, the cannulae may be forced out of position and generate a torque at the fixation 
site.  This torque may generate bleeding through the RVAD inflow cannulation site in the friable right 
atrium and the RVAD outflow cannula at the pulmonary artery anastomosis site [164].  Meanwhile, the 
anastomosis site on the pulmonary artery can be technically challenging for surgeons due to limited 
visibility [164].  RVAD outflow cannulation has previously been performed with success through the right 
ventricular free wall, with the tip of the cannula placed through the pulmonary valve and into the 
pulmonary artery [164].  This study demonstrated increased visibility for the surgeon while expected 
limitations such as pulmonary valve regurgitation or trauma were negligible in the five patients who 
received this procedure.  However, long term VAD support with this cannulation technique may result in 
thrombus formation within the right ventricle as ejection through the pulmonary valve will be impeded 
by the outflow cannula.   
 
There is also a lack of surgical visibility at the ventricular apex for inserting the LVAD inflow [165].  Inflow 
cannulation through the left atrium can be disastrous due to the thin walled vessel, while attempted 
reoperations often lead to further bleeding [6].  Reasonable visibility and access can be achieved for 
LVAD outflow placement in the ascending aorta, with a skilled surgeon capable of securing a VAD 
outflow connection which will result in minimal postoperative bleeding. VAD outflow cannulation, 
achieved through an end-to-side anastomosis on the artery, requires the artery to be cross-clamped 
while the cannula is sutured to the vessel.   
 
2.8.7 Suture Techniques 
Several suture techniques are used for fixation of 
inflow and outflow cannulae. Purse string sutures are 
commonly used to close circular wounds, and may be 
used for cannula fixation. A purse string suture (Figure 
29) consists of a continuous stitch which runs parallel 
to the edge of a circular wound. The wound edges are 
then inverted when tied. A running suture (Figure 30) 
is made with one continuous length of suture material 
and is commonly used to close tissue layers which 
require close approximation. Mattress sutures (Figure 
31) are a double stitch made parallel (horizontal 
 
Figure 29 – A purse string suture [166]. 
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mattress) or perpendicular (vertical mattress) to the wound edge and provide a strong, deep closure. 
Mattress sutures are commonly used to attach reinforcing pledgets around the cannula insertion site. 
 
2.8.8 Fixation of the Atrial Inflow Cannula 
Atrial cannulation can be difficult due to the thin walled vessel, particularly in congestive heart failure 
patients. DiCorte et al. (1999) [84] described a typical procedure for placement of the Abiomed BVS 
5000 atrial inflow cannula. Left and right atrial cannulation was performed with the same technique. 
Following exposure of the heart, two concentric 2-0 polypropylene purse-string sutures were placed and 
reinforced with two felt pledgets each, placed at 180 degrees from each other. Placement of too many 
pledgets may lead to bleeding due to bunching of the pledgets. The sutures were brought out at right 
angles and controlled with tourniquets before a stab incision was made at the centre of the sutures 
(Figure 32). The cannula was inserted through the stab wound to a marked point on the cannula and the 
cannula was filled through a Valsalva maneuver. The tourniquets were tightened around the cannula 
and the sutures were tied through two large buttons over the tourniquets, ensuring enough suture 
length remains to close the incision upon later removal of the cannula (Figure 33).  
 
Securing haemostasis can be a difficult challenge with a thin walled vessel. Golding et al. (1992) [168] 
reported severe bleeding in 87% of the 91 patients support with centrifugal blood pumps (Medtronic or 
 
Figure 30 – A running suture [166]. 
 
 
 
Figure 31 – A mattress suture [167]. 
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Biomedicus pumps), with a mean transfusion requirement of 53 units of blood. Cannulation was 
achieved with a 32 or 36 F inflow cannula placed through the right superior pulmonary vein into the left 
atrium and secured with Teflon buttress sutures and tourniquets, while outflow was achieved through 
the ascending aorta. While the reported bleeding rates were high in this study, it should be noted that 
this was an early report of continuous flow VAD support and the clinical management may not have 
been optimal at the time.  
 
Meanwhile, cannula purse-string sutures may loosen over time during long term VAD support.  Wyatt et 
al. (1993) [32] attempted successful placement of a reinforcing Dacron sleeve in atrial cannulation. The 
atrial cannula was initially placed in normal fashion with purse-string sutures.  Following confirmation of 
appropriate cannula orientation, a Dacron sleeve was placed over the atrial cannula and secured end-to-
 
Figure 32 – (A) Placement of concentric purse string sutures with felt pledgets, (B) controlling the sutures 
with tourniquets and (C), the stab incision was made at the centre of the sutures. 
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side to the atrial wall with a continuous, running suture.  The suture was tied and the distal end secured 
to the cannula with a tubing band.  This arrangement acted as reinforcement to the usually friable atrial 
cannulation site while reducing bleeding in all cases.  
 
Grinda et al. (2006) [155] presented a method to reduce bleeding from the RVAD inflow cannula fixation 
site with the Medos HIA-VAD. After median sternotomy, CPB was started with cannulation through the 
right atrium and aorta for inflow and outflow respectively. The right atrial CPB cannula was tunneled 
through the skin at approximately 4 cm below the right costal margin. Standard procedures were used 
for LVAD inflow (ventricular apex), LVAD outflow (aorta) and RVAD outflow (pulmonary artery), with a 
side-biting clamp used on the arteries to prevent bleeding. The three attached BiVAD cannulae were 
tunneled through the skin and attached to the respective VADs. CPB was then interrupted, and the right 
atrial CPB cannula was attached to the RVAD inflow port before BiVAD support was initiated. This 
technique was used in 18 consecutive patients, with re-intervention required for bleeding in six and one 
case of thrombosis of the right atrial cannula. Meanwhile, the first eight used a 40 F right atrial cannula, 
while the last ten used a 51 F cannula and experienced higher RVAD flow rates (4.3±0.6 L/min vs 5.2±0.9 
L/min respectively).  
 
Stepanenko et al. (2011) [169] described an alternative technique for RVAD (Levitronix CentriMag) 
implantation in a patient who experienced right ventricular failure one day after LVAD (HeartWare 
HVAD) implantation. After femoral-femoral CPB was initiated, LVAD insertion was achieved with a left 
lateral thoracotomy in the fifth intercostal space with the left ventricular apex and descending aorta for 
inflow and outflow cannulation respectively. The groin incision, previously used for CPB access, was 
reopened and two purse-string sutures were placed on the femoral vein before the RVAD inflow cannula 
was advanced through the inferior vena cava to the right atrium using the Seldinger technique (use of a 
guide-wire, inserted through a trocar, to guide the sheath / cannula into place). Location of the cannula 
and haemostasis were secured by the purse-string sutures and cutaneous fixation. The chest was then 
reopened through the LVAD insertion point before the RVAD outflow cannula was attached to the main 
pulmonary artery with two purse-string sutures supported with pledgets. The patient was successfully 
weaned from RVAD support after 10 days. 
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Figure 33 – (A) The atrial inflow cannula, (B) insertion of the atrial inflow cannula, (C) the tourniquets were 
tightened around the inflow cannula, (D) the tourniquets were secured to inflow cannula. 
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VAD support may be required after chest closure for a separate procedure. Gregoric et al. (2008)[170] 
presented the insertion of cannulae for a Levitronix CentriMag through a right mini-thoracotomy 
without the use of CPB. The chest was entered through the fourth intercostal space and the right 
superior pulmonary vein and aorta were exposed. Purse-string sutures were placed on both vessels prior 
to cannula fixation and the cannulae were tunneled through the sixth intercostal space. The inlet 
(superior pulmonary vein) and outlet (aorta) were then cannulated and rapidly attached to the already 
primed pump. The pump was started and speed was increased to provide 4 L/min of perfusion before 
the chest was closed. While the procedure was deemed a success, the patient experienced infection and 
multi-organ failure and died in the second week of support. No mention was made of surgical blood loss 
in this procedure. 
 
2.8.9 Fixation of the Ventricular Inflow Cannula 
Optimal fixation of the ventricular inflow cannula is required to prevent postoperative bleeding due to 
the higher pressures in the ventricle compared to the atrium. The thickness of the ventricular 
myocardium, however, promotes improved fixation as the connection can be reinforced. Nakatani et al 
(1996) [171] demonstrated that in 15 patients supported with a LVAD, ventricular posterior wall 
thickness increased from approximately 10 mm to 13 mm directly after LVAD placement.  However, no 
long term changes were noted after this increase, with 13mm posterior wall thickness recorded at the 
time of cardiac transplantation (mean support duration of 73 days). Nakatani attributed the initial 
change in posterior wall thickness to a conservation of muscle mass as the overall left ventricle size 
decreased after unloading by the VAD. 
 
Bradfield et al. (1977) [172] evaluated the minimum thickness of the myocardium and overlying 
epicardial fat of the left and right ventricles in 60 hearts to discuss the efficacy of implanted pacemakers. 
Diseased hearts were excluded from this study and all hearts were evaluated at necropsy. All hearts 
were from adults with a mean age of 68, while 37% were women. In all hearts, there was always a point 
at the left ventricular apex where the myocardial thickness was 3 mm or less. The mean thinnest 
myocardial section of the left ventricle, consistently at the ventricular apex, was 1.3 ± 0.7 mm, while the 
thinnest section in some hearts was less than 1 mm. Two of the 60 patients had two apical thin points in 
the left ventricle; however the remaining population only had one thin point. Myocardial thickness 
tended to increase rapidly about the thin point, with mean values of 3.7 ± 2.3 mm on the thinner side 
and 7.9 ± 6.3 mm on the thicker side, both only 5 mm from the thin point. Epicardial fat at the apex 
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ranged between 4.5 and 4.7 mm and was 
usually at least three times the thickness 
of the myocardium at the thinnest point. 
The right ventricle had no single thin 
point. Several equally thin points existed 
between the trabeculae, with a mean 
thinnest myocardial section of 1.3 ± 0.8 
mm and epicardial fat layer similar to that 
seen with the left ventricle. These thin 
points, particularly on the left ventricular 
apex and right ventricular free wall, may 
influence the method of cannula fixation 
and subsequent postoperative bleeding if 
limited myocardium is available for 
attachment. 
 
Along with obtaining haemostasis at the 
cannulation points, exposure of the left 
ventricular apex prior to inflow cannula 
insertion may also be difficult, particularly 
in weakened and dilated hearts. 
Schmauss et al. (2009) [173] presented a novel technique using Tentacles to elevate the heart for LVAD 
inflow access (Figure 34). The Tentacles device included three small silicon suction cups which are 
attached to individual silicon tubes with stopcocks. The proximal ends of the tubes were connected to a 
negative pressure source of 300 mmHg via a 3-way connector. The suction cups were soft and flexible to 
allow easy attachment to any position of the ventricular epicardial surface. The three Tentacles 
(Sumimoto Bakelite Co Ltd, Tokyo, Japan), initially developed for improved access during coronary 
surgery, were placed on the right ventricle, lateral wall of the left ventricle and inferior wall of the left 
ventricle and attached to a thorax retractor to expose the left ventricular apex. While on CPB, a standard 
apical cannulation technique was then performed to attach the LVAD before the Tentacles were 
disconnected.  
 
(a) 
 
(b)
 
(c) 
 
Figure 34 – Tentacles suction device with (a) the three 
tentacles, (b) the suction cups and (c) the tentacles elevating 
the left ventricular apex for LVAD inflow cannula insertion 
and fixation [173]. 
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2.8.9.1 Left Ventricular Inflow Cannula Fixation With Bypass 
Ventricular cannulation may be performed with or without the use of CPB and depends on the 
technique and preference of the surgeon. The Thoratec HeartMate II instructions for use recommend 
inspection of the left ventricle for clots prior to insertion of the inflow cannula [89]. Hill et al. (2002) [86] 
also recommended visual inspection for apical thrombi while on CPB, however identified the possibility 
of echocardiography to non-invasively detect any thrombus formation. Noon et al. (2001) [88] described 
the implantation technique used during the clinical trials of the MicroMed DeBakey axial flow VAD. After 
median sternotomy, an abdominal pump pocket was created with a model pump. Following 
implementation of CPB, the apical fixation ring was sewn to the elevated left ventricular apex. A 
rounded coring knife was then inserted through the apex to remove a core of myocardium. The ventricle 
was then examined for excess tissue or clots around the inflow site. The pump’s outflow graft was 
clamped and the inflow cannula was inserted through the fixation ring. The inflow cannula was 
orientated to point towards the aortic valve without interfering with the septum or free wall. The 
outflow cannula was then sewn end-to-side to the ascending aorta before the pump was de-aired. The 
patient was then weaned from CPB. This technique was reported in 51 patients, with the principle 
complication of late bleeding with events more than five days after device implantation. The authors 
attributed this complication to the anticoagulation process. The investigators noted the ease and 
reduced operation time for implantation and explantation of the DeBakey VAD compared to the larger, 
first generation devices.  
 
Prevention of postoperative bleeding from the left ventricular apex is crucial [5]. Charitos et al. (2010) 
[174] presented a technique for cannula fixation which included placement of several large (2 cm x 1 
cm) PTFE felt pledgets (Figure 35). After coring the ventricular apex, seven to ten large PTFE felt pledgets 
were placed around the apical core, about 1 cm away from the outer core edge. A 2-0 non-absorbable 
polyfilament suture was passed through each pledget to form an interrupted horizontal mattress suture, 
with each suture passed through the entire LV wall. The sutures were then passed through the apical 
ring, which was lowered into place and the sutures tied. Care was taken to ensure the sutures were not 
knotted too tight to prevent perforation or damage to the LV wall. A plastic shape holder was added and 
a size 2 non-absorbable polyfilament suture was passed around every pledget to form an additional 
interrupted horizontal mattress suture and tied securely against the metal cannula to seal. No mention 
was made of the postoperative outcome when this technique was used.  
 
67 
 
 
 
 
(i) 
(a) 
(ii) 
 
(iii) 
 
(b) 
 
 
(c) 
 
Figure 35 – LVAD inflow cannulation technique in the left ventricular apex by Charitos et al. (2010) [174]. (a) 
A schematic of the procedure including: (i) A suture being passed through every pledget to form an 
interrupted horizontal mattress suture which was also passed through the left ventricular wall and apical 
ring. (ii) With the plastic shape holder in place, sutures were passed around every pledget to form an 
additional interrupted horizontal mattress suture. (iii) After insertion of the metal inflow cannula, the second 
mattress suture was tied and secured against the cannula. (b) A photograph of the surgical procedure after 
the plastic shape holder was in place. (c) Final insertion of the metal inflow cannula with the second mattress 
suture tied to seal the connection. 
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Komoda et al. (2008) [5] attempted a similar 
technique to reduce postoperative bleeding with 
the Berlin Heart INCOR device. An apex ring was 
attached to the myocardium with eight mattress 
sutures while leaving several sutures loose for the 
connection between the apex ring and the cannula 
suture ring (Figure 36). The results of 58 patients 
implanted with an INCOR LVAD using this technique 
revealed no severe postoperative surgical 
hemorrhage, however due to the number of 
reinforcing sutures with Dacron felt pledgets, this 
technique would require extensive time on 
cardiopulmonary bypass (CPB). This could be 
addressed by attaching the apex ring prior to CPB if 
half bites of myocardium were employed for 
fixation. 
 
Other groups have also reported the use of 
reinforced mattress sutures to provide an improved 
seal at the ventricular apex inflow cannulation site. 
Hill et al. (2002) [86] used approximately 12 to 16 
Teflon felt-bolstered, permanent, braided, 
mattressed sutures placed and tied through the 
sewing ring to secure the cannula to the left 
ventricle. The Thoratec HeartMate II instructions for 
use recommend the sewing ring to be sutured to 
the myocardium with at least 12 pledgeted 
horizontal mattress sutures, with almost full 
thickness bites of the myocardium, approximately 
1.5 cm from the core. The inflow conduit can then 
be inserted and attached to the sewing ring. These 
(a)  
(b)  
(c)  
Figure 36 – Left ventricular inflow cannula 
fixation technique presented by Komoda et al. 
(2008) [5]. (a) The apex ring was sutured to the left 
ventricular apex with eight mattress sutures placed 
around the apical hole. (b) Eight overlapping 
mattress sutures were placed through the Dacron 
felt pledgets, myocardium, apex ring and collar of 
the inflow cannula. (c) A double purse-string 
suture was placed ont he Dacron felt pledgets and 
tied tightly. 
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techniques would increase the required time on CPB and thus expose the patient to the associated 
postoperative complications.  
 
LaRose et al. (2010) [175] reported on the HeartWare HVAD cannulation system, shown in Figure 37.  
The inflow cannula was 25 mm long with an outer diameter of 21 mm which almost joins the HVAD 
against the ventricular apex when connected.  Following coring of the myocardium, a small sewing ring 
constructed of titanium and Dacron polyester was sutured to the ventricular apex with 10-12 
interrupted, pledgeted sutures.  The inflow cannula, attached to the VAD, then passed through the 
sewing ring and cored myocardium until positioned correctly.  The inner portion of the sewing ring was a 
C-clamp that could be adjusted by turning a screw inside the clamp to seal the sewing ring against the 
inflow cannula.  A silicone O-ring was employed between the sewing ring and inflow cannula to ensure 
an appropriate seal.  Haemostasis was achieved through meticulous suturing of the sewing ring and 
pledgets to the myocardium, which extended the time on CPB.  
 
A disadvantage of sutured attachment of the ventricular apical inflow cannula is the potential for 
sutures to loosen over time [118]. Reinforcements may be applied such as the one shown in Figure 38 
which used a 12 mm Hemasheild graft attached to a Teflon felt square.  The inflow cannula was passed 
through the Hemasheild graft and ventricular apex until the Teflon felt square was in contact with the 
epicardium. The square was then circumferentially sutured to the ventricular apex to add reinforcement 
(a) 
 
(b)  
 
 
Figure 37 – (a) HeartWare device with inflow and outflow cannulae attached and (b) inflow cannula sewing 
ring with C-clamp [81].  
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to the connection before VAD support was started. However, in cases of massive left ventricular 
infarction, the myocardium may be friable and an alternative inflow cannulation site should be chosen 
[86].   
 
Kalangos et al. (1998) [11] identified the importance of a cannulation technique which provides easier 
insertion and removal of the device with less manipulation of the heart and reduced bleeding. Kalangos 
et al. presented a technique of using the ascending aorta for both inflow and outflow cannulation of a 
BioMedicus centrifugal blood pump (Figure 39). CPB was initiated using the right atrium for inflow and 
the distal ascending aorta for outflow. An obliquely cut, 14 mm diameter, straight, collagen-coated, 
Dacron tube was sutured about an incision on the laterally clamped proximal portion of the ascending 
aorta. Fibrin glue was placed around the running suture of the Dacron tube before the clamp was 
removed. A 36 F wire reinforced, straight cannula was passed through the Dacron tube into the aorta, 
with the distal end clamped once filled with blood. The heart was then volume loaded by reducing CPB 
flows before the straight cannula was passed across the aortic valve during ventricular systole. A 
tourniquet was maintained about the Dacron tube to seal against the straight cannula. After the straight 
 
Figure 38 – Ventricular apical inflow cannula 
reinforcement by Akhter et al. (2010) [118] 
 
Figure 39 – Inflow cannulation technique performed 
by Kalangos et al. (1998) [11] where the LVAD 
inflow cannula was placed in the ascending aorta and 
passed retrograde across the aortic valve. 
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cannula tip was located near the ventricular apex, it was secured to the Dacron tube with sutures and 
connected to the LVAD. CPB was stopped and the CPB outflow cannula was attached to the LVAD 
outflow port. Both cannulae exited through small, separate lateral incisions perpendicular to the 
superior aspect of the sternotomy incision. This technique was reported in five patients, with none 
requiring reoperation for excessive bleeding and aortic insufficiency was not identified with 
transesophogeal echocardiography in any patient. Two patients died of irreversible cardiac failure and 
one of septicemia. In the two survivors who were weaned from mechanical circulatory support, no 
aortic insufficiency or stenosis due to the transvalvular cannula was detected. However, this technique 
was only used for short term support, and the effects of placing an inflow cannula across the aortic valve 
has not been characterized for long term VAD support. A similar technique was performed by Duncan et 
al. (1991) [176] who noted the reduced CPB time due to elimination of apical cannulation. 
 
2.8.9.2 Left Ventricular Inflow Cannula Fixation Without Bypass 
With complications such as increased risk of bleeding, end-organ dysfunction and stroke associated with 
extended time on CPB, several institutes have attempted off-bypass VAD implantation. Fujimoto et al. 
(1987) [177] described an early attempt at an off-bypass technique for implantation of the LVAD inflow 
cannula in the left ventricle of calves.  The thinnest muscle area on the surface of the apex was 
identified by palpation, and this region was chosen as the site of inflow cannulation to avoid 
malpositioning of the cannula within the ventricle. Approximately five interrupted polyester sutures, 
reinforced with small Teflon pledgets, were placed circumferentially about the ventricular apex and 
passed through the fabric cuff of the inflow cannula. A corkscrew-type instrument was used to apply 
traction to the ventricular core which was cut by a surgical blade. Bleeding was avoided by manual 
occlusion of the apex by a surgeon pinching the ventricular wall. The inflow cannula was then inserted 
through the cored ventricle and the manual occlusion released. The sutures were then tied to secure the 
cannula and achieve haemostasis. Two failures occurred in early attempts at this procedure including a 
small apical hole resulting in difficult insertion and consequent ventricular fibrillation, and one case with 
the presence of a muscle flap over the cannula resulting in partial cannula obstruction. These problems 
have since been resolved by making the correct apical core size. While these techniques were developed 
for in-vivo evaluation in calves, they could be applied in the clinical setting with the addition of CPB. 
 
Griffith et al. (2009) [87] presented both on (n=2) and off (n=3) CPB techniques for implantation of the 
Terumo DuraHeart LVAD. On bypass, the technique involved a standard procedure of using a side-biting 
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clamp on the ascending aorta for end-to-side anastomosis of the LVAD outflow graft. The patient was 
placed in the Trendelenberg position and the apex of the heart was elevated. An apical punch was used 
to remove the ventricular core for LVAD inflow cannula placement. The apical cuff was then sewn to the 
apex with a series of pledgeted horizontal mattress sutures. The inlet conduit was then positioned and 
secured within the cuff before the left ventricle was de-aired. The off bypass procedure included the 
same process for LVAD outflow cannulation. However in this case, the series of pledgeted horizontal 
mattress sutures were placed on the left ventricular apex prior to coring. These sutures were placed 
through the apical cuff and the inflow conduit was secured within the cuff. An inflatable catheter was 
placed through the inflow conduit to prevent ejection of blood after insertion. The apex of the left 
ventricle was then pierced with a pointed scalpel and dilated to approximately 1 cm diameter before the 
inlet cannula was rapidly inserted to the point of the cuff. The sutures were then secured and the 
inflatable catheter removed before the pump was de-aired through the outflow conduit. The study 
reported significantly reduced time in the operating room for those patients who did not undergo CPB 
for implantation of the LVAD. Meanwhile, the patients who underwent CPB required more blood 
product transfusions and delayed sternal closure compared with those without CPB. No comparison of 
surgical blood loss was made between on and off bypass procedures. 
 
Frazier (2003) [35] reported the off-CPB insertion of a Jarvik 2000 LVAD in a 36 year old Jehovah’s 
Witness patient. Following clamped attachment of the outflow cannula to the descending aorta, 
accessed through a left thoracotomy, the ventricular apex was exposed. The suture ring was attached 
with interrupted mattress sutures and the patient was placed in the steep Trendelenburg position. The 
heart was fibrillated and the apex cored with a coring knife. The Jarvik 2000 LVAD was inserted and 
secured with an umbilical tape tie before the heart was defibrillated. Total fibrillated time was 90 
seconds while only 50 mL of blood was lost during fixation with this technique. While the patient 
survived, no mention of postoperative surgical related bleeding was mentioned.  
 
Slaughter et al. (2011) [178] described the off-bypass implantation technique of the HeartWare MVAD 
(Figure 40) in acute (n=4), 1 week (n=2) and 1 month (n=4) long studies in calves. A left thoracotomy was 
performed in the fifth intercostal space before 6-8 pledgeted sutures were placed at the left ventricular 
apex. A small incision was then made at the left ventricular apex and the MVAD was placed through the 
apex and fixed in place with the attached outflow cannula placed through the aortic valve. The entire 
procedure was completed without the need for CPB. Echocardiography was then used to ensure correct 
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placement of the outflow cannula. No complications due to device implantation or significant apical 
bleeding were reported in this study. 
 
2.8.9.3 Right Ventricular Inflow Cannula Fixation 
As the right ventricle is shaped differently to the left, particularly in respect to apical access, RVAD 
insertion through the right ventricle requires an alternative placement. For ventricular RVAD inflow, the 
right ventricle can be cannulated using similar methods as the LVAD inflow cannula, however the site 
should be halfway between the right ventricular base and apex. While the muscle is not as thick, it holds 
sutures well to satisfactorily fix and seal the cannula. RVAD inflow cannulation may also be achieved 
through the wall of the right atrium using a double purse-string suture [86].  
 
Hetzer et al. (2010) [56] described the implantation technique for the HeartWare HVAD when two 
devices were used to provide biventricular support. The LVAD was inserted with a standard procedure 
using the LV apex for inflow and the ascending aorta for outflow. RVAD inflow was achieved on the right 
ventricular free wall at the point of maximum distance from the septum, identified by transesophageal 
echocardiography. Two additional silicone rings (total thickness of 5 mm) were placed under the fixation 
ring of the HVAD inflow before insertion into the right ventricle to reduce the protrusion length of the 
inflow cannula within the ventricular chamber. The outflow graft, narrowed before surgery from 10 mm 
to 5 mm to reduce RVAD outlet pressure for the pulmonary circulation, was sutured to the pulmonary 
artery. This procedure allowed pericardial placement of both LVAD and RVAD devices.  
 
 
Figure 40 – Computer aided design model of the HeartWare MVAD device including the anchor which is 
attached to the ventricular apex, the standpipe which allows adjustment of the pump’s position within the 
ventricle and across the valve, the MVAD core assembly and the outflow cannula which crosses the aortic 
valve [178]. 
 
74 
 
Nonaka et al. (2001) [101] described the off-bypass implantation technique of two Gyro pumps for 
biventricular support. A left lateral thoracotomy was made through the fifth rib before an 11 mm 
albumin coated woven polyester graft was anastomosed to the descending aorta. The other end of the 
graft was attached to the pump (and combined actuator), which was placed in the preperitoneal space 
via a pararectal abdominal skin incision. The heart was exposed through opening of the pericardium 
before six to eight mattress sutures with pledgets and polypropylene purse string sutures with pledgets 
were placed around the left ventricular apex. The apex was cored with a blade and the inlet conduit was 
inserted before the ventricle was de-aired. An 11 mm albumin coated woven polyester graft was then 
anastomosed to the main pulmonary artery and attached to the RVAD outflow port. The RVAD was then 
placed alongside the LVAD in the preperitoneal space through the skin incision. Two mattress sutures 
with pledgets and purse string sutures were placed in the infundibular of the right ventricle. The right 
ventricular wall was then opened with a blade and the inlet tip of the RVAD was inserted within the 
chamber.  The RVAD was de-aired before BiVAD support was initiated. 
 
2.8.10 Sealing Techniques 
LVAD and RVAD inflow cannulae are susceptible to postoperative hemorrhage, even when particular 
care is taken to ensure haemostasis. Cannula fixation may be improved through use of Bioglue to 
reinforce the connection between the cannula and vessel [179], however must be applied in a dry field 
which, understandably, can be difficult in the operational setting [29].  Previous studies have also 
attempted wrapping the inflow and outflow cannulae with GoreTex patches, Vascutek tube grafts or 
pre-clotted Dacron tubes to reduce the incidence of postoperative bleeding [29, 30, 180].  It is also of 
vital importance that fixation of the cannula to each vessel can be achieved without air entering the 
system.  Air embolism can prove devastating to patient outcomes and may enter the system through the 
inflow cannula due to the negative pressure in this region either before chest closure or after chest 
closure due to patient movements such as coughing [181, 182]. 
 
Alternative hydraulic sealing techniques have been extensively researched in areas such as food, oil and 
chemical processing under high and low pressures [183-185].  O-rings are often employed in low or high 
pressure systems under low temperatures to provide a mechanical seal.  Increasing the fluid pressure 
against the O-ring essentially increases the O-ring pressure against the surface, thus improving the seal.  
Flat gaskets may also be employed to seal a connection between two surfaces, with the benefit of a 
larger surface area (in comparison to an O-ring) potentially increasing the resistance to leakage [183].  
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However, the larger surface area also results in reduced pressure against the surface compared to an O-
ring and may not be suitable for all applications.  Previously developed hydraulic sealing techniques 
could be employed to assist in cannula fixation design through incorporation of a silicone O-ring or 
gasket to reduce postoperative bleeding. 
 
2.8.11 Coring 
The success of the inflow chamber’s coring technique may dictate the degree of postoperative bleeding 
for both LVAD and RVAD applications. LVAD inflow coring is usually achieved through a cross-like 
incision of the left ventricular apex and manual removal of myocardial tissue with a scalpel [5].  
Ventricular apex coring devices have been used previously [186, 187], however reasonable force is 
required to press the circular knife through the myocardium.  This may result in distortion of the circular 
hole and a suboptimal seal around the inflow cannula, while misalignment of the cannula during 
insertion may promote haemolysis [188].  Accurate coring of the ventricular apex can be difficult due to 
the soft myocardium deforming under pressure. Circular punching or coring is employed in several 
industries such as metal forming, leather and the medical field.  Extensive literature is available on a 
variety of coring techniques for different applications including soft solids such as rubbers, gels and 
biological tissue [189-191].  Compliant, soft solids, such as ventricular myocardium, have an elastic 
behavior even after extensive deformation during penetration.  Small holes, such as those produce by a 
needle, under low pressure are generally plugged by the elastic recoil of the sample, however larger 
holes such as those used to core the ventricular apex do not completely recoil or self-seal under 
pressure [192].  Meanwhile, the penetration pressure required to core an elastic material is greater for 
higher material toughness, elastic shear modulus and punch cross-sectional surface area. Hollow 
punches, such as those used in coring devices in the food and rubber industries, benefit from rotational 
punching to reduce the downwards force required by adding a shear cutting force [192].  These 
techniques could be employed for the development of an improved coring device for cannula insertion.   
 
Following successful coring of the chamber and initiation of VAD support, the ventricles become 
unloaded and in some cases may recover. Myocardial recovery after LVAD occurs in 5-10% of patients 
with dilative cardiomyopathy, and less in those with ischemic cardiomyopathy. Potapov et al. (2010) 
[193] presented a plug which can be placed in the ventricular core after HeartMate II LVAD inflow 
cannula removal (Figure 41). The titanium alloy plug was sintered with titanium microspheres, similar to 
the inflow cannula of the HeartMate II LVAD. The diameter of the plug was the same as the HeartMate II  
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LVAD inflow cannula, and contained six small 
holes for fixation and a lip to prevent insertion 
too far through the myocardium. Fixation is 
achieved with sutures through the holes and 
HeartMate II LVAD sewing ring. The plug was 
constructed to be 8mm longer than the cuff of 
the sewing ring to reach the level of the 
endocardium without protruding into the left 
ventricle. The plug was used in four patients who 
had the HeartMate II LVAD explanted after 
myocardial recovery. CPB was initiated and the 
cannulae were removed with the patient 
positioned head down. After de-airing, the plug 
was placed within the myocardial core and sutured to the sewing ring. No thromboembolic events or 
significant bleeding was reported during ten months of follow-up.  
 
2.8.12 Summary of Cannula Fixation 
Postoperative hemorrhage is the most common complication following VAD support, with surgical 
related bleeding alone attributed with 11% of deaths in the INTERMACS trial. Influencing factors include 
the type of support (LVAD/BiVAD), time on CPB, VAD generation (continuous vs pulsatile flow), patient 
factors (blood and anatomical), anticoagulation, surgical skill and VAD-specific cannulation mechanisms. 
Meanwhile, the complications associated with severe postoperative hemorrhage include hypoperfusion, 
multi-organ failure, intracranial bleeding, and transplant-precluding allosensitization. Cannula fixation is 
commonly completed with sutures to the atria or ventricles for inflow and the arteries for outflow. 
Attempts to improve cannula fixation have revolved around adding more sutures and reinforcing 
pledgets which extends the CPB time and thus the risk of associated complications. Some institutes have 
attempted VAD implantation without CPB, however this provides an additional risk if the patient crashes 
without the CPB backup. Alternative sealing techniques from other industries exist, and should be 
implemented within this field to reduce surgical duration and CPB times while providing an improved 
seal to reduce postoperative hemorrhage.  
 
 
Figure 41 – The plug and plug holder ready for 
insertion following removal of the apical inflow 
cannula of the HeartMate II device [193]. 
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2.9 Cardiovascular Device Evaluation 
Cardiovascular devices are required to be evaluated extensively prior to clinical implementation. This 
evaluation stage may involve the use of numerical simulation techniques, mock circulation loops, 
isolated heart models and in-vivo evaluation in short and long term animal studies. Each evaluation 
technique is discussed in this section. 
 
2.9.1 Numerical Simulations 
Dynamic performance of a system is often neglected in the design phase, while the analysis of the 
system is often expensive and time consuming before the system is constructed. Using simulation 
packages (eg. MATLAB Simulink), systems can be evaluated in a small amount of time and at a low cost.  
Various numerical simulations of the cardiovascular system have been developed for the evaluation of 
cardiovascular devices [194-196]. A detailed review of numerical simulations is presented in Appendix 2. 
 
2.9.2 Mock Circulation Loops 
In-vitro evaluation of cardiovascular devices can be achieved with a mock circulation loop (MCL), which 
is a mechanical representation of the human cardiovascular system.  MCLs are used for in-vitro 
evaluation of artificial heart valves, pulsatile and continuous flow ventricular assist devices, total 
artificial hearts, aortic balloon pumps, and almost any other cardiovascular device.  Simple MCLs consist 
of just a preload chamber to deliver constant flow and a resistance valve to provide a pressure drop 
[197, 198].  Current systems are often far more advanced, including features such as variable vascular 
resistance, compliance and pulsatile flow [18, 199].  These systems are often limited to testing a single 
device under a small range of cardiac conditions.  Reproduction of the pulmonary circulation is often 
neglected [17, 200], limiting the assessment on right heart performance when mechanical circulatory 
support is supplied.  A variety of MCLs are discussed below to gain a detailed understanding of the 
current standards of in-vitro evaluation of cardiovascular devices. 
 
2.9.2.1 The Windkessel Model 
The Windkessel model is based on replication of the circulatory system through a lumped parameter 
model, where resistance, compliance and inertial elements are lumped into singular systems. MCLs are 
usually based on a three element Windkessel model, consisting of arterial compliance, peripheral 
resistance and characteristic resistance.  These systems ignore the influence of a fourth element, fluid 
inertia, which has been shown to improve pulse pressure values, and the aortic diastolic pressure wave 
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[201].  Addition of a fifth element, venous compliance, provides an improved representation of high 
frequency wave reflections [202, 203]. All elements are commonly grouped in MCL construction, 
resulting in lumped values that represent different segments of the human body. Although this practice 
compromises accuracy, it does allow the effective and simple alteration of these parameters in order to 
manually change physiological states. Simulated vascular resistances are most easily changed (with 
control valves); however, compliance and inertial effects are not. Since compliance is physically 
determined by Windkessel chambers [199, 204, 205], diaphragms [103, 206] or spring systems [207-
209], the MCL must be stopped when a change of compliance is required to transition between 
physiological states.  Inertial effects are influenced primarily by geometrical attributes (segment piping 
length / diameter; volume), and cannot be effectively changed once a MCL is constructed. These 
features are discussed in detail below. Simulation of the resistance, compliance and inertial elements is 
described in more detail later in this chapter. 
 
Sharp et al. (1999) [203] compared the benefits of two, three, four and five element Windkessel models 
of a MCL. The results of this study were then used to construct a MCL to compare with natural human 
results, the popular Donovan MCL, and the Penn State MCL, both of which are detailed below.  A 
computer analysis of RC, RCR, RLRC, and RCLRC models was conducted, where R stands for a resistance, 
C for a compliance and L for an inertial component.  The results of this study showed that as each 
element was added to the design, an improvement was made when comparing to human data.  When 
the fourth element was added, only a slight improvement over the three element design was noted, 
while the addition of a fifth element improved the circuit significantly.  Due to the common nature of 
the RCR model, and the difficulty of construction of an RCLRC model, the results of the simulation were 
ignored and RCR was chosen to take to a physical model stage.  This was seen to compare favorably 
against the Donovan and Penn State models when being measured against human data.  
 
Ruel et al. (2010) [210] evaluated 2 (RC), 3 (RRC) and 4 (RLRC) element Windkessel bioreactors in a 
numerical simulation and validated results with physical models. The RC and RRC numerical simulations 
had zero inertial characteristics, unlike their representative bioreactors which must have had some 
inertial contribution due to the length of the pipes.  The results were then compared to clinical data and 
revealed improved correlation between the clinical data and bioreactor as more elements were added 
to the bioreactor. However, the use of water rather than a fluid similar in viscosity to blood is a 
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limitation of this study. Meanwhile, a 
fifth element, venous compliance, was 
not evaluated and is essential to damp 
the pressure pulse which returns to the 
heart simulator.  
 
Stergiopulos et al. (1999) [201] aimed 
to find the difference in flow and aortic 
pressure measurements between the 
three and four element Windkessel 
models in dogs, humans and a mock 
circulation.  An example of the results 
obtained is shown in Figure 42, showing a significant difference in accuracy between the two models.  It 
was concluded in this study that the four element Windkessel model, which included an inertial 
element, represented aortic pressure and flow measurements with greater accuracy than the three 
element model. Ferreira et al. (2003) [211] compared the three and four element Windkessel models’ 
ability to estimate arterial compliance in 26 human subjects.  It was found that adding the fourth 
element, an inertial component, resulted in an improved representation of the arterial compliance.   
 
2.9.2.2 Previously Developed Mock Circulation Loops 
The first MCLs were primarily used for testing artificial heart valves and consisted of pulse duplicators 
driven by stepping motors to create an artificial heart beat [212].  Many of these systems include 
transparent, flexible ventricles for valve flow visualization [213-218]. An example of an early MCL is the 
system designed by Cornhill et al. (1977) [219], for the purpose of testing prosthetic aortic heart valves.  
This system used a collapsible silicone bag in a pressurized airtight box for a mock left ventricle which 
was supplied with pulses of compressed air, controlled by a solenoid valve.  With characteristic 
impedance, total arterial capacitance and peripheral resistance incorporated, the system reproduced 
appropriate conditions for the testing of artificial heart valves, however failed to simulate the 
pulmonary circulation and atrial systole and ignored inertial effects. 
 
The MCL designed by Kolff et al. (1959) [220] consisted of both systemic and pulmonary circulations 
(Figure 43).  The ventricles were operated by pulses of compressed air, while the pressures in the aorta  
 
Figure 42– Comparison of measured aortic pressure trace vs 
three and four element Windkessel simulations. [68] 
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and pulmonary artery were obtained by tall columns of water (82 cm or 60 mmHg for aorta and 26 cm 
or 20 mmHg for PA).  The diastolic pressure could be changed by altering the height of the fluid column.  
These columns created an undesirable effect of excessive inertia which had to be overcome to move 
fluid up the tube.  This was overcome by surrounding the bottom part of the tube with a pressurized air 
chamber to assist with the flow up the tube.  A single flow meter was used as it was said that the flow 
must be the same in both sides at all times, even though systemic-pulmonary flow imbalances may exist 
in the native circulation. No resistance valves were used in this study as the resistance was seen to 
increase with increased flow, and no attempt to simulate vessel compliance was mentioned. 
 
Reul et al. (1974) [221] constructed a systemic MCL using flexible tubing for the aorta and all of its 
branches.  This system was suspended in a water filled Perspex box which was connected to a 
 
Figure 43 – MCL by Kolff et al. (1959) [220] with tall columns of water representing the aorta (left) and 
pulmonary artery (right). 
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Windkessel chamber with adjustable air volume for compliance.  Separate resistances were applied for 
each branch of the system by a tube membrane.  The system was driven by a cam which supplies a 
pulsatile pressure to the mock ventricle, and fluid inertia was accounted for by appropriately 
dimensioning the aorta and its branches.  Although this system displayed a suitable mock version of the 
systemic circulatory system, it did not include a pulmonary circulation or a method of connecting and 
evaluating VADs. 
 
Donovan et al. (1975) [16] designed and built a complete MCL that has been replicated many times since 
its conception.  It was designed for testing new artificial heart designs in-vitro, however did not include 
atria or ventricles which limited the cardiovascular device testing capabilities of the rig.  This device used 
½ inch acrylic sheet to make a box, with several smaller compartments situated inside to replicate aortic, 
systemic venous, pulmonary arterial, pulmonary venous and ventricular components.  This system was 
fairly compact with dimensions of 605 mm wide, 403 mm high and 202 mm deep.  This MCL showed 
positive results when compared to a calf model, and has been the basis for many MCLs since.  
 
A MCL was developed by Scotten et al. (1979) [222] for evaluation of mitral valve prostheses.  A 
transparent mock ventricle was created which was driven by a cam which pushed fluid in a sealed 
chamber that included the ventricle.  This method gave a solution to finding the volume of the ventricle 
with respect to time by evaluating the cam position and cross sectional area with respect to time.  The 
ventricle pumped into a compliant latex rubber aorta, and then to resistance and compliance elements.  
Resistance was simulated by use of cellulose fiber water filters with pore sizes of 5 and 50 μm for 
characteristic and peripheral resistance respectively.  The lengths of these filters, and hence the 
resistance value, could be altered by insertion into a plastic tube while the MCL was in operation, 
however this produced a discretely variable resistance rather than a continuously variable system. 
Compliance was simulated by a volume of air trapped above the resistance elements.  Transparent 
materials were used for the ventricle, hydraulic chamber, and working fluids to allow flow visualization 
through the valves.  This MCL successfully produced pressure and flow results which allowed for 
detailed flow visualization to be completed and has since been modified and commercialized as the 
ViVitro pulse duplicator (ViVitro Labs Inc., Victoria, Canada). 
 
Rosenberg et al. (1981) [223] summarized the design and evaluation of the commonly repeated 
Pennsylvania State University MCL (Figure 44).  This system, first designed in 1971 for use on in-vitro  
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testing of VADs, has been refined in many ways since it was first introduced.  It replicated RLC elements 
for both the systemic and pulmonary circulation and incorporated VAD connections and adjustable 
cardiac conditions.  While resistance and compliance values were based on those seen in a healthy male, 
inertia values were incorrectly assumed to be equal for systemic and pulmonary circulations.   
 
Baloa et al. (2001) [224] developed a MCL with elastance-based control of the ventricles.  This concept 
used the elastance, defined as the instantaneous ventricular pressure versus ventricular volume, of the 
ventricle to develop a new control strategy for MCLs.  The maximum value for elastance was taken at 
the point of end systole, and can be interpreted as a measure of ventricular contractility.  Resistance and 
compliance were both changed manually in this system. The authors concluded that this design was 
successful in using elastance-based control to change the contractility of the ventricular chamber, 
resulting in a new way of reproducing difference cardiac conditions in a MCL for the evaluation of 
 
Figure 44 – Schematic of the Pennsylvania State MCL by Rosenberg et al. (1981) [223]. 
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cardiac assist devices. While the contractility of the ventricle was controlled, inertial effects in the 
ventricle and circulation were ignored, while only a systemic circulation was simulated.  
 
Pantalos et al. (2004) [17] developed a MCL which, according to the authors, included a Starling 
response for normal, heart failure, and partial recovery situations.  This system incorporated a flexible 
polyurethane atrium and ventricle.  The ventricle was situated inside an air chamber with a semi-rigid 
dome for mounting inflow and outflow valves, however was not anatomically shaped to produce 
accurate flow dynamics in the ventricle.  This configuration allowed for atrial or ventricular apex inflow 
and aortic outflow cannulation. A high fidelity pressure volume catheter was used for monitoring 
pressure and volume with respect to time and was placed inside the mock ventricle via the outflow 
valve.  A polyurethane aorta was connected to the ventricle which connected to the systemic and 
coronary vasculature. Inertial effects were accounted for in the cross sectional area and length of the 
tubing.  Pressure volume loops representing conditions of healthy, heart failure and recovery were 
produced, however the degree of Starling sensitivity is questionable. The pressure volume loop area 
appears to remain relatively constant over large changes in end diastolic volume, thus limiting the 
ventricular Starling sensitivity, even in the healthy condition. However, this MCL produced relatively 
accurate haemodynamic waveform magnitudes and morphology could be used for preliminary 
evaluation of cardiac devices. This MCL 
was then used by Glower et al. (2004) 
[225] to evaluate an artificial vasculature 
device and Koenig et al. (2004) [200] to 
investigate haemodynamic and pressure 
volume responses to continuous and 
pulsatile ventricular assist devices. 
 
Liu et al. (2005) [199] developed a 
systemic and pulmonary MCL for 
evaluation of continuous flow LVADs 
(Figure 45). The ventricles were 
simulated by semi-ellipsoidal shaped 
silicone diaphragms in pressure 
chambers which received pulses of 
 
Figure 45 - Mock circulation loop by Liu et al. (2005) [199] 
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compressed air for systole while a slight negative pressure was applied for diastole.  Check valves were 
used to achieve unidirectional flow.  Clear tygon tubing was used to connect all components in the loop, 
while the VAD was connected to the loop via the apex of the mock ventricle and the systemic arterial 
tank.  Testing was conducted with the loop under several different conditions including healthy resting, 
healthy sleeping, healthy exercise, congestive heart failure (CHF) and partially recovered CHF.  This mock 
circulation loop was sufficient for evaluation of continuous flow LVADs under various heart rates and 
contractility, however lacked a Starling response so was incapable of simulating the change in 
ventricular contractility with a change in preload. 
 
A complete mock circulation loop, including systemic and pulmonary circulations was developed by 
Timms et al. (2005) [18] (Figure 46).  This MCL was shown to produce accurate pressure and flow data 
for normal and heart failure conditions with a wide range of variable parameters.  Limitations in this 
study involve the use of heavy brass swing check valves for use in replacing the natural heart valves, 
restriction of flow in the pulmonary circuit due to a small flow meter orifice, an inability to measure 
ventricular volume with respect to time and an incorrect representation of the inertial characteristics of 
both systemic and pulmonary circulations.  
 
Figure 46 – Schematic of the MCL by Timms et al. (2005). ACl – left air compressor, ACr – right air 
compressor, AoC – aortic compliance, LA – left atrium, LV – left ventricle, PAC – pulmonary arterial 
compliance, PQ – pulmonary flow rate, PVC – pulmonary venous compliance, PVR – pulmonary vascular 
resistance, RA – right atrium, RV – right ventricle, SVC – systemic venous compliance, SVR – systemic 
vascular resistance, SQ – systemic flow rate, VAD – ventricular assist device. 
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Several other MCLs have been developed to evaluate heart valves [226] [213], VADs [227], 
extracorporeal membrane oxygenation (ECMO) [228] and infant haemodynamics [229]. While many 
MCLs have been previously developed, features such as a pulmonary circulation, accurate 
representation of fluid inertia, variable compliance and adhering to the Frank Starling law are often 
ignored.  A MCL capable of testing a large range of cardiovascular devices under various physiological  
conditions requires many components such as systemic and pulmonary circulations, variable vascular 
resistance, variable arterial compliance, venous compliance, attachment sites for mechanical support 
and pressure, volume and flow sensors. 
 
2.9.2.3 Simulation of the Heart 
Representation of the ventricles in a MCL can be achieved with various techniques. Several MCLs use 
pneumatically operated ventricles which use pulses of compressed air to simulate ventricular systole 
and vent to atmosphere or apply a vacuum for diastole [18, 206, 219, 230, 231]. Colacino et al. (2007) 
[232] compared the performance of a pneumatically operated ventricle in a MCL with a native ventricle 
through simulation techniques. Both pneumatically operated and native ventricles were implemented 
with the same closed vascular circuit. This study concluded that pneumatically operated ventricles were 
not preload sensitive and thus have an insufficient Starling response. Colacino suggested that pneumatic 
ventricles may not be applicable for testing active cardiac assist devices, such as VADs, due to the 
inadequate preload sensitivity.  
 
Various ventricle simulators have been developed for flow visualization studies. Khalil et al. (2009) [233] 
used a conical plastic hand-wash container to represent a left ventricle for flow visualization studies. A 
Jarvik 2000 device was attached to the apex of the conical container, with the outflow to a reservoir 
placed above the container before the flow visualization study was attempted.. While this study 
demonstrated several methods of evaluating flow paths in a mock ventricle, the method of replicating 
the ventricle with a plastic hand-wash container was not suitable to produce clinically relevant results.  
 
Yokoyama et al. (2010) [234] presented a passive filling left ventricle in a MCL. The ventricle was 
simulated with a thin latex rubber sack with an unstretched volume of 100 mL and placed inside a fluid-
filled, sealed chamber attached to a pusher plate and servomotor with linear actuator. The servomotor 
and linear actuator served to force the pusher plate into the chamber to pressurize the fluid to initiate 
ventricular systole. Ventricular elastance was controlled by altering a volume of air within the sealed 
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fluid chamber. As the air volume increased, contractility decreased. Passive filling was provided by the 
height of the atrial chamber, which was filled by a centrifugal pump acting as the right ventricle. While 
this system produced suitably various degrees of ventricular contractility, no Starling response was 
included and thus the volume dependant nature of the left ventricle was neglected. Meanwhile, the 
filling of the left ventricle resulted in negative left ventricle pressures of approximately -10 mmHg, 
indicating that perhaps the ventricle did not fill passively after all, possibly due to the recoil of the 
pusher plate mechanism. Finally, the pulsatile pressure and flow delivered as venous return to the left 
ventricle, although damped by the pulmonary venous compliance, could not be simulated with the use 
of a centrifugal blood pump to simulate the right ventricle. 
 
Muradbegovic et al. [235] (2011) developed a silicone heart model (Figure 47) to evaluate an artificial 
heart ‘muscle’ which could provide biventricular support in pediatric applications. CT scans of a 10 year 
old girl’s failing heart were obtained to base the silicone heart’s geometry; however ejection fractions of 
55% and 42% of the left and right ventricles respectively indicate the heart was certainly not in a severe 
heart failure condition. The authors then described scanning a synthetic foam rubber heart model with 
approximately the same dimensions as those on the CT scan; however it is not clear if the synthetic 
rubber heart model was based on patient data, or a generic model of the heart. The scanned foam 
rubber heart model images were then processed in SolidWorks software and formed with a 3D printer in 
silicone. The silicone used, MED 10-6607 from NuSil Technology Europe, was reported to possess similar 
mechanical properties to the human heart muscle, however no comparison of the mechanical 
properties was defined in the article. 
Meanwhile, the silicone would possess 
constant mechanical properties, yet the 
heart’s systolic and diastolic properties 
may change over time, such as the 
onset of ischemia. The left and right 
ventricles were created, without atria, 
and had volumes of 55 mL each; 
however it was not mentioned if this 
was the end systolic or end diastolic 
volume. Each ventricle was connected 
to an 8 mm ID pipette which 
 
Figure 47 – The silicone heart with Nitinol wires of the assist 
device wrapped around the silicone heart model by 
Muradbegovic et al. (2011) [235]. 
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represented both preload and afterload. The height of fluid in each pipette was used to calculate 
ejection volume, preload and afterload. Clearly this representation of the circulatory system was 
inadequate, as the preload of each ventricular chamber is directly influenced by the same ventricle’s 
afterload with no resistance or compliance elements to separate the two. Meanwhile, the resistance of 
the circuit was not representative of a native scenario, and thus the ventricular afterload was not 
accurately replicated. Another limitation with this study was the representation of compliance, with the 
small, 8mm diameter pipette not representative of the diastolic or systolic elastance of the atrium and 
aorta, for which it was used to simulate. As the heart model was static, apart from the motion of the 
BiVAD, the influence of the native heart’s remaining contractility was also not included, thus limiting its 
overall effectiveness in replicating a native heart model. 
 
Many more MCLs have been developed with flexible sacs in pressure chambers to simulate the 
ventricles and atria [17, 199, 205, 219]; however these systems do not accurately represent the shape or 
spiral contraction of a native ventricle.  Accurate representation of geometrical features such as the free 
walls, septum, valves, papillary muscles and trabeculae is difficult and can only be partially overcome 
through use of software such as Mimics to convert MRI data into physical moulds. Anatomically shaped 
mock ventricles have been previously developed, however these systems were used for valve testing 
and do not allow for VAD cannulation, while still limited by their form of contraction [226, 236]. 
Representation of the cardiac tissue mechanics such as toughness, elasticity and contractile function is 
also insufficient with a silicone model.  To overcome the insufficiencies of silicone heart models, isolated 
heart models (ISM), discussed later in this literature review, have been used in conjunction with 
coronary circulation loops [237-239].   
 
Attempts have been made to accurately define and replicate the native cardiac tissue mechanics.  To 
evaluate devices capable of recording left ventricular torsion, Cutri et al. (2010) [240] developed an in-
vitro test rig (Figure 48) to represent cardiac wall kinematics at the left ventricular apex.  Cardiac motion 
was defined as three major components including longitudinal (LV long axis direction), radial (LV short 
axis direction), and rotational (around the LV long axis).  Three brushless motors were interconnected on 
a metal structure to replicate the three cardiac motion components.  Velocity curves for each motor 
were obtained from in-vivo cardiac motion data for healthy and pathological hearts.  The test rig was 
shown to accurately represent apical motion when compared to in-vivo data, however could not be 
used for VAD evaluation as the apex was represented by a metal plate rather than a biological sample.   
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For evaluation of the interaction between the heart and cardiovascular devices, such as the cannula 
fixation technique, the degree of pulsatility and wall motion in pathological hearts must be replicated to 
ensure the model will provide sufficient results.  Van Eyll et al. (1992) [241] demonstrated that in 
patients with idiopathic dilated cardiomyopathy, there is very little wall motion at all, even when 
ejection fractions are relatively high at 35% (Figure 49).  The lack of wall motion was particularly 
noticeable at the apex in this patient population, which demonstrated that perhaps replication of 
cardiac wall kinematics may not significantly alter the results of apical cannula fixation studies.  Van Eyll 
also stated that following the onset of congestive heart failure, regional left ventricular function 
becomes almost indistinguishable between dilated and ischemic hearts.  This indicates that a lack of 
regional wall motion would be seen in most patients suitable for VAD implantation. Meanwhile, when 
the left ventricle dilates, the radius of curvature of the apex increases which increases the stress at this 
point.  The apex then becomes thinner, thus further increasing the stress on the myocardium in this 
region.  The increase in stress may explain why, in most patients with heart failure, cardiac function is 
diminished further in the apex compared to the base.  This study only observed the shape of the inner 
ventricular wall, or endocardium, and as such motion of the outer layer, or epicardium, must also be 
evaluated to observe the magnitude of muscle thickening during ventricular contraction at the apex.  
 
Figure 48 – Cardiac motion simulator by Cutri et al. (2008) [240] 
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Similar to ventricular wall motion, 
relaxation of pathological ventricles is 
also different to a healthy case.  The 
peak negative change in pressure per 
change in time (dP/dt) is decreased in 
patients with dilated cardiomyopathy, 
indicating impaired and delayed 
ventricular relaxation [242]. Rotation 
between the apex and base along the 
left ventricle long axis is also 
diminished in patients with severe 
heart failure [243]. The altered timing and magnitude of rotation influences both systolic and diastolic 
function in ischemic and dilated ventricles [244-247]. Gibbons et al. (1995) [244] studied the effect of 
regional ischemia on ventricular apex-base rotation in 16 open-chest dogs. The control group had 
maximum (end diastole) and minimum (end systole) rotation angles of 4.7 ± 1.1˚ and -15.9 ± 2.0˚ 
respectively. When ischemia was induced by occluding the left anterior descending artery for 50 
seconds, the maximum and minimum rotation angles reduced to 2.2 ± 1.8˚ and -13.9 ± 2.0˚ respectively.  
  
Figure 49– Left ventricular endocardial wall motion for 
anterior myocardial infarction (CAD) and idiopathic dilated 
cardiomyopathy (IDCM).  End diastolic shape is represented by 
a solid line, while end systolic shape is represented by a dotted 
line [241]. 
 
 
Figure 50 – Apex and base rotation vs time relationship during systole and diastole for controls (dotted line) 
and congestive heart failure patients (solid line).  ED – end diastole, AVO – aortic valve opening, ES – end 
systole, MVO – mitral valve opening, CW – clockwise, CCW – counter-clockwise. 
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Gibbons also stated that the base of the heart rotates only minimally (1-2˚) so rotation can be attributed 
almost solely to apical rotation. While this study demonstrated a reduction in apical rotation with 
ischemic hearts, the open-chest procedure in dogs may not produce comparable results to closed-chest 
humans. Fuchs et al. (2004) [247] evaluated cardiac rotation between base and apex in healthy and 
congestive heart failure (CHF) patients using tagged MRI. The rotation vs time graph (Figure 50) 
demonstrated that CHF patients had severely diminished rotation at the base and apex throughout the 
cardiac cycle when compared with the control group of healthy patients.  Rotation angle in Figure 50 is 
defined as positive when observing counter-clockwise motion from the apex.  
 
2.9.2.4 Frank Starling Response in Mock Circulation Loops 
Previous attempts to implement a Starling response in a MCL have been made. Baloa et al. [224] 
implemented an elastance based control scheme which calculated the desired ventricular pressure 
based on instantaneous ventricular volume with a bellows pump ventricle. A separate control loop was 
then required to regulate the ventricular pressure based on the output of the elastance control loop. 
While demonstrating changing ventricular pressure with changed ventricular volume, the end systolic 
pressure volume relationship (ESPVR), usually non-linear in humans [248], was linear. Meanwhile, no 
right ventricular Starling response was simulated. Loh et al. [249] developed, in simulation, a MCL 
Starling response based on the work completed by Baloa et al., but with the addition of right atrial 
compliance and pressure dependent flow. Again, this simulation included no right ventricular Starling 
response, and only a limited range of preload was evaluated.  
 
A Starling response was implemented in a systemic only MCL with pneumatically operated ventricles by 
Pantalos et al. [17]. Little detail of the Starling implementation was given, however results were shown 
for varying Starling sensitivity. For all degrees of Starling sensitivity, the ESPVR appeared as though it 
would cross the x-axis at negative ventricular volumes. The x-intercept should occur at positive 
ventricular volumes as ventricular contraction will cease while a small residual volume remains [250]. A 
positive x-intercept was obtained by Ferrari et al. [208], who incorporated both left and right ventricular 
Starling responses in a MCL. This system controlled ventricular pressure based on ventricular volume 
with piston-cylinder type ventricles. While variable Starling response sensitivity was demonstrated with 
varying preload and afterload, the ESPVR was linear rather than concave towards the volume axis.  
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2.9.2.5 Blood Volume and Flow 
The majority of blood in the human body is stored in the venous circulation.  This is due to the compliant 
nature of the veins in comparison to the arteries, which allows the veins to hold significantly more 
blood.  Table 3 illustrates the volume of blood in the primary vessels of the body.  
 
Vessels Total Blood Volume (%) 
Systemic Circulation  
Veins 64 
     Large veins      (39%)  
     Small veins      (25%)  
Arteries 15 
     Large arteries  (8%)  
     Small arteries  (5%)  
     Arterioles        (2%)  
Capillaries 5 
Total in systemic vessels 84 
Pulmonary vessels 9 
Heart 7 
Total blood volume 100 
Table 3 - Vessel blood volume by Seeley et al. (2003). [251] 
 
Bevegard et al. (1960) [252] conducted a study on the effect of body position on circulation at rest and 
exercise, paying particular attention to stroke volume.  Ten healthy male subjects were used for this 
study with right heart catheterization obtained through the brachial artery.  Standing, sitting and the 
supine position (lying down, face up) were all examined at different levels of exercise.  Cardiac output in 
resting conditions averaged 7.89 L/min for supine position and 5.85 L/min for sitting position while the 
highest workload due to exercise produced averages of 17.93 L/min and 15.94 L/min for the same 
positions respectively.  Stroke volume varied for different positions with an average of 115.7 mL for the 
supine position and 70.0 mL while sitting.  The mean increase in stroke volume when transitioning from 
rest to work in the sitting position was recorded at 51%.  With a change of posture from supine to sitting 
positions at rest, it was noted that the pulse rate increased and the stroke volume decreased 
significantly.  It was found that the filling pressures of the right ventricle were unchanged during the 
transition from rest to exercise in the sitting position, while the absolute diastolic pressure in the right 
ventricle decreased during exercise in the supine position. 
 
Flow through the circulatory system is primarily laminar, with turbulent flow seen in the heart and 
where the arteries branch.  It is usually measured in liters per minute (L/min) and typical values are 
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around 5 L/min for a healthy adult at rest and 2-3L/min for a heart failure situation [18].  The flow of 
blood in a vessel is related to the pressure difference in that vessel, and the resistance of that vessel (R).  
Blood will always flow from an area of higher pressure (P1) to an area of lower pressure (P2).  The flow of 
blood through a vessel (Q) can be represented as –  
 
  
     
 
          (2.1)  
 
The amount of blood pumped out of the heart per minute is known as the cardiac output (CO).  This can 
be found by multiplying the heart rate by the stroke volume.  
 
2.9.2.6 Blood Pressure 
The blood pressure traces seen in native human situations must be replicated in both magnitude and 
form. Typical values of systolic and diastolic aortic pressure for a healthy human are 120 mmHg and 80 
mmHg respectively [251].  Pulse pressure, the difference between systolic and diastolic aortic pressure, 
is primarily influenced by stroke volume and compliance levels. With an increase in stroke volume, 
and/or a decrease in vascular compliance, the pulse pressure will increase.  If stroke volume is 
decreased and/or vascular compliance increased, the pulse pressure will decrease.  As the blood flows 
away from the heart, the pulse pressure is gradually damped due to the compliant circulation, resulting 
in an almost non-existing difference in the arterioles. The pressures for a resting condition used by 
Timms et al. (2005) [18] when considering MCL design are shown in Table 4.                                                                           
               
Region of circulatory system Pressure (mmHg) 
Left atrial (LAP) 
Left ventricular (LVP) 
Left ventricular end diastolic (LVPED) 
Aortic (AoP) 
Mean arterial (MAP) 
Right atrial (RAP) 
Right ventricular (RVP) 
Right ventricular end diastolic (RVPED) 
Pulmonary arterial (PAP) 
Mean pulmonary arterial (MPAP) 
Mean circulatory (Pmc) 
8-10 
0-120 
8 
120/80 
93 
3 
0-25 
3 
25/10 
15 
7 
Table 4 - Pressure values used by Timms et al. (2005) [18]. 
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2.9.2.7 Compliance 
Compliance is the tendency for blood vessel volume to increase as the blood pressure increases [251].  
Compliance is inversely related to stiffness, meaning that a high level of compliance results in a vessel 
wall stretching easily.  It can be expressed by equation 2.2.  
 
 Compliance =     Change in volume (mL)          (2.2) 
   Change in pressure (mm Hg) 
 
The compliance of the veins is approximately 24 times greater than that of arteries [251]. This gives the 
veins the ability to hold large amounts of blood in comparison to arteries.  Ventricular compliance 
influences the ventricle’s end diastolic pressure volume curve.  If the compliance of the ventricle is 
decreased, this increases the end diastolic pressure for any given end diastolic volume.  This is 
represented graphically in Figure 51.  
 
Donovan et al. (1975) [16] simulated vessel compliance with a trapped volume of air above the 
circulatory fluid in each chamber, known as a Windkessel chamber.  Windkessel chambers have been 
used in several MCLs for simulation of vessel compliance [199, 204, 205, 230, 236, 253-262]. These 
chambers are capable of producing continuously variable levels of compliance through manipulation of 
the chamber air volume, however require MCL shutdown for each compliance change.  The volumes of 
the chambers used by Litwak et al. (2005) were 4.9, 43.6, 5.6 L for systemic arterial, systemic venous, 
and pulmonary compliances respectively. The values chosen by Litwak et al. for systemic arterial and 
venous compliance were 2.2 mL/mmHg and 50 
mL/mmHg respectively. 
 
Spring and piston systems have also been used 
to simulate vessel compliance (Figure 52) [17, 
207-209]. Spring based compliance chambers 
are smaller than Windkessel chambers, thus 
allowing for more compact MCL design.  
Woodruff et al. (1997) [207] chose the spring 
constants based on equation 2.3.  
 
Figure 51 - Effect of ventricular compliance [37]. 
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       (2.3)  
 
Where K is the spring constant, Ac is the area of the piston, and C is the desired value of compliance.  
Variable compliance was achieved by alternating the springs with different spring constants, however 
this process required shut-down of the MCL each time. Previously reported values for compliance of the 
systemic arterial and pulmonary venous systems are shown in Table 5. 
 
Segment Donovan et al. 
(1975) [16] 
Arabia et al. 
(1984) [209] 
Woodruff et al. 
(1997) [207] 
Timms et al. 
(2005) [18] 
Systemic arterial 1 3.6 0.5-1.5 1-2 
Systemic venous 10 82.5 5-15 10-200 
Pulmonary arterial 1 4.8 N/A 2-4 
Pulmonary venous 5 10 N/A 4-6 
Table 5 – Comparison of vessel compliance values chosen for various MCLs. All values of compliance have 
units of mL/mmHg. 
  
 
Figure 52 - Spring compliance chamber by Arabia et al. (1984).  
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2.9.2.8 Resistance 
The resistance to blood flow has a significant effect on the circulatory system.  As arteries and veins 
decrease in radius (r), their resistance (R) increases.  The viscosity (η) of blood and the length of the 
artery (L) also influence the resistance, which can be expressed by equation 2.4.  
 
  
   
  
         (2.4) 
 
The ascending aorta exhibits very little resistance to the flow of blood, and so only a very small pressure 
drop exists.  Meanwhile, parts of the systemic circulation such as the smaller arteries and the arterioles, 
show a high level of resistance and produce a significant pressure drop. The body has the ability to 
change the resistance to flow by constricting or dilating the arteries.  Constriction increases resistance 
and reduces flow through the artery or vein, thus redirecting flow elsewhere. Vessel dilation produces 
the opposite effect.  The resistance to blood flow by the whole systemic circulation is known as systemic 
vascular resistance (SVR) and is primarily determined by blood vessel diameters.  If the central venous 
pressure is known, SVR can be calculated by using equation 2.5. 
 
    
       
  
       (2.5) 
 
Lumped resistance is usually simulated with a pinch valve in conjunction with flexible tubing and has 
been used in a variety of MCL studies [18, 205, 206, 263-265].  The valve is usually lowered by an 
electrical signal to occlude the valve, resulting in a variable level of resistance.  Donovan et al. (1975) 
[16] used an innovative form of obtaining resistance (Figure 53) in the design of a complete mock 
circulation loop.  Pulmonary and systemic resistance was obtained by a plate which rotated about a 
pivot to occlude the flow tube.  The value of resistance depended on the angle of rotation.  The angle of 
rotation of the plate was controlled by a lever arm connected to a bellows which was situated inside the 
chamber filled with water at a specified pressure.  When the pressure in the aortic / pulmonary arterial 
chambers increased, the pressure difference across the bellows forced the bellows to contract, which 
pulled on the lever arm and rotated the valve plate about the pivot.  This caused the valve plate to move 
giving a greater cross-sectional area for the fluid to travel through the flow tube, and hence lower 
resistance, which also served to lower the arterial pressure.  The systemic resistance system operated in 
the same manner as the pulmonary resistance; however an extra spring was present in parallel to the 
bellows to allow for the higher pressure on the systemic side. 
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Scotten et al. (1979) [222] et al. simulated vascular resistance in a MCL with several small, flexible tubes 
that were compressed to varying degrees by a flat plate (Figure 54). Resistance was controlled by 
manipulation of the flat plate. Vascular resistance was calculated by Scotten et al. using equations 2.6 
and 2.7.  
 
              (2.6) 
 
  
      
  
         (2.7)  
 
Where ∆P is the pressure drop, R is the resistance, Q is the volumetric flow rate, μ is the fluid viscosity, 
LR is the effective length of the resistor tubing and AR is the area of the resistance tubing.  Patel et al. 
(2003) [266] chose values for systemic vascular resistance of 0.85 and 1.2-1.4 mmHg.s/mL respectively 
for healthy and congestive heart failure. Timms et al. 
(2005) [18], however, chose systemic vascular 
resistance values of 1.463 and 1.8 mmHg.s/mL 
respectively for healthy and congestive heart failure 
and pulmonary vascular resistance values of 0.106 and 
0.160 mmHg.s/mL respectively based on values 
reported in previous literature [267, 268]. 
 
2.9.2.9 Inertia 
Inertia relates to the ability of an object to resist a 
change in motion, and has a significant influence on 
circulatory haemodynamics.  As blood flows through 
the circulatory system, its pulsatile nature requires 
constant changes in motion.  Noble et al. (1968) 
conducted a study on the contribution of blood 
momentum to left ventricular ejection in dogs.  This 
study was conducted by placing pressure transducers in 
the aorta and left ventricle, and a flow probe in the 
aorta.  Controls were noted first and showed that the  
 
Figure 53 - Resistance mechanism used by 
Donovan et al. (1975) [16]. 
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ventricular pressure was higher during the early ejection period, with the aortic pressure increasing 
above ventricular pressure in the last 30-50% of ejection.  An aortic occlusion device 
 
was then placed around the aorta, with the theory that when the aorta was fully occluded during late 
systole, the ventricular pressure would drop if the flow was primarily dependent on blood momentum.  
As the aorta was being occluded by the device, which required about 20 milliseconds to fully close, a 
spike was seen in the ventricular pressure trace, followed by a distinct reduction in pressure.  This result 
proved that blood momentum has a significant effect on ejection.  Fluid momentum can be represented 
in a MCL by incorporating an inertial component in the system.  By finding the correct values for the 
volume of fluid moving in each section of the circulatory system, and representing these values in a MCL 
with pipe lengths and diameters, an inertial component can be added. 
 
The circulatory system is frequently based on the Windkessel model for MCLs.  This system incorporates 
features such as resistance, compliance, and inertia and represents these as electrical drawings.  Many 
mock circulation loop simulations use a three element Windkessel model, which includes characteristic 
resistance (Rc), arterial compliance (C), and a peripheral resistance (Rp).  Four element Windkessel 
models also include an inertial component (L) which is vital for accurate simulation of the pressure and 
 
Figure 54- Resistance segment used by Scotten et al. (1979) 
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flow waveforms, as discussed earlier in this literature review [201, 203, 210, 211].  Electrical analogues 
of three and four element Windkessel models are shown in Figure 55. 
 
Stergiopulos et al. (1999) [201] reported that the inertia of a tapered arterial segment (Li) can be found 
using equation 2.8.  
 
   
   
  
 
   
 
        (2.8) 
 
Where ρ is the blood density, ls is the segment length, A is the cross sectional area and cu is a coefficient 
that accounts for a non-flat velocity profile, equaling 4/3 for low frequencies.  Inertia in series and 
parallel are calculated in the same manner as spring constants, with inertia in series being calculated by 
the sum of all inertia, and parallel situations being calculated by using equation 2.9.  
 
 
    
 
 
  
 
 
  
        (2.9) 
 
Scotten et al. (1979) [222] used equations 2.10 and 2.11 to solve for the required inertia incorporated in 
a four element Windkessel model of a MCL. 
  
      
  
  
         (2.10) 
 
     
  
  
        (2.11) 
 
Figure 55 - Three and four element Windkessel models by Stergiopulos et al. (1999).  
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Where ∆P is the change in pressure,   is the inertia, Q is the volumetric flow rate, t is time, ρ is fluid 
density, L1 is the length of the pipe and A1 is the cross sectional area of the pipe.  The values for the 
inertia in certain areas of the MCL were too small to be measured experimentally, and a more complex 
method was later described.  This method included inertia effects by placing them upstream of the 
compliance chambers, where the flow is much more pulsatile.  Inertial effects were reduced in the MCL 
by shortening the length of the tubing upstream of the compliance chambers. 
 
2.9.3 Isolated Heart Models 
Developed over a century ago by Langendorf [269], mammalian isolated heart models (ISM) operate on 
the Starling principle of the heart after it has been excised from an animal, with an example shown in 
Figure 56.  Providing oxygen and nutrient rich fluids are passed through the coronary system, and a 
preload is applied to the native ventricle, the heart will contract in its usual manner.  These systems 
usually provide retrograde perfusion to the coronary arteries through a cannula inserted in the aorta. 
The aortic valve prevents backflow into the ventricle, while ventricular preload is simulated through an 
inflatable balloon inserted through the mitral valve.  The balloon is inflated to induce a preload on the 
myocardium which responds through ventricular contraction and hence balloon compression. Aortic 
cannula flow is driven by a pump, usually a roller pump, with inflow achieved through a reservoir of 
oxygen and nutrient rich blood or Krebs Henseleit solution.  The reservoir is continuously gassed with 5% 
CO2 and 95% O2 at a constant temperature of 37°C to maintain an appropriate pH of 7.4.  The solution 
exits the coronary arteries through the right atrium via the coronary sinus and is returned to the 
reservoir for oxygenation.  The mock circulatory system and heart are kept in either 37°C circulating 
water or warm, moist air. Preload and afterload conditions must be physiologically representative of the 
in-vivo situation.   
 
ISMs possess several limitations such as potential aortic valve insufficiency and may deteriorate in 
function over time [270].  Meanwhile, the excised hearts generally possess a healthy shape and 
contractile function which may limit the model accuracy if assessing cannula fixation for diseased hearts.  
It is quite possible that results taken from an isolated heart model will provide false conclusions when 
compared to an in-vivo model [271]. To overcome some of the deficiencies associated with isolated 
heart models, cadaveric models have been previously used to evaluate cardiac devices such as stents 
[272] and valves [273] and may provide a more suitable evaluation tool for cardiovascular devices 
compared to an animal model. 
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2.9.4 In-Vivo Models 
In-vivo evaluation of cardiovascular devices is required prior to clinical trials and is usually conducted in 
calves, sheep, dogs or goats for cardiovascular devices. A brief review of in-vivo cardiovascular device 
evaluation is presented in Appendix 3. 
 
2.9.5 Summary of Cardiovascular Device Evaluation 
This review of cardiovascular device evaluation techniques has discussed current technology in the field 
of numerical simulations, MCLs, isolated heart models, cardiac wall kinematics and in-vivo studies. MCLs 
provide an improved platform for device evaluation however most systems ignore the pulmonary 
circulation and the Starling response which are vital for accurate replication of the cardiovascular 
system. Methods of simulating the beating heart in-vitro have primarily involved pneumatic and/or 
silicone ventricles, however some attempts have been made to replicate ventricular dynamics. However, 
in congestive heart failure cases this may not be necessary, particularly at the apex of the heart where 
vertical and rotational movement are limited. Isolated heart models provide an evaluation tool 
somewhere between common MCLs and in-vivo studies, however are complicated to start and operate 
and diminish in performance over time. Meanwhile, in-vivo models are expensive, time consuming, 
 
Figure 56 – An isolated heart model setup including perfusate reservoir, excised heart, flow meter, 
ventricular balloon and control computer. 
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require ethical approval and are commonly performed in healthy animals which are not a clinical 
representation of a congestive heart failure scenario. This review has demonstrated the need for a 
suitable MCL for evaluation of a variety of cardiovascular devices. 
 
2.10 Conclusion 
The aim of this literature review was to determine the areas for improvement in cannula design. This 
review has demonstrated the shortfalls with current VAD design, physiological control, MCL design, 
cannula placement studies, cannula design, and postoperative surgical related hemorrhage related to 
cannula fixation for LVAD, RVAD and BiVAD support.  
 
The prevalence of heart failure is increasing due to the lack of donor organs. The requirement for 
ventricular assistance or replacement is evident based on the growing number of patients receiving 
mechanical circulatory support worldwide. Biventricular heart failure poses a particularly hazardous 
problem due to the lack of a long term device capable of supporting both sides of the heart. Several 
devices have sufficient clinical experience in biventricular support, however are usually incapable of long 
term applications due to the wearable components on these first generation pumps. Second and third 
generation LVADs are being used clinically as a BiVAD, however their capabilities to provide lower 
pressure for the pulmonary circulation with banding and reduced pump speeds requires further 
investigation.  
 
One of the features of a biventricular support system that must be enhanced is the cannula design and 
placement. The cannulation site influences the resultant haemodynamics and flow dynamics within the 
cardiovascular system, and therefore will have some impact on the postoperative outcome. Left 
ventricular cannulation is usually preferred for LVAD inflow due to the increased ventricular ejection 
fraction and improved washout of the pump, however left atrial cannulation may still be used. RVAD 
inflow may be performed in the right atrium or ventricle. Previous studies have focused on the LVAD 
inflow cannulation site; however no repeatable, Starling-responsive test rig has been used. Meanwhile, 
RVAD inflow cannulation site is almost neglected in the literature, with only pulsatile flow devices 
evaluated in right atrial and ventricular cannulation. With the development of continuous flow RVADs, 
there is a clear need to evaluate which cannulation site is most suitable.  
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The design of the cannulation system also influences the haemodynamics and flow dynamics. Cannula 
tip design and insertion length has been shown to alter the postoperative outcomes of VAD patients, 
with a noticeable difference in postoperative stroke rate with a change of cannula insertion length. 
Meanwhile, the mechanical characteristics of the cannulae affects the performance of the pump, with 
rigid inflow cannulae promoting flow obstruction as the heart remodels. The mechanical properties of 
the cannulae should be explored in order to determine their overall effect on the VAD-patient interface. 
 
A key region of the VAD-patient interface is the fixation point. Postoperative hemorrhage is the most 
common complication following VAD support, with surgical related bleeding attributed with 11% of 
deaths in the INTERMACS trial. Various factors influence the postoperative bleeding rates, and 
complications such as multi-organ failure and transplant precluding allosensitization exacerbate this 
problem. Cannula fixation is achieved with various suture techniques, with some surgeons reinforcing 
these connections with additional sutures and pledgets to provide strength around the often friable 
tissue. These attempts to reduce postoperative bleeding often increase the CPB time, which is 
associated with complications such as increased rates of postoperative bleeding, end-organ dysfunction, 
cognitive impairment and stroke. Alternative techniques of sealing and fixation exist in other industries 
and an effort to use these mechanical solutions should be attempted to address this issue. 
 
While this literature review has identified several improvements required in mechanical circulatory 
support, it is also necessary to improve the evaluation techniques for these devices. MCLs are capable of 
providing a simple method of cardiovascular device evaluation; however usually lack a pulmonary 
circulation and Starling response. Isolated heart models provide an intermediate balance between MCLs 
and in-vivo studies, however these systems are extremely complex, expensive and time consuming to 
set up and operate. In-vivo trials are required prior to clinical testing, but the expense and time 
consuming processes of ethical approval and organization hinder the efficiency of device evaluation. 
This review has demonstrated the need for an improved in-vitro test rig which incorporates features 
such as a pulmonary circulation and Starling response, while providing some level of variability to 
evaluate a wide range of devices. 
 
In conclusion, this literature review summarized a wide range of topics which require improvement in 
the field of VAD cannula design and cardiovascular device evaluation. The information gathered in this 
literature review will allow for an appropriate path of research on cannula design and associated fields. 
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Chapter 3 
Mock Circulation Loop Development 
 
3.1 Aims 
Several designs of VADs and their associated systems are under development and require in-vitro 
evaluation prior to in-vivo or clinical trials. For accurate evaluation of cannula placement and design, a 
MCL was required. As identified in the literature review, previously developed MCLs vary from simple 
systems consisting of a preload chamber and resistance valve to obtain constant flow, to complex 
systems which accurately represent the resistance, compliance, fluid inertia and pulsatile nature of both 
the systemic and pulmonary circulations. As the aim of this thesis was to evaluate LVAD and RVAD 
support, simulation of both systemic and pulmonary circulations in the MCL was necessary, while the 
addition of pulsatile flow and accurate representations of resistance, compliance and fluid inertia was 
required to increase the clinical relevance of results.  
 
A MCL was designed in the candidate's Masters by Research [274], which used numerical simulation 
techniques to enhance the performance of a MCL [275]. In brief, equations for fluid pressure and flow 
throughout the MCL were implemented within the Matlab/SIMULINK environment. Features such as 
horizontal and vertical tubing, gravitational effects, resistance, inertia, compliance, air volume and 
pressure, pulsatile air supply, and atmospheric pressure were all included within the simulation. Physical 
parameters such as pipe lengths and diameters from a previous MCL were included within the numerical 
simulation to compare the resultant haemodynamics from the MCL and simulation. This stage 
completed the validation process of the simulation, which was then used to alter the physical 
parameters to enhance the resultant haemodynamics. A MCL was then designed, but not constructed, in 
the Masters program by using the parameters obtained by the enhanced numerical simulation. The 
numerical simulation was used throughout the MCL development and construction process. 
 
The primary aim of this chapter was to describe the construction and validation of the physical MCL 
based on the results from the numerical simulation. Secondary aims of this study included shaping the 
regulator pressure waveforms to improve MCL ventricular function and implementation of a Starling 
response in the MCL's left and right ventricles. This improved MCL could then be used to accurately 
evaluate cannula design and placement in an in-vitro setting. 
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3.2 Methods 
The MCL was designed to approximate the haemodynamics of the human cardiovascular system by 
using lumped equivalent hydraulic components. Each circuit (systemic and pulmonary) of the MCL was 
based on a five element Windkessel model, consisting of characteristic resistance (1st), arterial 
compliance (2nd), peripheral resistance (3rd), an inertial component (4th) and venous compliance (5th). 
A number of components were used to simulate a wide range of features and are described in detail in 
this section. 
 
3.2.1 The Heart 
 The four chambers of the heart were represented by clear vertical PVC pipes (ALSCO, Lithia Springs, GA, 
U.S.A.) with T-sections connecting the inflow, heart chamber and outflow. Light weight, clear, swing 
check valves (ALSCO, Lithia Springs, GA, U.S.A.) of 30mm diameter were connected to the heart 
chambers for unidirectional flow. Left and right 
ventricular systole was simulated by an injection 
of compressed air into the vertical chambers. 
Pulses of compressed air were regulated by 3/2 
way solenoid valves (VT325-035DLS, SMC 
Pneumatics, Brisbane, Australia), high pressure 
manual regulators (IR3000-04, SMC Pneumatics, 
Brisbane, Australia), electro-pneumatic 
regulators (ITV2030-012BS5, SMC Pneumatics, 
Brisbane, Australia) and low pressure, precision 
regulators (AR40-04H-01, SMC Pneumatics, 
Brisbane, Australia) (Figure 57). The solenoid 
valve provided the pulsatile air supply by either 
delivering compressed air to the ventricles 
(systole) or venting the compressed air to 
atmosphere (diastole). Systolic periods of 0 to 
100% of the cardiac cycle were achievable by 
controlling the solenoid valve input voltage 
signal.  
 
 
Figure 57 - Schematic of the MCL ventricles 
including connection of pressures sensors (VPS) and 
level magnets (LM) with magnetostrictive level 
sensors (MLS) for data acquisition. IV - inflow valve, 
OV - outflow valve, AC - compressed air supply, 
HPMR - high pressure manual regulator, EPR - 
electro-pneumatic regulator, LPMR - low pressure, 
precision regulator, SV - electrically actuated solenoid 
valve. 
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The air pressure delivered to the ventricle chambers could be increased or decreased by changing the 
current supplied to the electro-pneumatic regulator, thus simulating a change in contractility.  However, 
this regulator was best suited to high pressures, thus the low pressure, precision regulator was required 
to produce lower pressures such as those seen in the pulmonary circulation. A left and right atrial kick 
was simulated in a similar way to the ventricle contraction, however with reduced pressures.  A systolic 
duration of 20% of the cardiac cycle was applied at a phase delay of 80% of the cardiac cycle compared 
to the start of ventricular contraction.  The contractility of the atrium was controlled using only the low 
pressure, precision regulator due to the cost of the electro-pneumatic regulators. 
 
3.2.2 Ventricular Pressure Shaping 
Use of only the solenoid valves to transition between systole and diastole resulted in square ventricular 
pressure waves which did not match the curved traces seen in the literature. To overcome this problem, 
left and right ventricular electro-pneumatic regulator current supply was altered every 0.05 seconds to 
provide a more physiological ventricular pressure waveform. The current supply for each 0.05 second 
step was manipulated for each ventricle independently through trial and error using a graphical look-up 
table. The left ventricle regulator current supply was adjusted to produce a similar waveform to the left 
ventricle pressure. However, the right ventricle regulator current supply required manual adjustment 
through trial and error until an appropriate right ventricular pressure waveform was produced. Traces of 
the left and right ventricle regulator current supplies are shown in Figure 58. 
 
(a) 
 
(b) 
 
Figure 58 - Regulator current supply gains over one cardiac cycle at 60 beats per minute for (a) left and (b) 
right MCL ventricles. 
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3.2.3 Simulation of the Starling Response 
A Starling response was simulated in the MCL’s pneumatic left and right ventricles through a 
proportional controller based on the real-time measurement of ventricular end diastolic volume (EDV). 
A natural logarithmic function of EDV was used to scale the electrical current supply sent to the electro-
pneumatic regulators. The natural logarithmic function was estimated to fit the left and right ventricular 
function curves described by Guyton (2005) [71] (Figure 59). The sensitivity of the MCL’s Starling 
response (and hence level of native ventricular function) was controlled by passing the output of the 
logarithmic function through a gain block.  The gain block was used to proportionally scale the output of 
the ventricular pressure shaping lookup table, resulting in a time varying electro-pneumatic regulator 
current signal that was dependent on preload. To ensure suitably low systolic pressures at low 
ventricular volumes, an offset constant was added to the EDV. The value of offset varied with heart 
function and was chosen manually. To allow minor, manual changes in the final MCL end systolic 
pressure volume relationship (ESPVR) curve, including a tail-off region to simulate ventricular 
overloading, a lookup table was added to the Starling response function after the sensitivity gain. The 
lookup table provided an additional offset for the electro-pneumatic regulator current supply 
dependent on the end diastolic ventricular volume. A schematic of the controller is shown in Figure 60.   
 
 
Figure 59 - Left and right ventricular function curves from Guyton (2005) [71] to estimate the mock 
circulation loop left and right ventricular Starling response curves. 
 
108 
 
 
Figure 60 - Schematic of the MCL Starling control and ventricular pressure shaping to control electro-
pneumatic regulator current. EDV - end diastolic volume, ln - natural log function. 
 
3.2.4 Vascular Resistance 
The characteristic resistance of each section in the MCL was determined by the length and cross-
sectional area of the pipe.  Systemic (SVR) and pulmonary (PVR) vascular resistance can change quite 
dramatically so a variable, lumped SVR and PVR was also required.  This was achieved with valves which 
provided lumped vascular resistance for both circuits.  SVR was manipulated with a 3/8" proportional 
control valve (EPV-375B, Hass Manufacturing, Averill Park, NY, USA) while PVR was adjusted with a 1" 
socket valve with rubber sleeve (VMP025.03X.71, Convair Engineering, Epping, Australia) which was 
controlled by an electro-pneumatic regulator (ITV2030-012BS5, SMC Pneumatics, Brisbane, Australia) 
and was capable of producing lower values of resistance. Approximate resistance values for each 
segment are calculated using Equation 3.1 (Poiseulle's law) where R is the segment resistance, μ is the 
fluid viscosity, LR is the effective length of the pipe and AR is the area of the pipe.  These resistance 
values, displayed in Table 6, were based solely on pipe dimensions and do not include corrections for 
wall friction or fittings, elbows or T-sections. While MCL resistance values for some segments were 
smaller than those reported in the literature, the variable vascular resistances accounted for these and 
ultimately restored the lumped systemic and pulmonary vascular resistances to clinically representative 
values. 
 
  
      
  
          (3.1)  
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Anatomical Segment Value in Literature 
 (mmHg.s.mL-1) 
 
Pipe Diameter 
(mm) 
Pipe Length 
(mm) 
MCL Resistance 
(mmHg.s.mL-1) 
Left atrium 
     Pipe 
     Valve (mitral) 
0.003 - 0.01  
25 
25 
 
40 
40 
 
2.8e-5 
2.8e-5 
Left Ventricle 
     Pipe 
     Valve (aortic) 
0.008 - 0.04  
25 
25 
 
40 
40 
 
2.8e-5 
2.8e-5 
Systemic Arterial 
     Pipe 
     Valve (SVR) 
0.9 - 1.83  
25 
0-9.45 
 
530 
90 
 
3.7e-4 
0.003 - inf. 
Systemic Venous 
     Pipe 
0.075 – 0.3  
25 
 
530 
 
3.7e-4 
Right Atrium 
     Pipe 
     Valve (tricuspid) 
0.003 – 0.01  
25 
25 
 
40 
40 
 
2.8e-5 
2.8e-5 
Right Ventricle 
     Pipe 
     Valve (pulmonary) 
0.003 – 0.04  
25 
25 
 
40 
40 
 
2.8e-5 
2.8e-5 
Pulmonary Arterial 
     Pipe 
     Valve (PVR) 
0.11 – 0.312  
25 
0-25.2 
 
530 
80 
 
3.7e-4 
5.42e-5 - inf. 
Pulmonary Venous 
     Pipe 
0.006 - 0.045   
25 
 
600 
 
4.2e-4 
Table 6 – Approximate values for resistance of each segment of the physical mock circulation loop 
determined by Poiseulle's law compared to those seen in the literature [17, 18, 195, 196, 223, 224, 229, 276, 
277]. SVR - systemic vascular resistance, PVR, pulmonary vascular resistance, inf - infinity. 
 
3.2.5 Arterial and Venous Compliance 
The compliance of the MCL was required to accurately mimic the values seen in the human body.  
Resting values for systemic arterial and pulmonary arterial compliance were chosen based on those seen 
in the human circulatory system and reported in the literature as 1.5 mL/mmHg and 3 mL/mmHg 
respectively [18]. However, these values can vary depending on the level of arterial stiffness due to 
heart and vascular disease. Therefore, the arterial compliance chambers were designed to be variable. 
Windkessel chambers were used as a lumped representation of compliance with maximum air volumes 
of 2.5 and 5 L for aortic and pulmonary arterial segments respectively. These chambers were made from 
100 mm diameter PVC pipe with a permanent cap on one end and a moveable test plug on the other 
end. The moveable test plug was used so the volume of air within the Windkessel chamber could be 
altered before testing, thus changing the arterial compliance. A hole was drilled through the permanent 
cap to insert a bulkhead which connected the Windkessel chamber to the MCL.  
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The systemic venous system was 
represented by an 8 L cylindrical pressure 
vessel partially filled with fluid and placed 
at a height below the rest of the MCL.  A 
compressed air supply was attached to the 
top of the vessel to alter the chamber 
pressure and hence shift fluid from the 
systemic venous chamber to the rest of 
the MCL. When fluid levels in the MCL 
were required to be lower, the systemic 
venous chamber air supply was open to 
atmosphere, thus venting the compressed 
air and allowing fluid to return to the chamber from the MCL. This was further controlled by including 
two, 2-way solenoid valves (VX2360-04-5D1, SMC Pneumatics, Brisbane, Australia) and a high pressure 
manual regulator (IR3000-04, SMC Pneumatics, Brisbane, Australia) on the compressed air line (Figure 
61). This feature was useful in altering mean circulatory pressure, as well as mimicking the effect of the 
skeletal muscle pump during exercise (i.e. increase venous return). Pulmonary venous compliance was 
obtained using a non-variable Windkessel chamber. 
 
3.2.6 Fluid Volume and Inertia 
Pipe lengths and diameters of each segment of the MCL were chosen to create segment volumes which 
represent those seen in the literature for an adult circulation. Unstressed segment volumes are 
displayed in Table 7 and compared with those reported in the literature. For cases where the MCL 
volume was required to change, such as a transition between healthy and congestive heart failure, the 
systemic venous compliance chamber was used to move fluid between the MCL and systemic venous 
system, or to add or remove fluid from the entire circulation if necessary. The working fluid used in the 
MCL was a water and glycerol mixture (40% and 60% by weight respectively) which was a close 
representation in viscosity and density to that of blood. 
 
The pipe lengths and diameters were also chosen to represent the correct inertial characteristics of the 
systemic and pulmonary circulations, while also considering the viscosity of the fluid. Values for inertia 
of the systemic and pulmonary circulations for a healthy adult were taken from the literature to assist in  
 
Figure 61 - Schematic of the systemic venous compliance 
chamber (SVC) air supply. The compressed air supply 
(CAS) was regulated by a manual regulator (MR). For MCL 
filling, solenoid valve 1 (SV1) was opened while solenoid 
valve 2 (SV2) was closed, thus pushing air into the SVC and 
fluid from the SVC to the MCL. For MCL emptying, SV1 
was closed and SV2 was open, thus venting the air in the 
SVC to atmosphere (Atm.) and allowing fluid to pass from 
the MCL to the SVC. 
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Anatomical 
Segment 
Value in 
Literature (mL)  
 
Pipe Diameter 
(mm) 
Pipe Length 
(mm) 
Pipe Volume (mL) 
Left Heart 50 25 160 78 
Systemic Arterial 
 
715 25 
9.45 
100 
530 
90 
50 
260 
6 
393 
Sum = 659 
Systemic Venous 2785 25 530 260 
0-8000* 
Sum = 260-8260 
Right Heart 50 25 160 78 
Pulmonary Arterial 90 25 
25.2 
100 
 
530 
80 
50 
260 
40 
393 
Sum = 693 
Pulmonary Venous 490 25 
100 
600 
50 
294 
393 
Sum = 687 
Total 4180 - - 2377-10377 
Table 7– Physical mock circulation loop volumes compared to those seen in the literature [278] for the 
unstressed volume of a healthy adult. Note that heart volumes are representative of end systolic volume. * 
The systemic venous chamber was varied between 0 and 8 L/min, depending on the simulated patient status. 
 
 
 
 
 
 
Anatomical 
Segment 
Value in Literature 
(mmHg.s2.mL-1)  
 
Pipe Diameter 
(mm) 
Pipe Length 
(mm) 
Inertia 
(mmHg.s2.mL-1) 
Systemic Arterial 0.0007 - 0.02 
 
25 
9.45 
 
530 
90 
 
0.0081 
0.0095 
Total 0.00437 
Pulmonary Arterial 0.0017 - 0.01575 25 
25.2 
 
530 
80 
 
0.0081 
0.0012 
Total 0.00105 
Table 8– Inertia of the systemic and pulmonary circulations for the physical mock circulation loop (found by 
multiplying density by length over area [222]) compared to those seen in the literature for a healthy adult [17, 
195, 196, 223, 229, 276] 
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choosing pipe dimensions, while the numerical simulation was also consulted throughout the design 
process. As inertia has the greatest effect on systems with large pressure changes, the arterial segments 
are of the most importance and are presented in Table 8 and compared with values from the literature. 
 
3.2.7 Defects and VAD connections 
Several physiological defects were included in the MCL to allow for cardiovascular device evaluation 
under a wide range of patient scenarios. Heart valve regurgitation was simulated in the mitral and aortic 
valves with the inclusion of a 2-way solenoid valve (VX2360-04-5D1, SMC Pneumatics, Brisbane, 
Australia) controlled circuit parallel to the mitral and aortic valve. This circuit attached to the ascending 
aorta and left ventricle for aortic valve regurgitation, and the left ventricle and left atrium for mitral 
valve regurgitation. The 2-way solenoid valve allowed for the heart valve defect to be switched either on 
or off, however a variable degree of valve regurgitation was not possible with this design.  
 
Septal defects between the atria and ventricles were simulated by connecting a 2-way solenoid valve 
(VX2360-04-5D1, SMC Pneumatics, Brisbane, Australia) controlled circuit between the chambers. For the 
atrial septal defect, the circuit was attached to both the left and the right atria. For the ventricular septal 
defect, the circuit was attached to both the left and right ventricles. Due to the on or off nature of the 
solenoid valve, the size of the septal defect could not be altered. 
 
Cannulation points were included throughout the MCL for cardiovascular device evaluation. LVAD inflow 
cannulation ports were connected to the left atrium and left ventricle with 1/2" tubing connectors and 
gate valves to allow or occlude the LVAD flow. An LVAD outflow cannulation port was connected to the 
ascending aorta with 1/2" tubing connectors and gate valves to allow or occlude LVAD flow. RVAD inflow 
and outflow cannulation ports were connected with the same components as the LVAD circuit to the 
right atrium and right ventricle for RVAD inflow and the pulmonary artery for RVAD outflow. Ports in 
both atria and ventricles allowed for comparison of the inflow cannulation site for both LVADs and 
RVADs.  
 
3.2.8 Data Acquisition and Control  
Circulatory and cardiovascular device pressures were recorded using silicone-based transducers 
(PX181B-015C5V, Omega Engineering, Connecticut, USA) attached to the MCL through luer connectors. 
These pressures included, but were not limited to, left atrial pressure, left ventricular pressure, aortic  
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pressure, right atrial pressure, right ventricular pressure, pulmonary arterial pressure, LVAD inflow 
pressure, LVAD outflow pressure, RVAD inflow pressure and RVAD outflow pressure. 3-way taps were 
included in each pressure line to allow air to vent from the circuit. Systemic and pulmonary flow rates 
were recorded with magnetic inductive flow meters (OPTIFLUX 1010C/D, Krohne, Germany) combined 
with signal converters (IFC010C/D, Krohne, Germany).  The systemic flow meter had an orifice size of 
3/8" while the pulmonary flow meter had an orifice size of 1" to account for the much lower pulmonary 
vascular resistance. Although the MCL is a closed loop system, flow meters were required on both 
systemic and pulmonary circulations to record transient changes in flow rates and hence shifts in fluid 
volume. VAD inlet and outlet flow rates were recorded with clamp on ultrasonic flow sensors (10PXL, 
Transonic Systems, NY, USA) attached to tubing flow meters (TS410-10PXL, Transonic Systems, NY, USA). 
Left and right ventricular volumes were recorded using magnetostrictive level sensors (IK1A, GEFRAN, 
Italy) which calculated the height of a float in each ventricle. The float height was multiplied by the cross 
sectional area of the vertical PVC pipe ventricles to calculate instantaneous ventricular volume. When 
combined with the left ventricular pressure trace, these ventricular volume measurements produced 
pressure volume loops. Post processing of the pressure volume loops enabled capture of left ventricular 
ejection fraction and stroke work.   
 
All inputs (pressures, flow rates, volumes) were captured at 100Hz and displayed in real-time using a 
dSPACE data acquisition system (DS1103, dSPACE, Novi, MI, USA). A graphical user interface (GUI) was 
made in ControlDesk to display the input data graphically and numerically. The ControlDesk GUI was 
interfaced with a SIMULINK file which applied gains and offsets to the input parameters from dSPACE 
and the output parameters to dSPACE. Example screenshots from the SIMULINK model are shown in 
 
Figure 62 - A screenshot of an example dSPACE input for reading systemic flow rate. The 0-10V signal from 
the flow meter passed through the fourth analogue to digital (AD4) dSPACE port. An offset and gain were 
applied to ensure accurate flow meter readings to ControlDesk before a low pass filter (SQfilter) was used to 
remove signal noise and display the real time flow rate. An averaging filter (MSQfilter) was also used to 
obtain a mean flow rate value. 
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Figure 62 and Figure 63. Both the GUI and data acquisition system were also combined to control the 
electro-pneumatic regulators, solenoid valves and proportional control valves. This enabled computer 
controlled systemic and pulmonary vascular resistance, ventricular and atrial contractility, heart rate, 
systolic time, and defect regulation.  A summary of all input and output parameters is displayed in Table 
9. The MCL GUI, shown in Figure 64, enabled real time manipulation of all MCL outputs while recording 
and displaying all MCL inputs.  
 
MCL Parameter Instrument 
 
Number Signal 
Inputs 
    Pressure 
 
Silicone based pressure transducers (PX181B-015C5V) 
 
10 
 
0-10V 
    MCL flow rate Magnetic flow meter (OPTIFLUX 1010C/D and IFC010C/D) 2 0-10V 
    VAD flow rate Ultrasonic flow meter (10PXL and TS410-10PXL) 2 0-10V 
    Volume Magnetostrictive level sensors (IK1A) 2 0-10V 
Outputs 
    Contractility 
 
Electro-pneumatic regulator (ITV2030-012BS5) 
 
2 
 
0-10V* 
    Heart rate 3/2 way solenoid valve (VT325-035DLS) 2 0/24V# 
    Atrial kick rate  3/2 way solenoid valve (VT325-035DLS) 2 0/24V# 
    SVR Proportional control valve (EPV-375B) 1 1-5V 
    PVR Electro-pneumatic regulator (ITV2030-012BS5)  
and socket valve (VMP025.03X.71) 
1 
1 
0-10V* 
N/A 
    Defects 2 way solenoid valve (VX2360-04-5D1) 4 0/24V# 
    MCL volume 2 way solenoid valve (VX2360-04-5D1) 2 0/24V# 
Table 9 - Summary of MCL data acquisition and control parameters, the instruments used to achieve 
acquisition / control, the number of instruments required and their respective signals. * A circuit was 
included to convert the dSPACE 0-10V output to 4-20mA for the electro-pneumatic regulator input current 
supply. 
#
 Solenoid valves were controlled through digital output signals from dSPACE which passed through 
a switch to close (0V) or open the solenoid valve (24V). SVR - systemic vascular resistance, PVR - pulmonary 
vascular resistance. 
 
Figure 63 - A screenshot of an example dSPACE output for controlling the systemic vascular resistance 
proportional control valve. An output voltage value was selected in ControlDesk which passed through to the 
SVR value in SIMULINK. The signal then passed through a dSPACE output gain to the first digital to 
analogue port (DA1) which sent a 1-5V signal to the proportional control valve. 
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Figure 64 - Main MCL GUI in ControlDesk. (a) Atrial kick and ventricle solenoid valve control, (b) left and 
right ventricle regulator control, (c) systemic and pulmonary vascular resistance control. All inputs including 
pressures, flow rates and ventricular volumes are displayed numerically on this screen. RAP - right atrial 
pressure, RVOL - right ventricular volume, RVP - right ventricular pressure, PAP - pulmonary arterial 
pressure, MPAP - mean pulmonary arterial pressure, PVR - pulmonary vascular resistance, RVEDV - right 
ventricular end diastolic volume, RVESV - right ventricular end systolic volume, RV_SV - right ventricular 
stroke volume, RV_EF - right ventricular ejection fraction, RVAD in - RVAD inflow pressure, RVAD out - 
RVAD outflow pressure, LAP - left atrial pressure, LVOL - left ventricular volume, LVP - left ventricular 
pressure, AoP - aortic pressure, MAP - mean aortic pressure, SVR - systemic vascular resistance, LVEDV - 
left ventricular end diastolic volume, LVESV - left ventricular end systolic volume, LV_SV - left ventricular 
stroke work, LV_EF - left ventricular ejection fraction, LVAD in - LVAD inlet pressure, LVAD out - LVAD 
outlet pressure, BPM - beats per minute. 
 
3.2.9 Simulation of Various Cardiac Conditions 
The systemic venous compliance chamber was filled with fluid (60% water, 40% glycerol by weight) 
before compressed air was supplied to shift fluid from this chamber into the MCL to a predetermined 
‘zero’ level. Pressure, flow and ventricle volume sensors were then offset to read 0 mmHg, L/min and 
mL respectively at a steady state. Additional compressed air was supplied to the systemic venous 
chamber through the MCL's fill / empty function to create the desired mean circulatory pressure/central 
venous pressure. 
 
MCL parameters such as left and right ventricular contractility, systemic and pulmonary vascular 
resistances and arterial compliances, heart rate, fluid volume and defects were manipulated to 
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represent a variety of healthy and pathological conditions. The basic haemodynamics which were used 
to define each condition are outlined in Table 10. The haemodynamic data is based on values found in 
the literature [18, 212, 223, 266] and through personal communication with clinical experts. The MCL 
hardware parameters required to replicate those haemodynamics are summarized in Table 11. For 
initial assessment purposes, these conditions included: 
 - healthy rest: simulated by a left ventricular systolic pressure (LVPsys) of 120 mmHg, mean 
 aortic pressure (MAP) of 100 mmHg, right ventricular systolic pressure (RVPsys) of 25 mmHg, 
 mean systemic (MSQ) and pulmonary (MPQ) flow rates of approximately 5 L/min and a heart 
 rate (HR) of 60 beats per minute. 
 - healthy exercise: simulated by an increase in LVPsys, RVPsys and HR and a decrease in 
 systemic (SVR) and pulmonary (PVR) vascular resistance to increase cardiac output. 
 - myocardial infarction: simulated by a decrease in LVPsys, RVPsys which resulted in 
 decreased cardiac output. 
 - congestive left heart failure (LHF) class IV: simulated by a decrease in LVPsys and an 
 increase in PVR and HR to reduce cardiac output and increase pulmonary congestion. 
 - congestive LHF class IV with LVAD support (BP-80, Biomedicus Inc., Eden Prairie, MN, USA) 
 via left ventricular cannulation: simulated by a decrease in LVPsys with an LVAD used to 
 compensate for the reduction in cardiac output. 
 - congestive biventricular heart failure (BHF) class IV: simulated by a decrease in LVPsys and 
 RVPsys with an increase in SVR, PVR and HR to reduce cardiac output. 
 - healthy with atrial septal defect: simulated by opening the septal defect between the left and 
 right atria to create a flow shunt. 
 - healthy with ventricular septal defect: simulated by opening the septal defect between the 
 left and right ventricles to create a flow shunt. 
 - healthy with mitral valve regurgitation: simulated by opening the valve defect between the 
 left atrium and ventricle to create a flow shunt. 
 - systemic and pulmonary hypertension: simulated by increasing SVR and PVR to create higher 
 arterial pressures. The subsequent increase in ventricular afterload resulted in higher ventricular 
 pressures due to the ventricular Starling response. 
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Parameter Units Rest Exercise MI LHF 
IV 
LHF 
VAD 
BHF 
IV 
 
ASD VSD MR SPHT 
LVreg mmHg 111 141 72 64 64 47 103 81 84 123 
RVreg mmHg 25 46 28 30 30 16 30 34 30 47 
SVRv Volts 2.15 3.15 2.00 1.78 2.15 1.68 2.20 1.94 2.29 2.28 
PVRv Volts 3.8 2.0 4.4 5.9 3.8 5.6 2.4 4.2 2.0 5.5 
HR Bpm 60 120 60 90 60 90 60 60 60 60 
Tsys % 40 30 40 70 40 70 40 40 40 40 
AoCVol L 2 1 2 2 2 2 2 2 2 2 
PACVol L 3.8 4.3 3.5 3.5 3.5 3.5 3.5 3.5 3.5 2.7 
MCP mmHg 8 10 9 20 10 20 8 8 8 9 
VADS RPM - - - - 2000 - - - - - 
 
3.2.10 Validation 
The haemodynamics produced when simulating the physiological conditions in Table 11 were compared 
with those seen in the literature and textbooks where possible. Pressure, flow and volume magnitudes 
and waveforms were compared with those seen in the literature and textbooks to ensure an 
appropriate representation of the clinical scenario.  Systemic and pulmonary vascular resistance, left 
and right ventricular ejection fraction and stroke work and a variety of other parameters were recorded 
throughout to ensure reasonable values were simulated for each physiological condition. 
 Units Rest Exercise MI LHF 
 
LHF 
VAD 
BHF 
 
ASD VSD MR S+P 
HT 
LVPsys mmHg 120 160 85 80 70 75 120 90 100 140 
MAP mmHg 100 115 70 65 95 60 90 75 75 110 
MSQ L/min 5.2 10 3 2.7 5.2 2.1 5 3.5 4.6 5.5 
RVPsys mmHg 25 45 28 35 26 33 28 37 27 49 
MPAP mmHg 17 25 18 28 17 25 15 23 18 31 
MPQ L/min 5.0 9.8 2.8 2.5 5.0 1.9 6.2 6.4 4.3 5.3 
HR bpm 60 120 60 90 60 90 60 60 60 60 
Table 10 - Haemodynamics used to simulate various conditions in the MCL. MI - myocardial infarction, LHF 
IV - left heart failure class four, LHF VAD - left heart failure class four with LVAD support, BHF IV - 
biventricular heart failure class four, ASD - atrial septal defect, VSD - ventricular septal defect, MR - mitral 
valve regurgitation, SPHT - systemic and pulmonary hypertension, LVPsys - systolic left ventricular pressure, 
MAP - mean aortic pressure, MSQ - mean systemic flow rate, RVPsys - systolic right ventricular pressure, 
MPAP - mean pulmonary arterial pressure, MPQ - mean pulmonary flow rate, HR - heart rate. 
Table 11 - Hardware parameters for simulation of various conditions in the MCL. MI - myocardial 
infarction, LHF IV - left heart failure class four, LHF VAD - left heart failure class four with LVAD support, 
BHF IV - biventricular heart failure class four, ASD - atrial septal defect, VSD - ventricular septal defect, 
MR - mitral valve regurgitation, SPHT - systemic and pulmonary hypertension, LVreg - left ventricle systolic 
pressure supply, RVreg - right ventricle systolic pressure supply, SVRv - systemic vascular resistance valve 
voltage supply, PVRv - pulmonary vascular resistance valve voltage supply, HR - heart rate, Tsys - % of the 
cardiac cycle spent in systole, AoCVol - aortic compliance chamber air volume, PACVol - pulmonary arterial 
compliance chamber air volume, MCP - mean circulatory pressure, VADS - left ventricular assist device 
speed. 
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MCL Starling response validation was achieved by simulating healthy and heart failure (mild and severe 
failure of the left and / or right ventricles) conditions and plotting the left and right ventricular pressure 
volume (PV) loops over a range of ventricular preload. After the MCL parameters were manipulated to 
simulate each condition, the Starling response was initiated and the sensitivity gain and offset were 
manually adjusted through trial and error to produce an appropriate degree of contractility with a set 
ventricular preload. The shape of the end systolic pressure volume relationship (ESPVR) was then 
evaluated by slowly decreasing ventricular volume from maximum volume (approximately 280mL) until 
ventricular volumes approached zero. The end systolic point of each PV loop was taken to create the 
ESPVR for each case. The slope of the ESPVR at various points was taken and compared to values seen in 
the literature for validation. This was completed for all healthy and heart failure conditions to generate 
a range of validated ESPVR curves. 
 
3.2.11 Final Design Summary 
Using the knowledge gained from the extensive literature review and the numerical simulation 
developed in the candidate's Masters, a mock circulation loop was designed, constructed and validated. 
Variable arterial compliance was simulated with a Windkessel chamber and test plug arrangement, 
while variable vascular resistance was simulated with proportional control and socket valves. Inertial 
components of the systemic and pulmonary circulations were incorporated through appropriate 
selection of pipe lengths and diameters. A bronchial shunt was also included to simulate the bronchial 
circulation between the thoracic aorta and the pulmonary venous circulation. Each component was 
connected through clear PVC pipe (ALSCO, Lithia Springs, GA, USA) of 25mm diameter to ensure low 
circuit resistance. Contractility, heart rate, systolic time and Starling sensitivity were incorporated in 
both ventricles through solenoid and regulator arrangements with feedback mechanisms. Shaping of the 
ventricular pressure waves was achieved by varying regulator supply voltage in 0.05 second increments 
over the cardiac cycle. Defects were included in the MCL to enhance its capabilities of representing a 
wide range of clinical scenarios, while connection points for cardiovascular devices were attached at 
various locations around the rig. A GUI was included alongside a data acquisition system to allow 
complete control of the MCL and recording of all haemodynamic variables. A wide range of healthy and 
pathological conditions were simulated and validated against previous literature. A schematic of the 
final design is shown in Figure 65. 
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Figure 65 - Schematic of the final MCL design. LA - left atrium, MV - mitral valve, LV - left ventricle, AoV - 
aortic valve, AoC - aortic compliance chamber, SQ - systemic flow meter, SVR - systemic vascular resistance 
valve, SVC - systemic venous compliance chamber, RA - right atrium, TV - tricuspid valve, RV -right 
ventricle, PV - pulmonary valve, PAC - pulmonary arterial compliance chamber, PQ - pulmonary flow meter, 
PVR - pulmonary vascular resistance valve, PVC - pulmonary venous compliance chamber, ASD - atrial 
septal defect, VSD - ventricular septal defect, MVR - mitral valve regurgitation port, AVR - aortic valve 
regurgitation port, BS - bronchial shunt. 
 
3.3 Results 
Results were taken from the MCL to ensure it was capable of simulating a wide range of physiological 
conditions and for validation against patient data and data reported in previous literature. 
 
3.3.1 MCL Construction 
The MCL was successfully constructed from various PVC pipes and fittings. Small leaks throughout the 
circulation were rare and patched with PVC glue and silicone sealant. Figure 66 shows the ventricular 
and arterial chambers with connections for cardiovascular device evaluation and simulation of aortic 
valve regurgitation. The valves used to simulate lumped SVR and PVR are shown in Figure 67, while the 
entire MCL is shown in Figure 68 with a generic rotary LVAD attached to the circulation. 
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Figure 66 - Final MCL construction of (a) systemic and pulmonary arterial and ventricular chambers and (b) 
the aortic valve regurgitation port and LVAD outflow connection port to the aortic compliance chamber. 
PAC - pulmonary arterial compliance chamber, AoC - aortic compliance chamber, RV - right ventricle, LV - 
left ventricle, LVADout - LVAD outflow connection to the MCL, AoVR - aortic valve regurgitation port, AoV 
- aortic valve. 
 
(a) 
 
(b) 
 
Figure 67 - MCL vascular resistances including (a) the proportional control valve in the systemic circulation 
and (b) the socket valve in the pulmonary circulation. 
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Figure 68 - Final constructed MCL with a rotary LVAD attached. 
 
3.3.2 Replication of Haemodynamics for Simulation of Various Conditions 
Recorded haemodynamics for all simulated conditions are presented in Table 12. Examples of systemic 
and pulmonary pressures, flow rates and left ventricular pressure volume loops for conditions of healthy 
resting, ventricular septal defect, LHF class IV and LHF class IV with LVAD support are shown in Figure 69. 
In the simulated healthy resting condition, MCL hardware parameters were modified to successfully 
produce typical values of aortic pulse pressure (120/80 mmHg) and systemic cardiac output (MSQ) (5.2 
L/min). Pulmonary arterial pulse pressures of 26/11 mmHg were reproduced in this condition. The 
pulmonary flow rate (MPQ) was slightly less than that seen on the systemic side, with a reduction to 
approximately 4.9 L/min due to the bronchial shunt re-circulating flow on the systemic side. The left 
ventricular ejection fraction (LVEF) of 64% revealed good ventricular function and a left ventricular 
stroke work (LVSW) of 1.11 Watts was expected for this physiological condition. 
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 Units Rest Exercise MI LHF 
 
LHF 
VAD 
BHF 
 
ASD VSD MR S+P 
HT 
LVPsys mmHg 120 160 83 80 70 74 118 92 98 138 
LVPdias mmHg 7 8 10 16 5 16 6 6 8 6 
AoPsys mmHg 120 150 80 75 100 65 118 90 97 136 
AoPdias mmHg 80 80 60 60 92 52 77 63 62 92 
MAP mmHg 98 115 71 67 96 58 92 75 77 110 
MLAP mmHg 10 16 12 20 8 20 9 11 16 18 
MSQ L/min 5.2 10.1 3 2.7 5.2 2.1 5 3.5 4.6 5.5 
RVPsys mmHg 26 45 28 35 26 33 28 37 27 49 
RVPdias mmHg 5 5 3 3 3 10 3 5 3 3 
PAPsys mmHg 26 40 26 30 26 28 26 35 26 45 
PAPdias mmHg 11 15 15 24 10 23 7 13 12 19 
MPAP mmHg 17 26 18 28 17 25 15 23 18 31 
RAP mmHg 5 14 4 6 5 15 7 9 6 7 
MPQ L/min 5.0 9.8 2.8 2.5 5.0 1.9 6.2 6.4 4.3 5.3 
HR bpm 60 120 60 90 60 90 60 60 60 60 
LVSV mL 88 90 55 30 50 24 83 110 120 96 
LVEF % 64 60 31 10 30 9 72 78 71 67 
LVSW Watts 1.11 3.52 0.54 0.375 0.34 0.24 1.16 1.06 1.28 1.65 
SVR Dynes.
s.cm-5 
1431 800 1787 1807 1400 1638 1360 1509 1235 1498 
PVR Dynes.
s.cm-5 
112 82 171 256 144 210 77 150 37 196 
Table 12 – Haemodynamic results for all simulated cardiac conditions. MI – acute myocardial infarction, 
LHF – left heart failure, VAD – ventricular assist device, BHF – bi-ventricular heart failure, ASD – atrial 
septal defect, VSD – ventricular septal defect, MR – mitral valve regurgitation, S+P HT – systemic and 
pulmonary hypertension,  LVPsys - systolic left ventricle pressure, LVPdias - diastolic left ventricle pressure, 
AoPsys - systolic aortic pressure, AoPdias – diastolic aortic pressure, MAP – mean aortic pressure, MLAP – 
mean left atrial pressure, SQ – mean systemic flow rate, RVPsys - systolic right ventricle pressure, RVPdias - 
diastolic right ventricle pressure, PAPsys - systolic pulmonary artery pressure, PAPdias – diastolic 
pulmonary artery pressure, MPAP – mean pulmonary artery pressure, RAP – right atrial pressure, PQ – 
mean pulmonary flow rate, HR – heart rate, LVSV – left ventricular stroke volume, LVEF – left ventricular 
ejection fraction, LVSW – left ventricular stroke work, bpm - beats per minute. 
 
 
 
 
 
123 
 
(i) Rest (ii) VSD (iii) LHF (iv) LHF + VAD 
(a)     
(b)        
(c)     
(d)      
Figure 69 – Example results for (a) systemic and (b) pulmonary pressure distributions, (c) flow rates and (d) 
PV loops for conditions of (i) healthy rest, (ii) VSD, (iii) LHF class IV and (iv) LHF class IV with VAD 
support.  LAP – left atrial pressure, LVP – left ventricle pressure, AoP – aortic pressure, MAP – mean aortic 
pressure, RAP – right atrial pressure, RVP – right ventricle pressure, PAP – pulmonary artery pressure, 
MPAP – mean pulmonary artery pressure, LV Volume – left ventricle volume, LHF - left heart failure. 
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Simulation of exercise was achieved at an increased heart rate (HR) of 120 beats per minute (bpm) and 
increased ventricular contractility which increased MSQ to 10.1 L/min. Decreased SVR (800Dynes.s.cm-5) 
and PVR (82 Dynes.s.cm-5) also promoted the increased cardiac output expected during exercise 
conditions. Elevated mean arterial pressure (MAP) was observed at 115 mmHg while increased mean 
pulmonary arterial pressure (MPAP) of 26 mmHg was also noted. While the LVEF (60%) remained 
relatively similar to a resting condition, the LVSW increased dramatically to 3.52 Watts.  
 
Simulation of acute myocardial infarction (MI) induced cardiogenic shock induced a dramatic drop in 
MSQ to 3 L/min with a HR of 60 bpm. MAP was also markedly reduced to 71 mmHg with escalated SVR 
(1787 Dynes.s.cm-5) and PVR (171 Dynes.s.cm-5). A consequential increase in left atrial pressure (LAP) 
also indicated a prelude to pulmonary congestion. LVEF and LVSW were also reduced to 31% and 0.54 
Watts respectively. Congestive LHF (stage IV) further decreased LVEF and LVSW to 10% and 0.375 Watts 
respectively with a LAP of 20 mmHg strongly indicating pulmonary congestion. This was further 
demonstrated by the increased MPAP of 28 mmHg, while the MAP was reduced to 67 mmHg. Large end 
diastolic ventricular volumes of up to 300 mL were noted and, combined with the reduced left 
ventricular stroke volume (LVSV) (30 mL), resulted in the drastically reduced LVEF. Addition of a LVAD to 
support the failing left ventricle increased MAP and MSQ to 96 mmHg and 5.2 L/min respectively. 
Pulmonary congestion was eased with LAP reduced to 8mmHg and MPAP reduced to 17 mmHg. LVSW 
remained similar (0.34 Watts) to the unsupported case while LVEF increased to 30%. Progression to the 
simulation of BHF class IV resulted in drastically reduced MAP (58 mmHg) and MSQ (2.1 L/min). While 
the MPAP was still elevated (25 mmHg), the right atrial pressure was high (15 mmHg), revealing a 
pressure difference over the right heart of only 10 mmHg. LVEF and LVSW were reduced even further to 
9% and 0.24 Watts respectively.  
 
Replication of an atrial septal defect revealed an intra-cardiac shunt, demonstrated by the imbalance in 
MSQ (5 L/min) and MPQ (6.2 L/min). This shunt resulted in a reduced MAP to 92 mmHg while LVSV 
increased to 83 mL. The ventricular septal defect resulted in a far greater flow imbalance with a MSQ of 
3.5 L/min and MPQ of 6.4 L/min due to the higher pressure difference between the ventricles compared 
to the atria. MAP was further reduced to 75 mmHg and MPAP increased to 23 mmHg due to the 
increased pulmonary flow. Simulation of mitral valve regurgitation also resulted in reduced MAP (77 
mmHg) and MSQ (4.6 L/min) due to backflow in the systemic circulation. This regurgitant flow increased 
LVSW to 1.28 Watts and LVEF to 71%. Finally, systemic and pulmonary hypertension was characterized 
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by increased SVR (1498 Dynes.s.cm-5) and PVR (196 Dynes.s.cm-5), which resulted in elevated MAP (110 
mmHg) and MPAP (31 mmHg). LVSW was also dramatically increased (1.65 Watts), demonstrating the 
increased load on the heart in hypertension. 
 
3.3.3 Haemodynamic waveforms 
Comparisons of a systemic pressure trace seen in humans, the numerical simulation of the MCL and the 
physical MCL (Figure 70) revealed many similarities. The native pressure trace for a healthy condition 
recorded aortic pulse pressures of 120/80 mmHg, which was also observed in the numerical simulation 
and physical MCL. While the magnitude of the aortic pressure was similar to that seen in the native 
situation, the inertial characteristic between the left ventricle and aortic compliance chamber (where 
aortic pressure was taken) caused a lag in AoP compared to LVP. This was observed to similar degrees in 
both the numerical simulation and physical MCL, and is a limitation of reading the AoP at a distance 
from the mitral valve. LVP peaked at approximately 120 mmHg in all cases, while the minimum LVP was 
in the region of 0-10 mmHg for all three cases. LVP waveforms for the physical MCL and numerical 
simulation closely matched that seen in the native case. An atrial kick was observed in each case, 
demonstrated by the small increase in LAP shortly before ventricular systole. The atrial kick served to 
rapidly push fluid from the atrium to the ventricle in the final stages of filling, with the volume shift 
represented by the small increase in LVP during this period. Following closure of the mitral valve at the 
start of systole, atrial pressure was initially reduced in the numerical simulation and physical MCL due to 
the end of atrial contraction. In the native case, however, the atrial pressure demonstrated a small 
notch directly after systole due to closure of the mitral valve and the contracting ventricle pushing back 
on the atrium. As non-compliant mechanical valves were used in the physical MCL, and simulated in the 
numerical simulation, this phenomenon was not experienced in these cases. Following this stage, atrial 
pressure gradually increased for the remainder of ventricular systole due to venous return gradually 
(a) 
 
(b) 
 
(c) 
 
Figure 70 - Comparison of systemic pressure traces between (a) a human at rest, (b) the numerical simulation 
of the MCL at rest and (c) the MCL simulating a resting condition. LAP - left atrial pressure, LVP - left 
ventricle pressure, AoP - aortic pressure, MAP - mean aortic pressure. 
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filling the atrial chamber. Upon completion of ventricular systole, the atrial pressure dropped as the 
mitral valve opened in all cases, representing the start of ventricular diastole.  
 
The smooth pressure waveforms for both the systemic and pulmonary circulations, obtained by  varying 
electro-pneumatic regulator voltage supply over the cardiac cycle, are shown in greater detail in Figure 
71 and compared to pressure waveforms without varied electro-pneumatic regulator voltage in Figure 
72. Both were representative of those seen clinically and in the literature in both form and magnitude. 
(a) 
 
(b) 
 
Figure 71 - Haemodynamic waveforms for (a) systemic pressure trace and (b) pulmonary pressure trace. 
LVP - left ventricle pressure, AoP - aortic pressure, MAP - mean aortic pressure, LAP - left atrial pressure, 
RVP - right ventricle pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial 
pressure, RAP - right atrial pressure. 
 
(a) (b) 
               
              
Figure 72 - Comparison between systemic pressure waveforms (a) without and (b) with electro-pneumatic 
regulator voltage smoothing. 
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While results are only shown for a healthy condition, similarly smooth ventricular pressure waveforms 
were observed in all simulated physiological conditions.  
 
3.3.4 Starling Response 
Pressure volume (PV) loops for the left and right ventricles with varying preload were created to 
evaluate the MCL’s simulated Starling response. Examples of both left and right ventricular PV loops for 
a healthy condition are shown in Figure 73. As ventricular preload was increased, the end diastolic 
volume of each ventricle increased. This caused the MCL Starling control to increase the current supply 
to the electro-pneumatic regulators and hence increase the contractility of the ventricles. Maximum 
ventricular pressures of 290 and 46 mmHg were reached for left and right ventricles respectively. As 
preload increased past the point of maximum left ventricular pressure, the contractility reduced due to 
simulation of over-stretching the ventricles. This tail-off region continued until the maximum left 
ventricular volume was reached (285 mL). 
 
The left and right ventricular ESPVR curves for conditions of healthy, mild and severe heart failure 
(Figure 74) were taken from the pressure volume loop traces, such as those shown in Figure 73. An 
increased gradient of the ESPVR was noticed with increased heart function (eg. transition from severe 
heart failure to healthy conditions). At low volumes (≈50 mL), the gradient of the left ventricular ESPVR 
(a) 
 
(b) 
 
Figure 73 - Pressure volume (PV) loops for a) left and b) right ventricles in a healthy, resting simulation with 
gradually increasing preload. LVP - left ventricular pressure, LVvol - left ventricular volume, RVP - right 
ventricular pressure, RVvol - right ventricular volume. 
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was 2.4, 1.18 and 0.38 mmHg/mL for healthy, mild heart failure and severe heart failure respectively. 
The concave relation to the x-axis reduced these gradients to 0.57, 0.41 and 0.21 mmHg/mL respectively 
for healthy, mild heart failure and severe heart failure respectively at high volumes (≈150 mL). The right 
ventricular ESPVR gradient was also higher at low volumes, with values of 0.69, 0.23 and 0.1 mmHg/mL 
for healthy, mild heart failure and severe heart failure respectively. For high volumes, the gradient for 
each condition had decreased to 0.1 mmHg/mL for all conditions. 
 
Comparisons between the MCL's Starling response and those in the literature revealed a sufficient slope 
of the ESPVR in all cases. An example of this is shown in Figure 75 which compares the MCL Starling 
response and that reported by Guyton et al. [71]. In this case, the slope of the ESPVR by Guyton at 
various points was calculated based on the graph x and y axis. The ESPVR slope, taken at similar points 
for the MCL and Guyton ESPVR curves, matched closely at low volumes (MCL: 2.4 mmHg/mL, Guyton: 
2.5 mmHg/mL) and high volumes (MCL: 0.57 mmHg/mL, Guyton: 0.6 mmHg/mL).     
         
 
(a) 
 
(b) 
 
Figure 74 - End systolic pressure volume relation (ESPVR) for conditions of healthy, mild heart failure and 
severe heart failure in the a) left and b) right ventricles. MLHF = mild left heart failure, SLHF = severe left 
heart failure, MRHF = mild right heart failure, SRHF = severe right heart failure, LVPsys = systolic left 
ventricular pressure, LVVsys = end systolic left ventricular volume, RVPsys = systolic right ventricular 
pressure, RVVsys = end systolic right ventricular volume. 
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(a) 
 
(b) 
 
Figure 75 - Left ventricular end systolic pressure volume relationships of (a) the MCL and (b) that shown by 
Guyton et al. (2005) [71] for a healthy condition with the slopes of each curve calculated at two points for 
comparison. mespvr - slope of the end systolic pressure volume relationship. 
 
3.4 Discussion 
An ideal MCL is required to represent the human circulation with as much accuracy as possible. This 
discussion focuses on the methods used to develop the MCL and the resultant haemodynamics 
produced by the system. 
 
3.4.1 Design and Construction 
Dynamic performance of a system is often neglected in the design phase due to the expense and the 
time required.  Using simulation packages, process systems can be evaluated in a small amount of time 
and at a low cost [279]. The MCL described in this thesis used previously presented numerical simulation 
techniques [274, 275] throughout the design process. This allowed for refinement of the systems 
physical characteristics, such as pipe length, pipe diameter and input pressures for each segment, in 
order to accurately replicate the compliance, resistance and inertial properties of the native human 
circulation.  
 
Using the numerical simulation and information gathered in the literature review of MCLs, several 
design issues were encountered throughout the development process. Although commonly excluded in 
other MCL designs [17, 225], a pulmonary circulation was deemed necessary in this case. This was not 
only due to the need to evaluate BiVADs in this study, but necessary to reproduce the appropriate 
venous return to the systemic circulation created by the behavior of the pulmonary system. This is 
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illustrated, for example, by the different Frank Starling responses of the ventricles which have a direct 
effect on venous return to the opposite circulations [280]. 
 
A five element Windkessel model was chosen to represent the arterial and venous compliance, vascular 
resistance and inertia of both the systemic and pulmonary circulations. Of particular importance was the 
effect of fluid inertia, which is often overlooked despite its influence on system dynamics. For example, 
previous MCLs [18, 199] produced uncharacteristic double pulse ventricle and aortic pressures due the 
absence of a tuned inertial term between the chambers, resulting in phase lags and wave reflections. 
The numerical simulation assisted to improve these issues by identifying critical geometrical properties 
of the system, resulting in drastically improved pressure waveforms. Our MCL did not produce any 
double pulse pressure waves in either the ventricles or arteries, and this could be attributed with the 
careful selection of the inertial characteristics of each circulation.  
 
The addition of a fifth element (venous compliance) in the Windkessel model further improved aortic 
pressure and ventricle outflow waveforms by representing the behavior of high frequency wave 
reflections with more accuracy [203]. Inclusion of this element within a cardiovascular device test rig is 
essential for an accurate representation of the clinical environment.  Consulting the five element 
Windkessel simulation during the design phase ensured that wave reflections in the loop were reduced, 
which resulted in reduced diastolic pressure oscillations when compared to previous designs [18].  The 
systemic venous compliance chamber, which was pneumatically controlled, also provided an effective 
method of changing blood volume distribution between the venous system and the rest of the 
circulation. This technique effectively raised or lowered mean circulatory pressure for each physiological 
state, whilst also providing the ability to replicate the acute effect of postural changes on the 
distribution of fluid volume and thus alterations in venous return. Windkessel chambers also allowed 
suitable representation of arterial and venous compliance for systemic and pulmonary circulations. Use 
of a test plug instead of a cap provided a variable degree of compliance, and was used for arterial 
compliance in both circulations.  
 
Each component of the MCL was joined by rigid, clear PVC pipe and held together with standard, clear 
plumbing glue which resulted in a good seal. The inner diameter of this pipe was chosen to be 25mm in 
order to reduce the characteristic resistance of the circuit. Additional resistance of the systemic and 
pulmonary circulations was achieved through incorporation of an adjustable valve. Variable SVR was 
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achieved with the proportional control valve, which provided a useful mechanism of altering the SVR 
with a simple change in valve supply voltage, controlled via the data acquisition system and GUI. When 
fully opened, the proportional control valve provided suitably low resistance for simulation of exercise 
conditions, thus flow rates of up to 10 L/min could be achieved. However, the small orifice size of this 
valve was not suitable for the lower resistance of the pulmonary circulation. The 25 mm diameter socket 
valve, however, provided an excellent method of varying PVR within the required range of resistance. 
Again, this valve was easily controlled through a variation in electro-pneumatic regulator current supply 
which was altered through the data acquisition system and GUI. 
 
Use of vertical chambers to represent the left and right atria and ventricles allowed for simple 
measurement of ventricular volume and control of ventricular function. Both high and low pressure 
manual regulators reduced the air pressure to a sufficient level to be actively controlled by the electro-
pneumatic regulators. Others have reported square or noisy ventricular pressure waves when using 
pneumatically controlled ventricles [18, 225]. In our system, control of the electro-pneumatic regulator 
current supply over the cardiac cycle resulted in smooth, physiological ventricular pressure waves, which 
in turn improved the pressure and flow waveforms of the arterial systems. The solenoid valves used to 
control systolic / diastolic timing allowed for passive filling of the ventricles during diastole by opening 
the chambers to atmosphere. Control of heart rate and systolic time was achievable through the 
interface of the solenoid valves and the data acquisition system and GUI, which enabled simple 
transition between physiological conditions. However, the use of separated vertical columns and 
independent ventricular control is a limitation in the MCL design as ventricular interdependence is not 
included. Future work should include altering the heart model to represent ventricular interaction 
through the septum and pericardium to provide a more clinically relevant method of evaluating 
cardiovascular devices, particularly physiological control systems.  
 
The data acquisition system interfaced well with the GUI, which enabled real time viewing and capture 
of pressures, flow rates and volumes throughout the MCL. The GUI also allowed for real time 
manipulation of all MCL output parameters for transitioning between physiological conditions. The data 
acquisition system was, however, the most expensive component of the entire MCL system, with an 
approximate cost of $27500 Australian dollars (AUD) for the dSPACE 1103 board and $800 AUD for the 
computer. Other significant expenses included the flow meters, which cost approximately $13000 AUD 
for the two channel tubing flow meter ($7000 AUD) and two flow sensors ($3000 AUD each). The flow 
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meters for the systemic and pulmonary circuits cost approximately $2700 AUD each, while the pressure 
sensors came to a total cost of just over $5000 AUD. The clear PVC pipe and consumables (piping and 
electrical) came to a combined cost of just over $4000 AUD, demonstrating that the majority of costs 
were attributed with data acquisition rather than construction of the physical system. The total cost of 
the entire MCL system, including all pneumatic, hydraulic and data acquisition components came to 
approximately $62846.61 AUD. This could have been reduced by, for example, replacing the expensive 
solenoid valves with hand operated valves for the ASD, VSD and valve regurgitation ports. A list of costs 
is presented in Table 13, while a full list of materials and suppliers is shown in Appendix 4. The size of 
the MCL was also considering throughout the design process. It was important that the entire system be 
capable of fitting adequately on a standard laboratory bench and have the potential to be transported. 
The final MCL dimensions, including all hydraulic components but excluding data acquisition and 
pneumatic components, were 800 x 600 x 1100 mm (width, depth and height respectively). The height 
could be reduced to 700 mm by removing the arterial compliance chambers, allowing for easier 
transportation.  
 
Product Category 
 
Supplier Cost 
(AUD) 
Clear PVC pipe and fittings ALSCO 1679.09 
Piping and electrical consumables Tony Powell, Bunnings, Jaycar 2590.07 
Process valves Hass Manufacturing, SMC Pneumatics, Convair 2655.12 
Regulators SMC Pneumatics 2491.43 
Level sensors Gefran 1386.00 
Flow meters Krohne, Peter Ayre, Transonics 18423.00 
Pressure sensors Kimble Dunster 5321.90 
Data acquisition dSPACE, Umart 28300.00 
 
TOTAL COST 
 
$62846.61 AUD 
Table 13 - Costs associated with the construction of the MCL and data acquisition system. AUD - Australian 
dollars. 
 
3.4.2 Haemodynamics 
Ventricular function in a healthy, resting condition produced haemodynamic magnitudes and 
waveforms representative of the general population and those seen previously in the literature (Table 
14). Haemodynamics could be easily manipulated through control of the resistance valves and ventricle 
air supply regulators. The form of ventricular pressures was significantly improved by altering the 
ventricular regulator current supply gain over the cardiac cycle (shown earlier in Figure 58, and again in 
Figure 76 for convenience), and this could also be manipulated to produce ventricular waveforms of 
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almost any desired shape. However, while the left ventricular regulator gain (LVRG) waveform appeared 
as a simple, smoothed step function, the right ventricular regulator gain (RVRG) waveform had a 
relatively sharp peak with a gradual decline. The timing of each peak throughout the cardiac cycle was 
also different between the two ventricle regulator gain waveforms. While the LVRG was at its highest 
between approximately 40% and 95% of the cardiac cycle (where the solenoid valves opened to initiate 
systole at 60%-100% of the cardiac cycle) the RVRG peaked between 0% and 40% of the cardiac cycle, 
followed by a gradual decline. In the case of the LVRG, this could be explained by the need to increase 
the supply pressure shortly before the solenoid valves opened to initiate systole, and decrease the 
supply pressure shortly before the end of systole to produce the smooth ventricular waveforms. In the 
case of the RVRG, however, the lower air pressure supplied to the right ventricle may have required an 
earlier peak in supply pressure before the solenoid valve opened in order to overcome the resistance of 
the valve and tubing which connected the solenoid valve and ventricle. Following this, the gradual 
decrease in RVRG served to smooth the right ventricular pressure trace. 
 
 Units MCL Timms et al. 
(2005) [18] 
Pantalos et al. 
(2004) [17] 
Natural 
[281] 
LVPsys mmHg 120 120 140 120 
LVPdias mmHg 7 5 2-5 8 
AoPsys mmHg 120 119 125 120 
AoPdias mmHg 80 78 68 80 
MAP mmHg 98 96 95 93 
MLAP mmHg 10 8-10 10 8-10 
MSQ L/min 5.2 5.1 5.0 5.0 
RVPsys mmHg 26 32 - 25 
RVPdias mmHg 5 4 - 3 
PAPsys mmHg 26 26 - 25 
PAPdias mmHg 11 11 - 10 
MPAP mmHg 17 17 - 15 
RAP mmHg 5 4 - 3 
MPQ L/min 5.0 5.1 - 5.0 
HR bpm 60 60 80 60-120 
LVSV mL 88 - 63 - 
LVEF % 64 - 48 - 
LVSW Watts 1.11 - - - 
SVR Dynes.s.
cm-5 
1431 1439 - 1463 
PVR Dynes.s.
cm-5 
112 133 - 106 
Table 14 - Haemodynamic data produced by the mock circulation loop (MCL) in a healthy condition 
compared with that from the literature for previous MCLs and the natural cardiovascular system. Note: The 
haemodynamic data from Pantalos et al. (2004) is taken from the 80 bpm condition. 
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(a) 
 
(b) 
 
Figure 76 - Regulator current supply gains over one cardiac cycle at 60 beats per minute for (a) left and (b) 
right MCL ventricles. 
 
While the shaping of ventricular regulator current supply gain produced smoothed ventricular pressure 
traces, this did not translate perfectly to the aortic pressure (AoP) trace. The negative AoP slope during 
diastole was uncharacteristically linear, presumably due to the rigidity of the valve and piping which did 
not allow expansion (and thus slightly reduced characteristic resistance) with changes in pulse pressure. 
Meanwhile, the lag between ventricular and aortic pressure was observed in all results and can be 
attributed to placement of the aortic compliance chamber and aortic pressure sensor at a distance of 
approximately 80 mm from the aortic valve. This inertial discrepancy could be partially overcome by 
design modifications, such as replacing the large, rigid check valves with prosthetic valves, to reduce the 
length between the chambers. 
 
Pressure and flow magnitudes, however, were not adversely affected by the inertial discrepancy, with 
suitable values recorded in all cases. Pulsatile flow rates, with mean values as high as 10 L/min, were 
noted in conditions such as exercise with high arterial pressures in the range of 115 and 26 mmHg for 
systemic and arterial circulations respectively. Pulsatile arterial pressures were also generated, and 
could be easily controlled by altering the systemic arterial compliance. For instance, the transition 
between healthy to exercise conditions increased the systemic arterial pulse pressures from 120/80 
mmHg to 150/80 mmHg by reducing the arterial compliance chamber air volume from 2 L to 1 L. With 
the capability of manipulating the compliance chamber air volume between 0 and 2.8 L for systemic 
arterial and 0 and 5.1 L for pulmonary arterial chambers, a wide range of pulse pressures could be 
produced. Set baseline values of approximately 1.5 and 3 mL/mmHg were used for systemic and 
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pulmonary arterial compliance respectively in most conditions. These values, which closely matched 
those seen in the literature [277, 282, 283], produced physiological pulse pressures in a wide range of 
simulated conditions. 
 
Atrial pressure traces matched those seen in the literature in both magnitude and form for all conditions 
[17, 18]. Atrial contraction assisted in ventricular filling during the later stages of diastole, and could be 
seen on both atrial and ventricular pressure traces. High atrial pressures were noted in left and 
biventricular heart failure conditions, indicating congestion in the systemic and / or pulmonary 
circulations. Atrial volumes, however, were not always representative of a clinical scenario. In the case 
of left heart failure, mean left atrial pressure was approximately 20 mmHg. This resulted in an atrial 
volume of approximately 500 mL in the MCL due to the constant diastolic compliance of the open-to-air 
atrial chambers. In the native circulation, tissue compliance reduces as the vessel fills, particularly with 
high volumes when the tissue cannot easily stretch [37]. The additional volume in the MCL atria could 
simply be attributed as part of the lumped venous circulation, however results from studies evaluating 
atrial suction may still be influenced by the larger atrial volumes. This limitation of the MCL could be 
addressed by modeling vessels, such as the atria, with compliant silicone segments which match the 
native vessels in both volume and wall compliance. 
 
Flow rate magnitudes were characteristic of their respective condition, with high flow rates during 
exercise and reduced flow rates during conditions of left and biventricular heart failure and myocardial 
infarction. The restoring effect of the LVAD was evident by the increase in flow rate between the 
unsupported and supported left heart failure cases. As expected, pulmonary flow rates were higher than 
those in the systemic circulation during simulation of atrial and ventricular septal defects due to higher 
systemic pressures causing recirculation through the defect. The degree was less pronounced with an 
ASD. Left atrial pressures/end diastolic ventricle volumes were found to be lower with these conditions, 
predisposing the left ventricle to collapse and therefore may warrant different VAD operational 
treatment strategies. Meanwhile, the 0.2 L/min left/right discrepancy during resting conditions reflected 
the bronchial circulation. Flow rate waveforms were pulsatile from the arterial system but smoothed by 
the arterial and venous compliance chambers which ultimately resulted in virtually continuous flow 
venous return to each atria.  
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Pulmonary pressure traces, although reduced in magnitude, resembled those of the systemic circulation. 
Smooth right ventricular pressure waveforms, created by shaping the right ventricular regulator current 
supply gain over the cardiac cycle, produced pulsatile flow and translated into pulmonary arterial pulse 
pressures of 26/11 mmHg for the healthy condition. Again, a phase lag was present between the right 
ventricular and pulmonary arterial pressure traces due to an inertial characteristic created by the 
distance between the pulmonary artery valve and the pulmonary arterial pressure sensor. Mean 
pulmonary arterial pressure was maintained within normal ranges, which varied between 15 and 31 
mmHg depending on the simulated condition.  
 
The cardiac output for each condition was controlled through manipulation of heart rate and stroke 
volume (through ventricular contractility, arterial compliance and vascular resistance). A baseline heart 
rate of 60 bpm was chosen for healthy conditions, with an increase to 90 bpm for left and biventricular 
heart failure and 120 bpm for exercise conditions. In the case of exercise, this increase combined with a 
high stroke volume to increase cardiac output. However, in the case of heart failure a reduced stroke 
volume was used to result in an overall decrease in cardiac output. This decrease in stroke volume, and 
inherent increase in overall ventricular volume due fluid congestion, resulted in a drastically decreased 
ejection fraction in left and biventricular heart failure. Apart from the obvious complications with 
reduced cardiac output, the decreased ejection fraction may promote thrombus formation due to low 
velocity flow and poor washout around the dilated ventricle in a clinical setting [284, 285]. The reduction 
in left ventricular stroke work was also expected, and demonstrates the incapability of the ventricle to 
create more work when in a failed state. Both left ventricular ejection fraction and stroke work were 
markedly increased when simulating septal defects due to the large stroke volume pushing some of the 
fluid to the pulmonary circulation rather than to the aorta. Even with the increase in ventricular stroke 
work, cardiac output to the systemic circulation was reduced in these cases due to the shunt flow.   
 
3.4.3 Starling Response 
Although some literature reports triangular right ventricular pressure volume (PV) loops [286], others 
have reported these to represent a lower pressure version of the left ventricular PV loops [287]. The 
right ventricular PV loops produced in our study represented lower pressure versions of the left 
ventricular PV loops due to the similar pneumatic operation of the two ventricles.  
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Addition of the Starling response in the MCL increased the system’s ability to simulate the native heart’s 
function and allowed for more reliable evaluation and refinement of cardiovascular devices. The 
methods used to implement the Starling response were relatively simple, with a basic proportional 
controller altering the ventricular regulator current supply gain dependant on ventricular end diastolic 
volume. The addition of a lookup table to manually alter the shape of the ESPVR provided the capability 
of reproducing the tail-off region at the end of the Starling curve as the ventricular myocardium was 
over-stretched. The ability to easily vary the Starling sensitivity through manipulation of the gain, offset 
and lookup table enabled simulation of almost any Starling response and was only limited by the 
minimum output capacity of the electro-pneumatic regulators. These regulators failed to operate 
consistently at low current supply which resulted in an almost random degree of ventricular contractility 
at volumes less than 30 mL. While the MCL was usually operated at ventricular volumes above 30 mL, 
this limitation could influence some studies such as those which operate just above the point of 
ventricular suction.  
 
Attempts to simulate a MCL Starling response have been made previously, however these systems 
generally only included the left heart and used a linear ESPVR which crossed the x-axis at negative 
values [17, 208, 224, 249]. Although not shown at low volumes, the ESPVR generated in the MCL 
appeared to cross the x-axis at positive values for all conditions in both the left and right ventricles. This 
is an important feature of the MCL Starling response, as the positive x-intercept demonstrated that 
there was still some residual volume remaining when ventricular contraction had ceased. This 
phenomenon has been reported previously in the literature [250], and was identified as a necessary 
feature during the MCL Starling response implementation. While often linear in smaller animals, the 
ESPVR is usually concave to the x-axis in humans [248]. This indicates that as preload increases, the rate 
of change of contractility reduces. The MCL Starling response achieved the concave ESPVR through 
multiplication of EDV with a natural log function along with the lookup table.  
 
Validation of the Starling response was necessary to ensure appropriate levels of contractility were 
present at various ventricular volume. Validation was achieved by comparison of the MCL ESPVR 
gradient at various points with those reported in the literature. The ESPVR gradient produced by the 
MCL matched closely with previously reported data for the left ventricle in healthy (MCL: 0.57-2.4 
mmHg/mL, literature: 0.6-2.22 mmHg/mL) and heart failure conditions (MCL: 0.21-0.38 mmHg/mL, 
literature: 0.28 mmHg/mL) [17, 208, 224]. Brown et al. [280] reported values for a healthy human right 
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ventricular ESPVR gradient vary between 0.32 and 1.23 mmHg/mL at low right ventricular volumes, 
which also fitted with the MCL results (0.69 mmHg/mL). However, no data for the right ventricular 
ESPVR gradient at high volumes could be found for validation of this condition. These comparisons of 
the MCL Starling response with those seen in the literature demonstrated that the methods used in this 
study were suitable for accurate simulation of a Starling response in pneumatically operated MCL left 
and right ventricles. 
 
The addition of a Starling response in the right ventricle for a pneumatically operated ventricle has not 
been reported previously. Manual tuning of the right ventricular Starling response was more difficult 
than that of the left ventricle due to lower pressures and more sensitive regulators which control right 
ventricular contractility. Throughout the validation process, however, the importance of a right 
ventricular Starling response was obvious, as it was this response which ultimately determined left 
ventricular preload. The difference in Starling sensitivity, or ESPVR slope, between the two ventricles 
demonstrated the dependence of each ventricle on the other, which cannot be simulated unless both 
circulations and ventricles are included. This demonstrated a noticeable limitation of systemic only 
Starling responsive MCLs, as they lack independent ventricular preload variability.  
 
It should be noted that the controller used to simulate a Starling response only altered the Starling 
sensitivity and not the preload sensitivity of the ventricles. Preload sensitivity cannot be defined as only 
a change in ventricular contractility, as several other native reflexes exist which alter cardiac output 
based on preload and afterload. For instance, the baroreceptor response alters ventricular contractility, 
heart rate and vascular resistance to maintain mean arterial pressures at suitable levels [288].  Others 
have also reported stretch receptors in the atria which alter heart rate based on preload [289]. Inclusion 
of native feedback responses such as these would be an important step in the improvement of the MCL 
to promote more accurate cardiovascular device evaluation. However, inclusion of all native responses 
was deemed beyond the scope of this project, thus only the Starling response was included at this stage.  
 
The addition of a variable Starling response allowed for manual manipulation of the systolic properties 
of the left and right MCL ventricles. However, the diastolic function of both ventricles was not 
considered and remained constant based on the compliance of the open to air (during diastole) 
ventricular chambers. This is not physiologic, as the end diastolic pressure volume relationship (EDPVR) 
varies in humans and influences the filling capacity of the ventricles [248]. The addition of a controllable 
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and non-linear EDPVR would be useful to simulate diastolic dysfunction in the MCL, and is listed as 
future work. 
 
3.5 Conclusion 
MCLs are required for in-vitro evaluation of cardiovascular devices prior to in-vivo and clinical trials. 
Previous systems varied from simple designs including only a preload chamber and resistance valve, to 
complex designs with systemic and pulmonary circulations, pulsatile flow, inertial characteristics, 
variable compliance and resistance, connections for cardiovascular devices, physiological defects and 
auto-regulatory responses. However, few MCLs include all of these features. Therefore, the aim of this 
study was to design, construct and validate a detailed MCL which could accurately simulate a wide range 
of physiological conditions for cardiovascular device evaluation. 
 
The development stage of the MCL involved a combination of previously developed numerical 
simulation techniques and practical implementation. Using this method, a physiologically and 
geometrically accurate MCL was designed, which incorporated both systemic and pulmonary circulatory 
systems. The numerical simulation was used to calculate suitable parameters for inertia, circuit volumes, 
resistance, and compliance, whilst appropriate computer controlled equipment was used to produce 
these variable values during each physiological state. Heart function was controlled through the use of 
electro-pneumatic regulators and solenoid valves, which allowed transition between various 
physiological states through alterations in ventricular contractility, heart rate and systolic time. 
Smoothed left and right ventricular pressure traces were simulated through variation of the electro-
pneumatic regulator current supply over each cardiac cycle to improve the haemodynamic response. 
 
Implementation of a Starling response in the left and right ventricles was achieved with a proportional 
controller which adjusted ventricular contractility (through electro-pneumatic regulator current supply) 
based on ventricular end diastolic volume. The Starling response was implemented in both ventricles 
and successfully demonstrated increased ventricular contractility with increased preload. ESPVR curves 
were generated and validated against previously reported human data to ensure the system response 
was a suitable human model under various healthy and pathological conditions.  
 
In conclusion, the MCL developed in this study was successful in accurately representing the human 
cardiovascular system under a wide range of healthy and pathological conditions, and provided a 
valuable research tool for the accelerated development of cardiovascular assist devices.   
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Chapter 4 
Cannula Placement 
 
4.1 Aims 
The VAD inflow cannulation site is the primary interface between the device and patient. Positioning of 
the cannulae in either atria or ventricles induce major changes in flow dynamics, however there is very 
little data available on precise quantification of these changes. Left ventricular cannulation (LVC) is often 
regarded as the preferred interface site for implantable LVADs [116, 117]. This is due to improved LVAD 
inflow conditions resulting from remnant heart activity, which in turn increases pump flow rate. Left 
atrial cannulation (LAC), on the other hand, allows for easier surgical insertion (generally off 
cardiopulmonary bypass) and also promotes the potential for cardiac ventricular recovery by alleviating 
ventricular workload and preserving remaining cardio-myocytes [116, 119].  However, a reduction in 
support efficiency is observed, resulting in lower VAD flow for comparable pump speed [117].  RVAD 
inflow cannulation (Figure 77) has previously been favored through the right atrium (RAC); however 
some centers now prefer right ventricular cannulation (RVC), particularly with the use of the HeartWare 
HVAD as an RVAD. RVAD inflow cannulation site has been evaluated clinically, however this recent study 
only used pulsatile flow devices [132]. No literature is available which compares right atrial and 
ventricular cannulation for continuous flow RVAD 
support. Therefore, the aim of this chapter was to 
characterize the difference between atrial and ventricular 
inflow cannulation for rotary LVAD and RVAD support in 
the MCL presented in Chapter 3 of this thesis.  
 
Comparisons between the cannulation sites were 
required at various degrees of left, right and biventricular 
heart failure to ensure a wide range of clinical scenarios 
were addressed. Particular ventricular and vascular 
haemodynamic parameters were of interest in this study 
to evaluate the risk of thrombus formation, the potential 
for myocardial recovery and the potential to improve 
cardiac output and VAD efficiency. The results from this 
 
Figure 77 - RVAD inflow cannulae placed in 
the right atrium and ventricle of a mock 
heart. 
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study will provide a recommendation of a suitable site for LVAD and RVAD inflow cannula fixation to 
maintain sufficient ventricular ejection and promote ventricular unloading for different levels of heart 
failure. 
 
4.2 Methods 
Inflow cannula placement for both LVAD and RVAD support was evaluated in the MCL, described earlier 
in this thesis. The experimental setup and testing procedure used to evaluate inflow cannula placement 
is described in this section. Although the MCL has been described in detail earlier in this thesis, a brief 
description of the key features involved in this study is presented. 
 
4.2.1 Experimental Setup 
The MCL, described in Chapter 3 of this thesis, was a five element Windkessel model with systemic and 
pulmonary circulations, an obvious requirement for this study. Manipulation of SVR was achieved by 
altering the voltage supply to the proportional control valve placed in the systemic circulation. This 
enabled simple adjustment of the MCL haemodynamics in order to simulate a variety of heart failure 
conditions. PVR was also variable, however a socket valve and electro-pneumatic regulator were used 
for this application to provide a wider range of vascular resistance in the pulmonary circulation. 
Ventricular systole was simulated through a pulsatile, pneumatic air supply which was controlled by a 
series of electro-pneumatic  (ITV2030-012BS5, SMC Pneumatics, Brisbane, AUS) and manual regulators 
(IR3000-04 and AR40-04H-01, SMC Pneumatics, Brisbane, Australia) and solenoid valves (VT325-035DLS, 
SMC Pneumatics, Brisbane, AUS). Changes in ventricular contractility, required to transition between 
heart failure conditions, were easily achieved by altering the electro-pneumatic regulator current 
supply. Ventricular contractility was reduced in this study due to simulation of heart failure conditions, 
while atrial systole was not simulated. The left and right ventricular MCL Starling response was 
manipulated by varying the sensitivity gain, offset and look-up table of the Starling control to simulate 
reduced Starling sensitivity in the heart failure conditions. 
 
Inflow cannulation was achieved to the left atrium, left ventricle, right atrium and right ventricle through 
1/2" brass fittings tapped into the PVC tee sections of each chamber. From the tapped connections, 1/2" 
ball valves and barbed fittings were connected to 1/2" tygon tubing. The tygon tubing was then attached 
to a tee section which joined the atrial and ventricular cannulation ports of each circulation. The tee 
sections were then joined to the respective VAD (LVAD or RVAD). Atrial and ventricular cannula lengths 
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were equal (approximately 300 mm) to ensure similar circuit resistance. This setup provided a single 
inflow port to the LVAD and another to the RVAD with the capability of easily alternating between 
inflow cannulation sites. Outflow cannulation was achieved with the same fittings (1/2" brass) tapped 
into the PVC tee sections of the aortic and pulmonary arterial compliance chambers. A detailed 
schematic of the MCL and VAD connections is shown in Figure 78.  
 
Haemodynamic and VAD parameters were captured at 100 Hz using the MCL data acquisition system 
described earlier in this thesis. In brief, data acquisition was achieved with a dSPACE data acquisition 
system (DS1104, dSPACE, MI, USA) which collected data for pressures, flow rates and ventricular 
volumes. Pressures were recorded with silicone-based transducers (PX181B-015C5V, Omega 
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PVRPVC
RVAD
AoCLV
PACRV
LVAD
RVAD Outflow 
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RVAD Inflow 
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LVAD Inflow 
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LVAD Outflow 
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LVAD flow 
meter
Pulmonary flow 
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Systemic flow 
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Figure 78 - Schematic of the MCL setup for evaluation of BiVAD cannula placement. LA - left atrium, MV - 
mitral valve, LV - left ventricle, AoV - aortic valve, AoC - aortic compliance chamber, SVR - systemic 
vascular resistance valve, SVC - systemic venous compliance chamber, RA - right atrium, TV - tricuspid 
valve, RV - right ventricle, PV - pulmonary valve, PAC - pulmonary arterial compliance chamber, PVR - 
pulmonary vascular resistance valve, PVC - pulmonary venous compliance chamber, RVAD - right 
ventricular assist device, LVAD - left ventricular assist device, x denotes a ball valve. 
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Engineering, Connecticut, USA) in the left atrium, left ventricle, aortic compliance chamber, right atrium, 
right ventricle, pulmonary arterial compliance chamber, LVAD inlet, LVAD outlet, RVAD inlet and RVAD 
outlet. Total systemic and pulmonary flow rates were recorded with magnetic inductive flow meters 
(OPTIFLUX 1010C/D, Krohne, Germany) combined with signal converters (IFC010C/D, Krohne, Germany). 
LVAD and RVAD flow rates were recorded by placing 1/2" clamp on flow sensors (10PXL, Transonic 
Systems, NY, USA) on the pump outlets. These sensors interfaced with a two channel tubing flow meter 
(TS410-10PXL, Transonic Systems, NY, USA) which sent the raw signal to dSPACE for processing. 
Ventricular volumes were recorded using magnetostrictive level sensors (IK1A, GEFRAN, Italy) and post-
processed to reveal the ventricular stroke volume and ejection fraction. Ventricular stroke work was 
determined through an integral calculation of the area inside the pressure volume (PV) loop over one 
cardiac cycle. 
 
4.2.2 VAD Cannula Placement Evaluation 
LVAD inflow cannula placement was evaluated first, followed by RVAD inflow cannula placement. A 
VentrAssist (Ventracor Ltd., Sydney, Australia) continuous flow, centrifugal device was used for LVAD 
support while the continuous flow, centrifugal BP80 (Bio-Medicus, Inc., Eden Prairie, MN, USA) device 
was used for RVAD support. The VentrAssist LVAD was connected to the accessory power supply and 
laptop for control. 
 
Cannulation of the left atrium was investigated first. The LVAD inflow cannulae were closed (via the ball 
valves) and the MCL turned on through initiation of the pulsatile compressed air supply to the left and 
right ventricles. MCL parameters such as the left and right ventricular Starling sensitivity, SVR valve 
voltage supply and PVR electro-pneumatic regulator voltage supply were manipulated to simulate a mild 
left heart failure condition (LHF). The MCL was allowed to settle before five seconds of data were 
recorded.  The base haemodynamics for each condition are shown in Table 15. 
 
LVAD speed was then set at the minimum VentrAssist speed of 1800 RPM. The left atrial LVAD inflow 
cannula was then opened (via the ball valve) to allow flow through the LVAD circuit. The system was 
allowed to settle before five seconds of data were recorded. LVAD speed was then increased in 
increments of 100 RPM until a maximum speed of 3000 RPM was reached or until a suction event 
occurred. A suction event was defined as a left ventricular volume equal to or less than 0mL. Speed 
ramp tests were completed to demonstrate the haemodynamic changes with increasing degrees of  
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mechanical circulatory support. The LVAD inflow cannulation site was then changed to the left ventricle 
by closing the LAC ball valve and opening the LVC ball valve. LVAD speed was again transitioned from 
1800 to 3000 RPM in increments of 100 RPM. All other MCL parameters were kept constant throughout 
the speed ramp tests. For each test, the system was allowed to settle before five seconds of data were 
recorded. 
 
To provide greater clinical relevance to this study, a test was also completed with restored 
haemodynamics. This was completed through manipulation of LVAD speed and the systemic and 
pulmonary vascular resistance to obtain a condition with a MAP of 100 mmHg, MSQ of 5 L/min, MPAP of 
18 mmHg and a MPQ of 5 L/min. Left and right ventricular contractility and Starling parameters 
remained constant throughout this test. LAC and LVC were evaluated to compare the two cannulation 
sites at restored conditions. Inflow cannulae were then closed before the MCL parameters were 
manipulated to simulate a severe LHF condition. Speed ramp and restored tests were then completed in 
the severe LHF condition for both left atrial and ventricular inflow cannulation. 
 
The LVAD inflow cannulae were then closed and the MCL parameters were manipulated to simulate a 
mild degree of biventricular heart failure (BHF). The BP80 device was then attached as an RVAD with 
1/2" tygon tubing and a 1/2" to 3/8" connector for the inlet and outlet conduits. Cannulation was 
initially achieved through the right atrium for inflow and the pulmonary artery, directly below the 
pulmonary arterial compliance chamber, for outflow. The VentrAssist LVAD was cannulated through the 
left ventricle and aorta for inflow and outflow respectively for all BiVAD tests. The BP80 and VentrAssist 
Haemodynamic 
Parameter 
 
Units 
 
Mild LHF Severe LHF Mild RHF Severe RHF 
LAP mmHg 10 12 10 12 
MAP mmHg 76 55 79 55 
MSQ L/min 4.0 2.0 4.0 1.9 
LVEDV mL 213 274 210 288 
RAP mmHg 8 8 10 12 
MPAP mmHg 20 29 19 16 
MPQ L/min 4.0 2.0 4.3 2.3 
RVEDV mL 145 155 190 253 
Table 15 - Mock circulation loop haemodynamic parameters used to simulate conditions of mild and severe 
left (LHF) and right (RHF) heart failure. LAP - left atrial pressure, MAP - mean aortic pressure, MSQ - 
mean systemic flow rate, LVEDV - left ventricular end diastolic volume, RAP - right atrial pressure, MPAP - 
mean pulmonary arterial pressure, MPQ - mean pulmonary flow rate, RVEDV - right ventricular end diastolic 
volume. 
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speeds were initially set at 400 and 2300 RPM respectively before the LVAD and RVAD inlet and outlet 
cannulae were opened. The MCL was allowed to settle before five seconds of data were recorded. An 
RVAD speed ramp test was then undertaken where RVAD speed was increased in increments of 100 
RPM from 400 to 1500 RPM or until a suction event occurred. A suction event was defined as the right 
ventricular volume being equal to or less than 0 mL. The RVAD inflow cannulation site was then changed 
to the right ventricle by altering the valve configuration before the speed ramp test was repeated. LVAD 
and RVAD cannulae were then closed and MCL parameters manipulated to represent a severe BHF 
condition before speed ramp tests were completed for right atrial and ventricular inflow cannulation 
sites. In this case, VentrAssist speed was set at 2400 RPM throughout all speed ramp tests in the severe 
BHF condition. A restored test, with the same haemodynamic conditions defined for the restored LVAD 
case, was then completed for mild and severe BHF in right atrial and ventricular cannulation. For all 
tests, the MCL was allowed to settle before five seconds of data were recorded. A flowchart of all the 
tests completed for LVAD and RVAD atrial and ventricular inflow cannulation is shown in Figure 79. 
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Figure 79 - Flowchart of the tests used to compare atrial (AC) and ventricular (VC) cannulation for 
conditions of mild and severe left (LHF) and biventricular (BHF) heart failure. RPM - revolutions per 
minute, MAP - mean aortic pressure, MSQ - mean systemic flow rate, MPAP - mean pulmonary artery 
pressure, MPQ - mean pulmonary flow rate. 
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4.3 Results 
Results were compared for atrial and ventricular inflow cannulation in mild and severe heart failure 
conditions at the various VAD rotational speeds and restored conditions to determine the influence of 
cannulation site. These results are broken down into LVAD and RVAD support. 
 
4.3.1 LVAD Inflow Cannulation Results 
Results for the speed ramp test in the mild LHF condition are presented in Figure 80. As expected, LVAD 
flow rate (LVADQ), mean systemic flow rate (MSQ) and mean aortic pressure (MAP) all increased with 
increasing LVAD speed in LAC and LVC. LVADQ was higher with LVC than LAC for all LVAD speeds due to 
the increased preload caused by left ventricular contractility. However, the rate of change of LVADQ 
decreased more with LVC than LAC as LVAD speed was increased. This can be attributed to the left 
ventricular Starling response decreasing left ventricular pressure (LVP) as left ventricular volume (LVV) 
decreased due to the increase in LVAD speed. As LVV approached zero when LVAD speed reached 2800 
RPM, left ventricular contractility and thus LVP diminished, thus the LVAD preload was at a similar level 
to LAC. This resulted in similar LVADQ (LAC: 5.1 L/min, LVC: 5.3 L/min) at an LVAD speed of 2800 RPM.  
 
Total MSQ, however, was only slightly higher in LVC compared to LAC. Similar trends were noted when 
comparing MAP in LAC and LVC, which was consistently higher in LVC. While the combination of 
increased MAP and LVADQ with LVC signifies higher LVAD efficiency, the discrepancy between LVADQ 
and MSQ in LAC (eg. At LVAD speed of 2200 RPM, MSQ: 4.6 L/min, LVADQ: 2.39 L/min) indicates higher 
flow through the aortic valve. For example, at a LVAD speed of 2200 RPM in LAC, the LVADQ was 2.39 
L/min while the total MSQ was 4.6 L/min, indicating that 2.21 L/min was passing through the aortic 
valve, compared to 0.94 L/min at the same LVAD speed in LVC. This trend of increased aortic valve flow 
in LAC compared to LVC was noted for all LVAD speeds, although this diminished during high levels of 
LVAD support (ie. high LVAD speed). In fact, constant aortic valve closure was noted at speeds above 
2200 RPM with LVC but only at much higher speeds (2600 RPM) with LAC. 
 
Left ventricular ejection fraction (LVEF) was consistently higher with LVC compared to LAC for all LVAD 
speeds. For example, at LVAD speeds of 2000, 2400 and 2800 RPM, the LVEF in LAC was 30.2, 17.6 and 
3.1% respectively, while LVC values were 33.1, 31.2 and 67.3% respectively. In LVC, LVEF increased with 
increasing LVAD speed as the left ventricular end diastolic volume (LVEDV) decreased with increasing 
LVAD support while left ventricular stroke volume was kept relatively high as flow passed through the 
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LVAD. In LAC, however, the LVEDV decreased with increasing LVAD speed while the left ventricular 
stroke volume decreased due to the inability of the weakened left ventricle to overcome the high aortic  
pressures and open the aortic valve. This decreased stroke volume at high LVAD speeds also influenced 
the left ventricular stroke work (LVSW) in LAC. LVSW was increased in LAC compared to LVC at low LVAD 
 
Figure 80 – Haemodynamics for left atrial (LAC) and left ventricular (LVC) inflow cannulation in the mild 
left heart failure condition during the speed ramp test. LVADQ – LVAD flow rate, MSQ – mean systemic 
flow rate, MAP – mean aortic pressure, LVEF – left ventricular ejection fraction, LVSW – left ventricular 
stroke work (Watts), RPM – revolutions per minute. 
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speeds when the higher LVEDV during LAC increased the left ventricular contractility (through the 
Starling response). While MAP was still relatively low during reduced LVAD speeds, the increased left 
ventricular contractility served to increase stroke volume and thus LVSW. However at high LVAD speeds, 
the drastically reduced stroke volume in LAC resulted in decreased LVSW compared to LVC. For example, 
at a LVAD speed of 1800 RPM, the LVSW was 0.664 and 0.557 W for LAC and LVC respectively. At high 
levels of LVAD support, such as a LVAD speed of 2700 RPM, the LVSW had drastically decreased to 0.008 
W for LAC while a much smaller decrease was noted for LVC (0.129 W).  
 
The trends observed with LAC and LVC in mild LHF were also noted in the severe LHF condition (Figure 
81). LVADQ was higher in LVC compared to LAC under low levels of LVAD support. For example, at a 
LVAD speed of 2000 RPM, the LVADQ was 1.37 and 2.18 L/min for LAC and LVC respectively. However, 
at higher levels of support, the LVADQ converged between the two cannulation sites. This was 
particularly noticeable at LVAD speeds above 2300 RPM as the left ventricle had been sufficiently 
unloaded where any remnant ventricular contractility was negligible, thus creating a similar LVAD 
preload between the cannulation sites. At LVAD speeds of 2600 RPM, for instance, the LVADQ was 2.67 
and 2.72 L/min for LAC and LVC respectively. Convergence of the LVADQ between the two cannulation 
sites occurred earlier than in the severe left heart failure condition due to the reduced Starling response 
of the left ventricle (approximately 2800 and 2300 RPM respectively for mild and severe LHF). MSQ was 
higher, although only slightly, in LVC compared to LAC at all LVAD speeds other than 2900 RPM (LAC: 2.9 
L/min, LVC: 2.9 L/min) in the severe LHF condition. Aortic valve closure again occurred earlier with LVC 
(LVAD speed > 1900 RPM) compared to LAC (LVAD speed > 2200 RPM). MAP was also higher in LVC 
compared to LAC at all LVAD speeds, indicating higher LVAD efficiency in LVC.  
 
At LVAD speeds above 1900 RPM, the LVEF was higher in LVC compared to LAC as ventricular ejection 
was still possible through the LVAD in LVC. In LAC, however, the high arterial pressures due to increased 
LVAD support prevented the aortic valve from opening at LVAD speeds of 2300 RPM and higher. Similar 
to the mild LHF condition, LVSW was higher in LAC compared to LVC at low LVAD speeds and lower in 
LAC compared to LVC at high LVAD speeds in the severe LHF condition. This can be attributed with the 
Starling response increasing ventricular contractility when LVEDV was high at low LVAD speeds in LAC. 
This, in turn, increased LVP and left ventricular stroke volume, resulting in a high LVSW. However, as 
LVAD speed increased, the LVP was no longer sufficient to overcome the high arterial pressures, thus 
drastically reducing the left ventricular stroke volume and LVSW. This transition, as LVSW in LAC reduced 
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below that of LVC, occurred much earlier in the severe LHF condition (approximate LVAD speed of 2100 
RPM) compared to the mild LHF condition (approximate LVAD speed of 2400 RPM) due to the reduced 
Starling sensitivity in the severe LHF condition. 
 
 
Figure 81 – Haemodynamics for left atrial (LAC) and left ventricular (LVC) inflow cannulation in the severe 
left heart failure condition during the speed ramp test. LVADQ – LVAD flow rate, MSQ – mean systemic 
flow rate, MAP – mean aortic pressure, LVEF – left ventricular ejection fraction, LVSW – left ventricular 
stroke work (Watts), RPM – revolutions per minute. 
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Results were taken from the restored haemodynamics test for mild and severe LHF in LAC and LVC to 
provide a higher degree of clinical relevance to the study. Haemodynamics for each cannulation site in 
the two conditions are presented in Table 16 while pressure volume (PV) loops are shown in Figure 82. 
In both mild and severe LHF conditions, a higher LVAD speed was required in LAC compared to LVC to 
maintain restored haemodynamics (MAP: 100 mmHg, MSQ: 5 L/min), indicating a greater LVAD 
efficiency with LVC. The increased LVAD efficiency was also represented by the increased LVADQ in LVC 
compared to LAC in mild LHF. Increased LVAD preload due to the left ventricular contractility resulted in 
a LVADQ of 4.4 L/min in LVC compared to 3.5 L/min in mild LHF. While this indicates increased LVAD 
efficiency in LVC, the discrepancy between LVADQ and MSQ indicates that flow through the aortic valve 
was higher in LAC (1.5 L/min) compared to LVC (0.6 L/min). In severe LHF, however, the LVAD provided 
full support in both LAC and LVC, resulting in zero flow through the aortic valve in both cases. 
 
The PV loops in both mild and severe LHF revealed differences in the ventricular dynamics between LAC 
and LVC. In mild LHF with LAC, the PV loop resembled that of an unsupported case with relatively 
vertical lines during isovolumetric contraction and relaxation. In mild LHF a stroke volume of 29 mL was 
recorded while in severe LHF this decreased to 3 mL, thus making the PV loop appear as a simple vertical 
line. This drastically decreased the LVSW, with values of 0.299 and 0.012 W respectively for mild and 
severe LHF. The shape of the PV loop was more triangular in LVC compared to LAC as LVV was constantly 
removed from the left ventricle by the LVAD. This meant that even during the usual isovolumetric 
contraction and relaxation, LVV reduced and created a triangular PV loop. The larger ventricular stroke 
Condition Mild LHF Severe LHF 
Cannulation Site LAC LVC LAC LVC 
LVADS (RPM) 2500 2400 2600 2500 
LAP (mmHg) 8.2 9.0 8.8 8.8 
MAP (mmHg) 100 100 100 100 
LVPsys (mmHg) 108 103 100 82 
MSQ (L/min) 5.0 5.0 5.0 5.0 
LVADQ (L/min) 3.5 4.4 5.0 5.0 
LVVsys (mL) 171 117 212 132 
LVVdias (mL) 200 164 215 171 
LVEF (%) 14.5 28.7 1.4 22.8 
LVSW (Watts) 0.299 0.373 0.012 0.196 
Table 16 - Haemodynamics for the restored test with left atrial (LAC) and left ventricular (LVC) inflow 
cannulation in mild and severe left heart failure (BHF) conditions. LVADS – LVAD speed, LAP – left atrial 
pressure, MAP – mean aortic pressure, LVPsys – left ventricular systolic pressure, MSQ – mean systemic 
flow rate, LVADQ – LVAD flow rate, LVVsys – systolic left ventricular volume, LVVdias – diastolic left 
ventricular volume, LVEF – left ventricular ejection fraction, LVSW – left ventricular stroke work (Watts), 
RPM – revolutions per minute. 
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volume with LVC (47 and 39 mL in mild and severe LHF respectively) and the relatively high systolic LVP 
(103 and 82 mmHg for mild and severe LHF respectively) resulted in higher LVSW compared to LAC. LVEF 
was notably decreased in LAC compared to LVC in both mild and severe LHF conditions. The LVEF was 
14.5 and 28.7% for LAC and LVC respectively for mild LHF and 1.4 and 22.8% respectively for severe LHF. 
This was due to both lower LVEDV in LVC in mild (LAC: 200 mL, LVC: 164 mL) and severe (LAC: 215 mL, 
LVC: 171 mL) LHF combined with a reduced left ventricular stroke volume in LAC compared to LVC.  
 
4.3.2 RVAD Inflow Cannulation Results 
Although this study was completed with biventricular support, only results for the RVAD inflow 
cannulation site will be discussed. Results from the speed ramp test for mild BHF in RAC and RVC are 
presented in Figure 83. RVAD flow rate (RVADQ) was higher in RVC compared to RAC for all RVAD 
speeds other than when the two had converged by 1500 RPM. At RVAD speeds of 700, 1000 and 1300 
RPM, RVADQ was 1.71, 3.09 and 4.39 L/min respectively for RAC and 2.22, 3.47 and 4.66 L/min 
respectively for RVC. This was not translated into total mean pulmonary flow rate (MPQ) though, as RAC 
consistently had equal-to or higher MPQ than RVC. This can be attributed with the right ventricular 
Starling response increasing right ventricular contractility due to the high right ventricular end diastolic 
volume (RVEDV) in RAC. This resulted in increased pulmonary arterial valve flow in RAC compared to 
RVC, which had a much lower RVEDV as the RVAD unloaded the right ventricle. Pulmonary arterial valve 
(a)
 
(b) 
 
Figure 82 – Pressure volume loops for left atrial (LAC) and left ventricular (LVC) inflow cannulation shown 
for conditions of mild (a) and severe (b) left heart failure. LVP – left ventricular pressure, LVV – left 
ventricular volume. 
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flow for RVAD speeds of 700, 1000 and 1300 RPM was 3.09, 1.91 and 0.81 L/min respectively for RAC 
and 2.58, 1.43 and 0.34 L/min respectively for RVC. Mean pulmonary arterial pressure (MPAP) was 
generally higher in RAC compared to RVC, particularly at higher levels of RVAD support. This indicates 
that although higher RVADQ is experienced with RVC, the right ventricular Starling response is able to 
compensate and result in increased cardiac output with RAC.  
 
Right ventricular ejection fraction (RVEF) was consistently higher in RVC compared to RAC, particularly at 
high levels of RVAD support. RVEF at a RVAD speed of 1500 with RVC was recorded as 116% as the right 
ventricular end systolic volume had progressed below zero due to suction from the RVAD, and can be 
attributed as an experimental error. The increased RVEF in RVC was due to the decreased RVEDV 
combined with a relatively consistent right ventricle stroke volume. RVEDV in RAC, however, was 
consistently higher than RVC, and combined with a much smaller right ventricular stroke volume 
resulted in a decreased RVEF. The decreased stroke volume in RAC also served to decrease right 
ventricular stroke work (RVSW) at high RVAD speeds. At low RVAD speeds, RVSW was relatively similar 
between the two cannulation sites. However, as right ventricular stroke volume reduced due the 
inability of the weakened right ventricle to overcome the high pulmonary arterial pressures caused by 
the RVAD outlet pressure, RVSW decreased. RVSW also decreased as RVAD speed increased in RVC, 
however to a lesser degree as the right ventricle maintained some ejection through the RVAD.  
 
Similar trends from the mild BHF condition were observed in the severe BHF condition in the RVAD 
speed ramp test (Figure 84). However, a maximum RVAD speed of only 1100 RPM, compared to 1500 
RPM in mild BHF, was reached due to the reduced Starling response in both left and right ventricles 
being unable assist in balancing flow rates, and hence volumes, between the systemic and pulmonary 
circulations. RVADQ was consistently higher with RVC compared to RAC at lower RVAD speeds. 
However, the diminished right ventricular contractility at higher RVAD speeds (due to reduced right 
ventricular volume and hence contractility through the right ventricular Starling response) resulted in 
similar RVAD preload between the two cannulation sites and therefore similar RVADQ. Similar to the 
mild BHF condition, higher RVADQ in RVC was not translated to an increased MPQ compared to RAC in 
the severe BHF condition. MPQ was similar between the two cannulation sites. The discrepancy 
between MPQ and RVADQ indicates that pulmonary arterial valve flow rates were 2.7, 1.3 and 0.1 L/min 
for RAC and 2.2, 0.8 and 0 L/min for RVC at RVAD speeds of 400, 700 and 1000 RPM respectively.  
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Figure 83 – Haemodynamics for right atrial (RAC) and right ventricular (RVC) inflow cannulation in the 
mild biventricular heart failure condition during the speed ramp test. RVADQ – RVAD flow rate, MPQ – 
mean pulmonary flow rate, MPAP – mean pulmonary arterial pressure, RVEF – right ventricular ejection 
fraction, RVSW – right ventricular stroke work (Watts), RPM – revolutions per minute. 
 
MPAP was similar between the cannulation sites which, combined with similar MPQ, indicated that 
neither RAC nor RVC is more efficient in severe BHF. RVEF was consistently higher in RVC compared to 
RAC, with values of 23, 22 and 36% for RVAD speeds of 400, 700 and 1000 RPM respectively. A slight 
discrepancy in the RVEF result was observed in RVC at a RVAD speed of 1100 RPM as the RVEF dropped 
to 20% rather than continuing to increase. This can be attributed to the very low right ventricular 
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volume (end systolic right ventricular volume: 8 mL) resulting in a drastically decreased right ventricular 
contractility through the right ventricular Starling response. RVEF was 21, 15 and 1% respectively with 
RAC for the same RVAD speeds, demonstrating improved ventricular washout with RVC. RVSW was 
generally lower with RAC except at the lowest (400 RPM) and highest (1100 RPM) RVAD speeds 
evaluated. RVSW was lower in RAC, demonstrating a decreased work load on the right ventricle. 
 
 
Figure 84 – Haemodynamics for right atrial (RAC) and right ventricular (RVC) inflow cannulation in the 
severe biventricular heart failure condition during the speed ramp test. RVADQ – RVAD flow rate, MPQ – 
mean pulmonary flow rate, MPAP – mean pulmonary arterial pressure, RVEF – right ventricular ejection 
fraction, RVSW – right ventricular stroke work (Watts), RPM – revolutions per minute. 
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To provide a higher degree of clinical relevance to the study, results were taken from the restored 
haemodynamics test for mild and severe BHF in RAC and RVC. The haemodynamics for each cannulation 
site in mild and severe BHF are presented in Table 17 while right ventricular PV loops are shown in 
Figure 85. In mild BHF, an RVAD speed of 900 RPM was required for RAC and RVC to maintain restored 
haemodynamics (MPAP: 18 mmHg, MPQ: 5 L/min), indicating similar efficiency between the cannulation 
sites. However, in severe BHF, a higher RVAD speed was required in RVC (1300 RPM) compared to RAC 
(1100 RPM), indicating that RAC is actually more efficient than RVC in severe BHF. This could be due to 
the high RVEDV in RAC increasing right ventricular contractility through the right ventricular Starling 
response, even with its diminished sensitivity in severe BHF. As expected, right atrial pressure (RAP) was 
lower in RAC compared to RVC as the RVAD pumped fluid from the cannulated chamber. RVAD flow rate 
was higher in RVC compared to RAC in both mild and severe BHF due to the increase preload from right 
ventricular systole in RVC. Evaluation of the right ventricular PV loops revealed increased RVEF in RVC  
compared to RAC, again indicating increased right ventricular washout with RVC. RVSW was similar 
between the two cannulation sites, while the right ventricular PV loops had similar characteristics to 
those observed in the left ventricle in mild and severe LHF.  
 
 
Condition Mild BHF Severe BHF 
Cannulation Site RAC RVC RAC RVC 
RVADS (RPM) 900 900 1100 1300 
RAP (mmHg) 6.5 9.0 4.8 6.5 
MPAP (mmHg) 18 18 18 18 
RVPsys (mmHg) 28 27 23 20 
MPQ (L/min) 5.0 5.0 5.0 5.0 
RVADQ (L/min) 2.67 3.03 3.9 4.8 
RVVsys (mL) 110 120 108 78 
RVVdias (mL) 152 176 125 116 
RVEF (%) 27.6 31.8 13.6 32.7 
RVSW (Watts) 0.10 0.13 0.03 0.05 
Table 17 – Haemodynamics for the restored test with right atrial (RAC) and right ventricular (RVC) inflow 
cannulation in mild and severe biventricular heart failure (BHF) conditions. RVADS – RVAD speed, RAP – 
right atrial pressure, MPAP – mean pulmonary arterial pressure, RVPsys – right ventricular systolic 
pressure, MPQ – mean pulmonary flow rate, RVADQ – RVAD flow rate, RVVsys – systolic right ventricular 
volume, RVVdias – diastolic right ventricular volume, RVEF – right ventricular ejection fraction, RVSW – 
right ventricular stroke work (Watts), RPM – revolutions per minute. 
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(a) (b) 
  
Figure 85 – Pressure volume loops for right atrial (RAC) and right ventricular (RVC) inflow cannulation 
shown for conditions of mild (a) and severe (b) right heart failure. RVP – right ventricular pressure, RVV – 
right ventricular volume. 
 
4.4 Discussion 
Neurologic complications remain one of the most serious adverse events for mechanical circulatory 
support [91]. The three predisposing factors to thromboembolic complications, described by Virchow’s 
triad, are vessel wall abnormalities, abnormal flow and coagulation state. If flow dynamics within the 
cannulated chamber are not optimal, abnormal flow and thus thromboembolic and subsequent 
neurologic complications may result. The choice of inflow cannulation site obviously influences the 
circulatory flow dynamics within the cannulated chamber due to the very different function of the atria 
and ventricles. Meanwhile, ventricular unloading is vital for patients identified for BTR treatment, as the 
aim of this strategy is to reduce the workload of the heart until it recovers.  The workload of the heart is 
ultimately determined by the myocardial oxygen consumption of the ventricle, which is directly related 
to the amount of energy consumed by the heart during each cardiac cycle [120, 121]. This energy is 
influenced by the external stroke work and end systolic volume and pressure inside the ventricle. These 
parameters change significantly with each cannulation site. In this study, LVAD and RVAD inflow 
cannulation site was evaluated to determine the potential for thrombus formation (by improving 
ventricular washout), ventricular recovery and to improve VAD efficiency. The key results are discussed 
below. 
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4.4.1 LVAD Inflow Cannulation Site 
The implantation of a LVAD is a proven therapeutic option to treat heart failure [290, 291]. The 
widespread application of this treatment is increasing as device reliability and functionality improves. 
The selection of a device with suitable performance accomplishes only part of the support solution, as 
the cardiac-device interface also greatly affects haemodynamic performance. The LVAD inflow cannula 
provides the conduit at this interface, and its connection to either atrium or ventricle induces major 
changes in flow dynamics. There is thus an apparent need to find the best inflow cannulation site to 
manipulate the performance of the cardiac-VAD interaction to suit the support strategy selected for 
each patient.  
 
Despite the relatively invasive procedure, apical LVC is the preferred interface site for implantable VADs 
aimed at treating end stage heart failure [116, 125]. The energetic contribution of the LVAD in either 
cannulation site increases the arterial pressure, making it almost impossible for the failing left ventricle 
to pump blood through the aortic valve. In LVC, this is compensated by remnant contractility pushing 
blood through the LVAD. However, this is not possible with LAC, resulting in a reduced LVEF, especially 
in patients exhibiting severely depressed cardiac function. LVEF was consistently higher with LVC 
compared to LAC throughout this study, particularly in the more severe degree of LHF. The difference in 
LVEF between LAC and LVC increased with increasing levels of LVAD support, with almost no aortic valve 
flow in the restored severe LHF with LAC. With a low LVEF and high end systolic and diastolic left 
ventricular volumes with LAC, particularly in severe LHF, ventricular washout is clearly reduced. The 
higher degree of blood stasis which results from reduced ventricular washout could result in increased 
thromboembolic events [119, 125, 130].  Handke et al. (2005) [127] reported that patients exhibiting a 
LVEF below 35% were predisposed to thrombus formation, while Pullicino predicted an increased risk of 
thrombus formation with a LVEF below 28% [122]. When LVAD speed was controlled to restore 
haemodynamic parameters to 5L/min and 100mmHg for MSQ and MAP respectively, the present study 
reported low LVEF for mild and severe LHF with values of 14.5% and 1.4%, respectively for LAC. While 
LVEF was greatly improved with LVC to values of 28.7% and 22.8% for mild and severe LHF respectively, 
it may still expose LVAD supported patients to risk of thrombus formation. Certain control strategies to 
increase LVEF, such as pulsing (increasing) LVAD speed during ventricular systole, should be investigated 
as future work. Nonetheless, these results indicate LVC may be more suitable for long term LVAD 
support to reduce risk of thrombus formation. Meanwhile, cyclic changes to inlet pressure caused by 
remnant ventricular contractions in LVC improves the washout of rotary type VAD internal surfaces, thus 
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reducing the potential for thrombus formation within the pump [116].  LVEF and LVAD washout are 
therefore not only dependant on cannulation site, but also the level of remaining systolic contractility of 
the failing heart.  
 
The increased left ventricular stroke volume with LVC, which increases LVEF, also influences the LVSW, 
found by calculating the area within the PV loop. Vandenberghe et al. (2004) [13] found no significant 
differences in LVEF between LAC and LVC. The use of a healthy animal model may have contributed to 
this unexpected result, as the strong ventricular Starling response may have been able to overcome the 
high, LVAD-driven arterial pressures. However, reduced left ventricular stroke volume and LVSW was 
noted with LAC in the in vivo study. Morley et al. (2007) [129] used numerical simulation techniques to 
compare LAC over LVC in less dilated and less dysfunctional hearts and stated that myocardial oxygen 
consumption, related to the area within a PV loop, could possibly effect the rate and extent of reverse 
remodelling. Morley stated that LVC would result in reduced myocardial oxygen consumption compared 
to LAC in mild LHF, however visual analysis of the PV loops produced in their study leave this conclusion 
to be questioned. Our study found the two cannulation sites resulted in similar LVSW in mild LHF, 
leading to the conclusion that either could be used to similar effect with the aim of myocardial recovery. 
However, atrial cannulation allows for easier surgical insertion off bypass, and also promotes the 
potential for cardiac ventricular recovery through preservation of the remaining cardio-myocytes by 
eliminating the need to core the apex [116, 119]. This leads to the conclusion that LAC should be 
preferred in mild LHF with a view to ventricular recovery. However, care should be taken when choosing 
LAC as the often more friable atrium can be more difficult to close and result in bleeding complications.  
 
In severe LHF, LVSW was significantly reduced with LAC yet remained relatively high with LVC. This can 
be attributed to a combination of high arterial pressures (due to LVAD support) and a reduced 
ventricular capacity to overcome these high arterial pressures (due to the severe LHF condition) leading 
to a small left ventricular stroke volume, and thus low LVSW with LAC. With LVC, however, ejection 
through the LVAD was still possible, thus maintaining reasonable end systolic, end diastolic and stroke 
volumes. Combined with the left ventricular pressure, the larger stroke volume with LVC resulted in a 
higher LVSW compared to LAC. The minimal ventricular ejection with LAC also resulted in large end 
systolic and diastolic ventricular volumes, and hence ventricular pressures via the Starling response. 
Therefore, LAC causes both pressure and volume loading of the left ventricle in severe LHF. Volume 
loading of the heart with LAC promotes higher tissue stress in the ventricular wall, which is an obvious 
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disadvantage for myocardial recovery in end stage heart failure [13]. These results agree with those 
presented by Korakianitis et al. (2007), who also noted higher left ventricular volumes with LAC [14]. 
 
Another advantage when aiming for bridge-to-recovery therapy is maintaining flow through the aortic 
valve. In severe LHF, LAC and LVC provided full ventricular support and, therefore, no flow passed 
through the aortic valve. This was due to higher arterial pressures caused by the LVAD, and the inability 
of the failed left ventricle to overcome these pressures with either inflow cannulation site. In mild LHF, 
however, there was some aortic valve flow in both LAC (1.5L/min) and LVC (0.6 L/min). Although not 
stated specifically in the results, analyzing Figure 2B in Morley et al. (2007) [129] also reveals higher 
aortic valve flow with LAC compared to LVC in a mild LHF condition. The increased aortic valve flow with 
LAC may prevent the valve from becoming stenotic and reduce the incidence of thrombus formation 
around the valve [13]. Therefore, LAC should be preferred in mild LHF with a view to recovery to reduce 
the potential for thrombus formation around the aortic valve and to prevent aortic valve stenosis.  
 
With a view to long term LVAD support, the efficiency of the pump becomes important to reduce power 
consumption, thus increasing battery life, and reduce mechanical wear. Vandenberghe et al. (2004) [13] 
reported increased LVAD efficiency with LVC when evaluating a RBP in a healthy animal model. This 
conclusion agreed with that by Meyns et al. (1998) [292] where higher LVADQ was noted with LVC in 
both healthy and simulated heart failure conditions in an in-vivo model. Our results also demonstrated 
similar trends, with LVC recording higher LVADQ, MSQ and MAP compared to LAC in both mild and 
severe LHF conditions in the LVAD speed ramp tests. Meanwhile, in the restored conditions, a lower 
LVAD speed was required in LVC to maintain the same haemodynamics as those in LAC in both LHF 
conditions. This can be attributed to the larger, pulsatile LVAD preload caused by remnant ventricular 
contractility in LVC, compared to a relatively low and steady preload in LAC. Therefore, LVC was 
characterized by an increase in support efficiency which may provide benefits to power consumption 
and device wear in long term, bridge to transplant or recovery scenarios.  
 
4.4.2 RVAD Inflow Cannulation Site 
The incidence of right heart dysfunction after LVAD insertion may vary between 10-50% [54-58]. RVAD 
inflow cannulation has previously been favored in the right atrium. However, some are now favoring the 
right ventricular free wall, such as those implanting the DexAide RVAD or HeartWare HVAD as an RVAD 
[56, 82]. Despite trends toward favoring right ventricular inflow cannulation, few studies have 
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attempted to characterize the ideal inflow cannulation site for RVAD support. This study aimed to 
characterize the RVAD inflow cannulation site in a biventricular heart failure condition (with BiVAD 
support) with the same techniques used to evaluate LVAD cannulation site.  
 
Atrial and ventricular cannulation may result in a relatively large preload difference with the use of a 
LVAD, especially if some ventricular contractility remains due to the high pressure systemic circulation. 
However, a much lower pressure difference exists between the right atrium and ventricle, even in 
healthy conditions. This is further exacerbated in a heart failure condition, where the right ventricle has 
failed. Therefore, comparisons between LVAD inflow cannulation site may not be directly transferable to 
RVAD inflow cannulation site. Schlensak et al. (2011) [132] evaluated RVAD inflow cannulation site in 31 
patients, however this recent study used pulsatile, Thoratec PVADs for right ventricular support. 
However, the reported increase in pulsatile RVADQ agreed with the results in our study taken with a 
rotary device in mild and severe BHF. In our study, this was particularly noticeable at low RVAD speeds 
when the right ventricle was severely dilated and the right ventricular Starling response increased RVAD 
preload with RVC. At high RVAD speeds in mild and severe BHF, when the right ventricular volume had 
reduced due to the RVAD redistributing blood volume to the arterial network, the Starling response had 
diminished and RVADQ between the two cannulation sites converged. This occurred much earlier in the 
severe BHF condition (1100 RPM) compared to the mild BHF condition (1500 RPM) due to the decreased 
Starling response sensitivity in severe BHF. 
 
MPQ did not follow the same trend as RVADQ, with higher MPQ noted in RAC compared to RVC in 
almost all RVAD speeds in the mild BHF condition and similar values recorded between the cannulation 
sites in the severe BHF condition. This can be attributed to the high right ventricular volume with RAC 
triggering increased right ventricular contractility through the Starling response, thus ejecting some fluid 
through the pulmonary valve. This was less noticeable in the severe BHF condition due to the diminished 
Starling sensitivity; however some pulmonary valve flow was present in all cases with RAC. The 
discrepancy between MPQ and RVADQ was clear when evaluating the restored test results, with higher 
RVADQ in RVC in both mild and severe BHF. As is the case with LVAD support, the higher and more 
pulsatile RVADQ with RVC may improve the washout of the rotary RVAD and reduce the risk of 
thrombus forming in the pump [116].  
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While higher RVADQ was observed with RVC compared to RAC, thus indicating higher device efficiency 
with RVC, the overall haemodynamic effect was improved with RAC due to the right ventricular Starling 
response. This was particularly noticeable in the mild BHF condition, where MPQ and MPAP were higher 
in almost all RVAD speeds with RAC compared to RVC. With the reduced Starling sensitivity in severe 
BHF, MPQ and MPAP were similar between the cannulation sites even though RVADQ was higher with 
RVC. Meanwhile, the same RVAD speed (900 RPM) was required to restore haemodynamics in the mild 
BHF condition. Surprisingly, a higher RVAD speed was required to restore haemodynamics with RVC 
(1300 RPM) compared to RAC (1100 RPM). In this case, RVADQ was much higher with RVC but MPQ was 
the same for both cannulation sites, indicating that the right ventricular Starling response was influential 
even in the severe BHF condition. This may indicate that the Starling sensitivity was too high in these 
tests and needs to be reduced for the severe BHF condition. Alternatively, it could be explained by the 
low pressures in the pulmonary circuit and the slight haemodynamic changes required to alter MPQ and 
RVADQ. For example, in the severe BHF condition, the higher end diastolic right ventricular volume with 
RAC resulted in a higher systolic right ventricular pressure (RVPsys) through the Starling response. The 3 
mmHg difference in RVPsys between the cannulation sites was sufficient to generate enough flow 
through the pulmonary valve and reduce the support requirement of the RVAD. The sensitivity of the 
pulmonary circulation to slight pressure and flow changes is not only important for evaluating inflow 
cannula placement, but also in the design of rotary RVADs. 
 
The reduced right ventricular contractility, and subsequent reduced RVEF, may promote thrombus 
formation within the right atrium or ventricle or the RVAD. Virchow’s triad identifies vessel wall 
abnormalities, abnormal flow and coagulation state as the three key risk factors for thrombus 
formation. LAC is generally considered to reduce LVEF while LVC appears to decompress the ventricle 
and thus produces less blood stagnation and thromboembolic events [117, 119]. While no literature 
could be found on RVEF with rotary RVAD support in atrial and ventricular cannulation, similar 
assumptions can be made for right ventricular support, such as the increased risk of thrombus formation 
with reduced RVEF. In this study, RVEF was consistently higher with RVC compared to RAC, indicating 
that RVC should be favored for long term support to reduce the potential for thrombus formation and 
subsequent pulmonary embolism. Two small discrepancies existed with the RVEF results. In mild BHF 
with RVC, the RVEF was above 100% due to the RVAD continuing to draw fluid from the right ventricle 
even after the right ventricular volume had progressed below the pre-set zero level. This could be 
addressed through the addition of a suction replication mechanism which closed the inflow cannula 
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when right ventricular volume reached 0 mL. In the severe BHF condition with RVC, RVEF unexpectedly 
decreased as RVAD speed increased from 1000 to 1100 RPM. This can be attributed to instability in the 
right ventricular Starling response. As right ventricular volume approached 0 mL, the right ventricular 
Starling response would, on some occasions, become unstable and result in reduced ventricular 
contractility, and thus a smaller RVEF in this case. 
 
Ventricular unloading is vital for patients identified for bridge to recovery treatment, as the aim of this 
strategy is to reduce the workload of the heart until it recovers, and thus is less critical for bridge to 
transplant and destination therapy patients.  The workload of the heart is ultimately determined by the 
myocardial oxygen consumption of the ventricle, which is directly related to the amount of energy 
consumed by the heart during each cardiac cycle [120, 121]. This energy is influenced by the external 
stroke work, and the end systolic volume and pressure inside the ventricle and changes significantly with 
each cannulation site. This study demonstrated reduced RVSW with RAC compared to RVC in almost all 
cases in the RVAD speed ramp tests. In mild and severe BHF, RVSW was similar between the cannulation 
sites at very low and very high RVAD speed. At low RVAD speed, RVSW was high in both cases as the 
right ventricle was not significantly unloaded so the RVSW was similar to an unsupported case. At high 
RVAD speed, the change in right ventricular pressure (RVC) or volume (RAC) over the cardiac cycle was 
minimal which resulted in a RVSW of almost 0 W for both cannulation sites. RVSW was slightly reduced 
with RAC compared to RVC in both mild and severe BHF in the restored conditions test, indicating that 
RAC may promote improved recovery of the right ventricle. McGee et al. (2008) [144] stated that 
decompression of the right ventricle with RVC may improve ventricular recovery; however coring the 
right ventricular muscle may be detrimental in this case. It is for these reasons that RAC should be 
favored for short term support with a view to myocardial recovery. This choice, however, is often 
dependant on the preference of the surgeon, and can be limited by anatomical constraints or the 
presence of thrombus within a vessel [11, 115]. 
 
4.4.3 Experimental Evaluation 
Previous in-vivo studies which evaluated atrial vs. ventricular cannulation are limited through use of 
healthy animal hearts with increased Starling responsiveness [13]. The MCL used in this study allowed 
for repeatable evaluation of LVAD and RVAD inflow cannulation site with enlarged, failed ventricles and 
a ventricular Starling response. Furthermore, difficulties in conductance catheter operation often noted 
with in-vivo research were eliminated with the MCL, thus allowing the exact energetic effects to be 
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quantified. However, the primary limitation with this study was the lack of accurate autoregulation 
mechanisms in the MCL. Manual manipulation of the vascular resistance in restored tests provided a 
reasonable approximation of the baroreceptor reflex; however changes in heart rate and ventricular 
contractility were not incorporated. Meanwhile, the ventricular Starling response of the MCL provided 
an excellent representation of various end systolic pressure volume relationships (ESPVR); however no 
mechanism was included to vary the end diastolic pressure volume relationship (EDPVR). This meant 
that no diastolic heart failure conditions could be simulated in the MCL. The lack of a variable EDPVR 
also resulted in linear ventricular filling and, therefore, increased end diastolic volume which influenced 
the ventricular Starling response. Simulation of atrial or ventricular suction was also lacking in this study 
and negative chamber volumes were recorded in some instances.  
 
4.5 Conclusion 
The aim of this chapter was to characterize the difference between atrial and ventricular inflow 
cannulation for rotary LVAD and RVAD support in a MCL. Left and right atrial and ventricular inflow 
cannulation sites were compared in a MCL under conditions of mild and severe left and biventricular 
heart failure.  
 
LVC should be preferred for long term LVAD support in a severe LHF condition to improve device 
efficiency and reduce the risk of thrombus formation. This is due to the remnant ventricular contractility 
increasing device preload and improving the washout in the ventricle.  LAC should be preferred for 
patients with mild LHF with a view to ventricular recovery as the workload on the heart is reduced, 
coring of the myocardium is unnecessary and the flow through the aortic valve is maintained, thus 
better preserving the valve. 
 
The difference in RVAD preload between RAC and RVC was much smaller than that seen with LVAD 
support, although similar conclusions can be drawn. RVC should be preferred for long term RVAD 
support in a severe BHF condition to reduce the potential for thrombus formation. RAC should be 
preferred in a mild BHF condition with a view to myocardial recovery to increase flow through the 
pulmonary valve, reduce the workload on the right ventricle and preserve the myocardium. However, 
the results shown in this study can only be taken as a guide and, ultimately, inflow cannula placement 
will be chosen based on patient constraints, device availability and the preference of the surgeon. 
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Chapter 5 
Compliant Inflow Cannula 
 
5.1 Aims 
Unlike the first generation pulsatile flow VADs, continuous flow devices are not passively filled. Low 
rotary blood pump inlet pressures due to imbalances in the systemic and pulmonary circulations may 
result in negative atrial or ventricular pressure causing chamber suction [19, 20]. This is particularly 
problematic in BiVAD support where neither ventricle possesses a sufficient flow balancing, Starling 
response. Suction of the cannulated chamber may draw the septum or free wall onto the cannula, 
resulting in intermittent VAD flow stoppages, endocardial damage and ventricular arrhythmias [14, 19, 
21, 22]. If left untreated, a leftward septal shift may impair right ventricular function and potentially 
result in right ventricular failure requiring RVAD support [23]. Previous studies have shown active 
control systems may be used to achieve flow balancing and reduce suction events with rotary blood 
pumps [24-26].  These systems use either sensor or sensor-less feedback control to alter VAD rotational 
speed depending on a controller input variable. Use of sensors, particularly pressure sensors, for VAD 
control presents several disadvantages.  Pressure sensors pose an ideal location for thrombus to form, 
while to the author’s knowledge no pressure sensor has been developed with zero drift [27].  
Meanwhile, the costs associated with reliable sensor development and implementation only adds to the 
already high costs of VAD support.  Sensor-less control systems have also been employed previously in 
VADs and usually rely on the relationship between VAD flow and a non-invasive measurement which can 
be easily taken from the VAD itself, such as VAD motor current [293].  However, these measurements 
may present gross inaccuracies, particularly if there is a blockage in the VAD circuit or thrombus 
attachment to the impeller [28].  Therefore, the aim of this chapter was to present the development and 
evaluation of a compliant inflow cannula to provide preload-based, passive control of rotary blood pump 
flow to reduce suction events. 
 
The compliant inflow cannula was required to be evaluated for LVAD and RVAD support under various 
degrees of left and right heart failure to increase the clinical relevance of the study. As identified in 
Chapter 4 of this thesis, both inflow cannulation sites have advantages and, therefore, the compliant 
inflow cannula should be evaluated in atrial and ventricular inflow cannulation. Initially, a compliant 
inflow cannula reservoir was used, before being refined to an in-line design. Construction and evaluation 
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of both designs are discussed in this chapter. Comparisons between rigid and compliant inflow cannulae 
were required in order to assess the capability of preventing suction events. In particular, left and right 
ventricular volumes, total systemic and pulmonary flow rates and mean arterial pressures were of 
interest to ensure suction events were prevented while maintaining sufficient haemodynamics at all 
times. The results from this study will provide a proof-of-concept for the use of a compliant inflow 
cannula to prevent suction events in rotary LVAD or RVAD support. This chapter presents an original 
idea and proof of concept with investigation into how the prototype device performs under various 
degrees of heart failure. Therefore, device optimization was beyond the scope of this preliminary study 
and will be explored in future work. 
 
5.2 Methods 
A compliant inflow cannula was designed and constructed before evaluation in the MCL, described in 
Chapter 3 of this thesis. The experimental setup and testing procedure used to evaluate the compliant 
inflow cannula is described in this section.  
 
5.2.1 Compliant Inflow Cannula Reservoir Construction 
The compliant inflow cannula reservoir was constructed by coating a custom-designed mould with 
silicone. The inner mould (Figure 86) was designed in SolidWorks (Concord, Massachusetts, USA) and 
printed with ABS plastic using a rapid prototyping machine (Dimension SST768, Stratasys Inc, Eden 
Prairie, USA).  The mould was coated with 20 mL layers of de-aired silicone (Silastomer P15, Dalchem, 
Cheltenham, Australia), with each layer allowed to set prior to adding the subsequent layer. Each layer 
was set rapidly by applying heat to the silicone with a heat gun. Three layers of silicone were applied to 
give a suitable wall thickness to withstand VAD inlet pressures without leaking / entraining air while also 
providing a compliant vessel. The rapid prototyped mould was then destroyed and removed from inside 
the silicone reservoir, leaving only the thin-walled vessel.  The constructed reservoir had a 2 mm 
average wall thickness, 100 mm total length and a 50 mL priming volume. These dimensions were 
chosen to give the reservoir sufficient length for MCL attachment and volume to account for small flow 
imbalances in the systemic and pulmonary circulations. 
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(a) 
 
(b) 
 
Figure 86 - The (a) side view and (b) schematic view of the mould for reservoir construction. 
 
5.2.2 Compliant Inflow Cannula Reservoir Evaluation 
The compliance of the inflow cannula reservoir was determined by measuring the change in pressure for 
a known change in volume. The two ends of the reservoir were capped, with one end attached to a 3-
way tap. The reservoir was filled with water until all air had been removed and the reservoir was at its 
unstressed shape (ie. the moulded shape). A pressure sensor was attached to the 3-way tap and offset 
to zero at the unstressed volume. Water was then gradually added to the reservoir through a syringe in 
5 mL increments until a maximum additional volume of 20 mL was reached. Water was then removed in 
5 mL increments until a maximum of 40 mL (in relation to the unstressed volume) had been removed. 
Pressure and volume were recorded at each increment to determine the compliance of the reservoir. 
Compliance was calculated using Equation 5.1. 
 
Compliance (C) = Change in volume (∆V) / Change in pressure (∆P)   (5.1) 
 
The inflow cannula reservoir was evaluated in LVAD support only for preliminary evaluation. The 
reservoir was attached to the MCL and a Levitronix CentriMag LVAD (Levitronix LLC, Waltham, USA) 
inflow cannula (Figure 87). The MCL has been described in Chapter 3 of this thesis. In brief, the MCL is a 
mechanical representation of the systemic and pulmonary circulations, which are each represented by a 
five element Windkessel model. Systemic and pulmonary vascular resistances are simulated with 
proportional control valves and socket valves respectively, while Windkessel chambers are used to 
simulate the lumped systemic and pulmonary arterial and venous compliance. Inertial characteristics are 
included through refinement of the pipe lengths and diameters. LVAD inflow cannula attachment was 
achieved via ½" tubes and connectors to the left atrium and left ventricle. Each port was connected to a 
gate valve before a tee section connected the two ports and the LVAD inflow cannula. Selection of the  
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inflow cannulation site was then determined by the orientation of the two gate valves. The compliant 
inflow cannula reservoir was then connected between the tee section and the LVAD inflow port. LVAD 
outflow cannulation was achieved via the ascending aorta of the MCL, directly below the aortic 
compliance chamber. A schematic of the MCL with the LVAD inflow cannula reservoir is shown in Figure 
87. The working fluid throughout this study was a water/glycerol mixture (60/40% by mass) with similar 
viscosity and density to that of blood.  
 
The MCL was initially configured to represent a medically treated severe left heart failure condition 
without LVAD support. Haemodynamics for this condition are defined in Table 18. Total inflow and 
outflow cannula length (3 m) and inside diameter (12 mm) were representative of an extracorporeal 
LVAD circuit for this preliminary evaluation. The reservoir was placed 0.6 m from the cannulated 
chamber. As the reservoir height with respect to the cannulated chamber influenced the reservoir 
performance, the height was dictated by trial and error. The reservoir was placed at a height which 
allowed sufficient perfusion during normal operation while preventing chamber suction events when 
preload was reduced. This is discussed further in the results section of this chapter. LVAD support was 
 
Figure 87 – Diagrammatic representation of the collapsible inflow cannula reservoir attached to either the left 
atrium or left ventricle in the mock circulation loop with the real reservoir shown in the inset. LA – left 
atrium, LV – left ventricle, Ao – aortic compliance chamber, LVAD – left ventricular assist device, SVR – 
systemic vascular resistance valve, SV – systemic venous compliance chamber, RA – right atrium, RV – right 
ventricle, PA – pulmonary arterial compliance chamber, PVR – pulmonary vascular resistance valve, PV – 
pulmonary venous compliance chamber, x –valve. 
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then initiated by increasing LVAD speed and unclamping the cannulae.  MCL resistances were altered to 
restore the haemodynamics to physiologically healthy levels (ie. mean aortic pressure ≈ 95 mmHg, mean 
systemic flow rate ≈ 5 L/min). 
 
Reservoir performance in atrial cannulation (AC) and ventricular cannulation (VC) was evaluated firstly 
through a reduction in left atrial / ventricular preload and secondly through an increase in LVAD speed. 
Reduced preload was simulated through a sudden increase in pulmonary vascular resistance (PVR) from 
130 to 400 Dyne.s.cm-5. The MCL was allowed to settle before data acquisition was stopped. PVR was 
then returned to normal levels before the LVAD speed was increased from 2700 RPM in increments of 
100 RPM until a maximum speed of 3800 RPM was reached. The tests were then repeated without the 
reservoir, using a rigid cannula, for comparison. Reservoir performance at different heights with respect 
to the cannulated chamber was then evaluated with PVR and LVAD speeds returned to normal levels.  
For this test, reservoir height was initially set at the height of the cannulated chamber and varied to 
determine the ideal reservoir height to reduce chamber suction events in AC and VC. A flowchart of the 
compliant inflow cannula reservoir evaluation is shown in Figure 88. 
 
5.2.3 In-line Compliant Inflow Cannula Construction 
A smooth, 12 mm diameter wooden rod was coated with two, 20 mL layers of silicone (Silastomer P15, 
Dalchem, Cheltenham, Australia), with each layer allowed to set prior to adding the subsequent layer. 
Two layers of silicone were applied to ensure the compliant section would not leak or entrain air while 
remaining suitably compliant. The rod was removed, leaving a thin-walled, compliant silicone tube. The 
compliant silicone tube had an average wall thickness of 2 mm, an inner diameter of 12 mm, a length of 
100 mm and a priming volume of 22 mL.  
 
LAP 
(mmHg) 
MAP 
(mmHg) 
MSQ 
(L/min) 
LVVsys  
(mL) 
LVVdias 
(mL) 
EF 
(%) 
SW 
(Watts) 
 
12 60 2.5 197 247 20 0.34 
Table 18 - Haemodynamic parameters for simulation of medically treated left heart failure (without LVAD 
support). LAP - left atrial pressure, MAP - mean aortic pressure, MSQ - mean systemic flow rate, LVVsys - 
end systolic left ventricular volume, LVVdias - end diastolic left ventricular volume, EF - ejection fraction, 
SW - stroke work. 
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5.2.4 In-line Compliant Inflow Cannula Evaluation 
The in-line compliant inflow cannula was evaluated in conditions of LVAD and RVAD support. The same 
MCL, described in Chapter 3 of this thesis, was used for the in-line compliant inflow cannula evaluation. 
Gate valves and a tee section were again used to switch between left atrial and ventricular inflow 
cannulation. A similar arrangement was installed for RVAD inflow cannula evaluation, with ½” tubes 
connecting the RVAD to both the right atrium and ventricle via gate valves and a tee section. A 
schematic of the MCL, with in-line compliant inflow cannulae added to the LVAD and RVAD circuits, is 
shown in Figure 89. The working fluid throughout this study was a water/glycerol mixture (60/40% by 
mass) with similar viscosity and density to that of blood.  
 
MCL parameters were manipulated to represent a medically treated, severe left heart failure condition 
without VAD support (Table 19). A VentrAssist (Ventracor Ltd., Sydney, Australia) rotary LVAD was  
 
Figure 88 – Flowchart of the compliant inflow cannula reservoir test. The compliant inflow cannula reservoir 
was evaluated against the rigid inflow cannula in atrial (AC) and ventricular (VC) cannulation. LVAD speed 
ramp and pulmonary vascular resistance (PVR) change tests were completed. RPM – revolutions per minute. 
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connected to the MCL initially via the left atrium for LVAD inflow and the aorta for LVAD outflow. The 
compliant section was added to the VentrAssist inflow cannula. LVAD support was initiated and LVAD 
speed was increased in increments of 100 RPM from 2000 to 3000 RPM to simulate a gradual change in 
preload. A step change in PVR (100 to 400 Dynes.s.cm-5) was simulated to induce a sudden reduction in 
LVAD preload. The sudden and gradual preload change tests were then repeated with the compliant 
section replaced by a section of rigid, PVC tubing. The LVAD inflow cannulation port was then changed 
to the left ventricle by switching the orientation of the two LVAD inlet valves before all tests were 
repeated. LVAD support was then ceased before MCL parameters were manipulated to represent a 
medically treated, mild left heart failure condition without VAD support. The entire experiment was 
then repeated to compare the LVAD in-line compliant and rigid inflow cannulae in atrial and ventricular 
cannulation under gradual and sudden changes of LVAD preload in a mild left heart failure condition. 
 
The MCL and LVAD were then stopped before a BP80 (Bio-Medicus, Inc., Eden Prairie, MN, USA) rotary 
RVAD was connected to the circuit through right atrial inflow and pulmonary arterial outflow 
cannulation. In-line compliant sections were added to both the LVAD and RVAD inflow cannulae. MCL 
parameters were then manipulated to represent a medically treated, mild biventricular heart failure 
condition without VAD support. LVAD speed was set at 2300 RPM for all tests in the mild biventricular 
 
Figure 89 - Simplified schematic of the mock circulation loop (left) with the compliant inflow cannulae (right) 
on the LVAD and RVAD. LA - left atrium, LV - left ventricle, Ao - aorta, SVR - systemic vascular resistance, 
SV - systemic venous system, RA - right atrium, RV - right ventricle, PA - pulmonary artery, PVR - 
pulmonary vascular resistance, PV - pulmonary venous system. 
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heart failure condition. The RVAD was started and RVAD speed was increased in 100 RPM increments 
from 800 to 1800 RPM to simulate a gradual change in RVAD preload. A step change in SVR (1500 to 
2500 Dynes.s.cm-5) was then simulated to induce a sudden change in RVAD preload. The RVAD inflow 
cannulation site was then changed to the right ventricle through manipulation of the RVAD gate valves 
before the gradual and sudden preload change tests were repeated. The in-line compliant sections were 
then removed before all tests were repeated to compare the compliant and rigid inflow cannulae. 
Finally, MCL parameters were manipulated to represent a medically treated, severe biventricular heart 
failure condition without VAD support. All tests were then repeated to compare RVAD compliant and 
rigid inflow cannula in atrial and ventricular cannulation under gradual and sudden changes in RVAD 
preload in a severe biventricular heart failure condition.  
 
Finally, the performance of the in-line compliant inflow cannula was evaluated at different heights with 
respect to the cannulated chamber. Conditions of mild and severe left and biventricular heart failure 
were simulated. The in-line compliant inflow cannula was then placed at heights varying from 100 mm 
below to 350 mm above the cannulated chamber for both left and right atrial cannulation. Data were 
recorded throughout to determine the ideal placement of the compliant section in each condition. A 
flowchart of all tests for the in-line compliant and rigid inflow cannulae is shown in Figure 90. 
 
Data acquisition 
Data acquisition for the compliant inflow cannula reservoir and in-line compliant inflow cannula studies 
was achieved with pressure, flow and volume sensors. Haemodynamic and VAD parameters were 
captured at 100 Hz using a dSPACE data acquisition system (DS1104, dSPACE, MI, USA). Systemic and 
pulmonary flow rates were recorded using magnetic flow meters (IFC010, KROHNE, Sweden) while LVAD 
and RVAD outlet flow rates were recorded with clamp on ultrasonic flow meters (TS410-10PXL, 
Transonic Systems, NY, USA). Circulatory and VAD pressures were recorded using silicon-based 
transducers (PX181B-015C5V, Omega Engineering, Connecticut, USA). Left and right ventricular volumes 
were recorded using a magnetostrictive level sensor (IK1A, GEFRAN, Italy) which, when combined with 
the respective ventricular pressure trace, produced pressure volume loops. Post processing of the 
pressure volume loops enabled capture of ventricular ejection fraction and stroke work for each 
ventricle.   
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Figure 90 – Flowchart of the tests with the in-line inflow cannula. Evaluation was completed with the 
compliant and rigid inflow cannulae in both LVAD and BiVAD support scenarios in left and right atrial and 
ventricular cannulation. VAD speed ramp and systemic (SVR) / pulmonary (PVR) vascular resistance step 
changes were evaluated in mild and severe left (LHF) and biventricular (BHF) heart failure conditions. RPM 
– revolutions per minute. 
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5.3 Results 
Results were taken to compare the rigid and compliant (both reservoir and in-line type) cannulae to 
determine which has the best resistance to suction events. As the study with the compliant inflow 
reservoir was a preliminary proof of concept study, results are only presented to demonstrate the 
capability of the reservoir to prevent suction events. However, detailed results are presented for the 
more extensive in-line compliant inflow cannula study to characterize the performance of the device 
and its influence on the cardiovascular system. 
 
5.3.1 Compliant Inflow Cannula Reservoir Results 
The compliance of the LVAD inflow cannula reservoir, calculated using Equation 5.1, was found to be 0.5 
mL/mmHg. Results were compared in left atrial (LAC) and left ventricular (LVC) cannulation for increased 
PVR to characterize the performance of the reservoir. An example of how the reservoir prevented a 
chamber suction event is demonstrated in Figure 91 which shows the left ventricular volume (LVV) 
before and after an increase in PVR.  Further recorded parameters for the increased PVR test are 
presented in Table 19 for both LAC and LVC.   
 
 
 
 
a)  b)  
Figure 91 – Left ventricular volume (LVV) vs. time (a) with and (b) without the compliant inflow cannula 
reservoir in ventricular cannulation before and after an increase in pulmonary vascular resistance. Note 
ventricular suction has occurred during end systolic periods after 50 seconds without the reservoir in the 
circuit. 
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Parameter 
LHF Ventricular Cannulation Atrial Cannulation 
No VAD Reservoir No Reservoir Reservoir No Reservoir 
NPVR NPVR EPVR NPVR EPVR NPVR EPVR NPVR EPVR 
LAP (mmHg) 12 9 6 8 3 6 2.5 6.5 -2 
MAP (mmHg) 60 95 86 95 95 96 83 96 93 
MSQ (L/min) 2.5 4.8 4.4 4.9 4.8 4.8 4.2 4.9 4.7 
LVVsys (mL) 197 100 36 98 0 156 37 148 22 
LVVdias (mL) 247 155 91 136 20 159 47 154 25 
EF (%) 20 35 60 28 100 2 21 4 12 
SW (Watts) 0.34 0.35 0.35 0.25 0.24 0.00 0.06 0.02 0.00 
LVADRin 
(Dyne.s.cm-5) 
N/A 500 750 400 400 700 1400 650 650 
Table 19 – Recorded parameters in ventricular and atrial cannulation with and without the reservoir before 
and after an increase in pulmonary vascular resistance.  LHF – left heart failure, NPVR – normal pulmonary 
vascular resistance, EPVR – elevated pulmonary vascular resistance, LAP – left atrial pressure, MAP – mean 
aortic pressure, MSQ – mean systemic flow rate, LVVsys – systolic left ventricular volume, LVVdias – 
diastolic left ventricular volume, EF – ejection fraction, SW – stroke work, LVADRin – LVAD inflow 
cannula resistance. 
 
In LVC, the increased PVR reduced LVAD preload and partially collapsed the reservoir, thus increasing 
the LVAD inlet resistance (LVADRin) (500 to 750 Dyne.s.cm-5).  This reduced the mean systemic flow rate 
(MSQ) from 4.8 to 4.4 L/min which assisted in maintaining a sufficient end systolic left ventricular 
volume (LVVsys) of 36 mL.  Without the reservoir, reduced LVAD preload had minimal effect on the 
LVAD flow rate, thus causing a ventricular suction event shortly after the PVR increase.  Similar results 
were noted in LAC, with the compliant inflow cannula reservoir increasing LVAD circuit resistance to 
1400 Dyne.s.cm-5 which maintained left atrial pressure (LAP) at positive levels following a reduction in 
preload. Without the reservoir, atrial pressure dropped below zero, indicating atrial suction.   
 
Before the PVR increase, left ventricular ejection fraction (LVEF) was higher with the reservoir (35%) 
compared to without the reservoir (28%) in LVC.  This was due to the left ventricular pressure pulse 
ejecting fluid into a compliant vessel capable of expanding with increased inlet pressure.  Combined with 
fairly consistent left ventricular systolic and diastolic pressures, the increased LVEF resulted in higher left 
ventricular stroke work (LVSW) in LVC with the reservoir (0.35 W) compared to without the reservoir 
(0.25 W). LVEF and LVSW before the PVR increase in LAC were similarly small with and without the 
reservoir as the ventricular volume barely changed over each cardiac cycle. However, after the PVR 
increase with the reservoir included in the circuit, the aortic pressure dropped which allowed some 
ejection through the aortic valve and an increased stroke volume and LVEF. An increase in LVEF was also 
noted in LAC without the reservoir after the PVR increase, however this was due to much lower LVV as 
the atrium collapsed.  
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Results were then compared with and without the reservoir in LAC and LVC to observe the point of 
chamber suction when LVAD speed was increased. LVV for LVC and LAP for LAC are plotted against LVAD 
speed in Figure 92, while haemodynamic parameters for each case are shown in Table 20. With LVC, the 
reservoir maintained LVVsys above 75 mL for all LVAD speeds up to 3800 RPM, however when the 
reservoir was removed ventricular suction occurred at 3100 RPM.  With the reservoir, MAP and MSQ 
increased slightly with increased LVAD speed, however the drastically increased LVADRin due to 
reservoir collapse restrained this increase.  Once again, similar results were recorded with LAC as the 
reservoir maintained LAP at 6 mmHg or above for all LVAD speeds up to 3800 RPM.  Reservoir collapse 
prevented atrial suction by passively increasing LVADRin from 700 to 4250 Dyne.s.cm-5 over a LVAD 
speed increase from 2800 to 3800 RPM. Without the reservoir, negative atrial pressures were recorded 
when the LVAD speed approached 3400 RPM, indicating atrial suction.   
 
Increased reservoir height resulted in reduced reservoir filling pressure for both cannulation sites, thus 
increasing the LVADRin.  This was particularly noticeable in LAC due to the lack of a systolic pulse to aid 
with reservoir filling, where the LVADRin increased from 650 to 3245 Dyne.s.cm-5 when the reservoir 
height was increased from 0 to 150 mm above the atrium (Figure 93). Meanwhile, little change was 
noted in LVADRin with VC until the reservoir height was increased to 200 mm above the ventricle. 
Therefore, lower reservoir placement was required in LAC compared to LVC. In this study, the ideal  
a)  b)  
Figure 92 – Trends with and without the reservoir for (a) left ventricular volume vs. LVAD speed in 
ventricular cannulation and (b) left atrial pressure vs. LVAD speed in atrial cannulation. LVV – left 
ventricular volume, LAP – left atrial pressure, RPM – revolutions per minute, LVVsys – systolic left 
ventricular volume, LVVdias – diastolic left ventricular volume, Res – with the reservoir, NoRes – without 
the reservoir. 
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reservoir height to eliminate suction events 
while preventing unnecessary reservoir 
collapse was found to be 150 mm above the 
ventricle for LVC and at the height of the 
atrium for LAC. Reservoir placement high 
above the cannulated chamber resulted in 
reservoir collapse well before chamber 
suction, thus unnecessarily reducing LVAD 
flows while chamber pressures were still at 
sufficient levels. However, reservoir 
placement well below the cannulated 
chamber increased the hydrostatic pressure 
within the reservoir, thus suction of the 
chamber occurred prior to reservoir collapse.   
 
 
LVAD 
Speed 
Reservoir No Reservoir 
LAP MAP MSQ LVVsys LVADRin LAP MAP MSQ LVVsys LVADRin 
RPM mmHg mmHg L/min mL Dyne.s.cm
-5
 mmHg mmHg L/min mL Dyne.s.cm
-5
 
Left ventricular cannulation        
2700 9 95 4.8 100 500 8 95 4.9 98 400 
2800 8 97 4.9 92 650 7 102 5.1 74 400 
3000 8 97 4.9 87 1100 5 116 5.5 16 450 
3200 8 97 4.9 87 1600 - - - - - 
3400 8 98 4.9 84 2100 - - - - - 
3600 8 99 4.9 81 2650 - - - - - 
3800 8 101 4.9 77 3250 - - - - - 
Left atrial cannulation        
2800 6 96 4.8 156 700 6.5 96 4.9 148 650 
3000 6 93 4.8 151 1300 4.5 109 5.3 143 700 
3200 6 93 4.8 149 1800 2 123 5.7 125 700 
3400 6 95 4.85 142 2300 - - - - - 
3600 6.5 93 4.8 142 3100 - - - - - 
3800 7 90 4.7 152 4250 - - - - - 
Table 20 – Recorded parameters in left ventricular and atrial cannulation with and without the reservoir 
under various LVAD rotational speeds.  LAP – left atrial pressure, MAP – mean aortic pressure, MSQ – 
mean systemic flow rate, LVVsys – systolic left ventricular volume, LVADRin – LVAD inflow canula 
resistance, rpm – revolutions per minute.  Dashed lines indicate chamber suction had occurred at a lower 
LVAD speed. 
 
 
Figure 93 – Plot of LVAD inflow cannula resistance 
(LVADRin) vs. reservoir height with respect to the 
cannulated chamber for ventricular (VC) and atrial 
(AC) cannulation. 
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5.3.2 In-line Compliant Inflow Cannula Results 
The compliance of the in-line, compliant inflow cannula, calculated using Equation 5.1, was found to be 
0.125 mL/mmHg. Results were compared in atrial and ventricular cannulation sites for LVAD and RVAD 
support under mild and severe heart failure conditions to determine the effect of replacing the rigid 
inflow cannula with an in-line, compliant segment. Comparisons between the rigid and compliant inflow 
cannulae for mild left heart failure (LHF) with atrial cannulation, severe LHF with atrial cannulation, mild 
LHF with ventricular cannulation and severe LHF with ventricular cannulation are shown in Figure 94, 
Figure 95, Figure 96, and Figure 97 respectively. As LVAD speed was incrementally increased from 1800 
RPM, the LAP / LVV initially reduced for both compliant and rigid inflow cannulae.  Meanwhile, the 
LVADRin stayed relatively constant and LVADQ gradually increased in each case. As the LVADRin 
remained relatively constant in all cases with the rigid inflow cannula, LVADQ continued to increase 
while LAP / LVV decreased until the point of suction (LVV / LAP < 0 mL / mmHg). However, with the 
compliant inflow cannula, LVADRin began to gradually increase once the preload had reached 
sufficiently low levels. This increase in LVADRin served to reduce or maintain LVADQ with increasing 
LVAD speed, thus keeping positive LAP / LVV and preventing a suction event. 
 
In the mild LHF condition with LAC, LVADRin remained relatively constant for both inflow cannulae until 
a LVAD speed of 2600 RPM was reached (Figure 94). After this point, LVADRin increased steadily from 
approximately 450 to 2550 Dyne.s.cm-5 at a LVAD speed of 3000 RPM with the compliant inflow cannula. 
The increase in LVADRin decreased LVADQ from 4.1 to 2.8 L/min as the LVAD speed increased from 2600 
to 3000 RPM. This flow reduction maintained a positive LAP, thus preventing a suction event. 
Meanwhile, LAP approached 0 mmHg at 3000 RPM with the rigid inflow cannula, indicating the onset of 
a suction event. With the compliant inflow cannula, an initial increase in LAP from 6 to 7.2 mmHg was 
noted after the sudden LVADRin increase between LVAD speeds of 2600 and 2700 RPM. Following this, 
the LAP gradually increased to 7.7 mmHg at a LVAD speed of 3000 RPM. The increase in LAP was also 
noticed in the severe LHF condition with LAC, with a rise from 3.4 to 7.5 mmHg when LVAD speed was 
increased from 2600 to 2700 RPM (Figure 95). Again, this increase in LAP was due to the suddenly 
increased LVADRin (from approximately 400 to 3800 Dyne.s.cm-5 with a LVAD speed increase from 2600 
to 3000 RPM) caused by sufficiently low preload restricting the compliant inflow cannula and preventing 
a suction event. A suction event was noticed, however, with the rigid inflow cannula as LAP progressed 
below 0 mmHg at a LVAD speed of 2800 RPM.  
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Figure 94 – Comparison between the left atrial pressure (LAP), LVAD inflow cannula resistance (LVADRin) 
and mean LVAD flow rate (LVADQ) for the compliant and rigid atrial LVAD inflow cannulae with 
increasing LVAD speed in the mild left heart failure condition. 
 
 
Figure 95 – Comparison between the left atrial pressure (LAP), LVAD inflow cannula resistance (LVADRin) 
and mean LVAD flow rate (LVADQ) for the compliant and rigid atrial LVAD inflow cannulae with 
increasing LVAD speed in the severe left heart failure condition. 
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The sudden increase in preload after the start of compliant inflow cannula restriction, which was seen in 
LAC, was not observed in LVC in mild (Figure 96) or severe (Figure 97) LHF. This could be attributed to 
the remnant ventricular pulsatility providing sufficient pressure to partially open the compliant inflow 
cannula and cause a more gradual increase in LVADRin as LVAD speed was increased. In mild LHF with 
LVC, the LVADRin increased from 580 to 1660 Dyne.s.cm-5 with a LVAD speed increase from 2400 to 
3000 RPM. A similar LVADRin increase was noted in severe LHF with LVC (680 to 2050 Dyne.s.cm-5 with a 
LVAD speed increase from 2400 to 3000 RPM), thus demonstrating the reduction in LVADRin rate of 
change with LVC compared to LAC (up to 2550 and 3800 Dyne.s.cm-5 for mild and severe LHF 
respectively).  
 
While the LVADRin of the compliant and rigid inflow cannula follow the same path until a point of 
sufficiently low preload in mild and severe LHF with LAC, and mild LHF with LVC, a slightly different trend 
was observed with severe LHF with LVC. In this case, the LVADRin gradually increased throughout the 
LVAD speed ramp test (from 430 to 780 Dyne.s.cm-5 with a LVAD speed increase from 2000 to 2600 
RPM), however it also displayed the sudden increase at LVAD speeds greater than 2600 RPM, similar to 
the other conditions. This gradual increase can be explained by the limited Starling response of the MCL 
ventricles. As LVAD speed increased from 2000 to 2600 RPM and LVV decreased, the Starling mechanism 
decreased the systolic left ventricular pressure (LVP) from 88 to 68 mmHg. The decreased LVP resulted 
in reduced preload to the compliant inflow cannula, thus slightly increasing the LVADRin as LVAD speed 
was incrementally increased. This was not observed in the mild LHF condition as the Starling sensitivity 
was significantly higher, thus providing adequate preload to maintain low LVADRin. This was also not 
observed in LAC as the Starling response did not directly influence LAP. 
 
The gradual LVADRin increase with LVC in both mild and severe LHF conditions maintained LVADQ at 
approximately 4.5 and 2.6 L/min respectively for high LVAD speeds. This was in comparison to the 
increased LVADQ shown with the rigid inflow cannula at 5.0 and 2.8 L/min for mild and severe LHF 
conditions respectively. The low LVADQ in severe LHF conditions was due to a constant SVR maintained 
throughout the LVAD speed increase tests. This resulted in high mean aortic pressure (MAP) and thus 
low cardiac output. The slightly decreased LVADQ with the compliant inflow cannula maintained systolic 
LVV above 78 and 62 mL for mild and severe LHF respectively, thus preventing a suction event. 
Meanwhile, suction events were noted with the rigid inflow cannulae at LVAD speeds of 2900 and 2700 
RPM for mild and severe LHF respectively. 
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Figure 96 – Comparison between the left ventricular end systolic volume (LVV), LVAD inflow cannula 
resistance (LVADRin) and mean LVAD flow rate (LVADQ) for the compliant and rigid ventricular LVAD 
inflow cannulae with increasing LVAD speed in the mild left heart failure condition. 
 
 
Figure 97 – Comparison between the left ventricular end systolic volume (LVV), LVAD inflow cannula 
resistance (LVADRin) and mean LVAD flow rate (LVADQ) for the compliant and rigid ventricular LVAD 
inflow cannulae with increasing LVAD speed in the severe left heart failure condition. 
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Comparisons between the rigid and compliant inflow cannulae for mild biventricular heart failure (BHF) 
with right atrial cannulation, severe BHF with right atrial cannulation, mild BHF with right ventricular 
cannulation and severe BHF with right ventricular cannulation are shown in Figure 98, Figure 99, Figure 
100, and Figure 101 respectively. Similar trends were noted between LVAD and RVAD support with the 
rigid and compliant inflow cannulae. Due to the reduced preload in right atrial (RAC) or right ventricular 
(RVC) cannulation, results resembled those seen with LAC particularly well. In all cases, reduced preload 
due to increased RVAD speed caused the compliant inflow cannula to restrict which resulted in 
increased LVADRin, decreased RVAD flow rate (RVADQ) and prevention of suction events through 
maintaining positive right atrial pressure (RAP) and / or right ventricular volume (RVV). 
 
In mild BHF with RAC (Figure 98), RVADRin remained relatively constant at about 1000 Dyne.s.cm-5 for 
both compliant and rigid inflow cannulae until RVAD speed reached 1200 RPM. A gradual increase in 
RVADRin (up to 6000 Dyne.s.cm-5) occurred as the compliant RVAD inflow cannula restricted flow as the 
RVAD speed increased to 1800 RPM. The relatively constant RVADRin with the rigid inflow cannula 
allowed RVADQ to increase to 4.8 L/min prior to a suction event (RAP < 0 mmHg) at 1400 RPM. While 
the RVADQ was reduced with the compliant inflow cannula (minimum of 2.15 L/min), no suction events 
occurred. Meanwhile, constant PVR during this test resulted in high mean pulmonary arterial pressure 
(MPAP) in excess of 25 mmHg, which explains the low RVADQ. Similar results were noted in severe BHF 
with RAC (Figure 99), with the rigid inflow cannula causing a suction event before RVAD speed had 
increased beyond 1100 RPM. The compliant inflow cannula, however, prevented suction events by 
increasing RVADRin (maximum of 5500 Dyne.s.cm-5) which passively decreased RVADQ (minimum of 2.2 
L/min) and maintained RAP above 3 mmHg, even at high RVAD speeds of 1800 RPM. 
 
Suction events occurred with RVC in mild (Figure 100) and severe (Figure 101) BHF at RVAD speeds of 
1500 and 1100 RPM respectively. Addition of the compliant inflow cannula prevented suction events in 
both cases, with a minimum RVV off 57 and 48 mL respectively. This was achieved by passive restriction 
of the RVAD compliant inflow cannula, with RVADRin climbing to 4300 and 4700 Dyne.s.cm-5 in mild and 
severe BHF respectively at RVAD speeds of 1800 RPM. RVADQ decreased to a minimum of 3.0 and 2.8 
L/min respectively at RVAD speeds of 1800 RPM, however high MPAP of approximately 20 mmHg (due 
to high PVR) in each case contributed to the low RVADQ. 
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Figure 98 – Comparison between the right atrial pressure (RAP), RVAD inflow cannula resistance 
(RVADRin) and mean RVAD flow rate (RVADQ) for the compliant and rigid atrial RVAD inflow cannulae 
with increasing RVAD speed in the mild biventricular heart failure condition. 
 
 
Figure 99 – Comparison between the right atrial pressure (RAP), RVAD inflow cannula resistance 
(RVADRin) and mean RVAD flow rate (RVADQ) for the compliant and rigid atrial RVAD inflow cannulae 
with increasing RVAD speed in the severe biventricular heart failure condition. 
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Figure 100 – Comparison between the right ventricular end systolic volume (RVV), RVAD inflow cannula 
resistance (RVADRin) and mean RVAD flow rate (RVADQ) for the compliant and rigid ventricular RVAD 
inflow cannulae with increasing RVAD speed in the mild biventricular heart failure condition. 
 
 
Figure 101 – Comparison between the right ventricular end systolic volume (RVV), RVAD inflow cannula 
resistance (RVADRin) and mean RVAD flow rate (RVADQ) for the compliant and rigid ventricular RVAD 
inflow cannulae with increasing RVAD speed in the severe biventricular heart failure condition. 
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Results were also taken to demonstrate the response of rigid and compliant inflow cannulae to a step 
change in SVR or PVR in both mild and severe LHF and BHF. An example transient result for LAC is shown 
in Figure 102, which shows the LAP, LVADRin and LVADQ before, during and after the step change in 
PVR. When PVR was increased from 100 to 400 Dyne.s.cm-5, LAP dropped with both the rigid and 
compliant inflow cannulae due to a decrease in venous return. During this stage, the LVADRin (500 
Dyne.s.cm-5) and LVADQ (4.7 L/min) remained relatively constant, demonstrating the lack of preload 
sensitivity of rotary blood pumps. As LAP gradually reduced with the rigid inflow cannula, LVADRin and 
LVADQ remained constant until a suction event (LAP < 0 mmHg) occurred approximately 20 seconds 
after the PVR increase. With the compliant inflow cannula, the reduction in preload began to restrict the 
compliant section, thus increasing the LVADRin when LAP dropped to approximately 3 mmHg. LVADRin 
increased from 500 to 1800 Dyne.s.cm-5 over approximately five seconds which reduced LVADQ from 4.7 
to 3.0 L/min. The reduction in LVADQ returned LAP to 5 mmHg and prevented a suction event. Similar 
trends were observed in all cases with left or right atrial cannulation. 
 
 
Figure 102 – Comparison of left atrial pressure (LAP), LVAD inflow cannula resistance (LVADRin) and 
LVAD flow rate (LVADQ) for atrial compliant and rigid inflow cannulae in the severe left heart failure 
condition before, during and after a step increase in pulmonary vascular resistance (simulated at 
approximately five seconds). 
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An example transient result for LVC in the severe LHF condition with a step change in PVR is shown in 
Figure 103. Prior to the PVR change, LVV oscillated between 132-171 mL and 117-155 mL for rigid and 
compliant inflow cannulae respectively. LVADRin was 500 and 550 Dyne.s.cm-5 for rigid and compliant 
inflow cannulae respectively, while LVADQ was approximately 4.7 L/min in both cases. When PVR was 
increased from 100 to 400 Dyne.s.cm-5, LVV began to reduce due to the decrease in venous return. With 
the rigid inflow cannula, LVADRin and LVADQ remained relatively constant, thus resulting in a suction 
event approximately 35 seconds after the PVR increase. With the compliant inflow cannula, however, 
the reduced preload restricted the compliant section over approximately a ten second period, thus 
increasing the LVADRin to 1100 Dyne.s.cm-5. This reduced LVADQ to 3.9 L/min and maintained LVV 
above 30 mL, thus preventing a suction event. The LVADRin increased more gradually in LVC compared 
with LAC due to the remnant ventricular contractility holding the compliant section at least partially 
open.  
 
(a) (b) 
 
Figure 103 – Comparison of left ventricular volume (LVV), LVAD inflow cannula resistance (LVADRin) and 
LVAD flow rate (LVADQ) for ventricular compliant (a) and rigid (b) inflow cannulae in the severe left heart 
failure condition before, during and after an increase in pulmonary vascular resistance (simulated at 
approximately five seconds). 
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Further results for the step changes in SVR or PVR were also taken to compare the haemodynamic effect 
of replacing a rigid inflow cannula with a compliant section. For mild LHF and mild BHF, these results are 
presented in Table 21, while severe LHF and severe BHF results are presented in Table 22. The 
haemodynamics in these tables suggest that high MAP, MSQ and LVADQ were maintained when LAP or 
LVVsys reached 0 mmHg / mL with the rigid inflow cannula. However, these results are an indication of 
the haemodynamics directly prior to the suction event occurring as no mechanical occlusion was 
included in our experimental apparatus. Suction events occurred with the rigid inflow cannula in mild 
and severe LHF and BHF with atrial and ventricular cannulation when SVR or PVR was increased, 
evidenced by the LAP / LVVsys dropping to 0 mmHg / mL or below. The compliant inflow cannula 
maintained LAP and LVVsys above 0 mmHg / mL in all cases, thus preventing suction events even with 
large changes in SVR or PVR. 
 
Prior to the increase in PVR in the mild LHF condition, haemodynamic results were similar between the 
rigid and compliant inflow cannulae in LAC and LVC. In the mild LHF condition with the compliant inflow 
cannula, an increase in PVR from 100 to 400 Dyne.s.cm-5 resulted in LVADRin increasing to 1500 and 
1050 Dyne.s.cm-5 for LAC and LVC respectively. This reduced LVADQ (LAC: 3.2, LVC: 3.9 L/min), and 
subsequently the total mean systemic flow rate (MSQ) (LAC: 3.9, LVC: 4.13 L/min), while MAP also 
dropped (LAC: 68, LVC: 74 mmHg). The reduction in MAP and MSQ was not as significant in LVC 
compared to LAC due to remaining ventricular contractility opening the compliant inflow section with 
each ventricular pulse. The reduction in preload caused by the step change of PVR resulted in reduced 
left ventricular contractility due to the Starling responsive ventricles. This decreased the systolic left 
ventricular pressure (LAC: 74, LVC: 70 mmHg) which reduced ventricular stroke volume and hence LVSW 
(LAC: 0.12, LVC: 0.179 Watts). However, the LVEF increased due to the large decrease in left ventricular 
end diastolic volume (LVdias). 
 
Similar trends were noted for RVAD support in the mild BHF condition when a step increase of SVR was 
simulated, however the mean pulmonary flow rate (MPQ) changes were much larger (RAC: 5 to 2.45 
L/min, RVC: 5 to 2.65 L/min) with the compliant inflow cannula than those seen with LVAD support. This 
may be due to a higher sensitivity of the right ventricular Starling response in mild BHF compared to the 
left ventricular Starling response, as similar changes in MPQ were noted with the rigid inflow cannula 
(RAC: 5 to 2.6 L/min, RVC: 5 to 2.6 L/min). Although the MPQ change after an increase in SVR was only 
slightly smaller with the rigid cannula compared to the compliant version, it was enough to cause 
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suction events in both RAC and RVC. Meanwhile, the compliant inflow cannula maintained positive end 
systolic right ventricular volume (RVVsys) (37 mL) in VC and right atrial pressure (RAP) (2.3 mmHg) in AC. 
This was due to an increase in RVADRin from 1400 to 2400 Dyne.s.cm-5 in RAC and from 1520 to 2200 
Dyne.s.cm-5 in RVC with the compliant inflow cannula. RVSW decreased after the SVR increase in both 
RAC and RVC with the compliant and rigid inflow cannulae. This was most likely due, again, to the right 
ventricular Starling response as the reduced preload served to reduce right ventricular contractility and 
thus stroke volume and right ventricular pressure, the two determinants of RVSW.  
 
LVAD Rigid Inflow Compliant Inflow 
Inflow cannulation LA LA LV LV LA LA LV LV 
PVR (Dynes.s.cm-5) 100 400 100 400 100 400 100 400 
LAP (mmHg) 8.2 -0.2 9 3 7.8 3.5 9 5.1 
LVPsys (mmHg) 108 69 103 70 108 74 100 70 
MAP (mmHg) 100 82.5 101 88 100 68 100 74 
LVVsys (mL) 171 65 117 0 165 67 115 50 
LVVdias (mL) 200 67 164 32 191 83 163 83 
MSQ (L/min) 5 4.3 5 4.5 5 3.9 5 4.13 
LVADQ (L/min) 3.6 4.3 4.5 4.5 3.8 3.2 4.5 3.9 
LVADRin (Dynes.s.cm-5) 450 490 550 500 490 1500 650 1050 
LVSW (Watts) 0.299 0.006 0.373 0.134 0.25 0.12 0.396 0.179 
LVEF (%) 14.5 3.0 28.7 100 13.6 19.3 29.4 39.8 
RVAD Rigid Inflow Compliant Inflow 
Inflow cannulation RA RA RV RV RA RA RV RV 
SVR (Dynes.s.cm-5) 1500 2500 1500 2500 1500 2500 1500 2500 
RAP (mmHg) 6.5 -0.7 9 1.8 7 2.3 9.5 3.8 
RVPsys (mmHg) 28 18 27 12 27 18 26 20 
MPAP (mmHg) 22 17.5 21 17.5 20.5 14 19.2 14.6 
RVVsys (mL) 110 30 120 0 113 45 120 37 
RVVdias (mL) 152 31 176 22 156 58 180 67 
MPQ (L/min) 5 2.6 5 2.6 5 2.45 5 2.65 
RVADQ (L/min) 2.67 2.53 3.03 2.6 2.49 1.7 2.65 2 
RVADRin (Dynes.s.cm-5) 1250 1280 1250 1300 1400 2400 1520 2200 
RVSW (Watts) 0.1 0.001 0.13 0.013 0.1 0.02 0.129 0.046 
RVEF (%) 27.6 3.2 32 100 27.6 22.4 33.3 44.7 
Table 21 – Haemodynamics for LVAD and BiVAD support with rigid and compliant inflow cannulae in atrial 
and ventricular cannulation in the mild left / biventricular heart failure conditions. LA - left atrium, LV - left 
ventricle, RA - right atrium, RV - right ventricle, SVR - systemic vascular resistance, PVR - pulmonary 
vascular resistance, LAP - left atrial pressure, LVPsys – systolic left ventricular pressure, MAP - mean aortic 
pressure, LVVsys - end systolic left ventricular volume, LVVdias – end diastolic left ventricular volume, 
MSQ - mean systemic flow rate, LVADQ – LVAD flow rate, LVADRin - LVAD inflow cannula resistance, 
LVSW – left ventricular stroke work, LVEF – left ventricular ejection fraction, RAP - right atrial pressure, 
RVPsys – systolic right ventricular pressure, MPAP - mean pulmonary arterial pressure, RVVsys - end 
systolic right ventricular volume, RVVdias – end diastolic right ventricular volume, MPQ - mean pulmonary 
flow rate, RVADQ – RVAD flow rate, RVADRin - RVAD inflow cannula resistance, RVSW – right 
ventricular stroke work, RVEF – right ventricular ejection fraction.  
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In the severe LHF condition (Table 22), suction events were noted with LAC (LAP: 0 mmHg) and LVC 
(LVVsys: 0 mL), after an increase in PVR. However, the compliant inflow cannula prevented suction 
events in LAC (LAP: 5 mmHg) and LVC (LVVsys: 31 mL) after the increase PVR. This was due to the 
increase in LVADRin from 550 to 1800 Dyne.s.cm-5 and from 590 to 1100 Dyne.s.cm-5 with LAC and LVC 
respectively as preload dropped due to the PVR increase. The increased LVADRin decreased LVADQ from 
4.9 to 3.2 L/min and from 4.9 to 4.1 L/min respectively for LAC and LVC, while the MAP also dropped in 
LAC (from 100 to 67 mmHg) and LVC (from 99 to 74 mmHg). This subsequently dropped the MSQ to 3.95 
and 4.1 L/min for LAC and LVC respectively. 
 
With the compliant inflow cannula in mild LHF, LVPsys dropped (LAC: from 96 to 74 mmHg, LVC: from 80 
to 48 mmHg) after the increase in PVR due to the Starling response decreasing ventricular contractility 
with the reduction in ventricular preload. This was more evident in LVC, as the diastolic left ventricular 
volume (LVVdias) remained higher in LAC (129 mL) compared to LVC (60 mL), which drastically 
decreased left ventricular contractility in LVC. The reduction in LVPsys, and the subsequent reduction in 
stroke volume, in LVC resulted in LVSW decreasing from 0.21 to 0.09 Watts due to the increase in PVR. A 
similar drop in LVSW was noted in LAC, with values of 0.25 and 0.12 Watts before and after the PVR 
increase respectively. LVEF, however, increased after the PVR change in both LAC (from 1.5 to 13.2%) 
and LVC (from 24.5 to 48.3%) due to the drastically decreased LVVdias. 
 
Similar trends to LVAD support were seen in RVAD support of severe BHF (Table 22). Again, the rigid 
inflow cannula resulted in suction events in RAC (RAP: 0 mmHg) and RVC (RVVsys: 0 mL), while the 
compliant inflow cannula prevented suction events, even after the SVR increase in RAC (RAP: 3.1 mmHg) 
and RVC (RVVsys: 27 mL). RVADRin increased in each case with the compliant inflow cannula, from 1080 
to 1650 Dyne.s.cm-5 for RAC and 1140 to 1750 Dyne.s.cm-5 for RVC. The RVADRin increase reduced the 
RVADQ in both cases (RAC: from 3.85 to 3 L/min, RVC: from 4.75 to 3.62 L/min), which also reduced the 
MPQ (RAC: from 5 to 3.65 L/min, RVC: from 5.1 to 3.75 L/min) and MPAP (RAC: from 17.3 to 14 mmHg, 
RVC: from 17.2 to 15 mmHg). RVSW, while already quite low, reduced even further after the SVR 
increase from 0.031 to 0.016 Watts in RAC and from 0.052 to 0.018 Watts in RVC due to the Starling 
response reducing right ventricular contractility with reduced preload. The RVEF remained relatively 
constant (14 and 13.6% before and after the SVR increase respectively) after the SVR increase in RAC as 
the right ventricular diastolic volume (RVVdias) decreased while the stroke volume also decreased. This 
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was not consistent with RVC, as the RVVdias decreased significantly more which increased the RVEF 
(from 30.4 to 40.9%), even with a decrease in stroke volume after the SVR increase. 
 
LVAD Rigid Inflow Compliant Inflow 
Inflow cannulation LA LA LV LV LA LA LV LV 
PVR (Dynes.s.cm-5) 100 400 100 400 100 400 100 400 
LAP (mmHg) 7.9 0 8.8 1.4 7.2 5 8.3 4 
LVPsys (mmHg) 100 -1 8.8 1 96 74 80 48 
MAP (mmHg) 100 95 100 87 100 67 99 74 
LVVsys (mL) 212 147 132 0 202 112 117 31 
LVVdias (mL) 215 149 171 18 205 129 155 60 
MSQ (L/min) 5 4.65 5 4.4 5 3.95 5 4.1 
LVADQ (L/min) 4.8 4.65 5 4.4 4.9 3.2 4.9 4.1 
LVADRin (Dynes.s.cm-5) 490 460 520 490 550 1800 590 1100 
LVSW (Watts) 0.012 0.1 0.196 0 0.25 0.12 0.21 0.09 
LVEF (%) 1.4 1.3 22.8 5.6 1.5 13.2 24.5 48.3 
RVAD Rigid Inflow Compliant Inflow 
Inflow cannulation RA RA RV RV RA RA RV RV 
SVR (Dynes.s.cm-5) 1500 2500 1500 2500 1500 2500 1500 2500 
RAP (mmHg) 4.8 0 6.5 -2 4.9 3.1 7 3.2 
RVPsys (mmHg) 23 18 20 -2 23 19 22 13 
MPAP (mmHg) 17.3 16.4 17.3 20 17.3 14 17.2 15 
RVVsys (mL) 108 71 78 0 110 76 89 27 
RVVdias (mL) 125 72 116 0 128 88 128 53 
MPQ (L/min) 5 3.84 5 3.92 5 3.65 5.1 3.75 
RVADQ (L/min) 3.9 3.67 4.8 3.9 3.85 3 4.75 3.62 
RVADRin (Dynes.s.cm-5) 1070 1080 1110 1120 1080 1650 1140 1750 
RVSW (Watts) 0.03 0 0.045 0 0.031 0.016 0.052 0.018 
RVEF (%) 13.6 1.4 32.7 0 14 13.6 30.4 49 
Table 22 - Haemodynamics for LVAD and BiVAD support with rigid and compliant inflow cannulae in atrial 
and ventricular cannulation in the severe left / biventricular heart failure conditions. LA - left atrium, LV - 
left ventricle, RA - right atrium, RV - right ventricle, SVR - systemic vascular resistance, PVR - pulmonary 
vascular resistance, LAP - left atrial pressure, LVPsys – systolic left ventricular pressure, MAP - mean aortic 
pressure, LVVsys - end systolic left ventricular volume, LVVdias – end diastolic left ventricular volume, 
MSQ - mean systemic flow rate, LVADQ – LVAD flow rate, LVADRin - LVAD inflow cannula resistance, 
LVSW – left ventricular stroke work, LVEF – left ventricular ejection fraction, RAP - right atrial pressure, 
RVPsys – systolic right ventricular pressure, MPAP - mean pulmonary arterial pressure, RVVsys - end 
systolic right ventricular volume, RVVdias – end diastolic right ventricular volume, MPQ - mean pulmonary 
flow rate, RVADQ – RVAD flow rate, RVADRin - RVAD inflow cannula resistance, RVSW – right 
ventricular stroke work, RVEF – right ventricular ejection fraction. 
 
Results were also taken of the LVADRin and RVADRin in mild and severe LHF and BHF at various 
compliant inflow cannula heights, with respect to the cannulated chamber, to characterise the 
performance of the device. As expected, LVADRin increased in mild and severe LHF as the height 
increased due to reduced preload to the compliant section (Figure 104). LVADRin remained constant at 
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approximately 550 Dyne.s.cm-5 until heights of 150 and 200mm were reached for LVC and LAC 
respectively, when LVADRin gradually increased to 1300 and 1800 Dyne.s.cm-5 by a height of 350 mm 
above the cannulated chamber. As expected, the decreased preload due to reduced left ventricular 
contractility in the severe LHF condition resulted in larger changes of LVADRin when the height of the 
compliant inflow section was increased. In this case, the LVADRin in LAC and LVC began to increase at a 
height of 150mm and increased to 2600 and 1550 Dyne.s.cm-5 by a height of 350 mm above the 
cannulated chamber. 
 
Similar trends were noted in mild and severe BHF with RAC and RVC (Figure 105). In mild BHF, the 
RVADRin remained about 1050 Dyne.s.cm-5 until compliant inflow cannula heights of 200 mm (RVC) and 
250 mm (RAC) were reached. After this point, RVADRin gradually increased to 2000 and 1750 Dyne.s.cm-
5 for RAC and RVC respectively as the compliant inflow cannula height increased to 350 mm.  As 
expected, reduced preload in the severe BHF condition resulted in larger increases in RVADRin (RAC: 
1100 to 2600 Dyne.s.cm-5, RVC: 1150 to 2200 Dyne.s.cm-5) from over the same height change as the mild 
BHF condition.  
 
 
(a) 
 
(b) 
 
Figure 104 – LVAD inflow cannula resistance (LVADRin) for (a) mild and (b) severe left heart failure 
conditions with the compliant inflow cannula placed at various heights with respect to the cannulated 
chamber. AC – atrial cannulation, VC – ventricular cannulation. 
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(a) 
 
(b) 
 
Figure 105 – RVAD inflow cannula resistance (RVADRin) for (a) mild and (b) severe biventricular heart 
failure conditions with the compliant inflow cannula placed at various heights with respect to the cannulated 
chamber. AC – atrial cannulation, VC – ventricular cannulation. 
 
5.4 Discussion 
In healthy humans, flow balancing between the systemic and pulmonary circulations is regulated by 
several closed loop biological control systems such as the Frank-Starling and baroreceptor responses 
[71, 72]. Pulsatile VADs, which operate in full-to-empty mode, have an inherent flow balancing capability 
which ensures the native circulations are not over- or under-loaded [50]. However, rotary VADs are 
relatively preload insensitive and are prone to flow imbalances. Support by just one device (eg. LVAD 
support) may rely on having one functional ventricle with a native control mechanism to balance flow. 
This is not always the case, and rotary LVAD support alone is still susceptible to flow imbalances. 
However, this is exacerbated with the use of two rotary VADs for biventricular support as any remnant 
native control mechanisms are absent due to the lack of left and right ventricular function. The few 
documented clinical studies of rotary biventricular support warn of haemodynamic instability [25, 73, 
74] and report the importance of continued controller development to prevent pulmonary edema and 
suction events in the cannulated chambers. Suction events may result in harmful consequences such as 
full or partial / transient flow stoppages, endocardial damage and ventricular arrhythmias [14, 19, 21, 
22]. In this study, a compliant inflow cannula was developed over two stages. The first stage involved 
the development of a compliant inflow cannula reservoir. This design was then refined as an in-line 
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compliant section on the inflow cannula in order to achieve improved blood flow characteristics. The 
results of each stage are discussed below. 
 
5.4.1 Compliant Inflow Cannula Reservoir 
Reesink et al. (2007) [22] reported that the usual method of avoiding suction with rotary VADs by a trial 
and error based approach of manipulating LVAD speed is not always successful, demonstrating the 
requirement for a control system to prevent suction events.  Despite improvements in active control 
systems for LVADs, limitations still exist. The control system must operate in a similar manner to the 
native heart by reducing cardiac output when preload is reduced.  The strategy appears simple; 
however, accurate, invasive preload measurement requires sensors which are still costly and unreliable, 
while non-invasive preload measurements rely on inferred data which can be grossly inaccurate in some 
circumstances. Therefore, the aim of this study was to develop a device which passively alters VAD flow 
based on preload. Initially, this was achieved with a compliant inflow cannula reservoir. As this stage 
was a preliminary proof of concept, only LVAD support was evaluated. 
 
Reesink et al. (2007) [22] demonstrated the ease with which ventricular suction can occur with 
increased LVAD speed or pulmonary resistance, which was also noted in our study when the rigid inflow 
cannula was used. In both LVAD speed ramp and PVR step change tests, suction events were noted in all 
cases with the rigid inflow cannula. The inflow cannula reservoir eliminated chamber suction events by 
passively increasing the LVADRin due to reservoir collapse as the preload decreased.  This increased 
LVADRin reduced the MSQ as preload dropped. LVAD support with the rigid inflow cannula, however, 
maintained a relatively constant MSQ until a suction event occurred. At and after this point, results were 
not presented as no physical suction replication existed in the experimental apparatus. The concept of 
altering LVAD cannula resistance has been presented previously for other applications. Manipulation of 
LVAD outflow resistance to alter subsequent haemodynamics has shown that a LVAD may be used to 
support the pulmonary circulation [294]. As expected, our study demonstrated that manipulation of 
inlet resistance reduced LVAD outlet pressure along with LVAD outflow.  
 
As this stage involved a preliminary evaluation of the large compliant inflow cannula reservoir, it was 
aimed for use in extracorporeal support due to implantability issues. Use of extracorporeal support is 
often unplanned due to patients presenting in a moribund state which can be difficult to manage and 
require early decision making and intervention [295]. Use of short term, extracorporeal devices provides 
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a suitable platform for patient stabilization and assessment before opting for a long term device or 
medical management with a view to ventricular recovery [295, 296]. The long cannulae required for 
extracorporeal LVAD support produced a large inlet resistance with a slight increase of approximately 50 
Dyne.s.cm-5 in all cases when the full reservoir was added to the circuit.  The increased resistance due to 
reservoir addition can be attributed to the various fittings required to secure the reservoir to the 
cannula. Meanwhile, LAC consistently resulted in higher inlet resistance, even with the rigid inflow 
cannula, compared to LVC due to additional fittings and tubing length on the LAC site in the MCL. 
Increased PVR resulted in partial reservoir collapse which increased the LVADRin in LAC more than that 
seen in LVC with values of 1400 and 750 Dynes.s.cm-5 respectively. Variations in LVAD speed once again 
revealed higher LVADRin for LAC compared to LVC, particularly at high VAD speeds. This can be 
attributed to the left ventricular systolic pressure filling the reservoir, and therefore lowering LVADRin, 
in LVC which is not experienced in LAC.   
 
With the reservoir in LVC, higher left ventricular stroke volume, LVEF and LVSW were recorded 
compared to LAC with the reservoir and both cannulation sites with the rigid inflow cannula both before 
and after the increase in PVR. This was due to the compliant nature of the inflow cannula reservoir and 
the pulsatile reservoir preload in LVC. During left ventricular systole, the increased inlet pressure of the 
compliant inflow cannula reservoir resulted in expansion of the reservoir, thus acting in a similar fashion 
to a high arterial compliance. While the increase in stroke volume and LVEF should improve the washout 
of blood within the left ventricle and subsequently reduce the risk of thrombus formation, the increase 
in LVSW may influence the potential for ventricular recovery.  
 
When LVAD speed was incrementally increased with the reservoir from 2800 to 3800rpm, MAP 
increased with LVC (95 to 101mmHg) however decreased with LAC (96 to 90mmHg).  Similar trends were 
noted with MSQ and could be attributed to the dramatically increased LVADRin with LAC. This may 
appear to restrict the LVAD output with the reservoir, however if increased cardiac output is required, 
the reservoir could simply be placed at a reduced height to decrease the LVADRin with extracorporeal 
support. Reductions in MAP and MSQ appeared more apparent during reservoir collapse with LAC, 
indicating the reservoir may be slightly more suitable for LVC. Despite the reported advantages of one 
cannulation site over another, preference of the surgeon and surgical or patient constraints may apply, 
indicating LVADs and their related products should be suitable or adaptable for both cannulation sites.  
197 
 
This study suggests that a collapsible inflow cannula reservoir can be used to prevent suction events in 
either inflow cannulation site.  
 
An ideal reservoir height with respect to the cannulated chamber in both LAC and LVC was determined 
in this study. However, this height was based on a trial and error method for one particular degree of 
left heart failure, and therefore must be addressed clinically on a patient by patient basis.  Patient 
volume status, ventricular contractility, and cannulation site, amongst other things, will influence the 
ideal reservoir height. As a guide for clinical implementation of the reservoir, the ideal reservoir height 
for both cannulation sites was the highest point at which the reservoir had not started to collapse. 
Therefore, an adjustable height mechanism is required, similar to the passively filled Abiomed BVS5000 
pulsatile VAD. The BVS5000 was particularly susceptible to thrombus formation, as the reservoir may 
also be if not designed to optimize the blood flow path [297].  The additional volume in the reservoir 
served to account for only minimal flow imbalances, thus leading to the development of an in-line 
compliant inflow cannula, which may also be applicable for use with intracorporeal VADs. Meanwhile, 
this design change may reduce the device’s potential for thrombus formation, which is of particular 
importance due to the risk of mortality associated with post-LVAD stroke [298].  
 
5.4.2 In-line Compliant Inflow Cannula 
The preload insensitivity of rotary blood pumps is particularly noticeable in biventricular support where 
both failing ventricles are lacking a normal Starling mechanism [299]. Previous attempts at BiVAD 
control have reported sensor drift [25], demonstrating the need for either a reliable sensor, reliable 
sensor-less controller, or a passive control mechanism. Passive control systems which don't rely on 
sensors or inferred data to control the pump have previously been used in the field of mechanical 
circulatory support. Gaddum et al. [79] used a two-sided, floating hub which was passively displaced by 
changes in LVAD and RVAD afterload which altered the clearance between the hub and the BiVAD 
impellers. The passively altered clearance aimed to alter LVAD/RVAD efficiency and thus balance the 
flow rates. However, this system resulted in hypersensitivity to afterload and insensitivity to preload, 
thus rendering it incapable of providing complete BiVAD control. Passive self-regulation is also used for 
the Cleveland Clinic continuous flow total artificial heart (TAH), which employs left and right supporting 
impellers on a single hub [300]. The position of the hub is dependent on the left / right atrial pressure 
difference and passively alters the right pump output through a change in outlet resistance, thus making 
it preload sensitive. However, remnant ventricular contractility experienced in a BiVAD application may 
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upset this ability for passive flow balance. The in-line, compliant inflow cannula demonstrated passive 
control of LVAD and / or RVAD flow based on preload in AC and VC under mild and severe degrees of 
heart failure.   
 
Previous reports have demonstrated the ease with which suction events can occur with rotary VAD 
support [22, 301]. Our study revealed similar results with a rigid inflow cannula by simulating 
incremental changes in LVAD speed, RVAD speed, SVR or PVR. The addition of the compliant inflow 
cannula prevented suction events in all cases, even at VAD speeds far greater than those reached until 
suction with the rigid inflow cannula. The mechanism of suction prevention with the compliant inflow 
cannula is fairly simple, and relies on the passively increasing resistance of the VAD circuit (via a 
reduction in cannula volume and thus diameter) as preload is reduced. This resistance increase alters 
the flow, rather than completely restricting it, and therefore preserves positive atrial and ventricular 
pressures and volumes while maintaining sufficient cardiac output. The reduction in cardiac output was 
never more than 27% with the LVAD or RVAD compliant inflow cannula evaluated under increases in 
SVR or PVR in atrial and ventricular cannulation. While the reduction in cardiac output could be 
considered significant, it prevented total occlusion of the inflow cannula by the ventricle walls and thus 
complete or intermittent cessation of flow which would be expected during a suction event. Meanwhile, 
the maximum reduction in cardiac output with the rigid inflow cannula was 23% prior to the suction 
event, and can be attributed to the reduction in ventricular contractility due to the MCL Starling 
response and the limited preload sensitivity of the of the rotary VAD.  
 
Due to the preload insensitivity of the rotary blood pump, cardiac output and arterial pressures were 
maintained at high levels with the rigid inflow cannula. While this ultimately resulted in a suction event, 
it could be argued that maintaining adequate haemodynamics is far more important than preventing 
suction events. However, clearly any control system which reduces VAD speed, and subsequent cardiac 
output, with a reduction in preload will be faced with a similar dilemma. It may be necessary to 
incorporate a maximum LVADRin through stenting the compliant section in order to maintain at least a 
minimum flow path and thus allow circulation, even in the case of an imminent suction event. Although, 
results with the compliant inflow cannula in both LVAD and BiVAD support demonstrated that even with 
a large step change in systemic or pulmonary vascular resistance, the total cardiac output remained at 
sufficient levels (ie. MSQ above 2.5 L/min). Ultimately, the requirement for stenting would need to be 
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confirmed in an in-vivo heart failure model, something that was beyond the scope of this preliminary 
work. 
 
The full haemodynamic influence of a compliant inflow cannula would also need validating in-vivo. For 
instance, with large increases in SVR or PVR both the LVAD / RVAD rigid and compliant inflow cannulae 
resulted in decreased cardiac output (due to either the MCL’s ventricular Starling response and / or the 
compliant inflow restriction), decreased arterial pressures, decreased atrial and ventricular volumes and 
decreased ventricular stroke work. Both cannulae had almost identical levels of LVSW and RVSW in both 
cannulation sites under mild and severe left and biventricular heart failure. This is contrary to the results 
seen with the compliant inflow reservoir, which had increased LVSW compared to when the rigid inflow 
cannula was used. This can be attributed to the reduced compliance and segment volume of the in-line 
design compared to the reservoir design. This essentially resulted in the in-line design performing 
almost identically to the rigid inflow cannula under suitably high levels of preload. Left and right 
ventricular ejection fractions were also consistent between the compliant and rigid inflow cannulae in all 
tests before the SVR or PVR step changes, again indicating similar performance between the two devices 
and a consistent testing protocol. Vastly different haemodynamics were recorded between the two 
cannulae following the step changes in SVR or PVR. In left or right ventricular cannulation, ejection 
fractions reached 100% after the vascular resistance changes as the ventricle had emptied through the 
rigid inflow cannula. While increased due to the reduced end diastolic ventricular volume, the left or 
right ventricular ejection fractions with the compliant inflow cannula remained at levels below 50%, 
indicating sufficient ventricular volume remained in all cases. Right and left ventricular stroke work 
usually reduced after the SVR / PVR changes with the rigid and compliant inflow cannulae, indicating a 
reduction in ventricular contractility and / or stroke volume due to the reduction in preload and MCL 
Starling response. 
 
The preload sensitivity of the VAD supported left ventricle, calculated by dividing the change in flow rate 
by the change in left atrial pressure from the step change in PVR test, averaged 0.0627 L/min/mmHg for 
atrial and ventricular cannulation with the rigid inflow cannula. This compares closely with results 
reported by Salamonsen et al. [302], who reported rotary LVAD preload sensitivity to vary between 0.03 
and 0.31 L/min/mmHg. Addition of the compliant inflow cannula increased average preload sensitivity 
to 0.343 L/min/mmHg for AC and VC, which slightly exceeded values previously reported for the healthy 
human left ventricle (0.213 L/min/mmHg) [302]. However, increases in cardiac demand beyond that 
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produced when the compliant inflow cannula is in its most expanded state may still require additional 
control strategies such as changes in VAD speed. 
 
Compliant inflow cannula restriction only occurred when the preload reached sufficiently low levels. 
Interestingly, the LVADRin and RVADRin increased relatively linearly after the point where restriction 
began in the VAD speed ramp tests. The resistance of a tube is directly proportional to the square of the 
cross sectional area (see Equation 5.2, assuming fluid viscosity and tube length remain constant and that 
the flow is laminar), indicating that if LVADRin and RVADRin increased linearly, the cross sectional area 
did not. This can be attributed to a non-linear compliance over the range of restriction. As the preload 
dropped, the compliance of the flexible segment decreased, thus requiring a higher change of negative 
pressure for a given negative change in volume and produced a non-linear change in cross sectional 
area. 
 
  
      
  
          (5.2)  
Equation 5.2: R - resistance, μ - fluid viscosity, LR - effective length of the resistor tubing, AR - area of the 
resistance tubing [222]. 
 
Passive restriction of the compliant inflow cannula was not only related to VAD preload. The point 
where restriction began varied between cannulation sites, LVAD or RVAD support and the degree of 
heart failure and was dependent on the pressure head between the compliant section and the 
cannulated chamber. This pressure head was dependant on the cannulation site (ie. Either a relatively 
constant atrial pressure, or a higher, pulsatile ventricular pressure), the degree of heart failure and the 
height of the compliant section relative to the cannulated chamber. For instance, in the RVAD speed 
ramp test, compliant inflow cannula restriction started at a RVAD speed of 1200 RPM in mild 
biventricular heart failure with RAC and at 1000 RPM in severe biventricular heart failure with RAC. The 
cannulation site influenced the restriction of the compliant section as the remnant ventricular 
contractility served to keep the restricted section open, thus decreasing the VAD inflow cannula 
resistance. This was less noticeable, however, at lower ventricular volumes as the Starling mechanism 
implemented in the MCL ventricles decreased contractility as ventricular preload reduced. Distance and 
orientation of the compliant section from the cannulated chamber also altered the nature of restriction 
as the increased pressure head with lower placement (with respect to the cannulated chamber) of the 
compliant section delayed the passive restriction. In the clinical setting, the compliant section should be 
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placed as close as possible to the cannulated chamber, thus rendering placement effects and changes in 
body position negligible. Meanwhile, the compliance and unstressed cannula dimensions influenced the 
performance of the compliant inflow cannula and may be used to improve the passive restriction 
mechanism.  
 
While this study presented an in-vitro evaluation of the compliant inflow cannula concept, there are 
several features that must be addressed before clinical implementation. The compliance of the 
restricting segment must be optimized, while appropriate biomaterials must be investigated to ensure 
the degree of compliance can be met. Implantability issues, such as the potential for tissue growth 
around the compliant section and its implications on device compliance must be addressed. Potential 
for increased haemolysis due to the introduction of a stenosis and ‘fluttering’ are also potential 
limitations that must be investigated. Meanwhile, a reduction in cannula lifetime / duration due to the 
cyclic mechanical wear of the compliant section must be investigated. However the occurrences of 
significant changes in compliant inflow cannula diameter are not anticipated during normal VAD 
operation. The performance of the compliant inflow cannula must also be assessed with reductions in 
systemic or pulmonary vascular resistance. While hysteresis was not observed during any of the in-vitro 
evaluation, it needs to be quantitatively assessed through extensive in-vitro and in-vivo evaluation. 
 
5.4.3 Experimental Evaluation 
In-vitro evaluation in a MCL proved an appropriate method for an initial characterization of the 
compliant inflow cannula reservoir.  This setting enabled controlled, repeatable testing and data 
collection. The capability of easily altering ventricular contractility and vascular resistances was useful in 
simulating various conditions of left and biventricular heart failure and step changes in vascular 
resistance. However, it also presented several disadvantages over an in-vivo study.  Firstly, suction 
typically occurs at the ventricular free wall, septum or when a valve is pulled onto the cannula, 
obstructing the fluid path. In this study, suction events were based on fluid levels in each chamber 
reaching a preset zero level with no physical suction occurring after this point, thus the physiological 
response during or after suction could not be observed.  Meanwhile, the lack of native autoregulation of 
the vascular resistances, such as the baroreceptor responses, in the VAD speed ramp tests resulted in 
high arterial pressures while flow rates increased only mildly. Implementation of a baroreceptor 
response in the MCL would influence the presented results by increasing VAD flow rate for each speed 
increment, thus resulting in earlier suction events. Although, the time domain response and magnitude 
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of such autoregulation would have to be carefully implemented and validated, as these responses such 
as the baroreceptor are reported to be reduced in heart failure [38, 303]. Meanwhile, the high cannula 
resistance, even with the rigid design, was due to the long cannula length required for our experimental 
setup and should be addressed in future studies. 
 
5.5 Conclusion 
The aim of this study was to develop and characterize a passive control system to prevent suction events 
with left, right or biventricular support. A compliant inflow cannula was developed, firstly through a 
design which included a reservoir and later refined as an in-line design, which aimed to restrict as 
preload dropped. This restriction would provide an increased circuit resistance, thus reducing the level 
of VAD support and preventing suction events. Both reservoir and in-line compliant inflow cannulae 
were evaluated in a MCL. The in-line compliant inflow cannula was evaluated for left and biventricular 
support under varying degrees of heart failure in atrial and ventricular cannulation to provide an 
extensive characterization of the device. Gradual changes in LVAD or RVAD speed and step changes in 
SVR and PVR were simulated in an attempt to induce suction events. Evaluation of a rigid inflow cannula 
in all conditions was also completed for comparison.  
 
The ease with which suction events can occur with the use of rigid inflow cannulae and no control 
mechanism was clearly demonstrated in all cases. However, the addition of a compliant, in-line section 
prevented suction events in all cases by passively increasing the circuit resistance with decreased 
preload, thus decreasing the VAD flow. Sufficient cardiac output and arterial pressures were maintained 
in all cases with the compliant inflow cannula, even after large changes in vascular resistance. However, 
as this study was an in-vitro proof of concept trial, further investigation is required in-vivo to 
characterize the implantability, durability and response to biological substances of the compliant inflow 
cannula.  
 
In conclusion, this study revealed a compliant inflow cannula may be used as a passive control system to 
prevent harmful suction events in rotary left, right or biventricular support under a wide range of heart 
failure conditions in atrial or ventricular cannulation. However, this was a proof of concept study and 
further device development, including optimization of the device geometry and compliance, is required. 
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Chapter 6  
Cannula Fixation 
6.1 Aims 
As described earlier, bleeding is the most common complication during VAD support and is a major 
contributing factor of operative mortality during VAD implantation and explantation [29-32, 138, 147-
149].  Complications associated with increased postoperative bleeding include hypoperfusion, multi-
organ failure and intracranial bleeding, while the necessary blood transfusions increase the risk of 
infection, respiratory failure and right heart failure [154]. Unfortunately, massive blood transfusions are 
also linked with allosensitization and transplant-precluding viral transmission, both of which can 
complicate or prevent successful heart transplantation [29, 31, 144]. Bleeding complications are 
increased with biventricular support [155], with Cleveland et al. (2011) [70] reporting a four-fold 
increase in postoperative hemorrhagic complications in patients supported with a BiVAD compared to 
those on only LVAD support. Decades of improvements to medical therapy, particularly focusing on 
anticoagulation regimes, has done little to overcome this complication [34, 154].  Therefore, the aim of 
this chapter is to present the development and evaluation of a novel VAD inflow cannula fixation device. 
 
Inflow cannula fixation to the atrium or ventricle requires different techniques due to the thickness and 
structure of the tissue. The results presented in Chapter 4 of this thesis revealed improved 
haemodynamics with ventricular cannulation in severe biventricular heart failure and with atrial 
cannulation in mild biventricular heart failure. However, as BiVAD implantation is mostly confined to 
patients with severe heart failure and the incidence of myocardial recovery is low [153], the fixation 
device was developed specifically for left ventricular cannulation. This chapter presents several concepts 
and a final design for an inflow cannula fixation device before progressing through an in-vitro evaluation 
process with animal and human cadaveric hearts. Particular focus was given to improving the seal 
between the inflow cannula and myocardium, reducing the time taken for inflow cannula fixation, 
having potential for off-bypass insertion and improving the flow dynamics within the ventricle. The 
results from this study will provide a proof-of-concept for the use of a novel inflow cannula fixation 
device to improve the postoperative outcomes of patients receiving LVAD, RVAD or BiVAD support. 
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6.2 Methods 
The design concepts and evaluation of the cannula fixation device are discussed in this section. 
Evaluation of the inflow cannula fixation device was completed in a new MCL designed specifically for 
use with cadaveric hearts.  
 
6.2.1 Inflow Cannula Fixation Design 
To assist with the design of the cannula fixation device, several design criteria were defined prior to the 
development stage. The design criteria for the new cannula fixation device include:  
1. It must include an improved sealing mechanism to reduce postoperative bleeding. 
2. It should include a simple design to allow for easy insertion. 
3. It should allow for simple removal if ventricular recovery occurs after VAD implantation. 
4. It should reduce or eliminate the time on cardiopulmonary bypass. 
5. It should improve the flow dynamics within the ventricle and not promote thrombus 
formation. 
6. It must be capable of withstanding the stresses during everyday activities such as postural 
changes and ventricular contraction.  
These design criteria were then applied in the design stage to develop several inflow cannula fixation 
concepts.  These concepts are discussed below.   
 
6.2.1.1 Concept 1 - Flexible Suture Ring  
The first concept (Figure 106) was based on a similar strategy to various inflow cannula designs 
previously used, such as the VentrAssist (Ventracor Ltd., Sydney, Australia) device. This design aimed to 
incorporate a more flexible suture ring for easier attachment to the ventricular apex. An O-ring was 
included between the suture ring and myocardium to reduce the potential for postoperative bleeding. 
Design criteria 3 and 6 were met with the use of a flexible suture ring, while design criteria 1 would 
improve on previously used cannulae with the addition of the O-ring. Meanwhile, using BioGlue around 
the O-ring would also improve the seal and connection strength. This design would require several of 
the same steps as clinically available inflow cannulae, thus the procedure would be relatively familiar to 
trained cardiac surgeons. However, the overall fixation procedure would still take some time as 
meticulous suturing would be required.  Meanwhile, the ventricular flow dynamics were not considered 
with this design. Therefore, design criteria 2, 4 and 5 were not met and further development was 
required. 
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Figure 106 – Preliminary design for ventricular apex inflow cannula with flexible suture ring and O-ring. 
 
6.2.1.2 Concept 2 - Self-Expanding Collar 
The second concept aimed to use a mechanical fixation device to replace the need for sutures through a 
self-expanding collar. A cross-sectional view of the entire assembly is shown in Figure 107, while a 
rendered image of the inflow cannula and collar is shown in Figure 108. The circular collar, attached to 
the inflow cannula and flared outwards, was designed to be made from a material which experienced 
only elastic deformation upon insertion within the ventricle. A thread was designed on the outer surface 
of the inflow cannula, beginning at the point of the flared collar and progressing towards the end which 
attaches to the VAD. This thread was designed to interact with another threaded component, 
resembling a flanged nut to be placed externally to the left ventricle. An O-ring was included on the 
flanged nut to improve the seal. The process of implantation with this design for LVAD inflow cannula 
fixation would progress through the following procedure: 
 Following median sternotomy and excision of the pericardium, the left ventricular apex would 
be cored with a coring device. 
 The inflow cannula would be passed through the core and into the left ventricle, with the collar 
flattening against the external cannula surface as it passed through the core. A thin-walled 
sleeve, placed around the inflow cannula and collar, could be used to pass the flattened collar 
through the myocardial core if required. 
 The inflow cannula would be progressed through the core until the collar had completely passed 
over the cored myocardium and expanded to its original shape. 
 The flanged nut would then be placed around the inflow cannula and moved to the point where 
the two threads engaged. 
 The flanged nut would then be tightened about the cannula until a tight seal would be created 
between the collar and the flanged nut, using the relatively soft myocardium to seal. 
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Design criteria 1 and 6 were met through the 
flexible collar – flanged nut arrangement 
which uses the myocardium to seal, while 
addition of an O-ring to the design also 
assisted to meet these criteria. Design criteria 
2 and 4 were met through the relatively quick 
and simple process of inserting the self-
expanding collar and tightening the nut. 
Design criterion 5 was met by the flared 
design which should improve flow dynamics 
within the ventricle and reduce the potential 
for wedge thrombus formation. However, 
design criteria 3 could not be met as the self-
expanding collar may be difficult to remove without causing significant damage to the myocardium. 
While this concept presented a promising development through the suture-less inflow cannulation 
technique, further research was required to address design criterion 3.  
 
 
  
Figure 108 – Inflow cannula concept 2 with circular, self-expanding collar. 
 
 
 
Figure 107 – Cross sectional view of the self- expanding 
collar with fixation nut and O-ring attached to the left 
ventricular apex. 
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6.2.1.3 Concept 3 - Collapsible Fixation Device 
Concept 
The third concept was a progression from Concept 2 with the aim to address 
design criterion 3. Concept 3 also included a suture-less fixation mechanism 
with a collapsing component within the ventricle to use the myocardium to seal. 
Concept 3 was based on the theory of a hollow wall anchor (Figure 109). Hollow 
wall anchors are used to fix a bolt within a hollow wall with a collapsing support 
mechanism within the wall (Figure 110). The design is a modification of the 
hollow wall anchor concept to allow a fluid passage through the central bolt for 
VAD inflow. The process of implantation with this design for LVAD inflow 
cannula fixation would progress through the following procedure: 
 Following median sternotomy and excision of the pericardium, the left 
ventricular apex would be cored with a coring device. 
 The inflow cannula, in its expanded state (Figure 111a) would be passed 
through the core and into the left ventricle until the flange meets the 
epicardium. 
 While holding the outer portion still with a custom-designed spanner, 
the inner portion would be rotated which, due to the interlocking threads between the two 
components, would force the struts to collapse (Figure 111b). 
 Following sufficient tightening of the device, which compresses the myocardium to create a seal, 
the custom-designed spanner would be removed and a VAD would be connected to the fixation 
device. 
 If the device is required to be removed, the flanges of the inner and outer components could be 
held together while one component is turned, thus reversing the tightening action and allowing 
complete device removal without additional surgery. 
 
Design criteria 1 and 6 were met through the mechanical fixation of the inner (collapsible) and outer 
flanges with the myocardium while O-rings could be added to improve the seal. The simple concept of 
turning the components for fixation addresses design criterion 2. This process could be completed quite 
rapidly and potentially off bypass, thus addressing design criterion 4. Removal of the device by simply 
undoing the tightening procedure addresses design criterion 3 while the fifth criterion is addressed 
through the extended protrusion of the device within the ventricular cavity. 
 
Figure 109 - A hollow 
wall anchor with 
centre bolt [304] 
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(a) (b) (c) (d) 
 
Figure 110 - Stages of inserting a hollow wall anchor: (a) A hole is drilled to the correct size. (b) The fixing, or 
collapsing component, is inserted through the hole. (c) The bolt or screw is then inserted within the fixing / 
collapsing component. (d) The bolt or screw is then turned until the collapsing component has collapsed, thus 
anchoring to the wall [305]. 
 
 
(a) 
 
(b) 
 
 
 
Figure 111 - Concept 3 based on the hollow wall anchor in (a) implantable state and (b) collapsed state. 
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6.2.1.4 Concept Selection 
The three concepts were compared against the previously defined design criteria (Table 23). As the third 
concept addressed all design criteria, a scoring system which weighted each criterion based on 
importance was not required. Therefore, the third concept was chosen to progress to in-vitro 
evaluation. 
 
Design Criterion Concept 1 
O-ring 
Concept 2 
Self expanding collar 
Concept 3 
Hollow wall anchor 
1: Bleeding 
   
2: Insertion Χ   
3: Removal 
 Χ  
4: CPB Χ   
5: Flow dynamics Χ   
6: Stresses 
   
Table 23 - Comparison of design criteria matching for the three inflow cannula fixation concepts. CPB - 
cardiopulmonary bypass. 
 
6.2.2 - Development of Concept 3 (Hollow wall anchor design) 
A variety of engineering challenges arose from adapting a simple hollow wall anchor to an inflow 
cannula fixation device. These include mechanisms to allow a fluid passage through the device, creating 
a suitable fixation and seal to the myocardium, designing for improved flow dynamics and design for 
manufacturing. Detailed design of the third concept is outlined in this section. 
 
Fluid Passage 
The hollow wall anchor design was modified by allowing a fluid passage through the bolt to transfer fluid 
from the ventricle to the VAD (Figure 112). This was achieved with a 12 mm fluid passage through the 
bolt, resulting in a hollow bolt wall thickness of 1 mm (14 mm outside diameter). The 12 mm fluid 
passage is larger than several previously designed inflow cannulae (eg. The VentrAssist device at 
approximately 10 mm), thus providing a reduced VAD inlet resistance and the potential for increased 
VAD flow rate. 
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Figure 112 - Hollow bolt of concept 3 including (a) rendered image and (b) sectioned view with dimensions. 
 
Fixation Mechanism 
For the purposes of explanation, ‘internal’ is used to define any part which protrudes within the 
cannulated chamber, while ‘external’ defines components which sit outside the cannulated chamber. 
The fixation mechanism was designed to work similarly to that of a hollow wall anchor. The hollow bolt 
was designed to be screwed into a collapsing component (Figure 113). As the flange of the hollow bolt 
and flange of the collapsing component meet, the hollow bolt cannot progress any further within the 
collapsing component. Therefore, as the thread is turned further, the collapsing component is forced to 
collapse by the downwards force applied by the turning thread. This results in the collapsing component 
expanding outwards and creating an internal flange which seals the myocardium against the external 
flange of the collapsing component (Figure 114). This sealing mechanism was designed to create a 
strong interface between the collapsed component and myocardium, thus addressing design criteria 6. 
Assembly images of the hollow bolt and collapsing component before and after collapse are shown in 
Figure 115 and Figure 116 respectively. 
 
 
(a) 
 
(b) 
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Mechanism of Collapse 
Due to the modification of the bolt to become hollow, the typical bolt head (eg. Phillips head drive) 
could not be used. The bolt head was replaced with an external, hexagonal cross-section along the 
hollow bolt so it could be turned while allowing fluid to travel through the end. The collapsing 
component was also modified by adding an external hexagonal cross-section component to prevent the 
collapsing component from rotating while the hollow bolt turns. Hollow bolt and collapsing components 
incorporated a thread (1mm pitch) which interlocked for 2 mm before the flanges came together. After 
this point, turning one of the components resulted in collapse of the expanding component. The 
collapsing component was designed to allow for fixation to a wide range of myocardial thicknesses. For 
instance, if the myocardium is thick, the hollow bolt should not be turned as many times as a case with a 
thinner myocardium. The thread lengths on the hollow bolt and collapsing component were designed to 
allow for attachment to myocardial thicknesses in a range between 1 mm and approximately 12 mm. 
The process of collapse was designed to be achieved simply and in a short time, therefore addressing 
design criteria 2 and 4. 
 
 
 
 
 
(a) 
 
(b) 
 
Figure 113– Expanding component (prior to collapse) of concept 3 including (a) rendered image and (b) 
sectioned view with dimensions. 
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(a) 
 
 
(b) 
 
Figure 114– Expanding component (after collapse) of concept 3 including (a) rendered image and (b) 
sectioned view with dimensions. 
 
 
 
(a) 
 
 
(b) 
 
Figure 115 – Assembly (prior to collapse) of concept 3 including (a) rendered image and (b) sectioned view 
with dimensions. 
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(a) 
 
 
(b) 
 
Figure 116 – Assembly (after collapse) of concept 3 including (a) rendered image and (b) sectioned view with 
dimensions. 
 
 
 
 (a) 
 
(b) 
 
Figure 117 – Custom spanner of concept 3 including (a) rendered image and (b) front and side views with 
dimensions. 
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Mechanism of Expansion 
Standard hollow wall anchors cannot expand back to their original shape because when the bolt is 
turned anti-clockwise, the bolt simply moves backwards along the thread rather than expanding the 
collapsing component. This was overcome through the flanges on the hollow bolt and collapsing 
component and a custom designed spanner (Figure 117) capable of holding the flanges together. The 
addition of the spanner to hold the flanges together was included so that as the hollow bolt is turned, it 
cannot move backwards along the thread and, therefore, forces the collapsing component to expand to 
its original shape due to the upwards force applied by the turning thread. This design change was made 
to address design criterion 3. 
 
Sealing  
Silicone O-rings (19 mm outer diameter, 1.5 mm cross-sectional width) were included between the 
external flange of the collapsing component and the epicardium and between the flanges of the 
collapsing component and the hollow bolt to prevent leaking from any point. O-ring grooves can be seen 
in the sectioned views in Figure 115 and Figure 116. An internal silicone sleeve was added around the 
expanding component to prevent blood flow about the braces and to provide an improved seal against 
the endocardium. The silicone sleeve was designed to have an inner diameter the same as the outer 
diameter of the collapsing component (prior to collapse). Inner and outer moulds were designed (Figure 
118) and made in a rapid prototyper (Objet Alaris 30). Silicone (Silastomer P15, Dalchem, Cheltenham, 
Australia) was de-aired using a vacuum chamber, poured into the mould and allowed to set. The moulds 
were removed, leaving a silicone sleeve of 2 mm thickness which was placed around the collapsing 
component. This sleeve not only prevents fluid from entering around the struts on the collapsing 
component, but also acts as a softer, webbed surface to create a good seal against the myocardium. The 
2mm thick silicone sleeve, combined with the 7 mm gap between flanges on the collapsing component, 
resulted in a 5 mm space for the myocardium to compress between. This was based on an approximate 
value of 50% compression of a 10 mm myocardial thickness, taken from the literature [171]. However, 
due to the variable compression / expansion of the collapsing component, the fixation device could be 
used with almost any myocardial thickness. The combination of O-rings, the silicone sleeve and 
myocardial compression by the fixation device addressed design criterion 1. 
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(a) 
 
(b) 
 
Figure 118 – Silicone sleeve moulder in (a) exploded view and (b) sectioned view. 
 
Flow Dynamics 
Throughout the design phase, the flow dynamics within the ventricles and around the inflow cannula 
was considered. This was based on experiences from research completed by the candidate at the 
Helmholtz Institute, Aachen, which demonstrated the advantages of increased inflow cannula 
protrusion and promoting recirculation regions around the ventricular apex [306]. For this reason, the 
collapsing component was designed to have a flared cross-section when fully collapsed in an attempt to 
promote higher flow regions around the apex and a reduced potential for wedge thrombus formation. 
However, it should be noted that this concept was not evaluated in this thesis and requires further 
evaluation through computational fluid dynamics (CFD), particle image velocimetry (PIV) and in-vivo 
trials. The insertion length within the ventricle, chosen as between 30 and 40 mm depending on 
myocardial thickness, was based on previous work by Schmid et al. (2008) [10] and a study completed by 
the candidate outside of the PhD thesis [306]. These studies demonstrated that the tip of the inflow 
cannula should progress approximately 35 mm into the ventricle to prevent tissue growth around the 
inflow cannula tip and improve the flow dynamics around the ventricular apex. The addition of an 
internal flared component and correct selection of inflow cannula insertion length addressed design 
criterion 5.  
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Manufacturing 
As it met all design criteria, design concept 3 was chosen for manufacturing and testing. For ease of 
manufacture, stainless steel (SS316, Midway Metals, Brisbane, Australia) was chosen for the hollow bolt, 
collapsing component and spanner. Manufacturing of three collapsing components and two hollow bolts 
was completed by the Queensland University of Technology mechanical workshop (Figure 119). An 
additional collapsing component was later required for the second cadaveric human heart test. A slight 
design modification to the collapsing component was made by the mechanical workshop (Figure 120). 
 
(a) 
 
(b) 
 
(c) 
 
Figure 119 – Manufactured stainless steel versions of the (a) hollow bolt, (b) collapsing component and (c) 
custom designed spanner. 
 
(a) 
 
(b) 
 
Figure 120 – Change to the collapsing component made by the manufacturing workshop including (a) the 
original design and (b) the modified design. 
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6.2.3 Cadaveric Mock Circulation Loop 
The MCL, described earlier in this thesis, could not be used for fixation device evaluation as cadaveric 
animal and human hearts were required to be connected to the MCL. Therefore, a new cadaveric MCL 
was required for fixation device evaluation. The MCL was required to simulate systemic and pulmonary 
circuits with lumped arterial compliance, venous compliance and vascular resistance while allowing 
connection to excised, cadaveric hearts. 
 
Arterial compliance chambers (Figure 121a) were constructed similarly to those used in the MCL 
presented earlier. Vertical PVC pipes, 100 mm in diameter, were fitted with a cap and bulkhead at the 
base to allow connection to the MCL and a test plug at the top as an adjustable cap. The test plugs were 
set at a height of 25 and 45 cm from the compliance chamber base to achieve approximate compliance 
values of 1.5 and 3 mL/mmHg respectively for aortic and pulmonary arterial compliance chambers. 
Systemic and pulmonary venous compliance chambers (Figure 121b) were also made with vertical PVC 
pipes of 100 mm diameter and fitted with a cap and bulkhead at the base to allow connection to the 
MCL. The venous compliance chambers, however, did not include test plugs and were left open to 
atmosphere to simulate a high degree of venous compliance (approximately 100 mL/mmHg). Vascular 
resistance was simulated with manually controlled ball valves (Figure 121c) of 15 and 25 mm diameter 
for systemic and pulmonary vascular resistance respectively.  
 
Connections to the cadaveric hearts were achieved with barbed fittings (Figure 121d) of either 15 or 25 
mm outer diameter, depending on the size of the vessel. Barbed fittings were attached to flexible, 25 
mm diameter, tygon tubing which was then connected to the MCL. Valves, taken from several Thoratec 
PVAD (Thoratec Corporation, Pleasanton, CA, USA) devices, were inserted within the tygon tubing and 
fixed with cable ties to compensate for the deteriorated cadaveric valves (Figure 121e). Arterial and 
venous compliance chambers, vascular resistance valves and cadaveric heart connections were all 
connected through threaded PVC fittings to form the systemic and pulmonary circulations. VAD 
connections were achieved via the cadaveric hearts for inflow and through PVC fittings and ½” tygon 
tubing to the arterial compliance chambers for outflow. A photograph of the cadaveric MCL, with a 
cadaveric animal heart, is shown in Figure 122. 
 
 
 
219 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
Figure 121 – Cadaveric MCL components including (a) arterial compliance chamber, (b) venous compliance 
chamber, (c) barbed fittings for cadaveric heart and tubing connection, (d) ball valve for manual 
manipulation of vascular resistance and (e) Thoratec PVAD valve fastened in tubing to a simulate a heart 
valve. 
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Figure 122 – MCL with cadaveric animal heart attached through the left atrium, right atrium, aorta and 
pulmonary artery. 
 
Small sections of tygon tubing were included in both circulations to attach clamp on flow sensors. Flow 
rates were recorded with clamp on ultrasonic flow sensors (10PXL and 20PXL, Transonic Systems, NY, 
USA) attached to tubing flow meters (TS410-10PXL, Transonic Systems, NY, USA). Circulatory pressures 
were recorded using silicone-based transducers (PX181B-015C5V, Omega Engineering, Connecticut, 
USA) attached to the MCL through luer connectors on the aortic compliance chamber (for aortic 
pressure), pulmonary arterial compliance chamber (for pulmonary arterial pressure), systemic venous 
compliance chamber (for right atrial pressure), pulmonary venous compliance chamber (for left atrial 
pressure) and shortly after the fixation devices (for respective ventricular pressures). All inputs 
(pressures and flow rates) were captured at 100Hz and displayed in real-time using a dSPACE data 
acquisition system (DS1103, dSPACE, Novi, MI, USA). The GUI, described earlier in Chapter 3 of this 
thesis, was used to display pressure and flow rates in real-time. 
 
Validation of the circulation loop was achieved by evaluating the capability of the system to replicate 
clinically representative haemodynamics when the cadaveric heart was attached with LVAD / BiVAD 
support. This included achieving sufficient systemic and pulmonary flow rates, mean arterial pressures 
and pulse pressures through manual pulsation of the cadaveric heart. 
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6.2.4 Fixation Evaluation in Cadaveric Animal Hearts 
Prior to full evaluation in the cadaveric MCL, a pilot study was completed to test the sealing mechanism 
of the fixation device. A pig’s heart was sourced from a butcher, which upon inspection had a partly 
excised right ventricle. The remaining right ventricle, right atrium and greater vessels were removed, 
leaving only the left ventricle, left atrium and aorta intact. A VentrAssist coring tool (Ventracor Ltd., 
Sydney, Australia) was used to create a core in the left ventricular apex. The fixation device, including 
the hollow bolt and collapsing component but without the silicone sleeve, was inserted through the left 
ventricular core until the outer flange reached the epicardium. The custom spanner was placed on the 
hexagonal section on the collapsing component and over the flanges of the collapsing component and 
hollow bolt. An adjustable spanner was then placed over the hexagonal section of the hollow bolt and 
turned while the custom spanner was held stationary. The hollow bolt was turned until the myocardium  
deformed about the outer flange. At this point, it was predicted that the left ventricle had been 
relatively well sealed. The coring tool, custom spanner, shifter and fixation device within the dissected 
pig’s heart is shown in Figure 123. The heart was then dissected by cutting around the left ventricle to 
create an arch which exposed the internal components of the fixation device and the quality of the seal. 
 
 
 
 
 
 
 
 
Figure 123 – The coring device (far left), fixation device sealed inside the pig’s heart (middle left), custom 
spanner (middle right) and adjustable spanner (far right) use for the pilot study. 
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For the remaining animal heart tests, calf hearts 
were sourced as they could be supplied with intact 
ventricles. Entire plucks (heart, lungs and liver) 
were sourced to ensure the greater vessels were 
not damaged. The lungs, liver and pericardium 
were removed. The aorta and pulmonary artery 
were incised prior to the point of bifurcation 
(pulmonary artery) or the point where the aortic 
arch vessels begin to branch. These points were 
approximately 50 mm from the semilunar valves. 
The aorta and pulmonary artery were then 
carefully separated with surgical scissors to allow a 
cable tie to pass around the entire artery. Each 
atrium was then trimmed and the veins were 
linked to allow for one common orifice in each 
atrium. Small holes were closed with sutures to prevent leaking. The cadaveric heart was then 
connected to PVC barbed fittings through the aorta, pulmonary artery, left atrium and right atrium 
(Figure 124). A combination of cable ties and tightly wound sutures held the vessels to the PVC fittings 
to prevent significant leaking. 
 
Fluid was added to the MCL and cadaveric heart to a pre-set zero level. The pressure sensors were then 
set to zero before further fluid was added until a central venous pressure of 12 mmHg was reached. The 
left ventricle was cored with the VentrAssist coring tool. Upon removal of the myocardial core, the 
fixation device, including the connected hollow bolt and collapsing component, was quickly inserted 
within the left ventricle until the external flange reached the epicardium. To prevent leaking through the 
fixation device, a short piece of silicone tubing was closed with a brass plug and attached to the external 
end of the hollow bolt prior to coring of the ventricle. The fixation device was tightened using the 
custom spanner to hold the collapsing component still and the two flanges together while an adjustable 
spanner was used to rotate the hollow bolt. The fixation device was tightened until the myocardium had 
visibly deformed due to compression of the internal and external flanges. The fixation device was then 
attached to ½” tygon tubing which had been previously attached to the inlet of a Levitronix CentriMag 
device (Levitronix LLC, Waltham, USA) (Figure 125).  
 
Figure 124 – Calf heart connected to the cadaveric 
MCL 
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The CentriMag speed was gradually increased to simulate clinically significant pressures (MAP ~ 100 
mmHg) and flow rates (MSQ ~ 5L/min). As there was no right ventricular contractility or RVAD in the 
circuit, the right ventricle acted as a Fontan (ie. a completely passive chamber) [307] and thus higher 
LVAD speeds were required to produce the required haemodynamics. Pressure and flow rates were 
recorded to demonstrate the ability of the fixation device to operate as a LVAD inflow cannula. To test 
the ability of the seal to withstand high pressures, the tubing attached to the LVAD, aorta and left atrium 
was clamped. Water was then added to the left ventricle in 30 mL increments through a 3-way tap while 
pressure within the left ventricle was monitored. However, due to leaking through various points 
around the heart’s connections to the MCL, a constant high pressure could not be maintained in the left 
ventricle. Therefore, to evaluate the seal of the fixation device under high pressure, 30 mL increments of 
water were rapidly added to the ventricle while the pressure was recorded. The area around the fixation 
device was observed for leaks throughout testing. These tests were performed with a total of two 
cadaveric calf hearts. 
 
Figure 125 – The cadaveric animal heart with the fixation device attached and connected to a Levitronix 
CentriMag LVAD. 
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6.2.5 Fixation Evaluation in Cadaveric Human Hearts 
To obtain more clinically relevant results, the fixation device was evaluated in cadaveric human hearts. 
Ethics approval was obtained through a cadaveric tissue form submitted to the Queensland University of 
Technology Office of Research (Approval number 1100000176). Cadavers were sourced from the 
Medical Engineering Research Facility (MERF) of Queensland University of Technology. This facility 
houses embalmed and frozen cadavers. Embalmed tissue, particularly highly vascular tissue, has a 
tendency to become more firm and rubbery over time, thus distorting the mechanical properties of the 
heart [308]. For this reason, the hearts were sourced from frozen cadavers only. Due to availability of 
specimens, only two cadavers were used in this study, with their basic information outlined in Table 24. 
 
Cadavers where placed on an operating table before a median sternotomy was performed using a 
sternal saw. Chest spreaders were used to gain access to the cavity and a scalpel was used to incise the 
pericardium. The aorta and pulmonary arteries were incised as far from the aortic and pulmonary valve, 
respectively, as possible (Figure 126). The superior and inferior vena cava were incised to expose the 
right atrium, while the pulmonary veins were incised to expose the left atrium. The heart was then 
removed from the cavity. A photograph of the removed heart from Cadaver 1 is shown in Figure 127. 
 
Cadaver Gender Approx. Weight (kg) Cause of Death 
1 Male 45 Unknown 
2 Male 70 Unknown 
Table 24 – General information on cadavers used to supply hearts tested with the fixation device. 
 
 
Figure 126 – The cadaveric aorta being incised with a 
scalpel. 
 
Figure 127 – The excised heart from cadaver number 
1. 
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The aorta and pulmonary artery were carefully separated with surgical scissors before both were 
trimmed to remove any loose tissue. The left and right atria were exposed and trimmed so that only one 
orifice existed into each atrium. Holes were sealed with meticulous suturing (Figure 128). For the first 
specimen, PVC barb fittings were attached to the aorta, pulmonary artery, left atrium and right atrium 
and sealed with cable ties (Figure 129). The PVC barb fittings were then attached to the cadaveric MCL. 
For the second specimen, cannulation was achieved prior to connection to the MCL. For the first 
specimen, water was added to the system until a pre-set zero level was reached. At this point, all 
pressure sensors were set to zero. Water was then added until a CVP of 12 mmHg was reached.  
 
Prior to cannulation of each specimen, a short piece of silicone tubing, closed with a brass plug, was 
attached to the external end of the hollow bolt to prevent leaking through the fixation device. An 
appropriate place on the left ventricular apex 
was then identified. This was more difficult in 
the cadaveric human hearts due to a thick 
layer of fat compared to the animal hearts.  A 
VentrAssist coring tool was used to core the 
left ventricular apex (Figure 130) before the 
fixation device was inserted. The original 
fixation design was used for the first 
specimen, while the modified design was 
used for the second specimen. The fixation 
device was tightened using the custom 
 
Figure 128 – Meticulous suturing of small leaks was 
required prior to connection with the MCL. 
 
Figure 129 – The cadaveric human heart connected 
to the barbed fittings which attached to the MCL. 
 
 
Figure 130 – Coring the left ventricular apex for LVAD 
inflow cannula insertion. 
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spanner to hold the collapsing component still and the two flanges together while an adjustable spanner 
was used to rotate the hollow bolt (Figure 131). The fixation device was tightened until the myocardium 
had visibly deformed due to compression of the internal and external flanges. This was slightly more 
difficult to notice in the cadaveric human hearts due to the thick layer of fat compared to the animal 
hearts (Figure 132), particularly with the second specimen.  
 
The fixation device used with the first specimen was then attached to ½” tygon tubing which was 
attached to the inlet of the CentriMag LVAD. The fixation device used with the second specimen, 
however, was not attached to the LVAD due to difficulties with cannulation at the apex. This was due to 
the apical core expanding far beyond the original cored size and the modified design being incapable of 
compensating with a smaller internal flange. In this case, the apical core was sutured closed and a 
second attempt was made through the left ventricular free wall. This attempt was also unsuccessful due 
to the core expanding and the modified design unable to compensate. Therefore, VAD support was not 
initiated with the second specimen and the remaining methods describe the procedure used for the first 
specimen only.  
 
For the test with the first specimen, the CentriMag speed was gradually increased to simulate a clinically 
significant pressure (MAP ~ 100 mmHg) and flow rate (MSQ ~ 5 L/min). Initially, there was no right 
ventricular contractility or RVAD in the circuit so the right ventricle acted as a Fontan in the early stages 
of this experiment. Therefore, higher LVAD speeds were required to produce the required  
 
Figure 131 – The fixation device was tightened by 
turning the hollow bolt with a shifter while the 
collapsing component was held still with the custom 
spanner. 
 
 
Figure 132 – The fixation device attached to the left 
ventricular apex. Note the deformation of the tissue 
about the external flange. 
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haemodynamics. CentriMag speed was then incrementally increased to obtain higher flow rates (MSQ ~ 
8 L/min) to demonstrate the capability of providing increased support. Pressure and flow rates were 
recorded in this continuous flow situation to demonstrate the ability of the fixation device to operate as 
a LVAD inflow cannula. Operating conditions for LVAD testing are displayed in Table 25. 
 
LVAD support was stopped before an RVAD was then added to the circuit. The VentrAssist coring device 
was used to create a hole in the posterior free wall of the right ventricle (Figure 133). This site was 
chosen due to the lack of fatty tissue and clear visibility of the right ventricular free wall. The fixation 
device was quickly inserted through the hole in the free wall and tightened by holding the collapsing 
component stationary with the custom spanner and turning the hollow bolt with an adjustable spanner 
(Figure 134). The hollow bolt was plugged on the external end with tygon tubing and a brass plug to 
Support Condition LVAD Speed (RPM) RVAD Speed (RPM) 
LVAD 
LVAD 
BiVAD 
BiVAD 
BiVAD 
BiVAD 
Restored 
High flow 
Restored 
High flow 
Small pulse 
Large pulse 
2500 
3100 
2350 
3000 
2350 
2350 
N/A 
N/A 
1390 
1780 
1390 
1390 
Table 25 – Operating conditions for fixation device evaluation in the first cadaveric heart specimen. Restored 
condition: MSQ ~ 5 L/min. High flow condition: MSQ ~ 8 L/min. RPM – revolutions per minute. 
 
 
Figure 133 – Coring the posterior wall of the right 
ventricle for RVAD inflow cannula fixation. 
 
 
Figure 134 – Tightening of the RVAD inflow 
cannula fixation device was achieved with a shifter 
to rotate the hollow bolt while the custom spanner 
held the collapsing component stationary. 
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prevent leaking. The fixation device was 
tightened until the right ventricular 
myocardium had visibly deformed between 
the two flanges, indicating a good seal. The 
tygon tubing was clamped before the plug 
was removed and the inlet of a BP80 (Bio-
Medicus, Inc., Eden Prairie, MN, USA) rotary 
RVAD was attached. A photograph of the 
LVAD and RVAD inflow cannula connections is 
shown in Figure 135.  
 
CentriMag and BP80 rotational speeds were gradually increased to obtain clinically significant 
haemodynamics (MAP ~ 100 mmHg, MPAP ~ 20 mmHg, MSQ ~ 5 L/min) to demonstrate the capability 
of the fixation device to operate as an LVAD and RVAD inflow cannula. LVAD and RVAD speeds were 
then gradually increased to demonstrate the capability of the device to provide increased support (MSQ 
~ 8 L/min) in a BiVAD scenario. A small and large pulse was then induced to pressurize both ventricles 
and simulate contractile-like movement through manual external pulsation of the cadaveric heart at 
approximately 50 BPM. Operating conditions for BiVAD testing are displayed in Table 25. 
 
Both VADs were stopped before the tygon 
tubing was removed from the fixation devices. 
The PVC barbs were removed from the 
cadaveric vessels, leaving only the cadaveric 
heart and fixation device. Surgical scissors were 
used to create an arch-like incision around the 
left ventricle to show the sealing mechanism 
and cannula tip position with respect to the 
septal wall (Figure 136). A similar incision was 
made on the right ventricle to expose the 
fixation device used for RVAD support.  
 
 
 
Figure 135 – LVAD and RVAD inflow cannula fixation 
devices in place. 
 
Figure 136 – An arch-like incision was made around the 
fixation device to expose the sealing mechanism. 
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6.3 Results 
Results were taken from cadaveric animal and human hearts to demonstrate the capability of the 
fixation device to rapidly cannulate, seal and be removed from hearts with varying myocardial thickness. 
 
6.3.1 Fixation Evaluation in Cadaveric Animal Hearts 
Total implantation time, including coring the apex, inserting the fixation device and turning the device to 
create a seal, took less than one minute in each case. Coring was relatively simple with the VentrAssist 
coring device. Meanwhile, the size of the apical core remained constant throughout insertion and 
testing, and can be attributed to the strong, fresh tissue. Although there was only low pressure in the 
cadaveric calf heart at the time of insertion, very little fluid loss was noticed during implantation, 
indicating that this technique may be applicable off-bypass in the clinical setting. Connection to the 
LVAD was simple, with ½” tygon tubing fitting perfectly over the external end of the hollow bolt. When 
LVAD speed was set at 3000 RPM, haemodynamics representing a restored condition (MAP: 107 mmHg, 
MSQ: 5.07 L/min) were recorded (Figure 137). When a pulse was induced through pulsatile manual 
external compression of the ventricles, MAP decreased to 92 mmHg and MSQ to 4.7 L/min (Figure 138). 
The manual pulse induced only slight pulse pressures of 93/91 mmHg while systemic flow rate (SQ) 
oscillated between 4.3 and 5.0 L/min. No leaking through the fixation device or from the device – 
myocardial interface was observed throughout these experiments. 
 
When the left ventricular inflow and outflow ports were clamped and fluid was added to the ventricular 
chamber, several pressure spikes were observed as each bolus of fluid was added (Figure 139). The 
maximum and mean pressure reached during this test was 207 and 77 mmHg respectively. In each case, 
the pressure in the left ventricle quickly reduced following the initial peak after addition of the fluid 
bolus. This can be attributed to the various smaller holes created around the heart during the initial 
dissection, with most stemming from the thin-walled left atrium. Although it was not possible to 
quantitatively demonstrate that the device prevented fluid loss, no leaking was observed through the 
device or at the device – myocardial interface at any point during the pressure test, therefore 
demonstrating the capability of the fixation device to seal under clinically significant pressure. 
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 (a) 
 
(b) 
 
Figure 137 – Haemodynamics recorded when the fixation device was used for continuous flow, rotary LVAD 
support in a cadaveric calf heart. MAP – mean aortic pressure, MSQ – mean systemic flow rate. 
 
 
 
 (a) 
 
(b) 
 
Figure 138 – Haemodynamics recorded when the fixation device was used for pulsatile flow, rotary LVAD 
support in a cadaveric calf heart. AoP – aortic pressure, SQ – systemic flow rate. 
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Figure 139 – Plot of left ventricular pressure (LVP) as 30 mL increments of water were added to the system 
to test for leaks. 
 
The combination of the silicone sleeve, a collapsible internal flange and an external flange which 
compressed the apical myocardium produced a good seal in all cases. In the pilot study with the 
cadaveric pig’s heart the silicone sleeve was omitted (Figure 140a) which resulted in an insufficient seal 
around thinner areas of the ventricular apex (Figure 140b). The myocardial thickness varied between 
approximately 3 mm at the thinnest points and 6 mm at the thickest points. In most areas, however, the 
stainless steel struts spread across the myocardium and created an appropriate seal by compressing the 
myocardium between the internal and external flanges (Figure 140c). The collapsing component used in 
this case had been collapsed and expanded four times previously for demonstration purposes. This 
weakened the struts, particularly around the base and top of each strut where maximum deformation 
occurred, and resulted in a fracture of one strut at the base when the collapsing component was 
expanded during removal (Figure 140d). While this was the only case of strut fracture throughout 
testing with cadaveric animal hearts, it demonstrated that a biomaterials investigation is required to 
prevent strut fracture if expanded / contracted more than once. 
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(a) 
 
(b) 
 
 
(c) 
 
 
(d) 
 
Figure 140 – Images during the dissection of the pig heart after the fixation device (without the silicone 
sleeve) was used including (a) following an arch-like incision to the anterior aspect of the left ventricular free 
wall, (b) following removal of the ventricular wall leaving only the apical tissue (note a region of tissue which 
had not been compressed is circled), (c) a top view of the fixation device with apical tissue demonstrating the 
sealed radius and (d) the fixation device after it had been expanded (note the circled broken strut). 
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A suitable fluid seal was obtained when the silicone sleeve was added to the fixation device and 
evaluated in two calf hearts. In each case, the myocardium deformed slightly as the fixation device was 
tightened (Figure 141a and Figure 142a), which indicated an appropriate seal. No significant leaks were 
noted in either case throughout testing with rotary LVAD support. Although no minor leaks were seen 
through the fixation device or at the device - myocardium interface, a gradual loss of fluid from the 
heart was noted throughout the experiments. This was mostly attributed to leakage through the 
cadaveric animal heart - MCL connection where the rigid fittings were sealed against the soft vessels 
with inconsistent thickness. It was particularly difficult to seal the ventricular inflow connections due to 
the thin atria, and it was here that most of the minor leaks occurred. Although it could not be 
quantitatively proven in this experiment, close observation of the fixation device - myocardial interface 
revealed minimal, if any, leakage throughout all experiments. 
 
While not clinically significant to human data, evaluation in the two calf hearts did reveal a difference in 
myocardial thickness at the ventricular apex between each case. This was revealed following dissection 
of the heart prior to removing the fixation device in both cases (Figure 141b and Figure 142b).  In the 
first example (Figure 141c), the myocardial thickness was relatively even about the circumference of the 
collapsed fixation device at approximately 5 mm. The apex was without any fatty tissue and was 
consistently thick and relatively rigid which provided a simple vessel to cannulate, particularly with the 
suture-less fixation device. The second calf heart, however, had a much thinner apex and provided a 
more clinically relevant evaluation of the fixation device. In this case, the apical thickness varied 
between approximately 1 mm and 2 mm around the circumference of the collapsed fixation device 
(Figure 142c), even though the left ventricular free wall was quite thick (Figure 142b). Although each 
case had a different apical thickness, both were simple to cannulate and sealed appropriately with the 
suture-less fixation device. 
 
Explantation was simple in both cases, although it was completed after dissection of the left ventricular 
free wall. Explantation of the fixation device took less than one minute with both calf hearts. Although 
no strut fractures occurred in either case with the calf hearts (both collapsing components were new at 
the time of implantation), the suture-less fixation device should still be recommended for single-use in 
its current form. However, further biomaterials investigations are to be conducted to ensure a more 
durable material is used.  
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(a) 
 
 
(b)   
   
 
(c) 
 
Figure 141 – Images taken during testing and dissection with the first calf heart including (a) the deformed 
myocardium about the external flange producing a good seal, (b) the exposed fixation device after the heart 
was dissected and (c) the excellent seal at the ventricular apex provided by the fixation device with silicone 
sleeve. 
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(a) 
 
 
(b) 
 
 
(c) 
 
Figure 142 – Images taken during testing and dissection of the second calf heart including (a) the deformed 
myocardium about the external flange producing a good seal, (b) the dissected heart exposing the seal and 
fixation device placement and (c) the seal created by the fixation device on the apical tissue (note the very thin 
apex in this case). 
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6.3.2 Fixation Evaluation in Cadaveric Human Hearts 
Results for the cadaveric human heart tests are presented separately for specimen one and two due to 
the difference in design, methods and outcome. 
 
6.3.2.1 First Specimen 
Implantation time, including coring the left ventricular apex, inserting the fixation device and tightening 
the fixation device, took less than two minutes. Coring of the apex was relatively simple with the 
VentrAssist coring device. While the core expanded slightly during the implantation, the internal flange 
was large enough to compensate and create a seal. The method of fixation was simple, while 
deformation of the myocardium about the external flange revealed the point at which a suitable seal 
was created. Fluid loss during implantation was minimal as the core closely surrounded the silicone 
sleeve of the fixation device. RVAD implantation time, including coring the right ventricular free wall, 
inserting the fixation device and tightening the fixation device, also took less than two minutes. While 
coring was relatively simple, the core expanded during implantation and evaluation during BiVAD 
support. This was compensated by the collapsed internal flange which created a suitable seal for the 
RVAD inflow cannula. Minimal fluid loss occurred during implantation of the fixation device within the 
right ventricle. Connection of the fixation device to the respective VAD was simple and achieved with 
1/2” tygon tubing. Photographs of the LVAD and RVAD inflow cannula fixation devices attached to the 
respective ventricles are shown in Figure 143. 
 
(a) 
 
(b) 
 
Figure 143 - The suture-less fixation device secured in (a) the left ventricular apex and (b) the right 
ventricular free wall. 
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Haemodynamics were recorded for various conditions in LVAD and BiVAD support scenarios with the 
fixation device to demonstrate the ability of the device to act as an inflow cannula without significant 
fluid loss. Results for the restored condition with LVAD support are shown in Figure 144. A mean aortic 
pressure (MAP) of 103 mmHg and a mean systemic flow rate (MSQ) of 4.9 L/min demonstrated the 
capability of the device to provide clinically representative pressures and flow rates of a restored 
condition. As expected, left atrial pressure (LAP) (6 mmHg) was lower than the recorded left ventricular 
pressure (LVP - taken just after the fixation device) (0 mmHg), due to continuous flow through the circuit 
from the atrium to the ventricle. Mean pulmonary arterial pressure (MPAP) was lower than expected at 
12 mmHg, indicating that pulmonary vascular resistance (PVR) was quite low due to only a 6 mmHg 
pressure drop to the left atrium. MPAP remained constant when LVAD speed was increased to simulate 
a high flow condition (Figure 145). In this condition, systemic vascular resistance (SVR) was manipulated 
to maintain AoP (103 mmHg) while MSQ was increased to 8 L/min to demonstrate the capability of the 
device to provide the pressures and flow rates of a high flow condition. LAP remained constant (6 
mmHg), while LVP reduced to -25 mmHg due to the increase in rotary LVAD speed. Right atrial pressure 
(RAP) and right ventricular pressure (RVP) were not recorded during evaluation with only LVAD support.   
 
As expected, MPAP increased (to 24 mmHg) when RVAD support was initiated (Figure 146). As this test 
aimed to represent a restored condition, MAP and MSQ were kept relatively similar to the LVAD 
restored test at 102 mmHg and 5.2 L/min. Mean pulmonary flow rate (MPQ) was slightly lower (5.0 
L/min) than MSQ, indicating a slight flow imbalance between the two rotary blood pumps. However, a 
higher MPQ would be expected with the high LAP (19 mmHg) and lower RAP (10 mmHg). This could be 
attributed to a recent change in LVAD / RVAD pump speed to compensate for the discrepancy in atrial 
pressures while not allowing enough time for the system to settle before capturing results. In either 
case, these data reiterates the difficulty in balancing flow rates and fluid volumes with rotary BiVAD 
support, as demonstrated in Chapter 5 of this thesis. When the high flow condition was simulated with 
BiVAD support (Figure 147), MSQ and MPQ were both recorded as 8.5 L/min, indicating that flow 
balancing had been achieved in this case with left and right atrial pressures of 12 mmHg and 19 mmHg 
respectively. Therefore, high levels of BiVAD support can be provided with the fixation device in the left 
and right ventricles. MAP was relatively similar to previous results (96 mmHg), while MPAP dropped to 
15 mmHg as the PVR was reduced to achieve higher flow rates.  
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Figure 144 - Haemodynamic results from the restored condition test with LVAD support only. P - pressure, Q 
- flow rate, AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left 
atrial pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, MSQ - mean 
systemic flow rate, MPQ - mean pulmonary flow rate. 
 
When a slight pulse was induced through manual external pulsation of the left and right ventricles 
(Figure 148), LVP oscillated between 0 and 31 mmHg and RVP oscillated between -5 and 10 mmHg. 
Neither ventricular pressure trace had a clinically representative waveform. The LVP waveform had a 
long systolic period (approximately 70% of the cardiac cycle) with a double pulse, while the RVP 
waveform was almost a ‘saw-tooth’ wave. The oscillation in ventricular pressures resulted in pulsatile 
aortic pressure (AoP) (between 107 and 113 mmHg), pulmonary artery pressure (PAP) (between 21 and 
25 mmHg), systemic flow rate (SQ) (between 2.7 and 8.5 L/min) and pulmonary flow rate (PQ) (between 
5.4 and 5.7 L/min).  
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When the magnitude of the external pulsation increased (Figure 149), LVP oscillated between -135 and 
48 mmHg and RVP oscillated between -8 and -3 mmHg. Again, neither ventricular pressure waveform 
was clinically representative, with the LVP having approximately an 80% systolic period and the RVP 
trace again representing a ‘saw-tooth’ shape. The oscillation in ventricular pressures resulted in pulsatile 
AoP (between 82 and 101 mmHg), pulmonary artery pressure (PAP) (between 25 and 29 mmHg), 
systemic flow rate (SQ) (between 1.4 and 7.5 L/min) and pulmonary flow rate (PQ) (between 4.7 and 5.5 
L/min). Left and right atrial pressures oscillated slightly in time with ventricular pressure oscillations, 
indicating the atrio-ventricular valves allowed some backflow. 
 
 
Figure 145 - Haemodynamic results from the high flow test with LVAD support only. P - pressure, Q - flow 
rate, AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left atrial 
pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, RVP - right 
ventricular pressure, RAP - right atrial pressure, MSQ - mean systemic flow rate, MPQ - mean pulmonary 
flow rate. 
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Figure 146 - Haemodynamic results from the restored condition test with BiVAD support. P - pressure, Q - 
flow rate, AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left 
atrial pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, RVP - right 
ventricular pressure, RAP - right atrial pressure, MSQ - mean systemic flow rate, MPQ - mean pulmonary 
flow rate. 
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Figure 147 - Haemodynamic results from the high flow test with BiVAD support. P - pressure, Q - flow rate, 
AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left atrial 
pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, RVP - right 
ventricular pressure, RAP - right atrial pressure, MSQ - mean systemic flow rate, MPQ - mean pulmonary 
flow rate. 
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Figure 148 - Haemodynamic results from the small pulse test with BiVAD support. P - pressure, Q - flow rate, 
AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left atrial 
pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, RVP - right 
ventricular pressure, RAP - right atrial pressure, MSQ - mean systemic flow rate, MPQ - mean pulmonary 
flow rate. 
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Figure 149 - Haemodynamic results from the large pulse test with BiVAD support. P - pressure, Q - flow rate, 
AoP - aortic pressure, MAP - mean aortic pressure, LVP - left ventricular pressure, LAP - left atrial 
pressure, PAP - pulmonary arterial pressure, MPAP - mean pulmonary arterial pressure, RVP - right 
ventricular pressure, RAP - right atrial pressure, MSQ - mean systemic flow rate, MPQ - mean pulmonary 
flow rate. 
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(a) 
 
(b) 
 
Figure 150 - Images showing (a) the RVAD inflow cannula slipping from the right ventricle after manual 
external pulsation and (b) the thin walled right ventricle and expanded core from which the fixation device 
was removed. 
 
Minimal fluid loss was observed throughout testing in LVAD and BiVAD configurations, however, the 
source of leaks could not be quantitatively identified due to various leaks in the heart and its 
connections to the MCL. The majority of these leaks came from the right atrium, where a minor hole 
was sutured prior to evaluation, yet leaked during testing. Meanwhile, small leaks were observed 
through the connections between the cadaveric human heart and 
the PVC barbed fittings attached to the MCL. However, the seal at 
the fixation device – myocardium interface was excellent, 
particularly with LVAD support.  
 
Following the pulsatile experiments, where the heart was manually 
pulsed through external compression of the ventricles, the RVAD 
inlet cannula began to slip from the right ventricle (Figure 150a). 
This could be attributed to the high degree of movement and force 
applied during pulsation combined with an expanded core and thin 
myocardium in the right ventricular free wall (Figure 150b). The 
myocardium was slightly thicker at the left ventricular apex 
(approximately 2 mm), however a layer of fat, approximately 2 mm 
thick, may have assisted the seal at the apex (Figure 151).  
 
Figure 151 - The seal at the left 
ventricular apex after the 
surrounding tissue was removed. 
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After exposing the seal created by the fixation device in the left 
ventricle (Figure 152), it was revealed that the internal and external 
flanges had compressed the myocardium and fat layer into a uniform 
thickness. The silicone sleeve created a firm web between the struts, 
thus sealing about the circumference of the device. Meanwhile, the 
tip of the inflow cannula appeared to be positioned quite centrally in 
the left ventricular chamber, with the flared design creating a fillet to 
promote circulation around the apex. 
 
Although completed after dissection of the heart and removal of the 
surrounding tissue, explantation of the device from the remnant 
apical tissue was simple. The entire explantation process, including 
turning the hollow bolt while holding the collapsing component still 
and the two external flanges together with the custom spanner and 
removing the device, took less than one minute. However, strut 
fractures were noticed with the LVAD and RVAD collapsing 
components due to overuse (Figure 153). 
 
Figure 152 - Left ventricular free wall cut-away view showing the protrusion of the fixation device within the 
left ventricle and the seal created by the fixation device at the left ventricular apex. 
 
 
Figure 153 - Broken struts from 
the original fixation design 
following expansion for the 
fourth time. 
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6.3.2.2 Second Specimen 
As indicated in the methods section of this chapter, the second cadaveric heart specimen was not 
attached to the MCL due to difficulties with fixing the device to the heart. Figure 154 shows the change 
in apical and free wall core size from the point of coring until the fixation device had collapsed. The 
apical and free wall cores, made with the VentrAssist coring device (with 16 mm diameter), expanded to 
approximately 30 and 25 mm respectively which could not be adequately sealed with the fixation 
device. The core expansion can be attributed to the poor tissue quality from the defrosted cadaveric 
heart specimen.  
 
The inability to provide an adequate seal with the fixation device in the second cadaveric heart 
specimen can also be attributed to an error during manufacturing which resulted in a design change of 
the collapsing component. The initial collapsing component had longer struts and a shorter distance 
between the internal and external flanges compared to the modified design. This design modification 
meant that the collapsing component had to collapse much further to compress the myocardial tissue to 
create a suitable seal. The requirement to collapse further, combined with the shorter struts, meant that 
the sealing diameter and area of the device was drastically reduced. In fact, basing the largest external 
diameter of the collapsing components on the position shown in Figure 155, the sealing diameters were 
34 and 30 mm respectively for the original and modified designs respectively. This, in turn, reduced the 
sealing area (area compressed by the two flanges) to 594 and 392 mm2 for the original and modified 
designs respectively. 
 
(a) 
 
(b) 
 
Figure 154 - The expanded core in (a) the left ventricular apex and (b) the left ventricular free wall. 
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(a) 
 
(b) 
 
Figure 155 - The difference in collapsed internal flange sizes between (a) the original fixation design and (b) 
the modified fixation design. 
 
6.4 Discussion 
Bleeding from the cannula fixation is one of the most common complications during VAD support and is 
a major contributing factor of operative mortality during device implantation and explantation [31].  In 
this study, a novel inflow cannula fixation device was developed and evaluated in cadaveric animal and 
human hearts. The design concepts, experimental techniques and experimental results are discussed 
below. 
 
6.4.1 Design Concepts 
The design criteria used to develop the suture-less fixation device stemmed from the extensive 
literature review, presented in Chapter 3 of this thesis. For instance, Kirklin et al. (2011) [153], amongst 
others, identified the significance of surgical-related postoperative bleeding which led to design criteria 
1. Design criteria 2 aimed for a simple insertion procedure which stemmed from the complex techniques 
developed by researchers such as Komoda et al. (2008) [5] and Charitos et al. (2010) [174]. The need for 
device removal, identified in design criteria 3, was influenced by Kumpati et al. (2001) [309] and the 
positive post-LVAD myocardial recovery results achieved by Birks et al. (2006) [48]. Complications 
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associated with institution of CPB have been described by many researchers, such as McBride et al. 
(2001) [8], which led to design criteria 4. Design criteria 5, concerning the flow dynamics and potential 
for thrombus formation within the ventricle, was created based on the change to inflow cannula 
dimensions presented by Schmid et al. (2008) [10] and the reports of wedge thrombus formation during 
LVAD support [142, 143]. Meanwhile, Charitos et al. (2010) [174] identified the need for a secure inflow 
cannula fixation due to the friable nature of the vessels, which led to design criteria 6. 
 
The initial concept involved the addition of a soft O-ring between a suture ring and the myocardium to 
reduce postoperative bleeding; however this concept didn’t address several of the design criteria. 
Concept 2 was not pursued due to the inability to be easily removed in the event of myocardial 
recovery, which led to the development and evaluation of concept 3. Although not all of the design 
criteria were proven quantitatively with the suture-less fixation device of concept 3, steps were taken 
throughout the design phase to address these issues. Simple, secure, off-bypass implantation and 
explantation (design criteria 2, 3, 4 and 6) were met by the collapsing component clamping the 
myocardium between internal and external flanges. Reduced bleeding (design criteria 1) was addressed 
with the clamped myocardium, O-rings and silicone sleeve. Enhanced flow dynamics should be achieved 
with this design based on the protrusion length within the left ventricle and the flared design to prevent 
wedge thrombus formation (design criteria 5). However, further research is required to evaluate and 
optimize the flow dynamics within the ventricle around the suture-less inflow cannula, particularly 
around the exposed thread of the hollow bolt which may promote thrombus formation. 
 
While not considered in this proof of concept study, additional design criteria could be assessed in the 
future development of the suture-less fixation device. For instance, manufacturability must be taken 
into account to ensure these devices can make it to clinic at a reasonable cost and manufacturing time. 
This may also include the required range of sizes for different myocardial thickness, and if one device 
can be developed to suit all patients. The ability of the device to prevent suction events should also be 
considered, which may be addressed by the internal flange stenting the ventricle open. 
 
6.4.2 Manufacturing 
Owing to the ability of the third concept to meet all the design criteria, it was chosen for manufacture. 
The dimensions of the hollow bolt and collapsing component were based upon values suggested in the 
literature including myocardial thickness and ideal inflow cannula protrusion length [10, 171]. These 
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dimensions were used to manufacture the fixation device tested in the cadaveric animal hearts and first 
human heart, all of which were successful. However, more devices were required due to fatigue of the 
collapsing components after expanding and collapsing several times. A materials selection process is 
required to ensure the final design does not suffer from fatigue issues on the struts. The newly 
manufactured components, evaluated only in the second cadaveric human heart, had slightly different 
dimensions and can be attributed to an error in manufacturing. This error was not realized until 
evaluation was underway, with the fixation device unable to create a seal in the cored cadaveric human 
heart.  
 
While this result was undesirable as further human data would have benefitted this thesis, it did reveal 
the importance of the original dimensions specified in the design. For instance, the change of distance 
between the internal and external flanges from 7 mm to 10 mm meant that the collapsing component 
had to collapse much further to seal a thin section of myocardium. The requirement to collapse further, 
combined with the shorter struts in the second version, meant that the struts did not expand outwards 
to a significant diameter which would provide an adequate seal. Therefore, future design iterations are 
required to determine the optimal strut length and distance between the flanges to suit a wide range of 
myocardial thickness. Alternatively, several designs could be available for varying myocardial thickness, 
with the fixation device chosen on a patient-by-patient basis. Such a concept may be required in any 
case, as VADs have been used to support patients in conditions such as hypertrophic cardiomyopathy 
where a much thicker myocardium is present [310]. 
 
6.4.3 Fixation Device Performance 
Although no literature could be found which commented on the exact time taken for inflow cannula 
fixation within the left or right ventricles, most detail a time consuming procedure involving meticulous 
suturing to attach the cannula and attempt to maintain haemostasis [5, 35, 118, 177, 311]. Meanwhile, 
most require initiation of CPB for inflow cannula insertion which can be associated with higher degrees 
of postoperative bleeding (due to additional anticoagulation therapy) and end-organ dysfunction. The 
implantation time in our study was under two minutes in all cases, demonstrating a clear advantage 
over previous inflow cannulation techniques. While the faster implantation offers the potential for off-
bypass insertion / minimal time on CPB, it also aims to reduce total theatre time, thus improving theatre 
availability and reducing the costs associated with VAD therapy.  
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The ease and simple procedure with which the 
suture-less inflow cannula fixation device can be 
attached to the cored myocardium is also a benefit 
over traditional inflow cannulation techniques. 
Meticulous suturing was not required in any of the 
cadaveric animal or human hearts to achieve 
haemostasis, with the compressed myocardium 
between the internal and external flanges combining 
well with the silicone sleeve to provide a water-tight 
seal. However, an option to combine the fixation 
device with sutures should be considered to make 
surgeons more comfortable with the procedure. This 
could be achieved with a ribbon-like suture attached 
around the circumference of the apex to constrict the myocardium and hold it between the internal and 
external flanges (Figure 156). The ribbon-like suture, placed with half-bites of myocardium, would be 
beneficial over traditional sutures to prevent cutting through the friable myocardium. While this would 
extend the implantation time, it could be a useful process to maintain long-term haemostasis in case of 
core deformation or a change in apical tissue properties which could otherwise cause slippage of the 
myocardial from the device. 
 
Additional reinforcement through a ribbon-like suture may also be required to ensure fixation is 
maintained, particularly through the early stages of support as the myocardial tissue becomes necrotic. 
Holmes et al. (2004) [312] reported that the necrotic phase in humans lasts approximately seven days 
after a myocardial infarct. It is during this necrotic phase that myocardial thinning and catastrophic 
infarct rupture is most common and the greatest care must be taken [312]. For this reason, further 
evaluation of the suture-less fixation device must be carried out in animal trials of at least seven days to 
progress past the necrotic phase. It has also been found through occlusion of the left anterior 
descending coronary artery in dogs that a lack of myocardial blood supply results in a decrease of wall 
thickness change from systole to diastole [313, 314]. This indicates that the heart muscle loses its ability 
to contract and may result in prolonged ischemia and irreversible tissue necrosis [315], possibly 
decreasing the potential for myocardial recovery with the suture-less fixation device. The subsequent 
fibrotic phase, however, increases collagen content in the myocardium and results in tissue thickening 
 
Figure 156 - Sketch of a ribbon-like suture 
attached around the circumference of the apex to 
constrict the myocardium about the fixation 
device. 
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[312], potentially improving the fixation of the suture-less cannulation device. The lack of research on 
compression at the myocardial apex indicates that original research is required in this field to ensure the 
suture-less fixation device does not cause catastrophic tissue necrosis. This could be investigated 
through the use of a tissue oximeter to ensure the myocardium remains perfused in long-term in-vivo 
studies. Meanwhile, a torque wrench should be used when tightening the device to ensure the 
myocardium cannot be over-compressed. 
 
The ability to easily remove the device was a key criterion during the design phase. The degree of 
myocardial recovery reported in the literature varies significantly. Birks et al. (2006) [48] reported 
sufficient myocardial recovery to undergo LVAD explantation in 11 out of 15 patients in a carefully 
selected cohort treated with LVAD and medical therapy to enhance remodeling. However, Kirklin et al. 
(2011) [153] reported from the large INTERMACS database that of 385 VAD recipients, only 1% had 
recovered sufficiently for device removal 12 months after implantation. Whatever the rate of 
myocardial recovery after VAD support, it is evident from the literature that this phenomenon does 
occur, and therefore should be accounted for in the design of VADs and the surrounding systems. The 
suture-less fixation device does account for the possibility of 
myocardial recovery through the use of a custom-designed spanner. 
Although the device uses a collapsing, internal flange to seal, the 
custom spanner can hold the external flanges of the hollow bolt and 
collapsing component together during removal. Without the custom 
spanner, the hollow bolt would simply turn and exit the collapsing 
component, which would remain within the ventricle. Evaluation in 
cadaveric animal and human hearts demonstrated the simple 
explantation of the device which took less than one minute in all 
cases. 
 
While device explantation was simple in the cadaveric animal and 
human hearts, the constant expanding and collapsing resulted in 
fatigue, and thus fracture of the struts. As expected, fractures 
occurred at the two locations which experienced the most 
deformation; the centre and base of the struts, as highlighted in 
Figure 157. While fractures usually occurred after the fourth time of 
 
Figure 157 – Fracture sites on 
the collapsing component 
including (a) the centre of the 
struts and (b) the base of the 
struts. 
b 
a 
252 
 
being expanded, the potential complications of complete strut fracture in a clinical scenario could be 
serious. In the event of all the struts failing after expansion, a large portion of the collapsing component 
would remain within the cannulated chamber and require surgical removal. This may not be significant 
in the case of bridge-to-transplant support, as the heart would be discarded in any case; however it 
might be more consequential for bridge-to-recovery support where additional surgery could further 
damage the myocardium. Meanwhile, failure of the silicone sleeve could result in severe adverse events 
as blood would enter, and most likely coagulate, around the struts. This may lead to dislodging large 
thrombii and increase the risk of postoperative stroke. Therefore, the fixation device should be 
recommended as a single use device only in its current form, while research into other materials should 
be completed to improve device durability. 
 
The haemodynamics recorded throughout evaluation of the fixation device in cadaveric animal and 
human hearts revealed the capacity of the device to operate as an inflow cannula. No leaking through 
the fixation device or around the device – myocardium interface was observed throughout testing, even 
during the pressure test completed with the calf heart. This test recorded pressures within the 
ventricular chamber of over 200 mmHg, much greater than expected in a failed ventricle [163]. In fact, 
pressures of this magnitude are not common even in healthy ventricles [37], thus demonstrating the 
capability of the device to provide a leak-proof seal following ventricular recovery and subsequent 
increased ventricular pressures.  High flow conditions were also simulated to demonstrate the capability 
of the fixation device to allow increased cardiac support, such as in the event of mild exercise. 
Conditions such as this are becoming more important as VAD therapy progresses; allowing patients to 
return home to a relatively normal lifestyle [31].  
 
Pulsatile results completed with the human cadaveric heart produced pressure oscillations between -
135 mmHg and 48 mmHg. The large negative pressure were the result of inflow cannula occlusion 
against the left ventricular free wall as the myocardium was manually pulsed against the cannula. 
Although the ventricular pressure waveforms were not representative of those seen clinically, the 
pulsatile results provided a suitable mechanism of fixation device evaluation under high and low 
pressures in a pulsating environment. No leaking occurred during the maximum pressures, while no air 
was observed being drawn into the system at the lower pressures. The requirement of the device to 
produce an excellent seal against air entrainment is also important for VAD support, as air entrainment 
due to negative pressure and its devastating effects have been reported previously [3, 182].  
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RVAD implantation with the fixation device was simple and similar to LVAD support. However, balancing 
flow rates and fluid volumes between the systemic and pulmonary circulations with rotary left and right 
ventricular support was not simple. Saeed et al. (2010) [25] highlighted the preload insensitivity of 
rotary blood pumps and how that can influence flow balancing, particularly with BiVAD support. This 
sentiment has been reiterated throughout the literature [22, 301], and was noticeable in our study. 
Imbalances in atrial pressures were a consistent problem throughout evaluation of the fixation device 
and changes in LVAD or RVAD speed were often required to prevent suction events. Atrial pressure 
differences of up to 13 mmHg were recorded throughout this study, and were compensated by 
maintaining high fluid volumes in the circuit to prevent frequent suction events. However, this is not 
always as simple / possible in a clinical situation, thus reiterating the requirement for flow control with 
rotary blood pumps as demonstrated in Chapter 5 of this thesis.  
 
6.4.4 Experimental Evaluation 
The combination of cadaveric human and animal hearts with a simplified MCL provided a suitable 
platform for preliminary suture-less fixation device evaluation. Although an in-vivo or Langendorff 
model may have provided improved pulsatile results, neither would have provided a close 
representation of a human heart. Meanwhile, the costs and preparation involved with in-vivo or 
Langendorff models was beyond the scope of this project. The use of cadaveric animal and human 
hearts did, however, present its own limitations. For instance, inducing ventricular pulses through 
manual external pulsation of the ventricles did not replicate the pressure and flow waveforms seen 
clinically.  
 
The myocardial tissue from the animal hearts was thick and strong with very little fatty tissue and 
provided an excellent material for the suture-less fixation device to seal. However, it is unlikely that 
tissue of this quality would be encountered often in a patient requiring LVAD support. Meanwhile, the 
tissue quality in the defrosted cadaveric human hearts was not ideal for suture-less fixation device 
evaluation. Over the course of testing with the first human heart, the size of the heart continued to 
increase due to the preload of the high-volume MCL. While the fixation device coped with the expanding 
tissue in this case and prevented any significant leaking, a similar phenomenon prevented any testing 
with the second cadaveric human heart. In this case, the tissue was so friable that it expanded from the 
cored size to approximately twice the original diameter, thus making it impossible to seal the tissue 
between the internal and external flanges of the fixation device.  
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The quality of the defrosted samples clearly did not assist in obtaining good results with the fixation 
device. However, evaluation in samples such as this presents a worst-case scenario and the positive 
results from the first cadaveric human heart reveal that the suture-less fixation device should be 
appropriate for inflow cannulation in most hearts. The use of water rather than blood or a viscous blood 
analogue also presented a worst-case scenario throughout evaluation. While blood viscosity has been 
reported to reduce with heparin administration from 4.5 mPa.s to a minimum of 2.5 mPa.s [316], these 
values are still higher than water at room temperature (0.8903 mPa.s) [317]. Therefore, greater degrees 
of leaking would be expected with water over blood. Meanwhile, the influence of having an O-ring 
between the external flange and myocardium is yet to be fully evaluated. Ideally, the blood viscosity and 
tissue quality limitations could be overcome through evaluation in a congestive heart failure animal 
model. While an in-vivo heart failure model was beyond the scope of this preliminary work, it should be 
completed in future research as the development of the suture-less fixation device continues. 
 
The in-vivo heart failure model may also provide a more accurate platform to assess bleeding / leakage 
from the fixation device - myocardial interface. Due to a general oozing of liquid from the heart and the 
heart - mock circulation loop connection, it was almost impossible to quantify the level of leakage in 
these preliminary tests. Instead, leaking results relied on a visual inspection. This must be identified as a 
limitation with this study as it could not be quantitatively confirmed that minimal leaking occurred with 
the suture-less fixation device. Future work will aim to quantify leakage from the device - myocardial 
interface. 
 
While an in-vivo heart failure model is required for a more accurate evaluation of the seal created by the 
device, various other avenues of future research are required which were beyond the scope of this 
initial work. For instance, the device was designed with flow dynamics in mind, yet no CFD or PIV studies 
were completed to optimize device geometry. Previous work has been completed in ventricular flow 
dynamics to improve cannula design or position [306], and should be considered prior to extensive in-
vivo evaluation. This work should also focus on removing the protruding threaded section after the 
device has collapsed within the ventricle as this could be a region for thrombus formation. Meanwhile, 
the curved interface between the silicone sleeve and the endocardium may result in flow stagnation and 
potential thrombus formation. Results from the in-vitro work may also be validated in-vivo through 
evaluation of thrombus formation around the inflow cannula. Meanwhile, use of the suture-less fixation 
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device in the pediatric population or in adults with repaired congenital heart defects should be assessed 
to determine if one size will suit all candidates or if patient-specific designs are required. 
 
An investigation is required to determine the amount of myocardial compression required to create a 
suitable seal with the fixation device. This study assumed that a suitable seal was only created when the 
myocardium had visibly deformed, but this may damage the myocardial tissue. The tissue damage 
caused by compression of the myocardium between internal and external flanges must also be 
evaluated in future work. While acute studies may reveal some necrosis, long term in-vivo studies are 
required to ensure a suitable seal remains if the apical tissue becomes fibrous. A custom torque wrench 
may be useful in this case to prevent over-tightening of the collapsing component and subsequent tissue 
damage. The degree of tissue damage may also influence the pull-out strength of the fixation device, 
which needs to be evaluated at various stages of support in-vivo.  
 
All of the future work mentioned in this chapter is vital to the progression of the device, but requires 
direct comparisons with commercially available cannulae for clinically significant comparisons. 
Therefore, it is vital that future work includes details comparisons between the novel fixation device and 
commercially available cannulae (eg. the HeartWare HVAD inflow cannula) in areas such as 
postoperative bleeding / leaking, insertion and fixation time, pullout strength and ventricular flow 
dynamics. 
 
6.5 Conclusion 
Surgical related bleeding is a major complication following VAD support and a significant contribution to 
mortality. Decades of improvements to medical therapy and development of improved cannula fixation 
techniques have resulted in the requirement for complex, reinforced, sutured attachments which 
require long periods of CPB support. Extended periods on CPB are associated with increased risk of 
postoperative bleeding, end-organ dysfunction and stroke. Therefore, the aim of this study was to 
develop and evaluate a novel, suture-less inflow cannula that can be rapidly implanted while reducing or 
eliminating the time on CPB.  
 
After several iterations, the final design was based on the concept of a hollow wall anchor with a fluid 
passage through the central bolt. The internal collapsing component was designed to form a flange once 
placed inside the ventricle, which compressed the myocardium against an external flange to seal. The 
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internal flange was designed to be chamfered to promote flow circulation around the ventricle and 
prevent wedge thrombus formation.  
 
Evaluation was completed in three cadaveric animal hearts and two cadaveric human hearts. The hearts 
were connected to a MCL and the suture-less fixation device was attached, which took less than two 
minutes for simple implantation or explantation. LVAD and RVAD support revealed that the device 
operated suitably as an inflow cannula in moderate and high flow conditions. Induced pulses through 
manual external pulsation of the heart revealed a suitable air- and water-tight seal at moderate positive 
and high negative pressures. Although not quantitatively proven, static pressure tests revealed no 
observable leaking though the device or the device-myocardium interface.  
 
Issues with a design modification and frozen cadaveric tissue properties resulted in an inconclusive 
experiment with one cadaveric human heart. Meanwhile, further research is required to optimize the 
design, improve the flow dynamics around the inflow cannula, prevent tissue necrosis and slippage 
during long-term support and evaluate the pull-out strength of the device. 
 
In conclusion, this novel device can provide rapid, suture-less LVAD or RVAD inflow cannula fixation and 
has the potential to be inserted off-bypass and improve the flow dynamics within the ventricle. 
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Chapter 7 
Conclusions and Future Research 
 
This chapter addresses the aims and summarizes the conclusions made for each chapter throughout this 
thesis. Possible avenues for future research are identified.  
 
7.1 Conclusions 
The primary objective of this thesis was to develop an inflow cannulae for BiVAD support. Conclusions 
for each chapter of this thesis are presented below.  
 
7.1.1 Literature Review 
The aim of this chapter was to review and discuss background and key developments in the field of 
heart failure, VADs and VAD cannulation. Gaps were identified in the literature, including the lack of 
detailed cardiovascular simulators for BiVAD testing; evaluation of LVAD, and more noticeably RVAD, 
inflow cannula placement; physiological control of VADs to prevent suction events; and an off-bypass, 
suture-less inflow cannula fixation device to reduce postoperative bleeding. The information gathered in 
this literature review provided a detailed background on the topics described in each chapter of this 
thesis, and was an excellent platform to base each topic of research. 
 
7.1.2 Mock Circulation Loop Development 
The aim of this chapter was to present the development of a detailed MCL for BiVAD inflow cannula 
evaluation. The systemic and pulmonary MCL with a ventricular Starling response successfully replicated 
the haemodynamics for a wide range of healthy and pathological conditions which were validated 
against data from patient records and the literature. The MCL was capable of representing almost any 
cardiac condition and can be used as an accurate, cost-effective tool for the evaluation of cardiovascular 
devices including BiVAD inflow cannulae. 
 
7.1.3 Cannula Placement 
This study aimed to evaluate LVAD and RVAD inflow cannula placement through either the atrium or 
ventricle. Inflow cannula placement was evaluated in the MCL which revealed left and right ventricular 
inflow cannulation should be preferred for long term LVAD / RVAD support to improve device efficiency 
and reduce the risk of thrombus formation in the ventricles. However, this conclusion is drawn from a 
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haemodynamic point of view rather than an in-depth assessment of localized flow dynamics. However, 
left and right atrial cannulation should be preferred for patients with mild heart failure with a view to 
ventricular recovery as the workload on the heart is reduced, coring of the myocardium is unnecessary 
and flow through the aortic valve is maintained, thus better preserving the valve.  
 
7.1.4 Compliant Inflow Cannula 
The aim of this chapter was to present the concept and preliminary development and evaluation of a 
compliant inflow cannula to prevent suction events with LVAD and / or RVAD support. Evaluation with 
the MCL revealed the ease with which suction events can occur with the use of rigid inflow cannulae and 
no control mechanism. However addition of a compliant inflow cannula prevented suction events in all 
cases by passively increasing the circuit resistance with decreased preload, thus decreasing the VAD 
flow. Therefore, a compliant inflow cannula may be used as a passive control system to prevent harmful 
suction events in rotary left, right or biventricular support.  
 
7.1.5 Cannula Fixation 
The aim of this chapter was to describe a novel suture-less inflow cannula fixation device to reduce 
postoperative bleeding, and implantation time for left, right or biventricular support. Evaluation of the 
fixation device in cadaveric animal and human hearts attached to a MCL proved the device could 
provide rapid fixation to the left and / or right ventricles and high VAD flow rates. Meanwhile, no leaking 
was observed through the device, even at high pressure. In conclusion, this novel device provided rapid, 
suture-less LVAD or RVAD inflow cannula fixation and has the potential for off-bypass insertion and 
improved flow dynamics within the ventricle. 
 
In conclusion, this thesis presented the development of a detailed cardiovascular simulator, a passive 
control system for BiVADs, a novel inflow cannula fixation device for BiVADs and the evaluation of VAD 
inflow cannula placement. Continued development of these systems will ultimately result in improved 
outcomes for heart failure patients worldwide. 
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7.2 Future Research 
Several avenues of future research have been identified throughout this thesis. These are discussed for 
each section below. 
 
7.2.1 Mock Circulation Loop Development 
While the mock circulation loop was successful in simulating the haemodynamic waveforms and 
magnitudes in a variety of healthy and pathological conditions, areas for future research include: 
 Implementation of native feedback responses such as the baroreceptor response to 
automatically control systemic vascular resistance, heart rate and contractility based on aortic 
pressure. 
 Improvement of the Starling response curve for left and right ventricles at low ventricular 
volumes. This could be achieved by switching ventricular pneumatic supply, through a control 
valve, to a parallel pneumatic circuit controlled by a low pressure regulator when ventricular 
volume is reduced. 
 Addition of a variable ventricular end diastolic pressure volume relationship would provide the 
capability of simulating diastolic ventricular failure and could be achieved with a variable 
resistance valve placed on the ventricular pneumatic supply. The valve could be set to 
completely open during systole and partially closed during diastole, thus simulating a degree of 
diastolic failure. 
 Implementation of left and right ventricular interaction. 
 Reducing the distance, and thus inertia, between the ventricles and arterial compliance 
chambers would improve the arterial pressure waveforms and reduce the lag between 
ventricular and arterial pressure.  
 Addition of cerebral and coronary circuits alongside the current systemic circulation would allow 
further evaluation of other cardiovascular devices, such as intra-aortic balloon pumps.  
 Alteration of the current Windkessel chambers to be variable while the MCL is running would 
improve testing efficiency and repeatability.  
 Replacement of the current atria with smaller chambers with non-linear compliance. This would 
prevent the large volumes seen in the current MCL and could be achieved by replacing these 
chambers with smaller, silicone vessels. 
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7.2.2 Cannula Placement 
This study successfully characterized atrial and ventricular cannulation for LVAD and RVAD support in 
mild and severe heart failure conditions. Avenues for future research include: 
 In-vitro evaluation with native auto-regulatory responses (eg. baroreceptor) included in the MCL 
may provide a more clinically significant characterization, particularly in the speed ramp tests. 
 In-vivo evaluation in a heart failure model would provide more significant data and validate in-
vitro results. However, this may rely on conductance catheter use in the left, and more 
problematic right, ventricles.  
 
7.2.3 Compliant Inflow Cannula 
This chapter presented a novel compliant inflow cannula which prevented suction events through 
passive restriction when preload dropped. Avenues for future research include: 
 Optimization of the cannula compliance and unstressed dimensions to prevent suction events 
without unnecessarily reducing flow rate. This would be completed initially in-vitro through MCL 
evaluation and validated in-vivo. 
 Evaluation of compliant inflow cannula biomaterials to match the optimized compliance and 
prevent undesirable tissue growth which may promote thrombus formation. This would include 
durability testing to ensure the compliant section will not fail during VAD support. 
 Evaluation of haemolysis through the compliant section during restriction or 'fluttering' to 
ensure the device won't cause significant blood damage. This would be achieved with a smaller 
MCL containing fresh whole human blood. 
 Evaluation of implantability and anatomic fitting issues. This would include finding if an external 
stent is required to prevent kinking of the compliant section during postural changes. An 
internal stent may also be required to ensure the compliant section always allows a minimum 
orifice size to prevent complete cessation of VAD support. 
 Evaluation of the compliant inflow cannula in tandem with an active control system. This is 
required to provide increased VAD support after the compliant section is fully expanded, and 
would be completed initially through in-vitro and finally through in-vivo investigations. 
 Validation of the compliant inflow cannula in an in-vivo heart failure model to ensure it can 
prevent suction events with various physiological changes (eg. change in body position or 
vascular resistance). 
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7.2.4 Cannula Fixation 
This study was a preliminary, proof-of-concept evaluation of a suture-less fixation device. Avenues for 
future work include: 
 Investigation into the apical thickness of VAD patients. This could be completed with MRI data 
and collection of the removed myocardial core sections following VAD implantation. 
 Optimization of the fixation device design to suit the required myocardial thickness. This may 
require several designs which can be matched on a patient-by-patient basis.  
 Optimization of the collapsed internal flange shape to provide the ideal circumferential seal. 
This will also involve investigating the manufacturing techniques to ensure the struts fold at the 
correct location. 
 Investigation into biomaterials selection for the hollow bolt, collapsing component and silicone 
sleeve. This will also require durability testing of all components to ensure no failures occur 
during implantation or VAD support; however the system will most likely be recommended as a 
single-use device only. The weight of the fixation device and durability of the struts will be key 
features in the biomaterials investigation. 
 Optimization of the internal shape for improved flow dynamics with the use of computational 
fluid dynamics and particle image velocimetry. This stage would also involve removing the 
extruded threaded section to prevent small clots from forming at the tip of the inflow cannula. 
 Investigation into tissue necrosis in the compressed myocardium. This would be completed with 
a long term in-vivo trial to ensure the myocardium remains firm to prevent device failure. 
 Implementation of a torque wrench to be used when implanting the fixation device. This stage 
would involve investigating the torque required until the fixation device is properly attached, 
without over-compressing the apical tissue. 
 Development of a smaller, custom coring tool to suit the outer diameter of the fixation device 
and ultimately provide an improved seal. 
 Evaluate the requirement / option for a 'ribbon suture' to provide improved fixation and 
reduced postoperative bleeding.  
 Extensively evaluate the fixation device in a larger human fitting study and a large in-vivo heart 
failure model. 
 In-vivo investigation of the suction prevention capabilities of the device. 
 Develop a method to quantitatively assess postoperative bleeding with the suture-less fixation 
device, and compare it to clinically available cannulae. 
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 Comparative evaluation of the suture-less fixation device with commercially available cannulae 
in all of the above mentioned points. 
 
 
 
 
 
 
 
  
264 
 
  
265 
 
References 
1. Vitali, E., T. Colombo, G. Bruschi, et al., Different Clinical Scenarios for Circulatory Mechanical 
Support in Acute and Chronic Heart Failure. Am J Cardiol, 2005. 96: p. 34-41. 
2. Terracciano, C.M., L.W. Miller, and M.H. Yacoub, Contemporary use of ventricular assist devices. 
Annu. Rev. Med., 2010. 61: p. 255-70. 
3. Thunberg, C.A., B.D. Gaitan, F.A. Arabia, et al., Ventricular assist devices today and tomorrow. 
Journal of Cardiothoracic and Vascular Anesthesia, 2010. 24(4): p. 656-80. 
4. Thuaudet, S., The Medos ventricular assist device system. Perfusion, 2000. 15: p. 337-343. 
5. Komoda, T., Y. Weng, and R. Hetzer, Technique for insertion of the inflow cannula of the INCOR 
left ventricular assist device. Ann Thorac Surg, 2008. 85: p. 1466-1467. 
6. Krause, T.J., ABIOMED BVS 5000 system: repair of venous cannulation site for excessive bleeding. 
Ann Thorac Surg, 1998. 66: p. 1817. 
7. Krishnamani, R., D. DeNofrio, and M.A. Konstam, Emerging ventricular assist devices for long-
term cardiac support. Nat. Rev. Cardiol., 2010. 7: p. 71-76. 
8. McBride, L.R., K.S. Naunheim, A.C. Fiore, et al., Risk analysis in patients bridged to 
transplantation. Ann Thorac Surg, 2001. 71: p. 1839-44. 
9. Cooper, B.T., G.D. Long, L.C. Knight, et al., A novel approach to the correlation of fluid dynamics 
and thromboembolism associated with cardiovascular prosthetic devices. IFMBE Proceedings, 
2009. 25: p. 1396-1399. 
10. Schmid, C., M. Jurmann, D. Birnbaum, et al., Influence of inflow cannula length in axial-flow 
pumps on neurologic adverse event rate: Results from a multi-center analysis. J Heart Lung 
Transplant, 2008. 27: p. 253-60. 
11. Kalangos, A., N. Murith, A. Baldovinos, et al., Conversion from routine CPB to centrifugal 
mechanical assist by transaortic inflow cannulation of the left ventricle. Ann Thorac Surg, 1998. 
65: p. 1168-70. 
12. Sethia, B., W. Martin, and D. Wheatley, The effects of left atrial and left ventricular cannulation 
on left ventricular function. The International Journal of Artificial Organs, 1985. 8(6): p. 331-334. 
13. Vandenberghe, S., T. Nishida, P. Segers, et al., The impact of pump speed and inlet cannulation 
site on left ventricular unloading with a rotary blood pump. Artificial organs, 2004. 28(7): p. 660-
667. 
14. Korakianitis, T. and Y. Shi, Numerical comparison of hemodynamics with atrium to aorta and 
ventricular apex to aorta VAD support. ASAIO, 2007: p. 537-548. 
15. Tevaearai, H., X. Mueller, D. Jegger, et al., Atrial, ventricular, or both cannulation sites to 
optimize left ventricular assistance. ASAIO, 2001: p. 261-265. 
16. Donovan, F., Design of a hydraulic analog of the circulatory system for evaluating artificial 
hearts. Artificial organs, 1975. 3(4): p. 439-449. 
17. Pantalos, G., S. Koenig, K. Gillars, et al., Characterization of an adult mock circulation for testing 
cardiac support devices. ASAIO, 2004. 50(1): p. 37-46. 
18. Timms, D., M. Hayne, K. McNeil, et al., A complete mock circulation loop for the evaluation of 
left, right, and biventricular assist devices. Artificial organs, 2005. 29(7): p. 564-572. 
19. Vollkron, M., P. Voitl, J. Ta, et al., Suction events during left ventricular support and ventricular 
arrhythmias. J Heart Lung Transplant, 2007. 26: p. 819-25. 
20. Kirkpatrick, J.N., S.E. Wiegers, J.E. Rame, et al., Use of echocardiography to optimize left 
ventricular assist devices. US Cardiology, 2010. 7(2): p. 11-15. 
21. Yu, Y.C. and J. Porter. Mathematical modeling of ventricular suction induced by a rotary 
ventricular assist device. in Proceedings of the 2006 American Control Conference. 2006. 
Minneapolis, Minnesota, USA. 
266 
 
22. Reesink, K., A. Dekker, T. Van der Nagel, et al., Suction due to left ventricular assist: implications 
for device control and management. Artificial Organs, 2007. 31(7): p. 542-9. 
23. John, R., S. Lee, and P. Eckman, Right ventricular failure - A continuing problem in patients with 
left ventricular assist device support. J of Cardiovasc. Trans. Res., 2010. In Press. 
24. Moscato, F., M. Arabia, F.M. Colacino, et al., Left ventricle afterload impedance control by an 
axial flow ventricular assist device: A potential tool for ventricular recovery. Artificial Organs, 
2010. 34(9): p. 736-744. 
25. Saeed, D., Y. Ootaki, C. Ootaki, et al., Acute in vivo evaluation of an implantable continuous flow 
biventricular assist system. ASAIO Journal, 2008. 54: p. 20-24. 
26. Nose, Y. and K. Furukawa, Current status of the Gyro centrifugal blood pump - Development of 
the permanently implantable centrifugal blood pump as a biventricular assist device (NEDO 
Project). Artificial Organs, 2004. 28(10): p. 953-958. 
27. Fritz, B., J. Cysyk, R. Newswanger, et al., Development of an inlet pressure sensor for control in a 
left ventricular assist device. ASAIO Journal, 2010. 56: p. 180-185. 
28. Yi, W. Physiological control of a rotary left ventricular assist device. in 26th Chinese Control 
Conference. 2007. Zhangjiajie, Hunan, China. 
29. Goldstein, D.J. and R.B. Beauford, Left ventricular assist devices and bleeding: adding insult to 
injury. Ann Thorac Surg, 2003. 75: p. 42-47. 
30. Hsu, R.B., S.H. Chu, and S.S. Wang, Simple method of hemostasis in implantation and 
explantation of HeartMate left ventricular assist device. European Journal of Cardio-thoracic 
Surgery, 2000. 17: p. 336-337. 
31. Slaughter, M.S., F.D. Pagani, J.G. Rogers, et al., Clinical management of continuous-flow left 
ventricular assist devices in advanced heart failure. J Heart Lung Transplant, 2010. 29: p. S1-S39. 
32. Wyatt, D.A., I.L. Kron, and C.G. Tribble, Use of a dacron cuff to decrease bleeding from atrial 
cannulas of ventricular assist devices. Ann Thorac Surg, 1993. 55: p. 1264-5. 
33. Uriel, N., S.W. Pak, U.P. Jorde, et al., Acquired von Willebrand syndrome after continuous-flow 
mechanical device support contributes to a high prevalence of bleeding during long-term support 
and at the time of transplantation. Journal of the American College of Cardiology, 2010. 56: p. In 
Press. 
34. Geisen, U., C. Heilmann, F. Beyersdorf, et al., Non-surgical bleeding in patients with ventricular 
assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg, 
2008. 33: p. 679-684. 
35. Frazier, O.H., Implantation of the Jarvik 2000 left ventricular assist device without the use of 
cardiopulmonary bypass. Ann Thorac Surg, 2003. 75: p. 1028-30. 
36. Healthwise. Blood flow through the heart.  2007; Available from: 
http://www.revolutionhealth.com/conditions/heart/congenital-heart-disease/understand-
overview/normal-blood-flow. 
37. Klabunde, R.E., Cardiovascular Physiology Concepts. 2004, Baltimore: Lippincott Williams & 
Wilkins. 
38. Gill, R.M., B.D. Jones, A.K. Corbly, et al., Exhaustion of the Frank-Starling mechanism in conscious 
dogs with heart failure induced by chronic coronary microembolization. Life Sciences, 2006. 79: 
p. 536-544. 
39. Hakeem.  2007; Available from: http://www.hakeem-sy.com/main/node/14011. 
40. Teach PE. The human circulatory system.  2011; Available from: 
http://www.teachpe.com/anatomy/circulatory_system.php. 
41. Heidenreich, P.A., J.G. Trogdon, O.A. Khavjou, et al., Forecasting the Future of Cardiovascular 
Disease in the United States: A Policy Statement From the American Heart Association. 
Circulation, 2011. 123(8): p. 933-944. 
267 
 
42. Farrar, D.J., J.D. Hill, D.G. Pennington, et al., Preoperative and postoperative comparison of 
patients with univentricular and biventricular support with the Thoratec ventricular assist device 
as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg, 1997. 113: p. 202-209. 
43. Min, B.C. and K. Sun, The total artificial heart and implantable biventricular assist device. J Artif 
Organs, 2002. 5: p. 147-148. 
44. Felker, G. and R. JG., Same bridge, new destinations rethinking paradigms for mechanical cardiac 
support in heart failure. J Am Coll Cardiol. , 2006. 47(5): p. 930-2. 
45. Copeland, J., R. Smith, F. Arabia, et al., Cardiac replacement with a total artificial heart as a 
bridge to transplantation. N Engl J Med, 2004. 351(9): p. 859-67. 
46. Ambardekar, A.V. and P.M. Buttrick, Reverse remodeling with left ventricular assist devices: A 
review of clinical, cellular, and molecular effects. Circulation, 2011. 4(2): p. 224-233. 
47. Dandel, M., Y. Weng, H. Siniawski, et al., Long-term results in patients with idiopathic dilated 
cardiomyopathy after weaning from left ventricular assist devices. Circulation, 2005. 112: p. I-37-
I-45. 
48. Birks, E.J., P.D. Tansley, J. Hardy, et al., Left Ventricular Assist Device and Drug Therapy for the 
Reversal of Heart Failure. The New England Journal of Medicine, 2006. 355: p. 1873-1884. 
49. Maybaum, S., D. Mancini, S. Xydas, et al., Cardiac improvement during mechanical circulatory 
support - A prospective multicentre study of the LVAD working group. Circulation, 2007. 115: p. 
2497-2505. 
50. Sorensen, E., Ventricular-assist devices and total artificial hearts. Biomedical Instrumentation & 
Technology, 2007. 41(5): p. 385-389. 
51. Stone, M.E., Current status of mechanical circulatory assistance. Semin Cardiothorac Vasc 
Anesth, 2007. 11: p. 185-204. 
52. Klovaite, J., F. Gustafsson, S.A. Mortensen, et al., Severely impaired von Willebrand factor-
dependent platelet aggregation in patients with a continuous-flow left ventricular assist device 
(HeartMate II). Journal of the American College of Cardiology, 2009. 53(23): p. 2162-7. 
53. Crow, S., R. John, A. Boyle, et al., Gastrointestinal bleeding rates in recipients of nonpulsatile and 
pulsatile left ventricular assist devices. The Journal of Thoracic and Cardiovascular Surgery, 2009. 
137(1): p. 208-215. 
54. Potapov, E.V., A. Loforte, Y. Weng, et al., Experience with over 1000 Implanted Ventricular Assist 
Devices. J Card Surg, 2008. 23: p. 185-194. 
55. Kavarana, M.N., M.S. Pessin-Minsley, J. Urtecho, et al., Right ventricular dysfunction and organ 
failure in left ventricular assist device recipients: A continuing problem. Ann Thorac Surg, 2002. 
73: p. 745-750. 
56. Hetzer, R., T. Krabatsch, A. Stepanenko, et al., Long-term biventricular support with the 
heartware implantable continuous flow pump. The Journal of Heart and Lung Transplantation, 
2010. 29(7): p. 822-824. 
57. Drakos, S.G., L. Janicki, B.D. Horne, et al., Risk Factors Predictive of Right Ventricular Failure After 
Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2010. 105(7): p. 
1030-5. 
58. Radovancevic, B., I.D. Gregoric, D.A. Tamez, et al., Biventricular support with the Jarvik 2000 
axial flow pump: A feasibility study. ASAIO Journal, 2003. 49: p. 604-607. 
59. Santambrogio, L., T. Bianchi, M. Fuardo, et al., Right ventricular failure after left ventricular 
assist device insertion: preoperative risk factors. Interactive Cardio Vascular and Thoracic 
Surgery, 2006. 5: p. 379-382. 
60. Radovancevic, B., I.D. Gregoric, D. Tamez, et al., Biventricular support with the Jarvik 2000 axial 
flow pump: A feasibility study. Asaio Journal, 2003. 49(5): p. 604-607. 
268 
 
61. Lee, S., F. Kamdar, R. Madlon-Kay, et al., Effects of the HeartMate II continuous-flow left 
ventricular assist device on right ventricular function. J Heart Lung Transplant, 2010. 29: p. 209-
15. 
62. Drakos, S.G., L. Janicki, B.D. Horne, et al., Risk Factors Predictive of Right Ventricular Failure After 
Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2010. In press. 
63. Matthews, J.C., T.M. Koelling, F.D. Pagani, et al., The Right Ventricular Failure Risk Score: A Pre-
Operative Tool for Assessing the Risk of Right Ventricular Failure in Left Ventricular Assist Device 
Candidates. Journal of the American College of Cardiology, 2008. 51(22): p. 2163-2172. 
64. Kormos, R.L., J.J. Teuteberg, F.D. Pagani, et al., Right ventricular failure in patients with the 
HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on 
outcomes. J Thorac Cardiovasc Surg, 2010. 139: p. 1316-1324. 
65. Fitzpatrick, J.R., J.R. Frederick, W. Hiesinger, et al., Early planned institution of biventricular 
mechanical circulatory support results in improved outcomes compared with delayed conversion 
of a left ventricular assist device to a biventricular assist device. The Journal Of Thoracic and 
Cardiovascular Surgery, 2009. 137(4): p. 971-977. 
66. Slaughter, M.S., J.G. Rogers, C.A. Milano, et al., Advanced heart failure treated with continuous-
flow left ventricular assist device. New England Journal of Medicine, 2009. 361(23): p. 2241-51. 
67. Amick, R.Z., Assessment of exercise capacity in an individual with LVAD explantation without 
heart transplantation, in Department of Kinesiology and Sport Studies. 2007, Wichita State 
University. p. 74. 
68. Craig, M.L., Management of right ventricular failure in the era of ventricular assist device 
therapy. Curr Heart Fail Rep, 2011. 8: p. 65-71. 
69. Kindo, M., R. Branislav, I.D. Gregoric, et al., Biventricular support with the Jarvik 2000 ventricular 
assist device in a calf model of pulmonary hypertension. ASAIO, 2004. 50(5): p. 444-450. 
70. Cleveland, J.C., D.C. Naftel, T.B. Reece, et al., Survival after biventricular assist device 
implantation: An analysis of the Interagency Registry for Mechanically Assisted Circulatory 
Support database. The Journal of Heart and Lung Transplantation, 2011. 30(8): p. 862-9. 
71. Guyton, A.C., Textbook of Medical Physiology. 11 ed. 2005: W.B. Saunders Company. 
72. Starling, E.H. and M.B. Visscher, The Regulation of the Energy Output of the Heart. J Physiol, 
1926. 62: p. 243-261. 
73. Endo, G., K. Araki, M. Oshikawa, et al., Control Strategy for Biventricular Assistance with Mixed-
Flow Pumps. Artificial Organs, 2000. 24(8): p. 594-599. 
74. Nonaka, K., J. Linneweber, S. Ichikawa, et al., Assessing the Calf Pulmonary Function During a 
Long-Term Biventricular Assist Device Study with a Centrifugal Blood Pump. Artificial Organs, 
2002. 26(11): p. 924-926. 
75. Nonaka, K., J. Linneweber, S. Ichikawa, et al., Development of the Baylor Gyro Permanently 
Implantable Centrifugal Blood Pump as a Biventricular Assist Device. Artificial Organs, 2001. 
25(9): p. 675-682. 
76. Timms, D., K. McNeil, J. Dunning, et al. Left/Right Flow Balancing with a Rotary BiVentricular 
Assist Device. in 14th Congress of the International Society for Rotary Blood Pumps. 2006. 
Leuven, Belgium: Blackwell Publishing, Inc. 
77. Saito, S., T. Sakagushi, S. Miyagawa, et al., Biventricular support using implantable continuous-
flow ventricular assist devices. J Heart Lung Transplant, 2011. 30: p. 475-8. 
78. Giridharan, G.A. and M. Skliar, Physiological Control of Blood Pumps Using Intrinsic Pump 
Parameters: A Computer Simulation Study. Artificial Organs, 2006. 30(4): p. 301-307. 
79. Gaddum, N.R., D.L. Timms, and M.J. Pearcy, Optimizing the response from a passively controlled 
biventricular assist device. Artificial Organs, 2010. 34(5): p. 393-401. 
269 
 
80. Boilson, B.A., E. Raichlin, S.J. Park, et al., Device therapy and cardiac transplantation for end-
stage heart failure. Curr Probl Cardiol, 2010. 35(1): p. 8-64. 
81. Tuzun, E., K. Roberts, W.E. Cohn, et al., In vivo evaluation of the HeartWare centrifugal 
ventricular assist device. Tex Heart Inst J, 2007. 34: p. 406-11. 
82. Ootaki, Y., D. Saeed, C. Ootaki, et al., Development of the DexAide right ventricular assist device 
inflow cannula. ASAIO Journal, 2008. 54: p. 31-36. 
83. Hetzer, R., V. Alexi-Meskishvili, Y. Weng, et al., Mechanical cardiac support in the young with the 
Berlin Heart EXCOR pulsatile ventricular assist device: 15 years' experience. Semin Thorac 
Cardiovasc Surg Pediatr Card Surg Annu., 2006: p. 99-108. 
84. DiCorte, C.J. and C.H. Van Meter, Abiomed RVAD and LVAD implantation. Operative Techniques 
in Thoracic and Cardiovascular Surgery, 1999. 4(4): p. 301-317. 
85. Medos Medizintechnik AG, Medos VAD III System - Mobile ventricular assist device system for 
adults, paediatrics and infants. 
86. Hill, J.D., Implantation of the Thoratec ventricular assist device. Operative techniques in Thoracic 
and cardiovascular surgery, 2002. 7(3): p. 158-170. 
87. Griffith, K., E. Jenkins, and F.D. Pagani, First American experience with the Terumo DuraHeart left 
ventricular assist system. Perfusion, 2009. 24: p. 83-89. 
88. Noon, G.P., D.L. Morley, S. Irwin, et al., Clinical experience with the MicroMed DeBakey 
ventricular assist device. Ann Thorac Surg, 2001. 71: p. 133-138. 
89. Thoratec Corporation, HeartMate II left ventricular assist system (LVAS): Instructions for use. 
2008. 
90. Yamada, Y., K. Yamazaki, S. Saito, et al. New tissue engineering inflow cannula improves 
biocompatibility. in 17th Congress of the International Society for Rotary Blood Pumps. 2009. 
Singapore: Artificial Organs. 
91. Mussivand, T., R. Hetzer, E. Vitali, et al., Clinical results with an ePTFE inflow conduit for 
mechanical circulatory support. J Heart Lung Transplant, 2004. 23: p. 1366-70. 
92. Jaski, B.E., D.A. Miller, P.M. Hoagland, et al., Assessment of recurrent heart failure associated 
with left ventricular assit device dysfunction. J Heart Lung Transplant, 2005. 24: p. 2060-7. 
93. Tsukiya, T., E. Tatsumi, T. Mizuno, et al. The effect of inflow cannula tip configuration on the flow 
field in the left ventricle. in 17th Congress of the International Society for Rotary Blood Pumps. 
2009. Singapore: Artificial Organs. 
94. Carr, C.M., F. Jacob, S.J. Park, et al., CT of left ventricular assist devices. RadioGraphics, 2010. 30: 
p. 429-444. 
95. Bergmann, L., E. Kottenberg-Assenmacher, and J. Peters, Management of a patient with right 
ventricular drainage cannula obstruction after biventricular assist device implantation. Journal of 
Cardiothoracic and Vascular Anesthesia, 2007. 21(2): p. 262-264. 
96. Goerbig-Campbell, J., R.M. Weiss, A. Guha, et al., Dynamic occlusion of the inflow cannula by 
multimodality cardiac imaging heralds serious adverse events in patients with a continuous flow 
left ventricular assist device. The Journal of Heart and Lung Transplantation, 2010. 29(2S): p. 
S10. 
97. Park, J.Y., C.Y. Park, and B.C. Min, A numerical study on the effect of side hole number and 
arrangement in venous cannulae. Journal of Biomechanics, 2007. 40: p. 1153-1157. 
98. Sumikura, H., K. Toda, Y. Takewa, et al., Development and hydrodynamic evaluation of a novel 
inflow cannula in a mechanical circulatory support system for bridge to decision. Artificial 
Organs, 2011. 35(8): p. 756-764. 
99. Bachman, T.N., J.K. Bhama, J. Verkaik, et al., In-vitro evaluation of ventricular cannulation for 
rotodynamic cardiac assist devices. Cardiovascular Eng Technol, 2011. 2(3): p. 203-211. 
270 
 
100. Antaki, J.F., T.J. Dennis, H. Konishi, et al., An improved left ventricular cannula for chronic 
dynamic blood pump support. Artificial Organs, 1995. 19(7): p. 671-675. 
101. Nonaka, K., J. Linneweber, S. Ichikawa, et al., Development of the Baylor Gyro permanently 
implantable centrifugal blood pump as a biventricular assist device. Artificial Organs, 2001. 
25(9): p. 675-682. 
102. Reichenbach, S., Advances in LVAD design: Improving reliability and minimizing risk of stroke and 
thrombosis, in Paradigm: Advances in heart failure technologies. 2011, Thoratec Corporation. 
103. Lick, S., J. Zwischenberger, D. Wang, et al., Improved right heart function with a compliant inflow 
artificial lung in series with the pulmonary circulation. Ann Thorac Surg, 2001. 72: p. 899-904. 
104. Jegger, D., P.G. Chassot, M.A. Bernath, et al., A novel technique using echocardiography to 
evaluate venous cannula performance perioperatively in CPB cardiac surgery. European journal 
of cardio-thoracic surgery, 2006. 29(2006): p. 525-529. 
105. Mueller, X.M., H.T. Tevaearai, D. Jegger, et al., A new expandable venous cannula for minimal 
access heart surgery. Ann Thorac Surg, 2002. 74: p. S1330-3. 
106. Mueller, X.M., I. Mallabiabrena, G. Mucciolo, et al., Optimized venous return with a self-
expanding cannula: from computational fluid dynamics to clinical application. Interact 
CardioVasc Thorac Surg, 2002. 1: p. 23-27. 
107. Von Segesser, L.K., E. Ferrari, D. Delay, et al., Routine use of self-expanding venous cannulas for 
cardiopulmonary bypass: benefits and pitfalls in 100 consecutive cases. European journal of 
cardio-thoracic surgery, 2008. 34: p. 635-640. 
108. Von Segesser, L.K., M. Kalejs, E. Ferrari, et al., Superior flow for bridge to life with self-expanding 
venous cannulas. European journal of cardio-thoracic surgery, 2009. 36: p. 665-669. 
109. Salamonsen, B., Personal communication of the limitations of the Smart cannula, S.D. Gregory, 
Editor. 2011: Brisbane. 
110. Shiose, A., H.I. Kim, T. Takeseya, et al., Performance of extracorporeally adjustable ventricular 
assist device inflow cannula. Ann Thorac Surg, 2010. 90: p. 1682-7. 
111. Grigioni, M., C. Daniele, U. U. Morbiducci, et al., Computational model of the fluid dynamics of a 
cannula inserted in a vessel: incidence of the presence of side holes in blood flow. Journal of 
Biomechanics, 2002. 35: p. 1599-1612. 
112. Mehta, S.M. and W.E. Pae, Erosion of inlet cannula of left ventricular assist device manifested as 
innocuous bleeding in stable patient: Lessons learned in prevention of catastrophic 
consequences. J Thorac Cardiovasc Surg, 1996. 112: p. 544-545. 
113. Benaroia, M., A.J. Baker, C.D. Mazer, et al., Effect of aortic cannula characteristics and blood 
velocity on transcranial Doppler-detected microemboli during cardiopulmonary bypass. Journal 
of Cardiothoracic and Vascular Anesthesia, 1998. 12(3): p. 266-269. 
114. Joubert-Huebner, E., A. Gerdes, P. Klapproth, et al., An in-vitro evaluation of aortic arch vessel 
perfusion characteristics comparing single versus multiple stream aortic cannulae. European 
journal of cardio-thoracic surgery, 1999. 15: p. 359-364. 
115. Platts, D., Echocardiographic Evaluation of Ventricular Assist Devices, in Ventricular Assist 
Devices, J.S. (Ed.), Editor. 2011, InTech. 
116. Meyns, B., T. Siess, Y. Nishimura, et al., Miniaturized implantable rotary blood pump in atrial–
aortic position supports and unloads the failing heart. Cardiovascular Surgery, 1998. 6(3): p. 288-
295. 
117. Saito, A., M. Shiono, Y. Orime, et al., Effects of Left Ventricular Assist Device on Cardiac Function: 
Experimental Study of Relationship between Pump Flow and Left Ventricular Diastolic Function. 
Artificial Organs, 2001. 25(9): p. 728-732. 
118. Akhter, S.A., J. Raman, and V. Jeevanandam, Technique for left ventricular apical cannulation for 
short-term mechanical circulatory support. Ann Thorac Surg, 2010. 89: p. 994-995. 
271 
 
119. Jett, G.K., Left Ventricular Apical Cannulation for Circulatory Support. Journal of Cardiac Surgery, 
1998. 13: p. 51-55. 
120. Denslow, S., Relationship between PVA and myocardial oxygen consumption can be derived from 
thermodynamics. Am. J. Physiol. HEart Circ Physiol, 1996. 270: p. H730-H740. 
121. Suga, H., Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J 
Physiol, 1979. 236: p. H498-505. 
122. Pullicino, P.M., J.L. Halperin, and J.L.P. Thompson, Stroke in patients with heart failure and 
reduced left ventricular ejection fraction. American Academy of Neurology, 2000. 54(2): p. 288. 
123. Di Pasquale, G., P. Passarelli, M. Ribani, et al., Prophylaxis of thromboembolic events in 
congestive heart failure. Archives of Gerontology and Geriatrics, 1996. 23: p. 329-336. 
124. Pullicino, P.a.J.T., Antithrombotics in heart failure: Background to the WARCEF study. . Seminars 
in Cerebrovascular Diseases and Stroke, 2003. 3(1): p. 4-7. 
125. Moazami, N. and N.G. Smedira, Temporary Mechanical Support. Journal of Cardiac Surgery, 
2001. 16: p. 193-202. 
126. Pullicino, P., J. Thompson, B. Barton, et al., Warfarin versus aspirin in patients with reduced 
cardiac ejection fraction (WARCEF): Rationale, objectives, and design. Journal of Cardiac Failure, 
2006. 12(1): p. 39-46. 
127. Handke, M., A. Harloff, A. Hetzel, et al., Predictors of left atrial spontaneous echocardiographic 
contrast or thrombus formation in stroke patients with sinus rhythm and reduced left ventricular 
function. Am J Cardiol, 2005. 96: p. 1342-1344. 
128. Vandenberghe, S., P. Segers, B. Meyns, et al., Unloading Effect of a Rotary Blood Pump Assessed 
by Mathematical Modeling. Artificial Organs, 2003. 27(12): p. 1094-1101. 
129. Morley, D., K. Litwak, P. Ferber, et al., Hemodynamic effects of partial ventricular support in 
chronic heart failure: Results of simulation validated with in vivo data. The Journal of Thoracic 
and Cardiovascular Surgery, 2007. 133(1): p. 21-28. 
130. Korakianitis, T. and S. Yubing, Numerical comparison of hemodynamics with atrium to aorta and 
ventricular apex to aorta VAD support. ASAIO, 2007. 53: p. 537-548. 
131. Kono, S., K. Nishimura, T. Nishina, et al., Comparison of left atrial versus left ventricular 
cannulation during left ventricular assist with centrifugal pump hemodynamics and myocardial 
oxygen consumption. Jpn J Artif Organs, 1999. 28(2): p. 416-420. 
132. Schlensak, C., D. Schibilsky, M. Siepe, et al., Biventricular cannulation is superior regarding 
hemodynamics and organ recovery in patients on biventricular assist device support. J Heart 
Lung Transplant, 2011. 30(9): p. 1011-7. 
133. Timms, D., S. Gregory, P.L. Hsu, et al., Atrial versus ventricular cannulation for a rotary 
ventricular assist device. Artificial Organs, 2010. 34(9): p. 714-720. 
134. Arabia, F.A., V. Paramesh, B. Toporoff, et al., Biventricular cannulation for the Thoratec 
ventricular assist device. Ann Thorac Surg, 1998. 66: p. 2119-20. 
135. Demirozu, Z.T., R. Radovancevic, W.E. Cohn, et al., HeartMate II left ventricular assist device 
inflow cannula implantation: Apical versus diaphragmatic approach. The Journal of Heart and 
Lung Transplantation, 2011. 30(4S): p. S44. 
136. Richenbacher, W.E. and J.D. Marks, Cannula selection and cannulation tequniques for 
nonpulsatile mechanical ventricular assistance. Artificial Orgams, 1995. 19(6): p. 519-524. 
137. Nicoara, A., G.B. Mackensen, M.V. Podgoreanu, et al., Malpositioned left ventricular assist device 
cannula: Diagnosis and management with transesophageal echocardiography guidance. 
International Anesthesia Research Society, 2007. 105(6): p. 1574-1576. 
138. Votapka, T., M. Swartz, F. Dressler, et al., Left ventricular cannula obstruction in a patient with 
previous ventricular aneurysmectomy. Ann Thorac Surg, 1994. 58: p. 1182-1184. 
272 
 
139. Bolen, M.A., Z.B. Popovic, G. Gonzalez-Stawinski, et al., Left ventricular assist device malposition 
interrogated by 4-D cine computed tomography. Jounral of Cardiovascular Computed 
Tomography, 2011. In Press. 
140. Potapov, E.V., A. Stepanenko, T. Krabatsch, et al., Managing long-term complications of left 
ventricular assist device therapy. Curr Opin Cardiol, 2011. 26: p. 237-244. 
141. Milano, C.A., A.A. Simeone, L.J. Blue, et al., Presentation and management of left ventricular 
assist device inflow cannula malposition. J Heart Lung Transplant, 2011. IN PRESS. 
142. Catena, E., F. Milazzo, E. Montorsi, et al., Left ventricular support by axial flow pump: The 
echocardiographic approach to device malfunction. J Am Soc Echocardiogr, 2005. 18: p. 1422e7-
e13. 
143. Kurihara, C., M. Ono, T. Nishimura, et al., Use of DuraHeart support for more than 1 year as the 
first successful bridge to heart transplantation in Japan. The Japanese Society for Artificial 
Organs, 2010. 14(1): p. 67-69. 
144. McGee, E.C., P.M. McCarthy, and N. Moazami, Temporary mechanical circulatory support, in 
Cardiac Surgery in the Adult, e. Cohn Lh, Editor. 2008, McGraw-Hill: New York. p. 507-534. 
145. Litwak, K.N., S.C. Koenig, H. Tsukui, et al., Effects of left ventricular assist device support and 
outflow graft location upon aortic blood flow. ASAIO, 2004. 50: p. 432-437. 
146. Tuzun, E., C. Narin, I.D. Gregoric, et al., Ventricular assist device outflow-graft site: Effect on 
myocardial blood flow. Journal of Surgical Research, 2010. In Press. 
147. Goldstein, D. and S. Neragi-Miandoab, Mechanical bridge to decision: What are the options for 
the management of acute refractory cardiogenic shock. Curr Heart Fail Rep, 2011. 8: p. 51-58. 
148. Pagani, F.D., Continuous-Flow Rotary Left Ventricular Assist Devices with “3rd Generation” 
Design Seminars in Thoracic and Cardiovascular Surgery, 2008. 20(3): p. 255-263. 
149. Matthews, J.C., F.D. Pagani, J.W. Haft, et al., Model of end-stage liver disease score predicts left 
ventricular assist device operative transfusion requirements, morbidity, and mortality. 
Circulation, 2010. 121: p. 214-220. 
150. Dickerson, H.A. and A.C. Chang, Perioperative management of ventricular assist devices in 
children and adolescents. Semin Thorac Cardiovasc Surg Pediatr Card Surg Ann, 2006. 9: p. 128-
139. 
151. Goldstein, D.J., M.C. Oz, and E.A. Rose, Implantable left ventricular assist devices. The New 
England Journal of Medicine, 1998. 339(21): p. 1522-1533. 
152. Haddad, M., P.J. Hendry, R.G. Masters, et al., Ventricular assist devices as a bridge to cardiac 
transplantation: the Ottawa experience. Artificial Organs, 2004. 28(2): p. 136-141. 
153. Kirklin, J.K., D.C. Naftel, R.L. Kormos, et al., Third INTERMACS annual report: The evolution of 
destination therapy in the United States. The Journal of Heart and Lung Transplantation, 2011. 
30(2): p. 115-123. 
154. Barnes, K., Complications in patients with ventricular assist devices. Dimens Crit Car Nurs., 2008. 
27(6): p. 233-241. 
155. Grinda, J.M., M.O. Bricourt, S. Salvi, et al., The use of cardio-pulmonary double stage venous 
cannula as right inflow cannula for bi-ventricular assist device. J Cardiovasc, 2006. 47: p. 593-4. 
156. Heilmann, C., U. Geisen, F. Beyersdorf, et al., Acquired von Willebrand syndrome in patients with 
ventricular assist device or total artificial heart. Thromb Haemost., 2010. 103(5): p. 962-7. 
157. Slaughter, M.S., J.G. Rogers, C.A. Milano, et al., Advanced heart failure treated with continuous-
flow left ventricular assist device. The New England Journal of Medicine, 2009. 361(23): p. 2241-
51. 
158. Broussard, D., E. Donaldson, J. Falterman, et al., Anesthesia for left ventricular assist device 
insertion: A case series and review. The Ochsner Journal, 2011. 11: p. 70-77. 
273 
 
159. White, J.K., A. Jagannath, J. Titus, et al., Funnel-tipped aortic cannula for reduction of 
atheroemboli. Ann Thorac Surg, 2009. 88: p. 551-7. 
160. Heise, D., A. Bräuer, and M. Quintel, Recombinant activated factor VII (Novo7®) in patients with 
ventricular assist devices: Case report and review of the current literature. Journal of 
Cardiothoracic Surgery, 2007. 2(47): p. Published online 2007 October 26. doi: 10.1186/1749-
8090-2-47. 
161. Kaplon, R.J., A.M. Gillinov, N.G. Smedira, et al., Vitamin K reduces bleeding in left ventricular 
assist device recipients. The Journal of Heart and Lung Transplantation, 1999. 18: p. 346-350. 
162. Osaki, S., N.M. Edwards, M. Velez, et al., Improved survival in patients with ventricular assist 
device therapy: the University of Wisconsin experience. Eur J Cardiothorac Surg, 2008. 34: p. 281-
288. 
163. Timms, D., S. Gregory, N. Greatrex, et al., A compact mock circulation loop for the in vitro testing 
of cardiovascular devices. Artificial Organs, 2010. 35: p. 384-91. 
164. Dewey, T.M., J.M. Chen, T.B. Spanier, et al., Alternative technique of right-sided outflow cannula 
insertion for right ventricular support. Ann Thorac Surg, 1998. 66: p. 1829 -30. 
165. Thomson, B., Surgical visibility during VAD implantation, S. Gregory, Editor. 2010: Brisbane. 
166. ResidentNet. Clinical update: Wound closure techniques.  1997; Available from: 
http://www.residentnet.com/sutures.htm. 
167. University of Ottowa. Wound Care - Department of Emergency Medicine.  2003; Available from: 
http://www.med.uottawa.ca/procedures/wc/e_treatment.htm. 
168. Golding, L.A.R., R.D. Crouch, R.W. Stewart, et al., Postcardiotomy centrifugal mechanical 
ventricular support. Ann Thorac Surg, 1992. 54: p. 1059-1064. 
169. Stepanenko, A., E.V. Potapov, T. Krabatsch, et al., Simple implantation of a temporary right 
ventricular device for right ventricular failure after left ventricular device implantation via a left 
lateral thoracotomy. ASAIO Journal, 2011. 57: p. 17-18. 
170. Gregoric, I.D., W.E. Cohn, M.H. Akay, et al., CentriMag left ventricular assist system - 
Cannulation through a right minithoracotomy. Tex Heart Inst J, 2008. 35(2): p. 184-5. 
171. Nakatani, S., P.M. McCarthy, K. Kottke-Marchant, et al., Left ventricular echocardiographic and 
histologic changes: impact of chronic unloading by an implantable ventricular assist device. 
JACC, 1996. 27(4): p. 894-901. 
172. Bradfield, J.W.B., B. G., and R.J. Vecht, Left ventricular apical thin point. Britich Heart Journal, 
1977. 39: p. 806-809. 
173. Schmauss, D., I. Kaczmarek, A. Beiras-Fernandez, et al., Tentacles: A novel device for exposing 
the heart for the insertion of left apical assist device cannulae. The Heart Surgery Forum, 2009. 
12(2): p. E116-8. 
174. Charitos, E.L. and H.H. Sievers, A modified suturing technique for the implantation of the apical 
cannula of the HeartMate II left ventricular assist device. Interactive CardioVascular and Thoracic 
Surgery, 2010. 11: p. 393-394. 
175. LaRose, J.A., D. Tamez, M. Ashenuga, et al., Design concepts and principle of operation of the 
HeartWare ventricular assist system. ASAIO, 2010. 56: p. 285-289. 
176. Duncan, J.M., R.T. Baldwin, S.R. Igo, et al., Myocardium-sparing cannulation technique for left 
ventricular assist device support. Ann Thorac Surg, 1991. 52(565-6). 
177. Fujimoto, L.K. and Y. Nose, A technique for apex cannulation without extracorporeal circulation. 
Artificial Organs, 1987. 11(3): p. 269-271. 
178. Slaughter, M.S., G.A. Giridharan, D. Tamez, et al., Transapical miniaturized ventricular assist 
device: Design and initial testing. J Thorac Cardiovasc Surg, 2011. IN PRESS. 
274 
 
179. Salzberg, S., M. Lachat, G. Zund, et al., Left ventricular assist device as bridge to heart 
transplantation - lessons learned with the MicroMed DeBakey axial blood flow pump. European 
journal of cardio-thoracic surgery, 2003. 24: p. 113-118. 
180. Schmid, C., H.H. Scheld, and D. Hammel, Control of perigraft bleeding during ventricular assist 
device implantation. Ann Thorac Surg, 2000. 69: p. 958-9. 
181. Piccione, W., Left ventricular assist device implantation: Short and long-term surgical 
complications. J Heart Lung Transplant, 2000. 19: p. S89-S94. 
182. Platts, D., D. Burstow, C.H. Craig, et al., Systemic air embolization originating from a pleural air 
leak via a left ventricular assist device cannula anastomosis site. J Am Soc Echocardiogr, 2010. 
23(341): p. e1-e2. 
183. Flitney, B., Sealing today Sealing Technology, 2006. 2006(8): p. 6-10. 
184. Bock, E. and P. Schreiner, New radial shaft seal concepts for sealing hydraulic pumps and 
motors. Sealing Technology, 2003. 2003(6-10). 
185. Flitney, B., Review of sealing technology features from the last year. Sealing Technology, 2004. 
2004: p. 10-13. 
186. Aggarwal, S., F. Cheema, M.C. Oz, et al., Cardiac Surgery in the Adult. Long-Term Mechanical 
Circulatory Support, ed. e. Cohn Lh. 2008, New York: McGraw-Hill. 
187. Piacentino, V., J. Jones, C.A. Fisher, et al., Off-pump technique for insertion of a HeartMate 
vented electric left ventricular assist device. J Thorac Cardiovasc Surg, 2004. 127: p. 262-264. 
188. Hagan, K., LVADs help mend a broken heart. The Nurse Practitioner, 2010. 35(6): p. 28-36. 
189. Shimizu, K. and S. Taya, The development of hi-speed punching system using a couple of rotating 
bodies Journal of Materials Processing Technology, 2004. 155-156: p. 1157-1163. 
190. Watari, H., H. Onab, and Y. Yoshidac, Flexible punching method using an elastic tool instead of a 
metal punch Journal of Materials Processing Technology, 2003. Volume 137(1-3): p. 151-155. 
191. Luo, S.Y., Studies on the wear conditions and the sheared edges in punching. Wear, 1997. 
Volume 208(1-2): p. 81-90. 
192. Atkins, T., The Science and Engineering of Cutting. 2009: Butterworth Heinemann. 432. 
193. Potapov, E.V., A. Stepanenko, E. Hennig, et al., A titanium plug simplifies left ventricular assist 
device removal after myocardial recovery. The Journal of Heart and Lung Transplantation, 2010. 
29(11): p. 1316-1317. 
194. Wu, Y., P. Allaire, G. Tao, et al., An advanced physiological controller design for a left ventricular 
assist device to prevent left ventricular collapse. Artificial organs, 2003. 27(10): p. 926-930. 
195. Vollkron, M., H. Schima, L. Huber, et al., Interaction of the Cardiovascular System with an 
Implanted Rotary Assist Device: Simulation Study with a Refined Computer Model. Artificial 
Organs, 2002. 24(4): p. 349-359. 
196. Korakianitis, T. and Y. Shi, A concentrated parameter model for the human cardiovascular system 
including heart valve dynamics and atrioventricular interaction. Medical Engineering & Physics, 
2006. 28: p. 613-628. 
197. Heise, M., U. Kruger, R. Ruckert, et al., Correlation of intimal hyperplasia development and shear 
stress distribution at the distal end-side anastomosis, in vitro study using particle image 
velocimetry. Eur J Vasc Endovasc Surg, 2003. 26: p. 357-366. 
198. Ohashi, Y., A. Andrade, and Y. Nose, Hemolysis in an electromechanical driven pulsatile total 
artificial heart. Artificial organs, 2003. 27(12): p. 1089-1093. 
199. Liu, Y., P. Allaire, H. Wood, et al., Design and initial testing of a mock human circulatory loop for 
left ventricular assist device performance testing. Artificial organs, 2005. 29(4): p. 341-345. 
200. Koenig, S., G. Pantalos, K. Gillars, et al., Hemodynamic and pressure-volume responses to 
continuous and pulsatile ventricular assist in an adult mock circulation. ASAIO, 2004. 50(1): p. 
15-24. 
275 
 
201. Stergiopulos, N., B. Westerhof, and N. Westerhof, Total arterial inertance as the fourth element 
of the windkessel model. Am J Physiol, 1999. 276: p. 81-88. 
202. Toy, S.M., J. Melbin, and A. Noordergraaf, Reduced models of arterial system. IEEE Trans Biomed 
Eng, 1985. 32(2): p. 174-176. 
203. Sharp, M. and R. Dharmalingam, Development of a hydraulic model of the human circulatory 
system. ASAIO, 1999. 45(5): p. 535-540. 
204. Athanassiou, L., S. Hancock, and R. Mahajan, Doppler estimation of zero flow pressure during 
changes in downstream pressure in a bench model of a circulation using pulsatile flow. 
Anaesthesia, 2005. 60(133-138). 
205. Litwak, K., S. Koenig, R. Cheng, et al., Ascending aorta outflow graft location and pulsatile 
ventricular assist provide optimal hemodynamic support in an adult mock circulation. Artificial 
organs, 2005. 29(8): p. 629-635. 
206. Bustamante, J., F. Barros Juan, A. Roldan, et al., Physical model of the cardiovascular system.  
Dynasim. 2003. 
207. Woodruff, S., K. Sharp, and G. Pantalos, Compact compliance chamber design for the study of 
cardiac performance in microgravity. ASAIO, 1997. 43(4): p. 316-320. 
208. Ferrari, G., C. De Lazzari, R. Mimmo, et al., A computer controlled mock circulatory system for 
mono- and biventricular assist device testing. The International Journal of Artificial Organs, 1998. 
21(1): p. 26-36. 
209. Arabia, M. and T. Akutsu, A new test circulatory system for research in cardiovascular 
engineering. Annals of Biomedical Engineering, 1984. 12: p. 29-48. 
210. Ruel, J. and G. Leachance, Mathematical modeling and experimental testing of three bioreactor 
configurations based on windkessel models. Heart International, 2010. 5(1). 
211. Ferreira, A.S., J. Barbosa Filho, and M.N. Souza, Comparison of segmental arterial compliance 
determined with three and four element windkessel models, in Proceedings of teh 25th Annual 
International Conference of the IEEE EMBS. 2003: Cancun, Mexico. 
212. Pantalos, G., S. Koenig, K. Gillars, et al., Characterization of an Adult Mock Circulation for Testing 
Cardiac Support Devices. ASAIO Journal, 2004. 50: p. 37-46. 
213. Verdonck, P., K. Dumont, P. Segers, et al., Mock loop testing of On-X prosthetic mitral valve with 
Doppler echocardiography. Artificial organs, 2002. 26(10): p. 872-878. 
214. Naemura, K., M. Umezu, and T. Dohi, Preliminary Study on the New Self-Closing Mechanical 
Mitral Valve Artificial Organs, 1999. 23(9): p. 869-875. 
215. Feng, Z., M. Umezu, T. Fujimoto, et al., In Vitro Hydrodynamic Characteristics Among Three 
Bileaflet Valves in the Mitral Position Artificial Organs, 2000. 24(5): p. 346-354. 
216. Grigioni M, Daniele C, D'Avenio G, et al., Hemodynamic Performance of Small-Size Bileaflet 
Valves: Pressure Drop and Laser Doppler Anemometry Study Comparison of Three Prostheses. 
Artificial Organs, 2000. 24(12): p. 959-965. 
217. Morsi, Y.S. and A.A. Sakhaeimanesh, Flow Characteristics Past Jellyfish and St. Vincent Valves in 
the Aortic Position Under Physiological Pulsatile Flow Conditions. Artificial Organs, 2000. 24(7): 
p. 564-574. 
218. Walther, T., S. Lehmann, V. Falk, et al., Experimental Evaluation and Early Clinical Results of a 
New Low-Profile Bileaflet Aortic Valve. Artificial Organs, 2002. 26(5): p. 416-419. 
219. Cornhill, J., An aortic-left ventricular pulse duplicator used in testing prosthetic aortic heart 
valves. The Journal of Thoracic and Cardiovascular Surgery, 1977. 73(4): p. 550-558. 
220. Kolff, W., Mock circulation to test pumps designed for permanent replacement of damaged 
hearts. Cleveland Clinic Quarterly, 1959. 26: p. 223-226. 
221. Reul, H., Hydromechanical simulation of systemic circulation. Medical and biological engineering, 
1974. 12: p. 431-436. 
276 
 
222. Scotten, L., D. Walker, and R. Brownlee, Construction and evaluation of a hydro-mechanical 
simulation facility for the assessment of mitral valve prostheses. Journal of Medical Engineering 
and Technology, 1979. 3: p. 11-18. 
223. Rosenberg, G., W. Phillips, D. Landis, et al., Design and evaluation of the Pennsylvania State 
University Mock Circulatory System. ASAIO, 1981. 4(April/June): p. 41-49. 
224. Baloa, L., J. Boston, and J. Antaki, Elastance-based control of a mock circulatory system. Annals 
of Biomedical Engineering, 2001. 29: p. 244-251. 
225. Glower, J., R. Cheng, G. Diridharan, et al., In vitro evaluation of control strategies for an artificial 
vasculature device. Proceedings of the 26th Annual International Conference of the IEEE EMBS, 
2004. September 1-5: p. 3773-3776. 
226. Verdonck, P., A. Kleven, R. Verhoeven, et al., Computer-controlled in vitro model of the human 
left heart. Med. & Biol. Eng & Comput., 1992. 30: p. 656-659. 
227. Vandenberghe, S., J. Van Loon, P. Segers, et al., In vitro evaluation of the PUCA II intra-arterial 
LVAD. The International Journal of Artificial Organs, 2003. 26(8): p. 743-752. 
228. Trittenwein, G., A. Zamberger, H. Trittenwein, et al., A simple neonatal mock circulation enabling 
pulsatility and different hemodynamical states for neonatal ECMO research: Application to 
assess the effect of a centrifugal pump operated neonatal ECMO system on the circulation. 
Artificial organs, 1998. 22(5): p. 414-418. 
229. Goodwin, J., W. Meurs, C. Sa Couto, et al., A model of educational simulation of infant 
cardiovascular physiology. Anesth Analg, 2004. 99(1655-1664). 
230. Ayre, P., N. Lovell, and J. Woodard, Non-invasive flow estimation in an implantable rotary blood 
pump: a study considering non-pulsatile and pulsatile flows. Physiol. Meas., 2003. 24: p. 179-
189. 
231. Narine, K., K. Kram, K. Dumont, et al., Hydrodynamic evaluation of kangaroo aortic valve 
matrices for tissue valve engineering. Artificial organs, 2006. 30(6): p. 432-439. 
232. Colacino, F.M., M. Arabia, F. Moscato, et al., Modeling, analysis, and validation of a 
pneumatically driven left ventricle for use in mock circulatory systems. Medical Engineering and 
Physics, 2007. 29: p. 829-839. 
233. Khalil, H.A., R.W. Metcalfe, S.J. Kleis, et al., Flow visualization techniques in a mock ventricle 
supported by a nonpulsatile left ventricular assist device. ASAIO Journal, 2009. 55: p. 323-327. 
234. Yokoyama, Y., O. Kawaguchi, T. Shinshi, et al., A new pulse duplicator with a passive fill ventricle 
for analysis of cardiac dynamics. J Artif Organs, 2010. 13: p. 189-196. 
235. Muradbegovic, M., S. Taub, E. Rizzo, et al., Ultimate test bench for pediatric biventricular assist 
device based on artificial muscles. ASAIO Journal, 2011. 57: p. 62-67. 
236. Cassot, F., D. Morvan, P. Issarteir, et al., New versatile physical model fitting the systemic 
circulation accurately. Med. & Biol. Eng & Comput., 1985. 23: p. 511-516. 
237. Fisher, A., R.E. Challis, and P. Swann, A controllable artificial afterload for isolated heart studies. 
J. Biomed. Eng., 1984. 6: p. 305-310. 
238. Chinchoy, E., C.L. Soule, A.J. Houlton, et al., Isolated four-chamber working swine heart model. 
The Annals of Thoracic Surgery, 2000. 70: p. 1607-1614. 
239. Kawaguchi, O., Y. Goto, S. Futaki, et al., The effects of dynamic cardiac compression on 
ventricular mechanics and energetics: Role of ventricular size and contractility. The Journal of 
Thoracic and Cardiovascular Surgery, 1994 107(3): p. 850-859. 
240. Cutri, E., P. Bagnoli, E. Marcelli, et al., A mechanical simulator of cardiac wall kinematics. ASAIO, 
2010. 56: p. 164-171. 
241. van Eyll, C., M.F. Rousseau, A.A. Charlier, et al., Regional wall motion analysis in patients with 
idiopathic dilated cardiomyopathy. The American Journal of Cardiology, 1992. 65(5): p. 364-370. 
277 
 
242. Hayashida, W., T. Kumada, F. Kohno, et al., Left ventricular relaxation in dilated cardiomyopathy: 
Relation to loading conditions and regional nonuniformity. J Am Coll Cardiol, 1992. 20(5): p. 
1082-91. 
243. Marcelli, E., G. Plicchi, L. Cercenelli, et al., First experimental evaluation of cardiac apex rotation 
with an epicardial coriolis force sensor. ASAIO, 2005. 51: p. 696-701. 
244. Gibbons Kroeker, C.A., J.V. Tyberg, and R. Beyer, Effects of ischemia on left ventricular apex 
rotation: An experimental study in anesthetized dogs. Circulation, 1995. 92: p. 3539-4358. 
245. Tibayan, F.A., F. Rodriguez, and F. Langer, Alterations in left ventricular torsion and diastolic 
recoil after myocardial infarction with and without chronic ischemic mitral regurgitation. 
Circulation, 2004. 110: p. 109-114. 
246. Nagal, E., M. Stuber, and M. Lakatos, Cardiac rotation and relaxation after anterolateral 
myocardial infarction. Coron Artery Dis, 2000. 11: p. 261-267. 
247. Fuchs, E., M.F. Muller, H. Oswald, et al., Cardiac rotation and relaxation in patients with chronic 
heart failure. Eur J Heart Fail, 2004. 6: p. 715-722. 
248. Burkhoff, D., I. Mirsky, and H. Suga, Assessment of systolic and diastolic ventricular properties via 
pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol 
Heart Circ Physiol, 2005. 289: p. H501-H512. 
249. Loh, M. and Y. Yu, Feedback control design for an elastance-based mock circulatory system. 
American Control Conference, 2004. Proceedings of the 2004, 2004. 2: p. 1639-1644. 
250. Sagawa, K., The end-systolic pressure-volume relation of the ventricle: definition, modifications 
and clinical use. Circulation, 1981. 63: p. 1223-1227. 
251. Seeley, R., T. Stephens, and P. Tate, Anatomy & Physiology. 6th ed. 2003, New York: McGraw-
Hill Companies, Inc. 
252. Bevegard, S., A. Holmgren, and B. Jonsson, The effect of body position on the circulation at rest 
and during exercise, with special reference to the influence on the stroke volume. Acta Physiol 
Scand., 1960. 49: p. 279-298. 
253. McMahon, T., C. Clark, V. Murthy, et al., Intra-aortic balloon experiments in a lumped-element 
hydraulic model of the circulation. J. Biomechanics, 1971. 4: p. 335-350. 
254. Swanson, W. and R. Clark, A simple cardiovascular system simulator: Design and performance. 
Journal of Bioengineering, 1977. 1: p. 135-145. 
255. Gabbay, S., D. McQueen, E. Yellin, et al., In vitro hydrodynamic comparison of mitral valve 
prostheses at high flow rates. The Journal of Thoracic and Cardiovascular Surgery, 1978. 76(6): p. 
771-787. 
256. Bowles, C., S. Shah, K. Nishimura, et al., Development of mock circulation models for the 
assessment of counterpulsation systems. Cardiovascular Research, 1991. 25: p. 901-908. 
257. Knierbein, B., H. Reul, R. Eilers, et al., Compact mock loops of the systemic and pulmonary 
circulation for blood pump testing. The International Journal of Artificial Organs, 1992. 15(1): p. 
40-48. 
258. Schima, H., H. Baumgartner, F. Spitaler, et al., A modular mock circulation for hydromechanical 
studies on valves, stenoses, vascular grafts and cardiac assist devices. The International Journal 
of Artificial Organs, 1992. 15(7): p. 417-421. 
259. Orime, Y., S. Takatani, K. Tasai, et al., In vitro and in vivo validation tests for total artificial heart. 
Artificial organs, 1994. 18(1): p. 54-72. 
260. Andrade, A., D. Nicolosi, J. Lucchi, et al., Auxillary total artificial heart: A compact 
electromechanical artificial heart working simultaneously with the natural heart. Artificial 
organs, 1999. 23(9): p. 876-880. 
261. Haft, J., J. Bull, R. Rose, et al., Design of an artificial lung compliance chamber for pulmonary 
replacement. ASAIO, 2003. 49(1): p. 35-40. 
278 
 
262. Avrahami, I., M. Rosenfeld, S. Raz, et al., Numerical model of flow in a sac-type ventricular assist 
device. Artificial organs, 2006. 30(7): p. 529-538. 
263. Williams, J., J. Antaki, J. Boston, et al., Load sensitive mock circulatory system for left ventricular 
assist device controller evaluation and development. IEEE, 1994. 1: p. 89-90. 
264. Conklin, B., S. Surowiec, P. Lin, et al., A simple physiologic pulsatile perfusion system for the 
study of intact vascular tissue. Medical Engineering & Physics, 2000. 22: p. 441-449. 
265. Dumont, K., J. Yperman, E. Verbeken, et al., Design of a new pulsatile bioreactor for tissue 
engineered aortic heart valve formation. Artificial organs, 2002. 26(8): p. 710-714. 
266. Patel, S., P. Allaire, H. Wood, et al., Design and construction of a mock human circulatory system. 
Summer bioengineering conference, 2003. June 25-29: p. 965-966. 
267. Milnor, W., Pulmonary hemodynamics. In: Bergel DH, ed. Cardiovascular Fluid Dynamics. 1972, 
Oxford: Academic Press. 
268. Burton, A., Physiology and Biophysics of the Circulation, 2nd Edition. 1965, Chicago: Year Book 
Medical Publishers. 
269. Langendorff, O., Untersuchungen am überlebenden Säugetierherzen. Pflügers Archiv, 1898. 61: 
p. 291−332. 
270. Skrzypiec-Spring, M., B. Grotthus, A. ASzelag, et al., Isolated heart perfusion according to 
Langendorff - Still viable in the new millennium. Journal of Pharmacological and Toxicological 
Methods, 2007. 55: p. 113-126. 
271. Partridge, C.R., C.D. Johnson, and K.S. Ramos, In vitro models to evaluate acute and chronic 
injury to the heart and vascular systems. Toxicology in Vitro, 2005. 19: p. 631-644. 
272. Canaud, L., P. Alric, M. Laurent, et al., Proximal fixation of thoracic stent-grafts as a function of 
oversizing and increasing aortic arch angulation in human cadaveric aortas. J Endovasc Ther, 
2008. 15: p. 326-334. 
273. Bolling, S.F., J.H. Rogers, V. Babaliaros, et al., Percutaneous aortic valve implantation utilising a 
novel tissue valve: preclinical experience. EuroInterv, 2008. 4: p. 148-153. 
274. Gregory, S.D., Simulation and Development of a Mock Circulation Loop with Variable 
Compliance. 2009, Queensland University of Technology: Brisbane, Australia. p. 167. 
275. Gregory, S.D., N. Greatrex, D. Timms, et al., Simulation and enhancement of a cardiovascular 
device test rig. Journal of Simulation, 2010. 4: p. 34-41. 
276. Mitsui, N., S. Fukunaga, T. Sueda, et al., Study of left ventricular bypass using Wankel type 
semipulsatile blood pump. Artificial organs, 1998. 22(5): p. 419-425. 
277. Marcus, R., C. Korcarz, G. McCray, et al., Noninvasive method for determination of arterial 
compliance using Doppler echocardiography and subclavian pulse tracings.  Validation and 
clinical application of a physiological model of the circulation. Circulation, 1994. 89: p. 2688-
2699. 
278. Batzel, J., F. Kappel, D. Schneditz, et al., Cardiovascular and Respiratory Systems: Modeling, 
Analysis, and Control. 2007: SIAM. 274. 
279. Gonzalez-Bustamante, J.A., J.M. Sala, L.M. Lopez-Gonzalez, et al., Modelling and dynamic 
simulation of processes with ‘MATLAB’. An application of a natural gas installation in a power 
plant. . Energy, 2007. 32: p. 1271-1282. 
280. Brown, K.A. and R.V. Ditchey, Human right ventricular end-systolic pressure-volume relation 
defined by maximal elastance. Circulation, 1988. 78: p. 81-91. 
281. Timms, D.L., Design, development and evaluation of centrifugal ventricular assist devices, in 
School of Mechanical, Manufacturing and Medical Engineering. 2005, Queensland University of 
Technology: Brisbane, Australia. p. 275. 
279 
 
282. Fiore, G., A. Redaelli, M. Rasponi, et al., Development of a model left ventricle with physiologic-
like diastolic behaviour for studying mitral valve surgical correction. Summer bioengineering 
conference, 2003. June 25-29: p. 429-430. 
283. Timms, D.L., M. Hayne, A. Galbraith, et al., A complete mock circulation loop for the evaluation 
of left- right- and bi- ventricular assist devices. Artif Organs, 2005. 29(7): p. 564–571. 
284. Pullicino, P., J. Halperin, and J. Thompson, Stroke in patients with heart failure and reduced left 
ventricular ejection fraction. American academy of neurology, 2000. 54(2): p. 288. 
285. Moazami, N. and N. Smedira, Temporary mechanical support. J Card Surg, 2001. 16: p. 193-202. 
286. Ali, A., P. White, K. Dhital, et al., Cardiac recovery in a human non-heart-beating donor after 
extracorporeal perfusion: Source for human heart donation? J Heart Lung Transplant, 2009. 28: 
p. 290-3. 
287. Kuehne, T., S. Yilmaz, P. Steendijk, et al., Magnetic resonance imaging analysis of right 
ventricular pressure-volume loops - In vivo validation and clinical application in patients with 
pulmonary hypertension. Circulation, 2004. 110: p. 2010-2016. 
288. Mushi, S. and Y.C. Yu. Control of a mock circulatory system to simulate the short-term baroreflex. 
in American Control Conference. 2008. Seattle, Washington, USA. 
289. Hakumaki, M.O.K., Seventy years of the Bainbridge reflex. Acta Physiol Scand, 1987. 130: p. 177-
185. 
290. Rose, E.A., A.J. Moskowitz, M. Packer, et al., The REMATCH trial: rationale, design, and end 
points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart 
Failure. Ann Thorac Surg, 1999. 67(3): p. 723-30. 
291. Rose, E.A., A.C. Gelijns, A.J. Moskowitz, et al., Long-term use of a left ventricular assist device for 
end-stage heart failure. The New England Journal of Medicine, 2001. 345(20): p. 1435-43. 
292. Meyns, B., T. Siess, Y. Nishimura, et al., Miniaturized implantable rotary blood pump in atrial-
aortic position supports and unloads the failing heart. Cardiovascular Surgery, 1998. 6(3): p. 288-
295. 
293. Slaughter, M.S., C.R. Bartoli, M.A. Sobieski, et al., Intraoperative evaluation of the HeartMate II 
flow estimator. J Heart Lung Transplant, 2009. 28: p. 39-43. 
294. Stepanenko, A., E. Hennig, and E.V. Potapov, Long-term biventricular support with the heartware 
implantable continuous flow pump. The Journal of Heart and Lung Transplantation, 2010. 29(7): 
p. 822-824. 
295. De Robertis, F., P. Rogers, M. Amrani, et al., Bridge to decision using the Levitronix CentriMag 
short-term ventricular assist device. The Journal of Heart and Lung Transplantation, 2008. 27(5): 
p. 474-478. 
296. Pagani, F.D., K.D. Aaronson, D.B. Dyke, et al., Assessment of an extracorporeal life support to 
LVAD bridge to heart transplant strategy. Ann Thorac Surg, 2000. 70: p. 1977-85. 
297. Guyton, R.A., J.P.A.M. Schonberger, P.A.M. Everts, et al., Postcardiotomy shock: Clinical 
evaluation fo the BVS 5000 biventricular support system. Ann Thorac Surg, 1993. 56: p. 346-56. 
298. Pagani, F.D., L.W. Miller, S.D. Russell, et al., Extended mechanical circulatory support with a 
continuous-flow rotary left ventricular assist device. J Am Coll Cardiol, 2009. 54: p. 312-321. 
299. Saeed, D., A.L. Massiello, S. Shalli, et al., Introduction of fixed-flow mode in the DexAide right 
ventricular assist device. J Heart Lung Transplant, 2010. 29: p. 32-36. 
300. Fukamachi, K., D.J. Horvath, A.L. Massiello, et al., An innovative, sensorless, pulsatile, 
continuous-flow total artificial heart: Device design and initial in vitro study. J Heart Lung 
Transplant, 2010. 29: p. 13-20. 
301. John, R., Current Axial-Flow Devices—the HeartMate II and Jarvik 2000  Left Ventricular Assist 
Devices. Seminars in Thoracic and Cardiovascular Surgery, 2008. 20(3): p. 264-272. 
280 
 
302. Salamonsen, R.F., D.G. Mason, and P.J. Ayre, Response of rotary blood pumps to changes in 
preload and afterload at a fixed speed setting are unphysiological when compared with the 
natural heart. Artificial Organs, 2011. 35(3): p. E47-E53. 
303. Wang, W., G.Q. Zhu, L. Gao, et al., Baroreceptor reflex in heart failure. Acta Physiologica Sinica, 
2004. 56(3): p. 269-281. 
304. Ningbo Johnson Industrial Co., L. Anchor Bolt.  2012  12/04/2012]; Available from: 
http://www.johsoncn.com/hollow_wall_anchor.htm. 
305. Trutek Construction Fastening Systems. Cavity dry wall anchors.  2012  [cited 12/04/2012; 
Available from: http://www.trutek.uk.com/cavity-dry-wall-anchors.htm. 
306. Laumen, M., T. Kaufmann, D. Timms, et al., Flow analysis of VAD inflow and outflow cannula 
positioning using a naturally shaped ventricle and aortic branch. Artificial Organs, 2010. 34(10): 
p. 798-806. 
307. Redington, A., The physiology of the Fontan circulation. Progress in Pediatric Cardiology, 2006. 
22: p. 179-186. 
308. Kelly, J., Personal communication: Discussion of cadaveric tissue properties. 2011: Brisbane. 
309. Kumpati, G.S., P.M. McCarthy, and K.J. Hoercher, Left ventricular assist device bridge to 
recovery: A review of the current status. Ann Thorac Surg, 2001. 71: p. S103-8. 
310. Topilsky, Y., N.L. Pereira, D.K. Shah, et al., LVAD therapy in patients with restrictive and 
hypertrophic cardiomyopathy. Circulation, 2011. IN PRESS(DOI: 
10.1161/CIRCHEARTFAILURE.110.959288). 
311. Tschirkov, A., D. Nikolov, and V. Papantchev, New technique for implantation of the inflow 
canula of Berlin Heart INCOR system. European journal of cardio-thoracic surgery, 2006. 30: p. 
678-679. 
312. Holmes, J.W., T.K. Borg, and J.W. Covell, Structure and mechanics of healing myocardial infarcts. 
Annu. Rev. Biomed. Eng., 2005. 7: p. 223-53. 
313. Osakada, G., O.M. Hess, K.P. Gallagher, et al., End-systolic dimension-wall thickness relations 
during myocardial ischemia in conscious dogs. The American Journal of Cardiology, 1983. 
51(1750-1758). 
314. Schamhardt, H.C., P.D. Verouw, and P.R. Saxena, Improvement of perfusion and function of 
ischaemic porcine myocardium after reduction of heart rate by alinidine. Journal of 
Cardiovascular Pharmacology, 1981. 3: p. 728-738. 
315. Manciet, L.H., D.C. Poole, P.F. McDonagh, et al., Microvascular compression during myocardial 
ischemia: mechanistic basis for no-reflow phenomenon. Am. J. Physiol., 1994. 266: p. H1541-
H1550. 
316. Hitosugi, M., M. Niwa, and A. Takatsu, Changes in blood viscosity by heparin and argatroban. 
Thrombosis Research, 2001. 104(5): p. 371-374. 
317. Kestin, J., M. Sokolov, and W.A. Wakeham, Viscosity of liquid water in the range -8 degrees 
celcius to 150 degrees celcius. J. Phys. Chem. Ref. Data, 1978. 7(3): p. 941-948. 
318. Samuels, L.E., E.C. Holmes, P. Garwood, et al., Initial Experience With the Abiomed AB5000 
Ventricular Assist Device System. Ann Thorac Surg, 2005. 80: p. 309 -12. 
319. Samuels, L.E., Biventricular mechanical replacement. Surg Clin N Am, 2004. 84: p. 309-321. 
320. Zhang, L., E. Kapetanakis, R.H. Cooke, et al., Bi-Ventricular Circulatory Support With the Abiomed 
AB5000 System in a Patient With Idiopathic Refractory Ventricular Fibrillation. Ann Thorac Surg, 
2007. 83: p. 298 -300. 
321. Leyvi, G., D.G. Taylor, S. Hong, et al., Intraoperative Off-Bypass Management of the ABIOMED 
AB5000 Ventricle. Journal of Cardiothoracic and Vascular Anesthesia, 2005. 19(1): p. 76-78. 
281 
 
322. Korfer, R., A.E. Banayosy, M. Morshuis, et al., Total artificial heart-implantation technique using 
the CardioWest or the Thoratec system. Multimedia Manual of Cardiothoracic Surgery, 2007. 
2485. 
323. Farrar, D.J. and J.D. Hill, Univentricular and biventricular thoratec VAD support as a bridge to 
transplantation. Ann Thorac Surg, 1993. 55: p. 276-282. 
324. Reichenbach, S.H., D.J. Farrar, and J. Donald Hill, A versatile intracorporeal ventricular assist 
device based on the Thoratec VAD system. Ann Thorac Surg, 2001. 71: p. 171-175. 
325. Cooper, D.S., J.P. Jacobs, L. Moore, et al., Cardiac extracorporeal life support: state of the art in 
2007. Cardiol Young, 2007. 17(2): p. 104-115. 
326. Hetzer, R., V. Alexi-Meskishvili, Y. Weng, et al., Mechanical cardiac support in the young with the 
Berlin Heart EXCOR pulsatile ventricular assist device: 15 years experience. Pediatric cardiac 
surgery annual, 2006: p. 99-108. 
327. Berlin Heart AG, Mobile Driving System Excor for EXCOR VAD. 2006. p. 65. 
328. Babatasi, G., M. Massetti, S. Bhoyroo, et al., Clinical experience with the Medos assist device. 
Cardiovascular Engineering, 1997. 2(1): p. 16-18. 
329. Waldenberger, F., B. Meyns, H. Reul, et al., Pre-clinical evaluation of a novel, pneumatic, 
ventricular assist device (Medos HIA-VAD) under pathophysiological conditions. The 
International Journal of Artificial Organs, 1997. 20(7): p. 389-396. 
330. Martin, J., K. Sarai, M. Schindler, et al., MEDOS HIA-VAD Biventricular Assist Device for Bridge to 
Recovery in Fulminant Myocarditis. Ann Thorac Surg, 1997. 63: p. 1145- 6. 
331. Waldenberger, F., Y.I. Kim, S. Laycock, et al., Effects of failure of the right side of the heart and 
increased pulmonary resistance on mechanical circulatory support with use of the miniaturized 
HIA_VAD displacement pump system. The Journal of Thoracic and Cardiovascular Surgery, 1996. 
112(2): p. 484-493. 
332. Thoratec Corporation. Thoratec CentriMag® Blood Pump.  2010  25/02/2010]; Available from: 
http://www.thoratec.com/medical-professionals/vad-product-information/thoratec-
centrimag.aspx. 
333. Frazier, O.H., T.J. Myers, and I.D. Gregoric, Biventricular assistance with the Jarvik FlowMaker: A 
case report. The Journal of Thoracic and Cardiovascular Surgery, 2004. 128: p. 625-626. 
334. Strueber, M., A.L. Meyer, D. Melehsa, et al., Successful use of the HeartWare HVAD rotary blood 
pump for biventricular support. The Journal of Thoracic and Cardiovascular Surgery, 2010. 
140(4): p. 936-937. 
335. Krabatsch, T., E. Hennig, A. Stepanenko, et al., Evaluation of the HeartWare HVAD centrifugal 
pump for right ventricular assistance in an in vitro model. ASAIO Journal, 2011. 57: p. 183-187. 
336. Min, B.G., J. Chung, K.W. Nam, et al. Recent Progress of Moving-Actuator type Mechanical 
Circulatory Support Systems: AnyHeart and T-PLS in Conf Proc IEEE Eng Med Biol Soc. 2004. 
337. Park, C.Y., J.W. Park, J.J. Lee, et al., Development of totally implantable pulsatile biventricular 
assist device. Artificial Organs, 2003. 27(1): p. 119-123. 
338. Min, B.C., J.W. Park, J. Choi, et al., AnyHeart: Heart-saving implantable artificial heart (BVAD). 
American Society of Artificial Internal Organs, 2002. 48(2): p. 150. 
339. Yoshikawa, M., K. Nonaka, J. Linneweber, et al., Development of the NEDO implantable 
ventricular assist device with Gyro centrifugal pump. Artificial Organs, 2000. 24(6): p. 459-467. 
340. Ichikawa, S., J. Linneweber, T. Motomura, et al., In Vivo Evaluation of the NEDO Biventricular 
Assist Device with an RPM Dynamic Impeller Suspension System. ASAIO, 2003. 49: p. 578-582. 
341. Okamoto, E., Y. Yamamoto, Y. Akasaka, et al., A new transcutaneous energy transmission system 
with hybrid energy coils for driving an implantable biventricular assist device. Artificial Organs, 
2009. 33(8): p. 622-626. 
282 
 
342. Gazzoli, F., A. Alloni, F. Pagani, et al., Arrow CorAide Left Ventricular Assist System: Initial 
Experience of the Cardio-Thoracic Surgery Center in Pavia. Ann Thorac Surg, 2007. 83: p. 279-82. 
343. Ootaki, Y., C. Ootaki, A. Massiello, et al., Human Clinical Fitting Study of the DexAide Right 
Ventricular Assist Device. Artificial Organs, 2009. 33(7): p. 558-561. 
344. Fukamachi, K., D. Saeed, A. Massiello, et al., Development of DexAide Right Ventricular Assist 
Device: Update II. ASAIO, 2008. 54: p. 589-593. 
345. Kurita, N., D.L. Timms, N. Greatrex, et al., Axial Magnetic Bearing Development for the BiVACOR 
rotary BiVAD/TAH, in 11th International Symposium on Magnetic Bearings. 2008: Nara, Japan. 
346. Greatrex, N.A., D.L. Timms, N. Kurita, et al., Axial Magnetic Bearing Development for the 
BiVACOR Rotary BiVAD/TAH. IEEE Trans Biomed Eng, 2010. 57(3): p. 714-21. 
347. Thomson, B., J.F. Fraser, D. Timms, et al., Initial acute in vivo animal experience with the 
BiVACOR rotary bi-ventricular assist device. Heart, Lung and Circulation, 2009. 18: p. 65-88. 
348. Timms, D., J. Fraser, M. Hayne, et al., The BiVACOR rotary biventricular assist device: concept 
and in vitro investigation. Artificial Organs, 2008. 32(10): p. 816-819. 
349. Timms, D., J. Fraser, B. Thomson, et al., The BiVACOR rotary BiVAD/TAH. ASAIO Bioengineering 
Abstracts, 2009: p. 174. 
350. Westerhof, N., F. Bosman, C. De Vries, et al., Analog studies of the human systemic arterial tree. 
J. Biomechanics, 1969. 2: p. 121-143. 
351. Shi, Y., T. Korakianitis, and C. Bowles, Numerical simulation of cardiovascular dynamics with 
different types of VAD assistance. Journal of Biomechanics, 2007. 40(13): p. 2919 - 2933. 
352. Korn, G., J. McLeod, and J. Wait, Dare/Physbe. SIMULATION, 1970. 15: p. 229-231. 
353. Ding, X. and F. P.M., Modelling, Control and Monitoring of Circulatory Systems with an Artificial 
Heart. International Journal of Quality & Reliability Management, 1994. 11(2): p. 41-50. 
354. Hassani, K., M. Navidbakhsh, and M. Rostami, Modeling of the aorta artery aneurysms and renal 
artery stenosis using cardiovascular electronic system. BioMedical Engineering OnLine, 2007. 
6:22doi:10.1186/1475-925X-6-22. 
355. Vrettos, A. The Importance of Arterial Compliance, When Blood Flows and Pressures are 
Assumed to be Random Processes. in The Twenty-Fourth IASTED Int. Conf. On Modelling, 
Identification and Control. 2005. Innsbruck, Austria. 
356. Gisolf, J., J. van Lieshout, K. van Heusden, et al., Human cerebral venous outflow pathway 
depends on posture and central venous pressure. J Physiol, 2004. 560: p. 317-327. 
357. Sun, K., H.S. Son, J.S. Jung, et al., Korean Artificial Heart (AnyHeart): An Experimental Study and 
the First Human Application. Artificial Organs, 2003. 27(1): p. 8-13. 
358. Fumoto, H., D.J. Horvath, S. Rao, et al., In vivo acute performance of the Cleveland Clinic self-
regulating, continuous-flow total artificial heart. J Heart Lung Transplant, 2010. 29: p. 21-26. 
359. Ichikawa, S., J. Linneweber, T. Motomura, et al., In Vivo Evaluation of the NEDO Biventricular 
Assit Device with an RPM Dynamic Impeller Suspension System. ASAIO, 2003. 49: p. 578-582. 
 
 
 
 
  
283 
 
  
284 
 
Appendices 
 
Appendix 1 - Technical Review of Biventricular Assist Devices 
Devices Used Clinically as a Biventricular Assist Device 
Abiomed BVS5000 
The Abiomed BVS5000 (Abiomed Inc., Danvers, MA, USA) (Figure 158) was approved in 1992 by the USA 
Food and Drug Administration (FDA). It is a first generation, extracorporeal, dual-chambered BiVAD with 
simplicity and low cost as advantages, making it one of the most frequently used BiVADs in the world for 
treatment of acute cardiogenic shock [318]. The pump is clamped to an IV-type pole, located next to the 
patient’s bed, at a height below the patient’s atrium to allow for passive filling [297].  The BVS5000 has 
two separate 100 mL pumping and filling bladders, and a 660 mL system extracorporeal volume [3]. 
Allowable pumping rates are between 3 and 140 beats per minute (BPM).  Abiomed tri-leaflet Angioflex 
polyurethane valves are placed at the filling and pumping chamber exits to prevent backflow, while the 
chamber bladders are made from the same material. Flow stagnation around these valves is a known 
cause for thrombus formation within the pump. These thrombi may dislodge and potentially contribute 
to patient mortality.  
 
The pumping chambers are driven by a large, pulsatile, pneumatic drive console which can operate the 
LVAD and RVAD separately, or together. This microprocessor-based drive console optimizes and 
balances left/right pumping ratios by automatically adjusting the systolic/diastolic intervals and beat 
 
Figure 158 – Abiomed BVS5000 VAD with pneumatic driveline and cannulae 
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rate based on measurements of the drive line air flow to/from the console. While this device has 
demonstrated reasonable success bridging patients to recovery from cardiogenic shock with short term 
support, portability issues and thrombus incidence present severe limitations should long term VAD 
support be required [319]. 
 
Abiomed AB5000 
The Abiomed AB5000 (Abiomed Inc., Danvers, MA, USA) (Figure 159) was approved by the FDA in 2003. 
Similar to the BVS5000, it is a first generation, pneumatically driven, volume displacement pump; 
however its paracorporeal location means that it can be used as a first choice VAD treatment or as a 
replacement to the BVS5000 should greater patient mobility be desired. In this latter case, the device 
can connect to the existing cannulae of the BVS5000, thus eliminating the need for additional surgery.  
The small number of pumps implanted to date have demonstrated safety and reliability [320, 321].   
 
The pump weighs 300 g when primed and has a 100 mL blood sac. The total extracorporeal system 
priming volume is less than 200 mL, which is less than the BVS5000. The outlet port uniquely exits 
centrally from the pump chamber in an attempt to improve flow dynamics and thus better chamber 
washout. The drive system automatically controls the 
AB5000 pump at a fixed rate mode, which usually outputs a 
70-80 mL stroke volume. However, this stroke volume is 
reduced at high beat rates up to a maximum of 150 BPM, 
which results in a maximum output of 6 L/min. The drive 
console is a fully automatic, vacuum-assisted console 
designed to support both Abiomed blood pumps and is 
smaller than the driver used for the BVS5000.  
 
Thoratec PVAD 
The Thoratec PVAD (Thoratec Corporation, Pleasanton, CA, 
USA) was approved by the FDA for bridge to transplant in 
1995 and postcardiotomy support in 1998. It is a first 
generation, pneumatically actuated, paracorporeal VAD 
suitable for left, right or biventricular assistance, however it  
 
Figure 159 – Abiomed AB5000 VAD with 
pneumatic driveline 
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has also been used as a TAH [322].  The PVAD, 
shown in Figure 160, consists of a rigid plastic 
chamber which houses a polyurethane 
multipolymer (BPS-215M polyurethane elastomer) 
pumping sac to provide extensive flex life, strength 
and thromboresistance. Mechanical valves are 
also included to provide unidirectional flow [323]. 
The total size of the device is approximately 125 x 
80 x 60 mm, with a total displacement volume of 
318 mL and weight of 417 g [324]. As the device is 
located external to the body, in front of the 
abdomen, the size and weight of the Thoratec 
PVAD can pose problems to patient mobility. To 
ensure balanced flow between the systemic and 
pulmonary circulations, the PVAD features a full-to-empty actuation mode.  A Hall-effect switch 
attached to the PVAD chamber senses when the pumping chamber is full and sends a signal to the 
controller which triggers the supply of compressed air to initiate systole.  The vacuum assisted pump has 
a fixed stroke volume of 65 mL and a variable pulse rate, producing a minimum and maximum pump 
output of 1.3 and 7.2 L/min respectively. The 
drive system can also operate in a fixed rate 
mode or synchronized with the patient’s ECG [3].  
 
Thoratec IVAD 
The intracorporeal, pneumatically actuated, 
pulsatile Thoratec IVAD (Thoratec Corporation, 
Pleasanton, CA, USA) has been approved by the 
FDA since 2004 to support the systemic and/or 
pulmonary circulations in a left, right or 
biventricular assist configuration.  With 
dimensions of 120 x 80 x 50 mm, a total 
displacement volume of 252 mL and a weight of 
339 g, the IVAD is sufficiently smaller and lighter 
 
Figure 160 – The Thoratec PVAD with pneumatic 
driveline 
 
Figure 161 – The Thoratec IVAD with pneumatic 
driveline 
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than the extracorporeal PVAD, yet provides the same 65 mL stroke volume and maximum VAD output of 
7.2 L/min [324].  The size of this first generation device does, however, limit BiVAD implantation to 
larger patients, with children and small women usually ineligible for biventricular IVAD support. The 
IVAD, displayed in Figure 161, incorporates similar internal pump materials and mechanical valves to the 
PVAD; however titanium alloy housing improves external surface biocompatibility.  Usually operating in 
full-to-empty mode, optical infrared sensors are used to detect the end systolic and diastolic position of 
the membrane, providing adequate systemic/pulmonary flow balancing. A 9 mm percutaneous 
pneumatic line with electrical cable for the sensor connects the IVAD to either of the drivers used to 
operate the Thoratec PVAD (DDC or TLC-II).   
 
Berlin Heart EXCOR 
Developed by Berlin Heart (Berlin Heart AG, Berlin, Germany), the EXCOR device (Figure 162) is a 
pneumatically actuated, paracorporeal, first generation VAD capable of left, right or biventricular 
support.  Adult pumps, available for use only outside the USA, come in 50, 60 and 80 mL sizes, while 
pediatric pumps, which were granted investigational device use status by the FDA in 2008, have smaller 
volumes at 10, 20 and 35 mL. Inside the transparent polyurethane housing, a triple layered polyurethane 
membrane separates the air and blood chambers [325]. The drive system, Ikus, is a large, 93 kg electro-
pneumatic drive unit which can produce pulse rates of 30-150 BPM, systolic pressures of 60-350 mmHg, 
diastolic pressures of -100 to 0 mmHg and systolic duration of 20-70% of the cardiac cycle. The higher 
pressure limits of -100 mmHg and 350 mmHg may be required to overcome the resistance of smaller 
pediatric cannulae at high heart rates [326]. A smaller, 9 kg portable drive unit, the EXCOR mobile 
driving system, can be used in a biventricular configuration with up to 5 hours of battery life [327].  
 
Medos HIA-VAD 
With transparent pump chamber sizes 
varying from 9-80 mL, the paracorporeal 
Medos HIA-VAD (MEDOS Medizintechnik, 
GmbH, Stollberg, Germany) can be used in 
adult, infant and pediatric cases.  Implanted 
for mechanical circulatory support since 
1994, this pneumatically actuated, first 
generation blood pump is capable of  
 
Figure 162 – The Berlin Heart EXCOR 
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assisting the left, right or both sides of 
the heart at flow rates ranging from 5-6 
L/min [328].  Adult sized pumps are 60 
mL while pediatric versions come in 25 
and 10 mL sizes (Figure 163).  To account 
for the extra bronchial circulation on the 
left side, the right side pumps have 
smaller pump membranes to deliver 
10% less cardiac output in a fixed rate 
operational mode [329].  The drive 
system is capable of applying systolic 
pressures of 50 to 300 mmHg and diastolic pressures of -1 to -99 mmHg, with systolic times of 20 to 50% 
and pulse rates of 40 to 180 BPM depending on the pump size [330]. The three-leaflet valves in the 
inflow and outflow tracts, and the seamless transparent pump casing, are made of biocompatible 
polyurethane [331].  
 
Levitronix CentriMag 
The Levitronix CentriMag (Levitronix LLC, Waltham, MA) obtained CE mark approval in 2002 for short 
term support of up to 30 days. The 
CentriMag is a third generation, electrically 
operated, extracorporeal, centrifugal blood 
pump. With FDA approval for up to 6 hours 
of ventricular support only, trials are 
underway in the US to investigate longer 
term support of up to 30 days [332]. 
Frequently used as a ‘bridge to decision’ 
device [295], the CentriMag contains a 
disposable rotor and polycarbonate pump 
housing assembly which is fitted to an 
external magnetic motor that controls radial 
rotor position and speed (Figure 164).  Each 
pump head has a total priming volume of  
 
Figure 163 – The Medos HIA-VAD with pneumatic driveline 
 
 
Figure 164 – The Levitronix CentriMag drive console, 
magnetic motor and disposable pump head 
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just 31 mL. Using bearing-less motor technology, the 
impeller is magnetically levitated and rotated at 
speeds of 1500-5500 RPM to provide maximum 
pump flow of 9.9 L/min.  Pump speed is altered 
using an interface on the 6.6 kg drive console, which 
is connected to the 1.7 kg magnetic motor.  
 
Jarvik 2000 
The Jarvik 2000 device (Jarvik Heart Inc., New York, 
USA) (Figure 165) has been included in a BTT trial 
since 2008 for FDA approval, subsequent to CE mark 
approval for the same application in 2005. The device is a second generation, axial flow LVAD that has 
also been used to support right ventricular function in humans [69, 333]. With a weight of just 90 g, 
length of 55 mm, diameter of 25 mm and total pump displacement of 25 mL, the Jarvik 2000 is small 
enough for BiVAD implantation in almost any patient. This electrically powered VAD can deliver flow 
rates of 3-7 L/min against 100 mmHg at 8000-12000 RPM while using 4-8 W of power [301].  The 
brushless electromagnetic DC motor inside the sealed pump housing powers the rotor through 
electromagnetic fields that cross the blood flow path. RVAD support was achieved with reduced VAD 
speeds (6000-10000 RPM) to compensate 
for the lower pulmonary pressures [69].  
 
HeartWare HVAD 
Originally developed as a LVAD and 
receiving CE mark approval for BTT 
applications in 2009, the HeartWare HVAD 
(HeartWare Inc, Massachusetts, USA) has 
also been used for biventricular support in 
humans [56, 334]. This third generation 
blood pump weighs 145 g and is capable of 
providing up to 10 L/min of blood flow with 
a wide-blade centrifugal impeller that 
rotates at a maximum speed of 4000 RPM 
 
Figure 165 – The Jarvik 2000 device with 
electrical lead 
 
Figure 166 – The HeartWare HVAD with electrical lead 
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[81]. A combined/hybrid passive magnetic and hydrodynamic thrust bearing suspend the impeller within 
the titanium-ceramic housing to improve device durability, while device reliability is improved with the 
use of independently driven dual motor stators. Power is delivered percutaneously through either an AC 
power supply, a 12 V DC supply, or two rechargeable batteries which can provide up to 12 hours of 
power. With a device displacement volume of just 50 mL, the HVAD (Figure 166) is small enough to be 
implanted in the pericardial cavity [175].  This eliminates the need for extensive abdominal dissection 
which is required for placement of larger implantable VADs. Integrated into the device, the smooth 
titanium inflow cannula (25 mm long and 21 mm outer diameter) is inserted through the left ventricular 
apex for the LVAD and the free wall of the right ventricle for the RVAD.  To prevent septal occlusion of 
the RVAD inflow, spacers are added between the outer RV free wall and the pump to reduce cannula 
insertion length [56]. The decreased pulmonary pressures are compensated by banding/restricting the 
HVAD outflow cannula to a smaller diameter, however little work has been completed to characterize 
the degree of banding which may vary from patient to patient [56, 335]. For biventricular support, 
patients are required to carry two controllers and power supplies.  
 
2.5.5.2 Devices Under Development to be Used as a Biventricular Assist Device 
Korean AnyHeart  
The Korean AnyHeart (BiomedLab Co., Seoul, Korea), is an electrically driven, pulsatile BiVAD which is 
also capable of operating as a TAH [336].  The left and 
right pumping chambers are each approximately 100 
mL in volume, while the entire device and connectors 
require about 500 mL of blood to prime [337].  These 
pumping chambers reside either side of a pendulum 
driver which swings side to side providing left systolic 
function during right side filling and vice versa.  A 
brushless DC motor drives the pendulum actuator via 
an epicyclic gear train to reduce motor shaft speed 
and increase torque.  The shaft and gear system, 
which control the pendulum actuator, are housed 
within the casing along with the ventricle chambers. 
This implantable or wearable design, with dimensions 
of approximately 110 x 88 x 66 mm and mass of 780 g, 
 
Figure 167 - The Korean AnyHeart, implanted 
sub-diaphragmatically as a BiVAD 
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can supply a pulse rate of up to 170 BPM without compromising pump filling [337]. However, the device 
size, similar to two Thoratec IVADs, would pose problems with small patients. The maximum ejection 
fraction and cardiac output of the AnyHeart (Figure 167) is approximately 65% and 9 L/min respectively 
with a power consumption of 28.8 W [336].  With 4 L/min pump flow against 100 mmHg, a total system 
efficiency of 8% and power consumption of less than 9 W has been reported [338]. The ventricle 
chambers are made of smooth, seamless segmented polyurethane encased in a rigid polyurethane 
chamber, with 26 mm polymer valves at the inflow and outflow ports [336]. The difference between left 
and right stroke volumes is reportedly compensated by a flexible 56 × 90mm polyurethane membrane.  
   
Gyro 
Contributions to the development of this second generation device have been made by the Baylor 
College of Medicine (Houston, USA), Miwatec (Tokyo, Japan), and the New Energy and Industrial 
Technology Development Organization (NEDO) (Kawasaki, Japan). The Gyro BiVAD (Figure 168) 
incorporates two permanently implantable centrifugal pumps, whose rotating impellers include 
additional secondary blades to accelerate blood flow beneath the impeller and reduce potential 
thrombus formation from blood circulation on the impeller back face. The seal-less titanium alloy pump 
housing encloses the impeller which is supported by a double pivot bearing.  The female and male pivot 
bearings are made of aluminium oxide ceramics and ultra-high molecular weight polyethylene 
(UHMWPE) respectively. The VAD impellers, with a diameter of 50mm, are magnetically driven, and 
during operation the magnetic forces approximately balance the induced axial hydrodynamic forces 
 
Figure 168 - The Gyro PI-710 device (left) including schematic sectioned view (right). 
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upon the rotor, allowing the impeller to float between the pivot bearings. High device lifetimes of 8 and 
10 years for LVAD and RVAD respectively are therefore expected [26, 339]. The magnetic drive actuator 
includes the pump controller and locates below the pump within the housing. The actuator has a 
brushless DC motor with coils fixed in a plastic mount surrounding a rotating disc with permanent 
magnets. The active magnetics of the RVAD, however, have an increased clearance between the 
impeller and magnetic coupling to reduce the magnetic force compared to the LVAD. Herein lies the 
only design difference between the two devices, permitting the lower pressure generation in the RVAD 
[340].  The VAD inlet port is placed off centre in an attempt to circulate the flow around the upper pivot 
bearing to decrease the risk of thrombus formation.  The Gyro pump has a priming volume of 20 mL and, 
combined with the housed motor, a weight of 305 g, height of 53 mm and diameter of 65 mm [26].  The 
overall system, including the pump and actuator, has a displacement volume and weight of 155 mL and 
480 g respectively. Meanwhile, a transcutaneous energy transfer system has been developed for the 
Gyro pump, with a maximum transmission efficiency of 87.3% [341]. 
 
CorAide/DexAide 
Developed at the Cleveland Clinic, the CorAide (LVAD) and DexAide (RVAD) (Figure 169) pumps (Arrow 
International, Reading, U.S.A.) are third-generation, implantable, centrifugal VADs which use 
hydrodynamic and magnetic forces to passively 
support the rotor. Both devices are characterized 
by their inverted motor configuration, with each 
consisting of an impeller mounted on a ‘hollow’ 
rotor surrounding the cylindrical motor stator. The 
CorAide has a displacement volume of 84 mL, 
pump weight of 293 g, a portable power supply (6 
hour battery life) and controller weight of 1350 g 
[25].  It can achieve flow rates from 2 to 8 L min-1 
and has an operational pump speed range of 2000 
to 3000 RPM.  Pumping 5 L/min against 100 mmHg, 
the CorAide LVAD uses less than 6 W of power at 
2850 RPM [342].  The DexAide RVAD was 
developed by modifying the CorAide device and has 
a diameter, length, weight and device displacement 
 
Figure 169 - The DexAide RVAD assembly 
including two different stator housings [299]. 
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volume of 44 mm, 48 mm, 280 g and 69 mL respectively [343].  The implantable centrifugal RVAD was 
developed by reducing the size of each primary vane, decreasing the number of primary vanes from 
seven to five and redesigning the volute.  The DexAide can pump at speeds ranging from 1800 to 3600 
RPM to provide over 5 L/min cardiac output to the pulmonary circulation. Using only 2.6 W of power 
while supplying a flow rate of 5.2 L/min at 2500 RPM, the DexAide has a battery life of over 12 hours on 
two fully charged batteries [344]. 
 
BiVACOR BV Assist 
The BiVACOR BV Assist (BiVACOR Pty Ltd., Brisbane, Australia) is a third generation BiVAD capable of 
providing complete circulatory support to treat end stage heart failure (Figure 170). This rotary device 
uses two centrifugal type impellers to simultaneously support the left and right ventricles on either side 
of a single rotating hub.  This essentially forms a double sided, rotary heart pump with one single 
moving part.  Passive radial stability of the rotor is managed via a hydrodynamic radial bearing between 
the outer cylindrical face of the rotating hub and the outer casing. To achieve axial stability, active 
magnetic bearings and active motor magnet arrays oppose each other on the RVAD and LVAD casings 
respectively, allowing suspension and rotation of the impeller hub [345, 346].  The interaction between 
the magnetic bearing and motor system can alter the axial position of the hub and therefore the 
respective clearance above the RVAD and LVAD semi-open impeller blades [347].  Flow rates of 5 L/min 
are obtainable with systemic and pulmonary mean arterial pressures of 100 mmHg and 20 mmHg 
respectively at a pump speed of 2300 RPM and 
equal axial clearances above the LVAD and 
RVAD impeller blades of 0.5 mm. While 
maintaining rotational speed and arterial 
pressures, an impeller axial displacement of 
+/-0.3 mm can lead to a relative left-right flow 
differential of 1.8 L/min [348].  The current 
prototype has a diameter of 60 mm and a 
length of 70 mm [349].  The rotor is capable of 
reaching speeds up to 3750 RPM to deliver 8 
L/min cardiac output, while a power 
consumption of less than 15 W is used at 2500 
RPM.  
 
Figure 170 - Non-functional fitting prototype of the 
BiVACOR BV Assist 
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Appendix 2 - Review of Numerical Simulations 
In order to model a system using numerical simulation techniques, a good knowledge of control is 
required, as well as a highly detailed knowledge of the system.  The reasons given by Bustamante et al. 
(2007) [279] for numerically simulating a system were for the design of regulation and control systems, 
and to predict the performance of the system.  A numerical simulation must include all components 
which have any effect on the dynamic behavior of the system, while having the ability to change model 
parameters that may influence the system and must follow mass, momentum and energy conservation 
principles and state equations.  Assumptions can be made in the simulation providing only a negligible 
effect is given, such as one-dimensional flow through a system.  Validation of the model can be 
performed by comparing the results using other recognized software, or by those of a similar physical 
model.  
Numerical simulations of the cardiovascular system are common. For example, Wu et al. (2003) [194] 
developed a numerical simulation of the cardiovascular system for evaluating a physiological controller.  
The cardiovascular system was modeled as an electric circuit analogue with resistance, compliance and 
inertial properties taken into account while the ventricles were modeled as nonlinear capacitors.  The 
simulation reproduced clinically relevant results, making it a suitable platform to analyze a physiological 
 
Figure 171 - Electric circuit analogue representation of a human artery segment [15] 
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controller system. Inclusion of the resistance, compliance and inertial (RLC) elements is standard 
practice in numerical simulations of the cardiovascular system, and is demonstrated by the electric 
circuit analogue version of the cardiovascular system presented by Westerhof et al. (1969) [350] (Figure 
171). Westerhof used the analogue to represent each arterial branch in the simulation, and combined 
these to form a representation of the systemic circulatory system.  
RLC elements were all included in the numerical simulation of the cardiovascular system by Mitsui et al. 
(1998) [276], who simulated the ventricles as a simple capacitor. The pumping capacity of the ventricles 
was altered by changing the capacitance value. The values chosen by Mitsui et al. for compliance, 
inertia, resistance and blood volume for the numerical simulation are shown in Table 26. 
Parameter 
 
Value Parameter Value 
Compliance 
     Left ventricular  
     Ascending aortic  
     Peripheral arterial 
     Systemic vein + right atrium 
     Right ventricle 
     Pulmonary artery 
     Pulmonary vein + left atrium 
Inertia 
     Descending aorta 
     Peripheral vessels of lung 
 
8.0D, 0.1S 
0.8 
1.0 
400 
8.0D, 0.5S 
3.0 
50 
 
0.01 
0.002 
Resistance 
     Descending aorta 
     Upper extremities + head 
     Lower extremities + abdomen 
     Coronary artery 
     Peripheral vessels of lung 
     Tricuspid valve 
     Pulmonary valve 
     Mitral valve 
     Aortic valve 
Blood volume in whole body 
 
0.5 
3.0 
1.2 
10D, 1000S 
0.12 
0.01 
0.04 
0.01 
0.04 
4500 
Table 26 - Parameter values used by Mitsui et al. (1998).  Compliance in mL/mmHg, inertia in mmHg.s
2
/mL, 
resistance in mmHg.s/mL and blood volume in mL.  S and D denote systolic and diastolic values respectively. 
 
Vollkron et al. (2002) [195] developed a numerical simulation of the cardiovascular system with an 
LVAD, inflow cannula and outflow cannula included (Figure 172). Left and right atrial and ventricular 
contractions were included through implementation of time variant capacitance for each chamber. RLC 
elements were included for both systemic and pulmonary circulations. Validation was performed by 
comparing data from the model to that in literature and previously obtained in-vitro and in-vivo results.  
Parameter variations were evaluated in comparison with in-vivo results, and finally a left ventricular 
assist device was added to the model and validated with in-vivo data.  The shape and values of the 
pressure and flow vs time traces produced by the model closely matched those seen in the literature 
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and in-vivo results, while accurate pressure volume loops were also produced.  This model is currently 
being used to investigate different strategies for physiological control.  
 
Magnetic resonance imaging (MRI) technology was used to obtain ventricle shapes and suitable inputs 
to the numerical simulation by Korakianitis et al. (2006) [196]. The ventricles were simulated by using a 
variable elastance, while the heart valves were modeled to include features such as pressure 
differences, frictional forces and vortex effects. RLC elements were also incorporated in this simulation 
(Figure 173). This simulation was further developed by Shi et al. (2007) [351], who added a VAD model 
to investigate the performances of several different types of pumps.  The simulation was shown to 
accurately represent the natural cardiovascular system with mechanical assistance, and produced 
results which replicated those previously seen from in-vivo and in-vitro studies. A variety of other 
numerical simulations have been developed for evaluation of the circulatory system [352], artificial 
hearts [353], hypertension [354], power requirements by the heart with changing arterial compliance 
[355], alternative surgical procedures [356] and more. This review of literature on simulation of 
cardiovascular systems demonstrates the importance and capabilities of simulating physical systems.   
 
Figure 172– Circulatory system presented by Vollkron et al. (2002). R - resistance, C - compliance, L - inertia. 
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Figure 173 - Schematic of full circulation used by Korakianitis et al. (2006) [196]. Nomenclature: Q - flow 
rate, P - pressure, R - resistance, C - compliance, L - inertia, E - elastance, CQ - flow coefficient, V - volume. 
Subscripts: ra - right atrium, ti - tricuspid valve, rv - right ventricle, po - pulmonary valve, pas - pulmonary 
artery sinus, pat - pulmonary artery, par - pulmonary arteriole, pcp - pulmonary capillary, pvn - pulmonary 
vein, la - left atrium, mi - mitral valve, lv - left ventricle, ao - aortic valve, sas - systemic aortic sinus, sat - 
systemic artery, sar - systemic arteriole, scp - systemic capillary, svn - systemic vein. 
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Appendix 3 - Review of In-Vivo Evaluation of Cardiovascular Devices 
Tuzun et al. (2007) [81] reported the use of six healthy sheep (weight 57-65kg) for the in-vivo evaluation 
of the HeartWare HVAD device. Following anesthesia, a left thoracotomy was performed in the fifth 
intercostal space. The outflow graft was sewn end-to-side to the descending aorta before the sewing 
ring was attached to the left ventricular apex. A conical coring knife was advanced through the sewing 
ring to remove the apical core of the beating heart before the LVAD inflow cannula was quickly inserted 
and secured. The pump was de-aired and started as an ultrasonic flow probe was attached to the LVAD 
outflow graft. The sheep were taken to an intensive care unit where the aortic pressure and pump flows 
were continuously monitored for any sign of distress or pain. No anticoagulation was provided and the 
sheep were allowed to eat four hours after extubation. The sheep were terminated after the study 
endpoint (90 days) and the device was explanted, photographed and evaluated. While this trial was 
successful in demonstrating the ability of the device to increase cardiac output over a period of 90 days, 
the use of healthy animals limited the clinical significance of these results.  
 
Sun et al. (2003) [357] reported the in-vivo evaluation of the Korean AnyHeart which was completed in 
29 various animals (19 calves, four sheep, three canines, two horses and one goat). The lightest animal 
was a 52 kg canine, while the heaviest was a 470 kg horse. Most were applied as an implantable BiVAD 
except one case of a wearable BiVAD and one for an implantable LVAD only; however no mention was 
made of why the AnyHeart device was implanted as only an LVAD. Like the choice of animals, the 
surgical technique also varied, with 17 receiving a right thoracotomy, seven with a median sternotomy 
and five with a left thoracotomy. No mention was made of anesthesia or CPB. The RVAD outflow 
cannula was grafted to the main pulmonary artery and the LVAD outflow to the brachiocephalic artery 
off the ascending aorta. Both inflow cannulae were placed in their respective atria. Anticoagulation was 
supplied and the longest observation was made in a calf which survived 37 days before intentional 
termination. For the implantation of the AnyHeart, the authors noted that a right thoracotomy is the 
preferred method of access and may be relevant for other BiVADs. This comment was reinforced by 
completing a cadaveric fitting study of the device, reported in the same article.  Again, healthy animals 
were used in this study while the inconsistency in choice of animal and surgical procedure makes 
comparison of results difficult. 
 
Ootaki et al. (2008) [82] implanted various inflow cannulae of the DexAide RVAD in 19 healthy calves 
(weighing between 76 and 160 kg) for durations of 14, 30 or 90 days. The surgery was similar to a 
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human RVAD implantation, with the animal anesthetized and placed on CPB for the procedure. A fifth, 
or fourth in three cases, left thoracotomy was performed to gain access to the heart before an end-to-
side anastomisis of the pulmonary artery and outflow graft was performed. The outflow portion of the 
RV (16 cases) and the diaphragmatic surface of the RV (three cases) was used for RVAD inflow. 
Perivascular flow probes were placed around the outflow graft and distal pulmonary artery to measure 
pump outflow and cardiac output respectively. The RVAD was secured in the chest and started. The 
postoperative care involved the animal transferring to a chronic care facility and maintained in cages. 
Continuous heparin administration was applied while blood samples were frequently taken and 
analysed to detect any signs of infection, renal or hepatic dysfunction or haemolysis. Animals were 
euthanized at the end of the study by inducing an overdose of sodium pentobarbital and potassium 
chloride. All implanted components were removed, inspected and photographed at autopsy. While this 
study demonstrated the success of the DexAide device and the influence of cannula design, the animal 
trial was completed in a healthy calf and therefore the haemodynamics and ventricular tissue mechanics 
were not representative of a congestive heart failure patient. 
 
Fumoto et al. (2010) [358] evaluated the Cleveland Clinic TAH in two calves (91 and 100.2 kg) in an acute 
study. A median sternotomy was performed under general anesthesia before CPB was initiated and 
heparin was administered. Both ventricles were resected at the atrioventricular groove and the inflow 
cuffs were sutured to the atria. The outflow grafts were sutured to the aorta and pulmonary artery 
before the primed pump was connected to the inflow and outflow conduits. After air was removed from 
the pump, full support was started with rapid weaning from CPB. Pressures in the left and right atria, 
aorta and pulmonary artery were monitored along with right and left pump flows. Calves were also used 
by Ichikawa et al. (2003) [359] to evaluate the NEDO Gyro pump for biventricular support. Six healthy 
calves were implanted with the LVAD from left ventricular apex to aorta and RVAD from right ventricular 
infundibulum to pulmonary artery. Various pump placements were evaluated in this animal trial. The 
calves were transferred to an animal intensive care unit for total support durations of between 37 and 
90 days. Trials by Fumoto and Ichikawa were performed in healthy animals which did not provide an 
accurate replication of the contractility and increased vascular resistance of a congestive heart failure 
patient.  
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Appendix 4 - Parts list and suppliers for MCL construction 
Category 
 
Product 
 
Length or 
Quantity 
 
Supplier 
 
Clear PVC 
pipe and 
fittings 
1" clear PVC pipe 10' Alsco 
1.5" clear PVC pipe 10' Alsco 
6" clear PVC pipe 10' Alsco 
1" clear tee - machined 9 Alsco 
1.25" clear cap 2 Alsco 
1.5" clear cap 2 Alsco 
1" clear PVC swing check valve 4 Alsco 
1" clear PVC elbow 12 Alsco 
Clear PVC 1" female thread 2 Alsco 
1" clear PVC male thread 1 Alsco 
1/2 Clear flexible tubing 200' Alsco 
Black / white 
PVC pipe 
and fittings 
150mm white PVC pipe 1 Bunnings 
100mm white PVC pipe 2 Reece 
65mm white PVC pipe 1 Reece 
PVC primer 2 Bunnings 
PVC glue 2 Bunnings 
Silicone 2 Bunnings 
Silicone gun 1 Bunnings 
1" female thread x 1" slip white PVC 3 Reese plumbing 
25mm white PVC union - machined 3 Reese plumbing 
25mm white PVC union - machined 4 Tradelink 
150mm white PVC cap 5 Reese plumbing 
150mm white PVC cap 3 Tradelink 
PVC cap 1/2 female thread 2 Reese plumbing 
1" bulkhead 4 Reese plumbing 
White PVC flange 1" slip ID, 120mm OD 4 Reese plumbing 
Rubber seal for flanges 4 Reese plumbing 
Brass and 
stainless 
steel fittings 
Brass elbow - 1/2" M x F threaded 2 Blackwoods 
Brass elbow - 1/2" M thread x 1/2" barb 12 Tony Powell 
Brass elbow 1/2" MxM 6 Blackwoods 
Brass elbow 1/2" FxF 3 Blackwoods 
Brass straight 1/2 M thread x 1/2 barb 18 Blackwoods 
Brass straight 1/2" barb x 3/8" threaded brass 3 Tony Powell 
Brass Tee 1/2M thread x 1/2 barb x 1/2 barb 3 Blackwoods 
Brass Tee 1/2" MxMxM 2 Blackwoods 
1/2" FxFxF brass tee 2 Blackwoods 
Brass nipple 1/2 MxM 25 Blackwoods 
Brass socket 1/2 FxF 5 Blackwoods 
Brass nipple 3/8" M x 3/16"M 3 Tony Powell 
Brass reducer 3/16"M x 1/2"M 4 Tony Powell 
Brass reducer 1/2" x 3/4" MxM 1 Tony Powell 
Brass reducer 1"F x 1/2"M 1 Tony Powell 
Brass reducer 3/4"M x 1"F  1 Blackwoods 
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Brass 4-way 1/2"FxFxFxF  2 Blackwoods 
Brass unions 1/2" 2 Blackwoods 
Connection from 1/2"F to gas supply 1 Tony Powell 
Stainless steel nipple 1/2" 2 Blackwoods 
Stainless steel elbow 1/2" Fx F 2 Blackwoods 
Stainless steel elbow 1/2" M x F 6 Blackwoods 
Stainless steel reducer 1/2"x1" 1 Blackwoods 
Stainless steel tee 1/2" FXFXF 6 Blackwoods 
Stainless ball valves 1/2" FXF 8 Blackwoods 
Stainless union 1/4" FxF 6 Blackwoods 
Stainless elbow MxF 1/4" 4 Blackwoods 
Stainless nipple 1/4" 16 Blackwoods 
Valve ball mini 1/4" FF 4 Blackwoods 
Stainless tee 1/4" FFF 2 Blackwoods 
Stainless flip connectors 1/2" FXF 3 Tony Powell 
10mm diameter 100mm stainless steel bolts and nuts 8 Connoly fasteners 
Electrical 
consumables 
Thin wire (5m roll) 1 Jaycar 
Wire with 4 wires inside (technical!) 15 Jaycar 
Speaker wire 20 Jaycar 
5 pin connectors, M and F 7 Jaycar 
4 pin connectors, M and F 7 Jaycar 
2 pin connectors, M and F 11 Jaycar 
BNC connectors, M 11 Jaycar 
BNC cables 16 Farnell 
Electronics box 2 Jaycar 
Relays 9 Jaycar 
Power supply 1 Farnell 
Wire cutters 2 Bunnings 
Process 
valves 
Resistance valves EPV-375B 1 Hass 
2 way solenoid valves 6 SMC pneumatics 
3/2 way solenoid valve 3 SMC pneumatics 
1" Socket Valve 1 Convair 
Regulators Electropneumatic regulator 3 SMC pneumatics 
Automatic regulator 2 SMC pneumatics 
Level 
sensors Level sensor 2 Gefran 
Flow meters Systemic and pulmonary flow meters 1 Krohne 
 
VAD flow meter and sensors 1 Transonics 
Pressure 
sensors 
Stainless steel luers 20 Cadence 
3-way stopcock 10  Hospital 
Pressure transducers and amp 8 Kimble 
Data 
acquisition 
dSPACE DS1103 1 dSPACE 
Computer 1 Umart 
 
